0001279363-19-000017.txt : 20190430 0001279363-19-000017.hdr.sgml : 20190430 20190430151451 ACCESSION NUMBER: 0001279363-19-000017 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190430 DATE AS OF CHANGE: 20190430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WELLCARE HEALTH PLANS, INC. CENTRAL INDEX KEY: 0001279363 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 470937650 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32209 FILM NUMBER: 19781053 BUSINESS ADDRESS: STREET 1: 8735 HENDERSON ROAD STREET 2: RENAISSANCE ONE CITY: TAMPA STATE: FL ZIP: 33634 BUSINESS PHONE: 8132906200 MAIL ADDRESS: STREET 1: 8735 HENDERSON ROAD STREET 2: RENAISSANCE ONE CITY: TAMPA STATE: FL ZIP: 33634 FORMER COMPANY: FORMER CONFORMED NAME: WELLCARE GROUP INC DATE OF NAME CHANGE: 20040210 10-Q 1 wcg-201903311910q.htm 10-Q Document
false--12-31Q120190001279363falseLarge Accelerated Filerfalse0.010.01100000000100000000499932195030221549993219503022150.05250.0537500000.010.012000000020000000000000000P5YP5Y 0001279363 2019-01-01 2019-03-31 0001279363 2019-04-29 0001279363 2018-01-01 2018-03-31 0001279363 2019-03-31 0001279363 2018-12-31 0001279363 us-gaap:CommonStockMember 2018-03-31 0001279363 us-gaap:CommonStockMember 2017-12-31 0001279363 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001279363 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001279363 2018-03-31 0001279363 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001279363 us-gaap:RetainedEarningsMember 2018-12-31 0001279363 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001279363 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001279363 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001279363 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001279363 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001279363 us-gaap:CommonStockMember 2018-12-31 0001279363 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001279363 us-gaap:CommonStockMember 2019-03-31 0001279363 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001279363 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001279363 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001279363 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001279363 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001279363 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001279363 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001279363 2017-12-31 0001279363 us-gaap:RetainedEarningsMember 2018-03-31 0001279363 us-gaap:RetainedEarningsMember 2019-03-31 0001279363 us-gaap:RetainedEarningsMember 2017-12-31 0001279363 2019-01-01 0001279363 wcg:AetnaPartDBusinessMember 2019-03-31 0001279363 wcg:MedicareAdvantageandPDPMember wcg:MedicareAdvantageMember 2019-03-31 0001279363 wcg:AetnaPartDBusinessMember 2019-01-01 2019-03-31 0001279363 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001279363 wcg:StatePartnersMember wcg:MedicaidMember 2019-03-31 0001279363 us-gaap:PremiumsReceivableMember 2019-03-31 0001279363 us-gaap:PremiumsReceivableMember 2018-03-31 0001279363 wcg:AetnaPartDBusinessMember 2018-12-31 0001279363 wcg:MeridianMember us-gaap:OtherIntangibleAssetsMember 2018-09-01 2018-09-01 0001279363 wcg:MeridianMember 2018-09-01 2018-09-01 0001279363 wcg:MeridianMember us-gaap:TradeNamesMember 2018-09-01 2018-09-01 0001279363 wcg:MeridianMember wcg:ProviderNetworkMember 2018-09-01 2018-09-01 0001279363 wcg:MeridianMember us-gaap:MembershipMember 2018-09-01 2018-09-01 0001279363 wcg:MeridianMember 2019-03-31 0001279363 wcg:MedicareHealthPlansMember 2019-03-31 0001279363 wcg:MedicaidMember 2019-01-01 2019-03-31 0001279363 wcg:MeridianMember 2019-01-01 2019-03-31 0001279363 wcg:MedicaidMember 2018-12-31 0001279363 wcg:MedicareHealthPlansMember 2018-12-31 0001279363 wcg:MeridianMember 2018-12-31 0001279363 wcg:MedicaidMember 2019-03-31 0001279363 wcg:MedicareHealthPlansMember 2019-01-01 2019-03-31 0001279363 wcg:MeridianMember 2018-09-01 0001279363 wcg:CenteneMember us-gaap:ScenarioForecastMember 2020-01-01 2020-06-30 0001279363 wcg:MeridianMember wcg:SeniorNotesDue2026Issued20185.375percentMember us-gaap:SeniorNotesMember 2018-08-31 0001279363 wcg:AetnaPartDBusinessMember 2018-11-30 2018-11-30 0001279363 wcg:CenteneMember us-gaap:ScenarioForecastMember 2020-06-30 0001279363 wcg:MeridianMember 2018-08-01 2018-08-31 0001279363 us-gaap:OperatingSegmentsMember wcg:MedicaidMember 2018-01-01 2018-03-31 0001279363 stpr:KY 2019-01-01 2019-03-31 0001279363 stpr:FL 2019-01-01 2019-03-31 0001279363 stpr:IL 2019-01-01 2019-03-31 0001279363 stpr:KY 2018-01-01 2018-03-31 0001279363 stpr:FL 2018-01-01 2018-03-31 0001279363 us-gaap:OperatingSegmentsMember wcg:MedicaidMember 2019-01-01 2019-03-31 0001279363 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-03-31 0001279363 us-gaap:OperatingSegmentsMember wcg:PrescriptionDrugPlansMember 2019-01-01 2019-03-31 0001279363 us-gaap:OperatingSegmentsMember wcg:MedicareHealthPlansMember 2019-01-01 2019-03-31 0001279363 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001279363 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0001279363 us-gaap:OperatingSegmentsMember wcg:PrescriptionDrugPlansMember 2018-01-01 2018-03-31 0001279363 us-gaap:OperatingSegmentsMember wcg:MedicareHealthPlansMember 2018-01-01 2018-03-31 0001279363 us-gaap:OperatingSegmentsMember 2018-01-01 2018-03-31 0001279363 stpr:FL wcg:MedicaidMember wcg:MedicalServicesManagedCarePlanMember 2018-07-01 2018-07-31 0001279363 stpr:FL wcg:MedicaidMember wcg:SeriousMentalIllnessSpecialtyPlanMember 2018-04-01 2018-04-30 0001279363 2018-08-01 2018-08-31 0001279363 2018-08-31 0001279363 wcg:AssetBackedAndMortgageBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:BankTimeDepositsMember 2019-03-31 0001279363 us-gaap:AssetBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:MunicipalBondsMember 2018-12-31 0001279363 us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:MunicipalBondsMember 2019-03-31 0001279363 us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:ResidentialMortgageBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:BankTimeDepositsMember 2018-12-31 0001279363 us-gaap:OtherAggregatedInvestmentsMember 2018-12-31 0001279363 us-gaap:OtherAggregatedInvestmentsMember 2019-03-31 0001279363 us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0001279363 us-gaap:CashMember 2019-03-31 0001279363 us-gaap:USTreasuryAndGovernmentMember 2019-03-31 0001279363 us-gaap:MoneyMarketFundsMember 2018-12-31 0001279363 us-gaap:CashMember 2018-12-31 0001279363 us-gaap:MoneyMarketFundsMember 2019-03-31 0001279363 us-gaap:PerformanceSharesMember 2018-12-31 0001279363 us-gaap:PerformanceSharesMember 2019-01-01 2019-03-31 0001279363 us-gaap:RestrictedStockUnitsRSUMember 2019-03-31 0001279363 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001279363 us-gaap:PerformanceSharesMember 2019-03-31 0001279363 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001279363 us-gaap:RevolvingCreditFacilityMember 2018-07-23 0001279363 wcg:SeniorNotesDue2025Issued20175.25percentMember us-gaap:SeniorNotesMember 2017-03-22 0001279363 wcg:SeniorNotesDue2020Issued20135.75percentMember us-gaap:SeniorNotesMember 2017-04-07 0001279363 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2018-07-23 2018-07-23 0001279363 wcg:SeniorNotesDue2026Issued20185.375percentMember us-gaap:SeniorNotesMember 2018-08-13 0001279363 us-gaap:RevolvingCreditFacilityMember 2019-03-31 0001279363 us-gaap:RevolvingCreditFacilityMember 2017-03-22 0001279363 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2018-07-23 2018-07-23 0001279363 us-gaap:RevolvingCreditFacilityMember 2018-07-23 2018-07-23 0001279363 us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2019-04-01 2019-04-30 0001279363 wcg:SeniorNotesDue2026Issued20185.375percentMember us-gaap:SeniorNotesMember 2018-12-31 0001279363 wcg:SeniorNotesDue2025Issued20175.25percentMember us-gaap:SeniorNotesMember 2018-12-31 0001279363 us-gaap:RevolvingCreditFacilityMember 2018-12-31 0001279363 wcg:SeniorNotesDue2025Issued20175.25percentMember us-gaap:SeniorNotesMember 2019-03-31 0001279363 wcg:SeniorNotesDue2026Issued20185.375percentMember us-gaap:SeniorNotesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2019-03-31 0001279363 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2019-03-31 0001279363 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001279363 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0001279363 us-gaap:CorporateAndOtherMember 2019-01-01 2019-03-31 0001279363 wcg:PrescriptionDrugPlansMember 2019-01-01 2019-03-31 0001279363 us-gaap:CorporateAndOtherMember 2019-03-31 0001279363 wcg:PrescriptionDrugPlansMember 2019-03-31 0001279363 us-gaap:CorporateAndOtherMember 2018-12-31 0001279363 wcg:PrescriptionDrugPlansMember 2018-12-31 0001279363 us-gaap:CorporateAndOtherMember 2018-01-01 2018-03-31 0001279363 wcg:MedicaidMember 2018-01-01 2018-03-31 0001279363 wcg:PrescriptionDrugPlansMember 2018-01-01 2018-03-31 0001279363 wcg:MedicaidMember 2017-12-31 0001279363 wcg:MedicareHealthPlansMember 2018-03-31 0001279363 wcg:PrescriptionDrugPlansMember 2018-03-31 0001279363 us-gaap:CorporateAndOtherMember 2017-12-31 0001279363 us-gaap:CorporateAndOtherMember 2018-03-31 0001279363 wcg:MedicareHealthPlansMember 2018-01-01 2018-03-31 0001279363 wcg:PrescriptionDrugPlansMember 2017-12-31 0001279363 wcg:MedicareHealthPlansMember 2017-12-31 0001279363 wcg:MedicaidMember 2018-03-31 0001279363 srt:MaximumMember 2019-01-01 2019-03-31 0001279363 us-gaap:DiscontinuedOperationsHeldforsaleMember wcg:TraditionalInsuranceBusinessMember 2019-03-31 0001279363 us-gaap:DiscontinuedOperationsHeldforsaleMember wcg:TraditionalInsuranceBusinessMember 2018-12-31 0001279363 2016-08-03 2016-08-03 0001279363 wcg:Mr.BehrensCaseMember wcg:DerivativeLawsuitsMember 2016-10-01 2016-10-31 0001279363 wcg:DerivativeLawsuitsMember 2019-03-31 0001279363 wcg:DerivativeLawsuitsMember 2012-01-31 0001279363 wcg:Mr.FarhaCaseMember wcg:DerivativeLawsuitsMember 2016-09-01 2016-09-30 0001279363 2013-06-30 0001279363 wcg:DerivativeLawsuitsMember 2013-06-30 0001279363 wcg:Mr.FarhaCaseMember wcg:DerivativeLawsuitsMember 2017-04-01 2017-04-30 0001279363 wcg:UnitedStatesSecuritiesAndExchangeCommissionMember wcg:Mr.BehrensCaseMember wcg:DerivativeLawsuitsMember 2018-05-01 2018-05-31 0001279363 wcg:UnitedStatesSecuritiesAndExchangeCommissionMember wcg:Mr.BehrensCaseMember wcg:DerivativeLawsuitsMember 2017-04-01 2017-04-30 0001279363 wcg:Mr.BeredayCaseMember wcg:DerivativeLawsuitsMember 2017-06-01 2017-06-30 0001279363 wcg:DerivativeLawsuitsMember 2008-01-31 0001279363 wcg:Mr.BehrensCaseMember wcg:DerivativeLawsuitsMember 2017-04-01 2017-04-30 0001279363 wcg:UnitedStatesSecuritiesAndExchangeCommissionMember wcg:Mr.FarhaCaseMember wcg:DerivativeLawsuitsMember 2017-04-01 2017-04-30 iso4217:USD xbrli:shares xbrli:pure wcg:member wcg:segment xbrli:shares iso4217:USD wcg:officer wcg:action wcg:associate wcg:former_officer wcg:subsidiary wcg:employee


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2019
or
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from               to             
Commission file number: 001-32209
WELLCARE HEALTH PLANS, INC.
(Exact name of registrant as specified in its charter)
Delaware
 
47-0937650
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
 
Identification No.)

8735 Henderson Road, Renaissance One
Tampa, Florida
 
33634
(Address of Principal Executive Offices)
 
(Zip Code)
(813) 290-6200
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x Accelerated filer o Non-accelerated filer o
Smaller reporting company o Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of April 29, 2019, there were 50,303,407 shares of the registrant's common stock, par value $0.01 per share, outstanding.


WELLCARE HEALTH PLANS, INC.

TABLE OF CONTENTS

 
Page
Part I — FINANCIAL INFORMATION
 
 
 
 
Item 1.
Financial Statements
 
 
 
 
 
Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2019 and 2018 (unaudited)
 
Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018 (unaudited)
 
Condensed Consolidated Statements of Changes in Stockholders' Equity for the three months ended
March 31, 2019 and 2018 (unaudited)
 
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018 (unaudited)
 
Notes to Condensed Consolidated Financial Statements (unaudited)
 
 
 
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
 
 
 
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
 
 
 
Item 4.
Controls and Procedures
 
 
 
Part II — OTHER INFORMATION
 
 
 
 
Item 1.
Legal Proceedings
 
 
 
Item 1A.
Risk Factors
 
 
 
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
 
 
 
Item 3.
Defaults Upon Senior Securities
 
 
 
Item 4.
Mine Safety Disclosures
 
 
 
Item 5.
Other Information
 
 
 
Item 6.
Exhibits
 
 
 
 
Signatures
 
 
 
 
Exhibit Index



Part I — FINANCIAL INFORMATION

Item 1. Financial Statements.

WELLCARE HEALTH PLANS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited) (In millions, except per share and share data) 
 
For the Three Months Ended
March 31,
 
2019
 
2018
Revenues:
 
 
 
Premium
$
6,609.4

 
$
4,626.3

Products and services
115.8

 
—

Investment and other income
37.0

 
19.9

Total revenues
6,762.2

 
4,646.2

 
 
 
 
Expenses:
 
 
 
Medical benefits
5,831.7

 
3,962.0

Costs of products and services
111.8

 
—

Selling, general and administrative
503.8

 
355.9

ACA industry fee
—

 
81.5

Medicaid premium taxes
31.7

 
32.1

Depreciation and amortization
69.6

 
36.4

Interest
29.5

 
17.1

Total expenses
6,578.1

 
4,485.0

Income before income taxes and equity in losses of unconsolidated subsidiaries
184.1

 
161.2

Equity in earnings (losses) of unconsolidated subsidiaries
0.8

 
(2.7
)
Income before income taxes
184.9

 
158.5

Income tax expense
33.5

 
56.8

Net income
$
151.4

 
$
101.7

 
 
 
 
Other comprehensive income (loss):
 
 
 
Change in net unrealized gains and losses on
available-for-sale securities, before tax
18.5

 
(10.3
)
Income tax expense (benefit) related to other
comprehensive income
4.7

 
(2.4
)
Other comprehensive income (loss), net of tax
13.8

 
(7.9
)
Comprehensive income
$
165.2

 
$
93.8

 
 
 
 
Earnings per common share:
 
 
 
Basic
$
3.02

 
$
2.28

Diluted
$
2.98

 
$
2.25

 
 
 
 
Weighted average common shares outstanding:
 
 
 
       Basic
50,100,509

 
44,605,892

       Diluted
50,842,304

 
45,196,127


See notes to unaudited condensed consolidated financial statements.

2


WELLCARE HEALTH PLANS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited) (In millions, except share data)

 
March 31,
2019
 
December 31,
2018
Assets
 
 
 
Current Assets:
 
 
 
Cash and cash equivalents
$
3,235.3

 
$
3,653.9

Short-term investments
968.6

 
830.1

Premiums receivable, net
1,567.6

 
1,223.4

Pharmacy rebates receivable, net
550.0

 
460.6

Funds receivable for the benefit of members
331.6

 
187.3

Prepaid expenses and other current assets, net
1,127.6

 
477.1

Total current assets
7,780.7

 
6,832.4

 
 
 
 
Property, equipment and capitalized software, net
424.9

 
428.2

Goodwill
2,206.4

 
2,227.7

Other intangible assets, net
986.0

 
996.2

Long-term investments
1,057.6

 
813.2

Restricted cash, cash equivalents and investments
274.3

 
234.7

Other assets
268.8

 
18.7

Assets of discontinued operations
207.2

 
213.6

Total Assets
$
13,205.9

 
$
11,764.7

 
 
 
 
Liabilities and Stockholders' Equity
 

 
 

Current Liabilities:
 

 
 

Medical benefits payable
$
3,212.6

 
$
2,897.4

Unearned premiums
16.9

 
1.4

Accounts payable and accrued expenses
1,304.9

 
964.6

Funds payable for the benefit of members
1,051.8

 
693.3

Other payables to government partners
491.1

 
458.9

Total current liabilities
6,077.3

 
5,015.6

 
 
 
 
Deferred income tax liability, net
149.0

 
134.2

Long-term debt, net
2,127.3

 
2,126.4

Other liabilities
253.9

 
34.9

Liabilities of discontinued operations
207.2

 
213.6

Total Liabilities
8,814.7

 
7,524.7

Commitments and contingencies (see Note 14)


 


Stockholders' Equity:
 
 
 
Preferred stock, $0.01 par value (20,000,000 authorized, no shares
issued or outstanding)
—

 
—

Common stock, $0.01 par value (100,000,000 authorized, 50,302,215 and 49,993,219 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively)
0.5

 
0.5

Paid-in capital
1,967.1

 
1,981.1

Retained earnings
2,418.7

 
2,267.3

Accumulated other comprehensive income (loss)
4.9

 
(8.9
)
Total Stockholders' Equity
4,391.2

 
4,240.0

Total Liabilities and Stockholders' Equity
$
13,205.9

 
$
11,764.7

See notes to unaudited condensed consolidated financial statements.

3


WELLCARE HEALTH PLANS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(Unaudited) (In millions, except share data)

 
Common Stock
 
Paid in Capital
 
Retained Earnings
 
Accumulated
Other
Comprehensive Income (Loss)
 
Total
Stockholders' Equity
Shares
 
Amount
Balance at January 1, 2019
49,993,219

 
$
0.5

 
$
1,981.1

 
$
2,267.3

 
$
(8.9
)
 
$
4,240.0

Common stock issued for vested equity-compensation awards
451,484

 
—

 
—

 
—

 
—

 
—

Repurchase and retirement of shares to satisfy tax withholding requirements
(142,488
)
 
—

 
(36.8
)
 
—

 
—

 
(36.8
)
Stock-based compensation expense, net of forfeitures
—

 
—

 
22.8

 
—

 
—

 
22.8

Comprehensive income
—

 
—

 
—

 
151.4

 
13.8

 
165.2

Balance at March 31, 2019
50,302,215

 
$
0.5

 
$
1,967.1

 
$
2,418.7

 
$
4.9

 
$
4,391.2

 
 
 
 
 
 
 
 
 
 
 
 
Balance at January 1, 2018
44,522,988

 
$
0.4

 
$
591.5

 
$
1,827.5

 
$
(2.7
)
 
$
2,416.7

Common stock issued for vested stock-based compensation awards
334,521

 
—

 
—

 
—

 
—

 
—

Repurchase and retirement of shares to satisfy tax withholding requirements
(104,274
)
 
—

 
(20.2
)
 
—

 
—

 
(20.2
)
Stock-based compensation expense, net of forfeitures
—

 
—

 
12.1

 
—

 
—

 
12.1

Comprehensive income (loss)
—

 
—

 
—

 
101.7

 
(7.9
)
 
93.8

Balance at March 31, 2018
44,753,235

 
$
0.4

 
$
583.4

 
$
1,929.2

 
$
(10.6
)
 
$
2,502.4


See notes to unaudited condensed consolidated financial statements.


4


WELLCARE HEALTH PLANS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in millions)

 
For the Three Months Ended
March 31,
 
2019
 
2018
Cash flows from operating activities:
 
 
 
Net income
$
151.4

 
$
101.7

Adjustments to reconcile net income to cash flows from operating activities:
 
 
 

Depreciation and amortization
69.6

 
36.4

Stock-based compensation expense
22.8

 
12.1

Deferred taxes, net
6.6

 
(19.5
)
Other, net
10.1

 
5.1

Changes in operating accounts, net of effects from acquisitions and divestitures:
 

 
 

Premiums receivable, net
(348.5
)
 
(187.9
)
Pharmacy rebates receivable, net
(89.4
)
 
(45.6
)
Medical benefits payable
315.2

 
64.0

Unearned premiums
15.5

 
527.0

Other receivables/payables to government partners
32.2

 
(15.8
)
Prepaid and other current assets
(110.9
)
 
(7.4
)
Accrued liabilities and other, net
(104.6
)
 
(24.4
)
Net cash (used in) provided by operating activities
(30.0
)
 
445.7

 
 
 
 
Cash flows from investing activities:
 

 
 

Purchases of investments
(979.0
)
 
(387.9
)
Proceeds from sales and maturities of investments
529.6

 
171.5

Additions to property, equipment and capitalized software, net
(38.1
)
 
(24.2
)
Net cash used in provided by investing activities
(487.5
)
 
(240.6
)
 
 
 
 
Cash flows from financing activities:
 

 
 

Repurchase and retirement of shares to satisfy employee tax withholding requirements
(36.8
)
 
(20.2
)
Funds received for the benefit of members, net
170.7

 
416.2

Other, net
1.3

 
21.4

Net cash provided by financing activities
135.2

 
417.4

 
 
 
 
(Decrease) increase in cash, cash equivalents and restricted cash and cash equivalents
(382.3
)
 
622.5

Balance at beginning of period
3,716.6

 
4,263.0

Balance at end of period
$
3,334.3

 
$
4,885.5

 
 
 
 
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
 

 
 

  Cash paid for taxes, net of refunds
$
6.7

 
$
2.0

  Cash paid for interest
$
54.6

 
$
32.1

SUPPLEMENTAL DISCLOSURES OF NON-CASH TRANSACTIONS:
 

 
 

Non-cash additions to property, equipment, and capitalized software
$
5.8

 
$
3.0


See notes to unaudited condensed consolidated financial statements.

5


WELLCARE HEALTH PLANS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited) (In millions, except member, per share and share data)


1. ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
 
WellCare Health Plans, Inc. (the "Company," "we," "us," or "our") focuses primarily on providing government-sponsored managed care services to families, children, seniors and individuals with complex medical needs primarily through Medicaid, Medicare Advantage ("MA") and Medicare Prescription Drug Plans ("PDP"), as well as individuals in the Health Insurance Marketplace. As of March 31, 2019, we served approximately 6.3 million members nationwide. 

As of March 31, 2019, we operated Medicaid health plans, including states where we receive Medicaid premium revenues associated with dually eligible special needs plans, in Arizona, Florida, Georgia, Hawaii, Illinois, Kentucky, Michigan, Missouri, Nebraska, New Jersey, New York, South Carolina and Texas.

In addition, as of March 31, 2019, we also operated MA coordinated care plans ("CCPs") in Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky, Louisiana, Maine, Michigan, Mississippi, New Jersey, New York, North Carolina, Ohio, South Carolina, Tennessee and Texas. We also offered stand-alone Medicare PDPs nationwide.

In September 2018, we completed the acquisition of Meridian Health Plan of Michigan, Inc., Meridian Health Plan of Illinois, Inc., and MeridianRx, LLC, a pharmacy benefit manager ("PBM") (collectively, "Meridian"). As a result of the acquisition, we expanded our Medicaid portfolio through the addition of Michigan; expanded our Medicaid presence in Illinois; and acquired an integrated PBM platform. Meridian also serves MA members in Illinois, Indiana, Michigan, and Ohio, as well as Health Insurance Marketplace members in Michigan.

Basis of Presentation

The accompanying unaudited condensed consolidated balance sheets and statements of comprehensive income, changes in stockholders' equity, and cash flows include our accounts and the accounts of our subsidiaries over which we have control or are the primary beneficiary. We eliminated all intercompany accounts and transactions.

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). Accordingly, certain financial information and footnote disclosures normally included in financial statements prepared in accordance with GAAP, but that are not required for interim reporting purposes, have been condensed or omitted. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto, for the fiscal year ended December 31, 2018, included in our Annual Report on Form 10-K ("2018 Form 10-K"), which was filed with the U.S. Securities and Exchange Commission ("SEC") in February 2019. Results for the interim periods presented are not necessarily indicative of results that may be expected for the entire year or any other interim period.

In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all normal recurring adjustments that we consider necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. In accordance with GAAP, we make certain estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. We base these estimates, including assumptions as to the annualized tax rate, on our knowledge of current events and anticipated future events and evaluate and update our assumptions and estimates on an ongoing basis; however, actual results may differ from our estimates. We evaluated all material events subsequent to the date of these condensed consolidated interim financial statements. Certain reclassifications were made to 2018 financial information to conform to the 2019 presentation.


6

Pharmacy Benefit Manager

The external revenues and costs for our PBM business are reported within "Products and Services" and "Cost of Products and Services", respectively, on the condensed consolidated statements of comprehensive income. Products and services revenues from our PBM consist of the prescription price (ingredient cost plus dispensing fee) negotiated with the retail pharmacies with which we have contracted, plus any associated administrative fees. This revenue is recognized when the claim is processed. We have the contractual obligation to pay network pharmacies for benefits provided to participating members and, therefore, act as principal in the arrangement and reflect the total prescription price as revenue, on a gross basis, in accordance with applicable accounting guidance. Costs of products and services is recognized at the time prescriptions are dispensed by pharmacies in the PBM's network to eligible members and consists primarily of ingredient costs and dispensing fees paid to retail pharmacies with which we have contracted. The overall results of our PBM business are immaterial.

Aetna Part D Membership Reinsurance

In November 2018, we completed the purchase of Aetna Inc.'s ("Aetna") entire standalone Medicare Part D prescription drug plan membership ("Aetna Part D membership"). In connection with the purchase, we also entered into an administrative services agreement and a reinsurance agreement pursuant to which Aetna provides administrative services to, and retains financial risk of, the Aetna Part D membership, effective for plan year 2019. We remain primarily liable to policyholders under this ceded insurance contract and are contingently liable for amounts recoverable from Aetna in the event that they do not meet their contractual obligations.  In the normal course, we evaluate the financial condition of our reinsurers and monitor concentrations of credit risk to minimize our exposure to significant losses from reinsurer insolvencies. As of March 31, 2019, related to the Aetna Part D membership, our condensed consolidated balance sheet included reinsured receivables of $30.8 million, primarily related to premiums receivable, and reinsured payables of $482.8 million, primarily related to pharmacy claims payables. These reinsured receivables and payables were included in prepaid expenses and other current assets, net, and accounts payable and accrued liabilities, respectively. The resulting net reinsurance recoverables of $452.0 million was included in prepaid expenses and other current assets, net on the condensed consolidated balance sheet. There were no reinsurance recoverables or reinsurance liabilities relating to the Aetna Part D membership recorded as of December 31, 2018.
 
In our condensed consolidated statements of comprehensive income, premium revenue and medical benefits were reported net of amounts ceded under this Aetna reinsurance arrangement. Premium revenue and medical benefits expense ceded relating to the Aetna Part D membership were $501.0 million and $473.7 million, respectively, for the three months ended March 31, 2019.

Unconsolidated Subsidiaries

We work with physicians and other health care professionals to operate Accountable Care Organizations ("ACOs") under the Medicare Shared Saving Program ("MSSP") and Next Generation ACO Models. ACOs were established by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the "ACA") to reward integrated, efficient care and allow providers to share in any savings they achieve as a result of improved quality and operational efficiency.
These ACOs are generally formed as limited liability companies. The ACOs are considered variable interest entities ("VIEs") under GAAP as these entities do not have sufficient equity to finance their own operations without additional financial support. We own a majority interest in our ACOs; however, we share the power to direct the activities that most significantly affect the ACOs with health care providers that are minority owners in the ACOs. This power is shared pursuant to the structure of the management committee of each of the ACOs. Accordingly, we have determined that we are not the primary beneficiary of the ACOs; therefore, we cannot consolidate their results. We perform an ongoing qualitative assessment of our variable interests in VIEs to determine whether we have a controlling financial interest and would therefore be considered the primary beneficiary of the VIE.
We account for our participation in the ACOs using the equity method. Gains and losses are immaterial and are reported on the face of our condensed consolidated statements of comprehensive income as equity in earnings (losses) of unconsolidated subsidiaries.

7

Significant Accounting Policies
Below is a discussion of our significant accounting policies, which affected the comparability of our consolidated results of operations, financial condition or cash flows for the periods presented. Refer to Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in our 2018 Form 10-K for a complete discussion of all of our significant accounting policies.
Premium Receivables and Unearned Premiums
We record premiums earned but not received as premiums receivable and record premiums received in advance of the period of service as unearned premiums in our condensed consolidated balance sheets. A complete discussion of premiums receivable and unearned premiums is included in Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in our 2018 Form 10-K. The premium receivable balance at March 31, 2019 is primarily related to Medicaid contracts with our state partners of approximately $1.2 billion, as well as net risk-adjusted premiums receivable under our MA and PDP contracts of approximately $364.0 million.
Medicaid Risk-Adjusted Premiums and Retroactive Rate Changes

As discussed further in Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in our 2018 Form 10-K, Medicaid premium rate changes are recognized in the period the change becomes effective, when the effect of the change in the rate is reasonably estimable and collection is assured. In some instances, our Medicaid premiums are subject to risk score adjustments based on the health profile of our membership. Generally, the risk score is determined by the state agency's analysis of encounter submissions of processed claims data to determine the acuity of our membership relative to the entire state's Medicaid membership. The frequency of when states adjust premiums varies, but is usually done quarterly or semi-annually on a retrospective basis. We recognize periodic changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Premiums receivable in our condensed consolidated balance sheets include net risk-adjusted premiums receivable from our Medicaid state partners related to retroactive rate changes and risk score adjustments of $121.5 million and $54.4 million as of March 31, 2019 and December 31, 2018, respectively.
Medicare Part D Settlements
We receive certain Part D prospective subsidy payments from the Centers for Medicare & Medicaid Services ("CMS") for our MA and PDP members as a fixed monthly per member amount, based on the estimated costs of providing prescription drug benefits over the plan year, as reflected in our bids. A discussion of the subsidy components under Part D is included in Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in our 2018 Form 10-K. CMS will fully reimburse these subsidies, or recoup overpaid subsidies made during the plan year, as part of its annual settlement process that typically occurs in the fourth quarter of the subsequent year and, accordingly, there is no insurance risk to us. Therefore, amounts received for these subsidies are not considered premium revenue, and are reported, net of the subsidy benefits paid, as funds receivable (payable) for the benefit of members in the condensed consolidated balance sheets. As of March 31, 2019 and December 31, 2018, our condensed consolidated balance sheets primarily include CMS Part D payables for the 2018 and 2016 plan years. Our condensed consolidated balance sheet as of March 31, 2019 additionally includes a payable for the 2019 plan year. We expect to settle a majority of the 2016 and 2018 net payables during the remainder of 2019.
ACA Industry Fee
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 imposed certain new taxes and fees, including an annual premium-based health insurance industry assessment (the "ACA industry fee") on health insurers, which began in 2014. In January 2018, Congress approved a one-year moratorium of the ACA industry fee for 2019, which also eliminated the Medicaid ACA industry fee reimbursement from our state government partners for 2019. Accordingly, we did not incur ACA industry fee expense nor recognize any Medicaid ACA industry fee reimbursement revenue for the three months ended March 31, 2019. We incurred $81.5 million for the ACA industry fee for the three months ended March 31, 2018. Additionally, we recognized $64.7 million of Medicaid ACA industry fee reimbursement revenue as premium revenue for the three months ended March 31, 2018.

Recently Adopted Accounting Standards

In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2018-07, “Compensation-Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting.” This update expands the scope of Topic 718, which currently only includes share-based payments issued to

8

employees, to include share-based payments issued to non-employees for goods and services. This guidance was effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance on January 1, 2019. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.

In February 2018, the FASB issued ASU 2018-02 "Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income", which allows entities to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 from accumulated other comprehensive income to retained earnings. The guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance prospectively on January 1, 2019. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.

In March 2017, the FASB issued ASU No. 2017-08, "Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities". This update shortens the amortization period for the premium on certain purchased callable debt securities to the earliest call date. Previously, entities generally amortize the premium as a yield adjustment over the contractual life of the security. The new guidance does not change the accounting for purchased callable debt securities held at a discount. This guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance on January 1, 2019 on a modified retrospective basis. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments in its balance sheet. This standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. Subsequently, in July 2018, the FASB issued ASU 2018-11, “Leases (Topic 842), Targeted Improvements” which, among other things, allows companies to elect an optional transition method to apply the new lease standard through a cumulative-effect adjustment, if any, in the period of adoption, rather than in the earliest period presented. We adopted the standard on January 1, 2019 using the optional transition method. We elected the practical expedients permitted under the transition guidance, which allows us to carryforward our historical lease classifications for existing leases. Additionally, we elected the practical expedient to not separate non-lease components from the associated lease component. As part of the adoption process, we implemented a new lease accounting system. The adoption of this guidance resulted in the initial recognition of operating lease right-of-use assets of approximately $259.5 million, operating lease liabilities of approximately $277.3 million and the elimination of $17.8 million of straight-line lease liabilities, as of January 1, 2019. This guidance did not have a material effect on our consolidated results of operations or cash flows.

Accounting Standards Pending Adoption

In August 2018, the FASB issued ASU 2018-15, "Intangibles-Goodwill and Other-Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract", which requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. We are currently assessing the effect this guidance will have on our consolidated results of operations, financial condition or cash flows.
In June 2016, the FASB issued ASU 2016-13, "Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments," which requires entities to use a current expected credit loss model, which is a new impairment model based on expected losses rather than incurred losses. Under this model, an entity would recognize an impairment allowance equal to its current estimate of all contractual cash flows that the entity does not expect to collect from financial assets measured at amortized cost. The entity's estimate would consider relevant information about past events, current conditions, and reasonable and supportable forecasts, which will result in recognition of lifetime expected credit losses upon loan origination. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted for annual reporting periods beginning after December 15, 2018. We are currently assessing the effect this guidance will have on our consolidated results of operations, financial condition or cash flows.


2. CENTENE PLAN OF MERGER AND ACQUISITIONS

Centene Plan of Merger


9

On March 26, 2019, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Centene Corporation ("Centene") under which Centene will acquire us for a combination of cash and stock. Under the terms of the Merger Agreement, our shareholders will receive $120.00 in cash and 3.38 shares of Centene common stock for each share of our common stock. The proposed transaction is subject to customary closing conditions, including, but not limited to, the approval of the Merger Agreement by our stockholders, the approval of the share issuance of Centene stock by Centene’s stockholders, and the receipt of U. S. federal antitrust clearance and certain other required regulatory approvals. The transaction is expected to close in the first half of 2020.

The Merger Agreement includes restrictions on the conduct of our business prior to completion of the Centene Transaction or termination of the Merger Agreement, generally requiring us to conduct our business in the ordinary course. However, we are subject to various specified restrictions unless we obtain Centene’s prior written consent, which may not be unreasonably withheld, delayed or conditioned, or expressly contemplated or permitted by the Merger Agreement or as required by applicable law. Among other things and in each case subject to certain exceptions, we may not:
•
incur additional indebtedness (excluding borrowings under our Revolving Credit Facility (as defined below) that are used to manage our ordinary course cash flow needs);
•
issue additional shares of our common stock, repurchase our common stock, or pay dividends;
•
acquire assets, securities or property, dispose of businesses or assets; or
•
authorize any payment of, accrual or commitment for capital expenditures in any calendar year that would exceed by more than 110% the aggregate amount of capital expenditures budgeted for such year.

Aetna Medicare Part D Asset Acquisition

As discussed in Note 1 - Organization, Basis of Presentation and Significant Accounting Policies of this 2019 Form 10-Q,
in November 2018, we completed the purchase of Aetna's Part D membership for total cash consideration of $107.2 million, which is subject to certain true-up provisions. These membership assets are recorded within other intangible assets, net in the condensed consolidated balance sheets as of March 31, 2019 and December 31, 2018, and have a weighted-average useful life of eight years beginning in 2020. Per the terms of the agreement, Aetna provides administrative services to, and retains financial risk of, the Aetna Part D membership through 2019. Therefore, the Aetna Part D membership is excluded from our membership and has had, or is expected to have, an immaterial effect on our results of operations until January 1, 2020.

Meridian Business Acquisition

On September 1, 2018 (the "Effective Date"), we acquired Meridian for an estimated purchase price of approximately  $2.5 billion in cash, subject to certain purchase price adjustments, as described in the purchase agreement. The Meridian acquisition was funded through a combination of cash on hand, our Revolving Credit Facility, net proceeds from the August 2018 issuance of our 5.375% of Senior Notes due 2026 ("2026 Notes") and net proceeds from an issuance of shares of our common stock. We included the results of Meridian's operations since the Effective Date in our condensed consolidated financial statements.

The following table summarizes the estimated fair values of major classes of assets acquired and liabilities assumed at the Effective Date, based on our valuation assumptions, reconciled to the total consideration transferred.

10

Assets
(in millions)
Cash, cash equivalents and restricted cash
$
484.4

Investments, including restricted investments
180.4

Premiums receivable, net
379.6

Other current assets
146.2

Property, equipment and capitalized software, net
49.3

Goodwill
1,539.4

Other intangible assets, net
622.0

     Fair value of total assets acquired
$
3,401.3

 
 
Liabilities
 
Medical benefits payable
$
534.3

ACA Fee liability
66.5

Other liabilities
280.4

     Fair value of liabilities assumed
881.2

     Fair value of net assets acquired
$
2,520.1

 
 

The fair value results from judgments about future events, which reflect certain uncertainties and rely on estimates and assumptions. The judgments used to determine the fair value assigned to each class of assets acquired and liabilities assumed, as well as intangible asset lives, can materially affect our operating results. As of the Effective Date, the expected fair value of all current assets and liabilities approximated their historical cost. As of March 31, 2019, we have preliminarily determined the fair value of assets acquired and liabilities assumed; however, the final fair values may be subject to, (i) the final valuation of intangible assets related to memberships and trade names, (ii) the final assessment and valuation of certain other assets acquired and liabilities assumed, including premiums receivable, property, equipment and capitalized software, medical benefits payable and other liabilities and (iii) the final assessment and valuation of certain income tax amounts. Therefore, the final fair values of the assets acquired and liabilities assumed may vary significantly from our preliminary estimates.

Identifiable intangible assets acquired

Under the Hart-Scott-Rodino Antitrust Improvements Act and other relevant laws and regulations, there were significant limitations on our ability to obtain specific information about Meridian's intangible assets prior to completion of the acquisition in September 2018. As of March 31, 2019, certain of the more significant assumptions inherent in the development of intangible asset fair values, including the following, are preliminary.
•final membership attrition rates;
•final discount rates selected to measure the risks inherent in the future cash flows;
•
key assumptions in the valuation of the acquired technology, including, but not limited to, estimated costs associated with developers' salaries, external direct costs of materials and services; and the estimated time to replace the acquired software applications; and
•working capital adjustments and the assessment of the assets' life cycle, among other key assumptions.

The following table summarizes the preliminary fair values and weighted average useful lives for identifiable intangible assets acquired in the Meridian acquisition as of the Effective Date of the acquisition. These preliminary estimates of fair value and weighted-average useful life may be different from the final acquisition accounting, and the difference could have a material effect on the consolidated financial statements.


11

 
 
Gross Fair Value
(in millions)
 
Weighted Average
Useful Life (in years)
Membership
 
$
406.6

 
8.1
Tradenames
 
110.4

 
4.9
Provider network
 
8.3

 
15.0
Technology and other
 
96.7

 
5.8
Total
 
$
622.0

 
7.3
 
 
 
 
 

Goodwill

We recorded $1.5 billion for the valuation of goodwill for the excess of the purchase price over the estimated fair value of the net assets acquired. The assignment of goodwill to our respective segments has not been completed at this time. The recorded goodwill related to the acquisition is deductible for tax purposes.

Deferred taxes

The Meridian acquisition included taxable and nontaxable components resulting in differences in amounts recognized for GAAP and tax purposes. In both taxable and nontaxable business combinations, the amounts assigned to the individual assets acquired and liabilities assumed for financial statement purposes are often different from the amounts assigned or carried forward for tax purposes. We recorded a $49.9 million deferred tax liability based on the estimated bases differences.

Goodwill

A summary of changes in our goodwill by reportable segment is as follows for the three months ended March 31, 2019:

 
Medicaid Health Plans
 
Medicare Health Plans
 
Not assigned(1)
 
Total
Balance as of December 31, 2018
$
274.7

 
$
392.3

 
$
1,560.7

 
$
2,227.7

Acquisition related adjustments
—

 
—

 
(21.3
)
 
(21.3
)
Balance as of March 31, 2019
$
274.7

 
$
392.3

 
$
1,539.4

 
$
2,206.4

 
 
 
 
 
 
 
 
(1) Goodwill related to our September 1, 2018 Meridian acquisition is considered preliminary, pending the final allocation of the applicable purchase price. The assignment of goodwill to our respective segments has not been completed at this time.

Unaudited Pro Forma Financial Information

The results of operations and financial condition for the Meridian acquisition have been included in our condensed consolidated financial statements since the Effective Date. The unaudited pro forma financial information presented below reflects our 2018 acquisition of Meridian, assuming the acquisition occurred as of January 1, 2018. Pro forma results are not provided for the three months ended March 31, 2019, as Meridian's operations were included in our results of operations for this time period.

These pro forma results are based on estimates and assumptions and do not reflect any anticipated synergies, efficiencies or other cost savings that we expect to realize from the acquisition. The following unaudited pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the results of operations that would have occurred had the acquisition actually consummated at January 1, 2018, or project the future results of the combined company.

12

 
 
Pro Forma - Unaudited
(in millions, except per share data)
 
Three Months ended
March 31, 2018
Total revenues
 
$
5,673.6

Net income
 
$
100.9

 
 
 
Earnings per common share:
 
 
   Basic
 
$
2.02

   Diluted
 
$
2.00

 
 
 
Weighted average common shares outstanding:
 
 
       Basic
 
49,890,397

       Diluted
 
50,446,757

 
 
 


The pro forma results presented in the schedule above include adjustments related to the following purchase accounting and other acquisition-related costs:

•
Elimination of historical intangible asset amortization expense and addition of amortization expense based on the current preliminary values of identified intangible assets;
•
Elimination of interest expense associated with retired obligations and addition of interest expense based on debt incurred to finance the Meridian transaction;
•
Elimination of results for Meridian operations not acquired;
•
Elimination of transaction and integration-related costs;
•
Include 5,207,547 shares of our common stock issued to finance the Meridian transaction;
•
Adjustments to align the acquisition to our accounting policies; and
•
Tax effects of the adjustments noted above.


3. SEGMENT REPORTING

On a regular basis, we evaluate discrete financial information and assess the performance of our three reportable segments Medicaid Health Plans, Medicare Health Plans and Medicare PDPs, to determine the most appropriate use and allocation of Company resources.

We allocate premium revenue, medical benefits expense, Medicaid premium taxes, the 2018 ACA industry fee and goodwill to our reportable segments. We do not allocate to our reportable segments any other assets and liabilities, investment and other income, selling, general and administrative expenses ("SG&A"), depreciation and amortization, or interest expense. The Company's decision-makers primarily use premium revenue, medical benefits expense and gross margin to evaluate the performance of our reportable segments.

Our Corporate and Other category includes net investment and other income, SG&A expenses, depreciation, amortization and interest. Also included in this category are results for operating segments that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles.

13



Medicaid Health Plans

Our Medicaid Health Plans segment includes plans for beneficiaries of Temporary Assistance for Needy Families ("TANF"), Supplemental Security Income ("SSI"), Aged Blind and Disabled ("ABD"), Children's Health Insurance Program ("CHIP") and Long-Term Services and Supports ("LTSS") programs, among others. TANF generally provides assistance to low-income families with children. ABD and SSI generally provide assistance to low-income aged, blind or disabled individuals. CHIP provides assistance to qualifying families who are not eligible for Medicaid because their income exceeds the applicable income thresholds. The LTSS program is designed to help people with chronic illnesses or who have disabilities and need health and long-term care services, such as home care or adult day care, to enable them to stay in their homes and communities as long as possible.

Our Medicaid operations in Florida, Illinois and Kentucky individually account for 10% or more of our consolidated premium revenue for the three months ended March 31, 2019. These states and the respective Medicaid premium revenue as a percentage of total consolidated premium revenue are as follows: 
 
For the Three Months Ended
March 31,
 
2019
 
2018
Florida
17%
 
13%
Illinois
13%
 
*
Kentucky
10%
 
15%

*Our Illinois Medicaid health plan accounted for less than 10% of our consolidated premium revenue for the three months ended March 31, 2018.

In July 2018, we received a Notice of Intent to Award a five-year contract from the Florida Department of Health to provide statewide-managed care services to children with medically complex conditions through the Children's Medical Services Managed Care Plan ("CMS Plan"). The five-year contract award began on February 1, 2019; however, this contract is still subject to protest and appeal. Additionally, in April 2018, we received a Notice of Agency Decision from the Florida Agency for Health Care Administration (“AHCA”) to award our subsidiary, Staywell, a new five-year contract to provide managed care services to Medicaid-eligible beneficiaries, including Managed Medical Assistance and Long-Term Care beneficiaries in 10 of 11 regions. As part of the Medicaid Managed Care program, we provide statewide-managed care services to beneficiaries in the Serious Mental Illness Specialty Plan; however, this contract is still subject to protest and appeal. We are one of two managed care plans providing services to the SMI beneficiaries. The new statewide Medicaid Managed Care program began on December 1, 2018.

Medicare Health Plans

Medicare is a federal program that provides eligible persons age 65 and over and some disabled persons with a variety of hospital, medical and prescription drug benefits. MA is Medicare's managed care alternative to the original Medicare program, which provides individuals standard Medicare benefits directly through CMS. Our MA CCPs generally require members to seek health care services and select a primary care physician from a network of health care providers. In addition, we offer coverage of prescription drug benefits under the Medicare Part D program as a component of most of our MA plans.

Medicare PDPs

We offer stand-alone Medicare Part D coverage to Medicare-eligible beneficiaries in our Medicare PDPs segment. The Medicare Part D prescription drug benefit is supported by risk sharing with the federal government through risk corridors designed to limit the losses and gains of the participating drug plans and by reinsurance for catastrophic drug costs. The government subsidy is based on the national weighted average monthly bid for this coverage, adjusted for risk factor payments. Additional subsidies are provided for dually-eligible beneficiaries and specified low-income beneficiaries. The Part D program offers national in-network prescription drug coverage that is subject to limitations in certain circumstances.





14


Summary of Financial Information

Reportable operating segments are defined as components of an enterprise for which discrete financial information is available and evaluated on a regular basis by the enterprise's decision-makers to determine how resources should be allocated to an individual segment and to assess performance of those segments. Accordingly, we have three reportable segments: Medicaid Health Plans, Medicare Health Plans and Medicare PDPs.

A summary of financial information for our reportable segments through the gross margin level and reconciliation to income from operations is presented in the table below.

 
Medicaid Health Plan
Medicare Health Plan
Medicare PDP
Corporate & Other
Consolidated
For the Three Months Ended March 31, 2019
(in millions)
Premium
$
4,473.5

$
1,843.1

$
288.8

$
4.0

$
6,609.4

Products and services
—

—

—

115.8

115.8

Total premium and products and services revenues
4,473.5

1,843.1

288.8

119.8

6,725.2



 



Medical benefits
4,022.7

1,548.2

258.4

2.4

5,831.7

Costs of products and services
—

—

—

111.8

111.8

ACA industry fee
—

—

—

—

—

Medicaid premium taxes
31.7

—

—

—

31.7

Total gross margin expenses
4,054.4

1,548.2

258.4

114.2

5,975.2



 



Gross margin
419.1

294.9

30.4

5.6

750.0



 



Investment and other income
—

—

—

37.0

37.0

Other expenses
—

—

—

(602.9
)
(602.9
)
Income from operations
$
419.1

$
294.9

$
30.4

$
(560.3
)
$
184.1







For the Three Months Ended March 31, 2018





Premium
$
2,809.9

$
1,556.5

$
259.9

$
—

$
4,626.3

Products and services
—

—

—

—

—

Total premium and products and services revenues
2,809.9

1,556.5

259.9

—

4,626.3

 
 
 
 
 
 
Medical benefits
2,424.4

1,307.1

230.5

—

3,962.0

Costs of products and services
—

—

—

—

—

ACA industry fee
49.3

27.6

4.6

—

81.5

Medicaid premium taxes
32.1

—

—

—

32.1

Total gross margin expenses
2,505.8

1,334.7

235.1

—

4,075.6

 
 
 
 
 
 
Gross margin (1)
304.1

221.8

24.8

—

550.7

 
 
 
 
 
 
Investment and other income
—

—

—

19.9

19.9

Other expenses (2)
—

—

—

(409.4
)
(409.4
)
Income from operations
$
304.1

$
221.8

$
24.8

$
(389.5
)
$
161.2




(1)
Effective July 1, 2018, the Company redefined gross margin as total revenues less investment and other income, medical expenses, cost of products and services, the ACA industry fee expense, and Medicaid premium tax expense. Accordingly, results for the three months ended March 31, 2018 were adjusted to include Medicaid premium taxes, which decreased gross margin by $32.1 million.

15


(2)
Effective July 1, 2018, other expenses include SG&A expenses, depreciation, amortization and interest. Accordingly, results for the three months ended March 31, 2018 were adjusted to exclude Medicaid premium taxes, which decreased other expenses by $32.1 million.


4. EQUITY AND EARNINGS PER SHARE

Issuance of Common Stock

In August 2018, we completed a public offering of our common stock and issued 5,207,547 shares of our common stock, at an offering price of $265.00 per share. The net proceeds from the offering were approximately $1.3 billion, after deducting underwriting discounts and offering costs of approximately $37.7 million. We used the net proceeds to fund a portion of the acquisition of Meridian.

Earnings per Common Share

We compute basic earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding. We compute diluted earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding plus the dilutive effect of our stock-based compensation awards using the treasury stock method.

The calculation of the weighted-average common shares outstanding — diluted is as follows:
 
For the Three Months Ended
March 31,
 
2019
 
2018
 
 
 
 
Weighted-average common shares outstanding — basic
50,100,509

 
44,605,892

Dilutive effect of outstanding stock-based compensation awards
741,795

 
590,235

Weighted-average common shares outstanding — diluted
50,842,304

 
45,196,127

Anti-dilutive stock-based compensation awards excluded from computation
67,130

 
277,390

 
 
 
 



16


5. INVESTMENTS

The Company considers all of its investments as available-for-sale securities. Excluding restricted cash, cash equivalents and investments, the amortized cost, gross unrealized gains or losses and estimated fair value of short-term and long-term investments by security type are summarized in the following tables.
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
March 31, 2019
 
 
 
 
 
 
 
Debt securities:
 
 
 
 
 
 
 
Asset-backed securities
$
154.2

 
$
0.2

 
$
(0.3
)
 
$
154.1

Corporate debt securities
1,127.9

 
3.5

 
(2.7
)
 
1,128.7

Municipal securities
197.1

 
2.7

 
(0.1
)
 
199.7

Residential mortgage-backed securities
10.1

 
—

 
(0.1
)
 
10.0

Short-term time deposits
237.5

 
—

 
—

 
237.5

Government and agency obligations
9.2

 
—

 
(0.1
)
 
9.1

Other securities
62.0

 
—

 
—

 
62.0

Total debt securities
1,798.0

 
6.4

 
(3.3
)
 
1,801.1

Equity securities(1)
225.1


—


—


225.1

Total
$
2,023.1

 
$
6.4

 
$
(3.3
)
 
$
2,026.2

December 31, 2018
 

 
 

 
 

 
 

Asset-backed securities
$
144.7

 
$
—

 
$
(0.5
)
 
$
144.2

Corporate debt securities
943.0

 
0.5

 
(10.1
)
 
933.4

Municipal securities
199.6

 
0.6

 
(0.9
)
 
199.3

Residential mortgage-backed securities
7.2

 
—

 
(0.2
)
 
7.0

Short-term time deposits
242.2

 
—

 
—

 
242.2

Government and agency obligations
44.9

 
—

 
(0.1
)
 
44.8

Other securities
72.5

 
—

 
(0.1
)
 
72.4

Total(1)
$
1,654.1

 
$
1.1

 
$
(11.9
)
 
$
1,643.3

 

(1) Investments in equity securities primarily consists of exchange traded funds in fixed income and preferred and hybrid securities. Equity securities were not material as of December 31, 2018.

Contractual maturities of debt securities at March 31, 2019 are as follows:
 
 
Amortized Cost
 
Fair Value
Due in one year or less
$
889.6

 
$
889.7

Due after one year through five years
571.6

 
573.2

Due after five years through ten years
147.3

 
149.1

Due after ten years
13.1

 
12.9

Asset-backed and mortgage-backed securities
176.4

 
176.2

 Total
$
1,798.0

 
$
1,801.1

 
 
 
 


Actual maturities may differ from contractual maturities due to the exercise of pre-payment options.

We sold available-for-sale investments totaling $420.6 million and $80.2 million during the three months ended March 31, 2019 and 2018, respectively. Realized gains and losses resulting from sales and redemptions of our available-for-sale investments were immaterial for all periods presented. Additionally, we did not realize any other-than-temporary impairment during any of these periods.


17


6. RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS

As a condition for licensure, we are required to maintain certain funds on deposit or pledged to various state agencies. Certain of our state contracts require the issuance of surety bonds. We classify restricted cash, cash equivalents and investments as long-term regardless of the contractual maturity date of the securities held, due to the nature of the states' requirements. The amortized cost, gross unrealized gains, gross unrealized losses and fair value of our restricted cash, cash equivalents and investment securities are as follows: 

 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
March 31, 2019
 
 
 
 
 
 
 
Cash
$
12.8

 
$
—

 
$
—

 
$
12.8

Money market funds
86.2

 
—

 
—

 
86.2

U.S. government securities and other
175.6

 
—

 
(0.3
)
 
175.3

Total
$
274.6

 
$
—

 
$
(0.3
)
 
$
274.3

December 31, 2018
 

 
 

 
 

 
 

Cash
$
11.3

 
$
—

 
$
—

 
$
11.3

Money market funds
51.4

 
—

 
—

 
51.4

U.S. government securities and other
172.5

 
—

 
(0.5
)
 
172.0

Total
$
235.2

 
$
—

 
$
(0.5
)
 
$
234.7

 
 
 
 
 
 
 
 

 
Realized gains and losses on sales and redemptions of our restricted cash, cash equivalents and investments were not material for all periods presented.


18



7. STOCK-BASED COMPENSATION

Our Compensation Committee awards certain equity-based compensation under our stock plans, including restricted stock units ("RSUs") and performance stock units ("PSUs"). Compensation expense related to our stock-based compensation awards was $22.8 million and $12.1 million for the three months ended March 31, 2019 and 2018, respectively. As of March 31, 2019, there was $121.0 million of unrecognized compensation cost related to unvested stock-based compensation arrangements that is expected to be recognized over a weighted-average period of 2 years. The unrecognized compensation cost for certain of our PSUs, which are subject to variable accounting, was determined based on our closing common stock price of $269.75 as of March 29, 2019 and amounted to approximately $33.9 million of the total unrecognized compensation cost. Due to the nature of the accounting for these awards, future compensation cost will fluctuate based on changes in our common stock price. We estimate stock-based compensation expense based on awards ultimately expected to vest over the related service period (generally the vesting period) of the award, or to an employee’s eligible retirement date under the award agreement, if earlier. We make assumptions of forfeiture rates at the time of grant and continuously reassess our assumptions based on actual forfeiture experience.

A summary of RSU and PSU award activity, at target, for the three months ended March 31, 2019, is presented in the table below. For our PSUs, shares attained over target upon vesting are reflected as awards granted during the period, while shares canceled due to vesting below target are reflected as awards forfeited during the period.
 

 RSUs
 
PSUs
 
Total
Outstanding as of January 1, 2019
253,235

 
606,708

 
859,943

Granted
99,434

 
347,539

 
446,973

Vested
(99,668
)
 
(351,648
)
 
(451,316
)
Forfeited
(2,372
)
 
(8,276
)
 
(10,648
)
Outstanding as of March 31, 2019
250,629

 
594,323

 
844,952

 
 
 
 
 
 


The weighted-average grant-date fair value of all equity awards granted during the three months ended March 31, 2019 was $205.27.

Refer to Note 2 - Summary of Significant Accounting Policies and Note 15 - Stock-based Compensation to the consolidated financial statements included in our 2018 Form 10-K for additional information regarding our equity-compensation awards and related compensation cost measurement.

8. DEBT

The following table summarizes our outstanding debt obligations and their classification in the accompanying condensed consolidated balance sheets (in millions):
 
March 31, 2019
 
December 31, 2018
Long-term debt, net:
 
 
 
5.25% Senior Notes, due April 1, 2025
$
1,200.0

 
$
1,200.0

5.375% Senior Notes, due August 15, 2026
750.0

 
750.0

Revolving Credit Facility
200.0

 
200.0

Debt issuance costs
(22.7
)
 
(23.6
)
     Total long-term debt, net
$
2,127.3

 
$
2,126.4

 
 
 
 


Senior Notes

In August 2018, we completed the offering and sale of 5.375% unsecured senior notes due 2026 in the aggregate principal amount of $750.0 million (the “2026 Notes”). The aggregate net proceeds from the issuance of the 2026 Notes were used to fund a portion of the cash consideration for our acquisition of Meridian.

19



In March 2017, we completed the offering and sale of 5.25% unsecured senior notes due 2025 in the aggregate principal amount of $1,200.0 million (the “2025 Notes”). The aggregate net proceeds from the issuance of the 2025 Notes were primarily used to redeem the full $900.0 million aggregate principal amount of our 5.75% unsecured senior notes (the "2020 Notes") on April 7, 2017, and for general corporate purposes, including organic growth and working capital.

The 2026 Notes and 2025 Notes are classified as long-term debt in our condensed consolidated balance sheet at March 31, 2019, based on their maturity date. Refer to Note 10 - Debt to the consolidated financial statements included in our 2018 Form 10-K for additional information regarding these 2026 Notes and 2025 Notes, including applicable covenants.

Revolving Credit Facility

In January 2016, we entered into a credit agreement, which provided for a senior unsecured revolving loan facility (the "Revolving Credit Facility"). In July 2018, this credit agreement was amended and restated (“Amended and Restated Credit Agreement”) to increase the aggregate principle amount available under our Revolving Credit Facility from $1.0 billion to $1.3 billion, extend the maturity date for borrowings under the Revolving Credit Facility from January 2021 to July 2023 and decrease the applicable margins for borrowings under the Revolving Credit Facility, as calculated in accordance with the Amended and Restated Credit Agreement. The Amended and Restated Credit Agreement also includes an accordion feature which allows the Company to increase the total commitments under the Revolving Credit Facility by up to an additional $500 million, subject to certain conditions.

Unutilized commitments under the Amended and Restated Credit Agreement are subject to a fee of 0.20% to 0.30% depending upon our ratio of total debt to consolidated EBITDA, as calculated in accordance with the Amended and Restated Credit Agreement.

As of March 31, 2019, $200.0 million was outstanding under the Revolving Credit Facility, which was drawn during the third quarter of 2018 to fund a portion of the Meridian acquisition in September 2018. These borrowings are classified as long-term debt in accordance with the contractual terms of the Amended and Restated Credit Agreement.

Subsequent to the balance sheet date, in April 2019, an additional $140.0 million was drawn on our Revolving Credit Facility for general corporate purposes, including organic growth and working capital.

As of March 31, 2019, and the date of this filing, we were in compliance with all covenants under the 2026 Notes, the 2025 Notes and the Amended and Restated Credit Agreement.

9. FAIR VALUE MEASUREMENTS

Our condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, investments, receivables, accounts payable, medical benefits payable, long-term debt, including any current portion of long-term debt, and other liabilities. We consider the carrying amounts of cash and cash equivalents, receivables, other current assets and current liabilities to approximate their fair value due to the short period of time between the origination of these instruments and the expected realization or payment. Certain assets and liabilities are measured at fair value on a recurring basis and are disclosed below. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see the consolidated financial statements and notes thereto included in our 2018 Form 10-K.


20


Recurring Fair Value Measurements

Assets and liabilities measured at fair value on a recurring basis at March 31, 2019 are as follows:

 
 
 
Fair Value Measurements Using
 
Carrying Value
 
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
 
Significant Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Investments:
 
 
 
 
 
 
 
Debt securities:
 
 
 
 
 
 
 
Asset-backed securities
$
154.1

 
$
—

 
$
154.1

 
$
—

Corporate debt securities
1,128.7

 
—

 
1,128.7

 
—

Municipal securities
199.7

 
—

 
199.7

 
—

Residential mortgage-backed securities
10.0

 
—

 
10.0

 
—

Short-term time deposits
237.5

 
—

 
237.5

 
—

Government and agency obligations
9.1

 
9.1

 
—

 
—

Other securities
62.0

 
49.7

 
12.3

 
—

Total debt securities
1,801.1

 
58.8

 
1,742.3

 
—

Equity securities(1)
225.1

 
220.9

 
4.2

 
—

Total investments
$
2,026.2

 
$
279.7

 
$
1,746.5

 
$
—

Restricted cash, cash equivalents and investments:
 

 
 

 
 

 
 

Cash
$
12.8

 
$
12.8

 
$
—

 
$
—

Money market funds
86.2

 
86.2

 
—

 
—

U.S. government securities and other
175.3

 
175.1

 
0.2

 
—

Total restricted cash, cash equivalents and investments
$
274.3

 
$
274.1

 
$
0.2

 
$
—

 
 
 
 
 
 
 
 

(1) Investments in equity securities primarily consists of exchange traded funds in fixed-income and preferred and hybrid securities.


21


Assets and liabilities measured at fair value on a recurring basis at December 31, 2018 are as follows:

 
 
 
Fair Value Measurements Using
 
Carrying Value
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
Investments:
 
 
 
 
 
 
 
Asset-backed securities
$
144.2

 
$
—

 
$
144.2

 
$
—

Corporate debt securities
933.4

 
—

 
933.4

 
—

Municipal securities
199.3

 
—

 
199.3

 
—

Residential mortgage-backed securities
7.0

 
—

 
7.0

 
—

Short-term time deposits
242.2

 
—

 
242.2

 
—

Government and agency obligations
44.8

 
44.8

 
—

 
—

Other securities
72.4

 
49.8

 
22.6

 
—

Total Investments(1)
$
1,643.3

 
$
94.6

 
$
1,548.7

 
$
—

Restricted cash, cash equivalents and investments:
 

 
 

 
 

 
 

Cash
$
11.3

 
$
11.3

 
$
—

 
$
—

Money market funds
51.4

 
51.4

 
—

 
—

U.S. government securities and other
172.0

 
171.8

 
0.2

 
—

Total restricted cash, cash equivalents and investments
$
234.7

 
$
234.5

 
$
0.2

 
$
—

 
 
 
 
 
 
 
 

 (1) Equity securities were not material as of December 31, 2018.

The following table presents the carrying value and fair value of our long-term debt outstanding as of March 31, 2019 and December 31, 2018:

 
 
 
Fair Value Measurements Using
 
Carrying Value
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
Long-term debt - March 31, 2019
2,127.3

 
2,034.7

 
200.0

 
—

Long-term debt - December 31, 2018
2,126.4

 
1,885.2

 
200.0

 
—



The fair value of our 2026 Notes and 2025 Notes were determined based on quoted market prices; therefore, would be classified within Level 1 of the fair value hierarchy. The fair value of obligations outstanding under our Revolving Credit Facility, as of March 31, 2019 and December 31, 2018, approximated the carrying value and would be classified within Level 2 of the fair value hierarchy.
 

22


10. MEDICAL BENEFITS PAYABLE

A reconciliation of the beginning and ending balances of medical benefits payable, by segment, is as follows:
 
 
For the three months ended March 31, 2019
 
 
Medicaid Health Plans
 
Medicare Health Plans
 
Medicare PDPs
 
Corporate and other (2)
 
Consolidated
Beginning balance (1)
 
$
2,012.8

 
$
823.5

 
$
59.1

 
$
2.0

 
$
2,897.4

Acquisitions
 
—

 
—

 
—

 
—

 
—

 
 
 
 
 
 
 
 
 
 
 
Medical benefits incurred related to:
 
 
 
 
 
 
 
 
 
 
Current year
 
4,182.7

 
1,612.7

 
284.7

 
3.2

 
6,083.3

Prior years
 
(160.0
)
 
(64.5
)
 
(26.3
)
 
(0.8
)
 
(251.6
)
Total
 
4,022.7

 
1,548.2

 
258.4

 
2.4

 
5,831.7

 
 
 
 
 
 
 
 
 
 
 
Medical benefits paid related to:
 
 
 
 
 
 
 
 
 
 
Current year
 
(2,769.2
)
 
(936.4
)
 
(187.7
)
 
(1.4
)
 
(3,894.7
)
Prior years
 
(1,147.9
)
 
(451.7
)
 
(21.6
)
 
(0.6
)
 
(1,621.8
)
Total
 
(3,917.1
)
 
(1,388.1
)
 
(209.3
)
 
(2.0
)
 
(5,516.5
)
Ending balance (1)
 
$
2,118.4

 
$
983.6

 
$
108.2

 
$
2.4

 
$
3,212.6

 
 
 
 
 
 
 
 
 
 
 


(1) The Medicaid Health Plans and Consolidated beginning and ending balances for 2019 include a premium deficiency reserve for our Illinois Medicaid programs ("Illinois PDR"), which amounted to $6.6 million and $16.1 million at March 31, 2019 and December 31, 2018, respectively. See Note 2 - Summary of Significant Accounting Policies in our 2018 Form 10-K for further discussion.
(2) The Corporate and Other category includes operating segments that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles.

 
 
For the three months ended March 31, 2018
 
 
Medicaid Health Plans
 
Medicare Health Plans
 
Medicare PDPs
 
Corporate and other
 
Consolidated
Beginning balance (1)
 
$
1,373.2

 
$
722.5

 
$
50.6

 
$
—

 
$
2,146.3

Acquisitions
 
—

 
—

 
—

 
—

 
—

 
 
 
 
 
 
 
 
 
 
 
Medical benefits incurred related to:
 
 
 
 
 
 
 
 
 
 
Current year
 
2,523.8

 
1,383.1

 
256.9

 
—

 
4,163.8

Prior years
 
(99.4
)
 
(76.0
)
 
(26.4
)
 
—

 
(201.8
)
Total
 
2,424.4

 
1,307.1

 
230.5

 
—

 
3,962.0

 
 
 
 
 
 
 
 
 
 
—

Medical benefits paid related to:
 
 
 
 
 
 
 
 
 
 
Current year
 
(1,659.4
)
 
(859.9
)
 
(218.0
)
 
—

 
(2,737.3
)
Prior years
 
(758.6
)
 
(389.3
)
 
(12.8
)
 
—

 
(1,160.7
)
Total
 
(2,418.0
)
 
(1,249.2
)
 
(230.8
)
 
—

 
(3,898.0
)
Ending balance (1)
 
$
1,379.6

 
$
780.4

 
$
50.3

 
$
—

 
$
2,210.3

 
 
 
 
 
 
 
 
 
 
 
(1) The Medicaid Health Plans and Consolidated beginning and ending balances for 2018 include a premium deficiency reserve for our Illinois Medicaid program ("Illinois PDR"), which amounted to $41.0 million and $45.6 million at March 31, 2018 and December 31, 2017, respectively.

We recognize the cost of medical benefits in the period in which services are provided, including an estimate of the cost of medical benefits incurred but not reported ("IBNR"). Medical benefits expense includes direct medical expenses and certain medically-related administrative costs. We evaluate our estimates of medical benefits payable as we obtain more complete claims information and medical expense trend data over time. We record differences between actual experience and estimates used to establish the liability, which we refer to as favorable and unfavorable prior year reserve developments, as increases or decreases to medical benefits expense in the period we identify the differences.


23


Medical benefits payable developed favorably by approximately $251.6 million and $201.8 million for the three months ended March 31, 2019 and 2018, respectively. The release of the provision for moderately adverse conditions included in our prior year estimates was substantially offset by the provision for moderately adverse conditions established for claims incurred in the current year. Accordingly, the favorable development in our estimate of medical benefits payable related to claims incurred in prior years does not directly correspond to a decrease in medical benefits expense recognized during the period in which the favorable development is recognized.

Excluding the prior year development related to the release of the provision for moderately adverse conditions, our estimates of consolidated medical benefits payable developed favorably by approximately $108.2 million and $71.5 million for the three months ended March 31, 2019 and 2018, respectively. Such amounts are net of the development relating to refunds due to government customers with minimum loss ratio provisions. The net favorable development recognized in both 2019 and 2018 resulted primarily due to a number of operational and clinical initiatives planned and executed, that contributed to lower than expected pharmacy and medical trends, and actual claim submission time being faster than we originally assumed (i.e., our completion factors were higher than we originally assumed) in establishing our medical benefits payable in the prior years. This development does not directly correspond to an increase in our current year operating results as these reductions were offset by estimated current period medical benefits expense when we established our estimate of the current year medical benefits payable. Both completion factor and medical trend assumptions are influenced by utilization levels, unit costs, mix of business, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, our ability and practices to manage medical and pharmaceutical costs, claim submission patterns and operational changes resulting from business combinations, among others. Our actual costs were ultimately less than expected.

Our Meridian acquisition in September 2018 resulted in an increase to medical benefits payable as of the acquisition date. See Note 2 - Centene Plan of Merger and Acquisitions, for additional information on the Meridian acquisitions.

11. LEASES

In determining whether a contract contains a lease, we assess whether the arrangement meets all three of the following criteria: 1) there is an identified asset; 2) we have the right to obtain substantially all the economic benefits from use of the identified asset; and 3) we have the right to direct the use of the identified asset. This involves evaluating whether we have the right to operate the asset or to direct others to operate the asset in a manner that it determines without the supplier having the right to change those operating instructions, as well as evaluating our involvement in the design of the asset.
We have right-of-use assets and liabilities for non-cancelable operating leases primarily for office space, data centers and other equipment. Our leases have remaining lease terms up to approximately 14 years. The depreciable life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.
For the three months ended March 31, 2019 operating lease expense of $17.4 million, was recorded as SG&A expense in our condensed consolidated statement of comprehensive income.
Balance sheet information related to our operating leases was as follows:
 
 
Classification
 
March 31, 2019
Assets:
 
 
 
 
Right of use assets
 
Other assets
 
$
249.9

 
 
 
 
 
Liabilities:
 
 
 
 
Current
 
Accounts payable and accrued expenses
 
$
32.9

Noncurrent
 
Other liabilities
 
235.6

Total liabilities
 
 
 
$
268.5

 
 
 
 
 

Maturities of our operating lease liabilities are as follows:

24


Maturity of Operating Lease Liabilities
March 31, 2019
2019 (remaining)
$
33.5

2020
44.9

2021
44.4

2022
40.4

2023
37.2

2024
34.9

Thereafter
114.7

Total lease payments
$
350.0

Less: imputed interest
$
81.5

Present value of lease liabilities
$
268.5

 
 

As of March 31, 2019 the weighted-average remaining lease term was 8.5 years. Our lease agreements do not provide a readily determinable implicit rate nor is it available to us from our lessors. Instead, we estimate our incremental borrowing rate based on information available at lease commencement in order to discount lease payments to present value. The weighted-average discount rate of our operating leases was 5.9%, as of March 31, 2019.

Supplemental cash flow information related to our operating leases is as follows:
 
Three Months Ended
March 31, 2019
Cash paid for operating leases
$
11.6

Leased assets obtained in exchange for new operating lease liabilities
10.4



12. INCOME TAXES

Our effective income tax rate on pre-tax income was 18.1% for the three months ended March 31, 2019 compared with 35.8% for the three months ended March 31, 2018. The year-over-year decrease was primarily driven by the one-year moratorium on the non-deductible ACA industry fee for 2019 and higher excess tax benefits resulting from the settlement of stock-compensation awards in 2019.

There were no significant changes to unrecognized tax benefits for the three months ended March 31, 2019. Our unrecognized tax benefits are not expected to change significantly during the next 12 months.
 
13. DISCONTINUED OPERATIONS

On August 3, 2016, our subsidiary, Universal American, completed the sale of its Traditional Insurance business prior to our acquisition of Universal American. This was accomplished by selling two life insurance subsidiaries, while retaining ownership of a third life insurance subsidiary, American Progressive Life & Health Insurance of New York ("Progressive"). The sale of the Traditional Insurance business underwritten by Progressive was accomplished through a 100% quota-share reinsurance treaty with a wholly-owned subsidiary of Nassau Re, that, when considered in combination with other reinsurance transactions previously entered into, resulted in the reinsurance of all of the Traditional Insurance policies that were underwritten by Progressive. Accordingly, the discontinued Traditional Insurance business did not materially affect our condensed consolidated statements of comprehensive income for any of the periods presented.

In accordance with ASC 360-10, Property, Plant and Equipment and ASC 205-20, Presentation of Financial Statements—Discontinued Operations, the Traditional Insurance business has been reported in discontinued operations in this 2019 Form 10-Q.

The following table summarizes the total assets and liabilities of our discontinued operations:

25


 
 
 
 
 
 
 
March 31, 2019
 
December 31, 2018
 
 
(in millions)
Assets
 
 
 
 
Cash and cash equivalents
 
$
0.5

 
$
0.1

Investments
 
40.6

 
42.8

Reinsurance recoverables
 
165.7

 
170.2

Other assets
 
0.4

 
0.5

Total Assets
 
$
207.2

 
$
213.6

 
 
 
 
 
Liabilities
 
 
 
 
Reserves and other policy liabilities
 
$
166.1

 
$
166.9

Other liabilities
 
41.1

 
46.7

Total liabilities
 
$
207.2

 
$
213.6

 
 
 
 
 


Progressive's traditional insurance products are reinsured under quota share coinsurance treaties with unaffiliated insurers, while the life insurance risks are reinsured under either quota share coinsurance or yearly-renewable term treaties with unaffiliated insurers. Under quota share coinsurance treaties, we pay the reinsurer an agreed upon percentage of all premiums and the reinsurer reimburses us that same percentage of any losses. In addition, the reinsurer pays us certain allowances to cover commissions, the cost of administering the policies and premium taxes. Under yearly-renewable term treaties, the reinsurer receives premiums at an agreed upon rate for its share of the risk on a yearly-renewable term basis. We also use excess of loss reinsurance agreements for certain policies whereby we limit our loss in excess of specified thresholds.

We evaluate the financial condition of our Traditional Insurance reinsurers and monitor concentrations of credit risk to minimize our exposure to significant losses from reinsurer insolvencies. We are obligated to pay claims in the event that a reinsurer to whom we have ceded an insured claim fails to meet its obligations under the reinsurance agreement. We are not aware of any instances where any of our reinsurers have been unable to pay any policy claims on any reinsured business.

14. COMMITMENTS AND CONTINGENCIES
 
Indemnification Obligations

Under Delaware law, our charter and bylaws and certain indemnification agreements to which we are a party, we are obligated to indemnify, or we have otherwise agreed to indemnify, certain of our current and former directors, officers and associates with respect to current and future investigations and litigation, including the matters discussed in this note. The indemnification agreements for our directors and executive officers with respect to events occurring prior to May 2009 require us to indemnify an indemnitee to the fullest extent permitted by law if the indemnitee was or is or becomes a party to or a witness or other participant in any proceeding by reason of any event or occurrence related to the indemnitee's status as a director, officer, associate, agent or fiduciary of the Company or any of our subsidiaries. The indemnification agreements require us to indemnify an indemnitee against all expenses, including attorney's fees, judgments, fines, settlement amounts and interest and other charges, and any taxes as a result of the receipt of payments under the indemnification agreement. We will not indemnify the indemnitee if not permitted under applicable law. We are required to advance all expenses incurred by the indemnitee. We are entitled to reimbursement by an indemnitee of expenses advanced if the indemnitee is not permitted to be reimbursed under applicable law after a final judicial determination is made and all rights of appeal have been exhausted or lapsed.

We amended and restated our indemnification agreements in May 2009. The revised agreements apply to our officers and directors with respect to events occurring after that time. Pursuant to the 2009 indemnification agreements, we will indemnify the indemnitee against all expenses, including attorney's fees, judgments, penalties, fines, settlement amounts and any taxes imposed as a result of payments made under the indemnification agreement incurred in connection with any proceedings that relate to the indemnitee's status as a director, officer or associate of the Company or any of our subsidiaries or any other enterprise that the indemnitee was serving at our request. We will also indemnify for expenses incurred by an indemnitee if the indemnitee, by reason of his or her corporate status, is a witness in any proceeding. Further, we are required to indemnify for expenses incurred by an indemnitee in defense of a proceeding to the extent the indemnitee has been successful on the merits or otherwise. Finally, if the indemnitee is involved in certain proceedings as a result of the indemnitee's corporate status, we are

26


required to advance the indemnitee's reasonable expenses incurred in connection with such proceeding, subject to the requirement that the indemnitee repay the expenses if it is ultimately determined that the indemnitee is not entitled to be indemnified. We are not obligated to indemnify an indemnitee for losses incurred in connection with any proceeding if a determination has not been made by the Board of Directors, a committee of disinterested directors or independent legal counsel in the specific case that the indemnitee has satisfied any standards of conduct required as a condition to indemnification under Section 145 of the Delaware General Corporation Law.

Pursuant to our obligations, we have advanced legal fees and related expenses to three former officers and two additional associates who were criminally indicted in connection with the government investigations of the Company that commenced in 2007 related to federal criminal health care fraud charges including conspiracy to defraud the United States, false statements relating to health care matters, and health care fraud in connection with their defense of criminal charges. In June 2013, the jury in the federal criminal trial reached guilty verdicts on multiple charges for the four individuals that were tried in 2013. In May 2014, the individuals were sentenced and our request for restitution was denied. All four individuals filed notices of appeal and the government filed notices of cross appeal on three of the four individuals, which the government has subsequently voluntarily dismissed. The appellate court affirmed the convictions in August 2016. Mr. Farha filed a petition for a writ of certiorari to the United States Supreme Court in January 2017. In April 2017, the United States Supreme Court declined to hear the appeal by Mr. Farha. The fifth individual, Mr. Bereday, entered a guilty plea in June 2017 in connection with the federal criminal charges, which was accepted by the court in July 2017. Mr. Bereday was sentenced in November 2017.

We have also previously advanced legal fees and related expenses to these five individuals regarding: a dispute in Delaware Chancery Court related to whether we were legally obligated to advance fees or indemnify certain of these individuals; the class actions titled Eastwood Enterprises, L.L.C. v. Farha, et al. and Hutton v. WellCare Health Plans, Inc. et al. filed in federal court; six stockholder derivative actions filed in federal and state courts between October 2007 and January 2008; an investigation by the United States Securities & Exchange Commission (the "Commission"); an action by the Commission filed in January 2012 against three of the five individuals, Messrs. Farha, Behrens and Bereday, and a qui tam action against Messrs. Farha, Behrens and Bereday in federal court. We settled the class actions in May 2011. In 2010, we settled the stockholder derivative actions and we were realigned as the plaintiff to pursue our claims against Messrs. Farha, Behrens and Bereday. Pursuant to the settlement agreements described below, Messrs. Farha, Behrens and Bereday were dismissed from the federal court and state derivative actions. Pursuant to the settlement agreement with Mr. Bereday described below, Mr. Bereday was dismissed from the fee advancement case in Delaware Chancery Court. The Commission action was closed in May 2018. The qui tam action is currently stayed and the stay is subject to being lifted at any time.

In April 2017, the Commission and Mr. Farha entered into a consent judgment to pay $12.5 million to the Commission and $7.5 million to us. In April 2017, the Commission and Mr. Behrens also entered into a consent judgment to pay $4.5 million to the Commission and $1.5 million to us. In May 2018, the Commission and Mr. Bereday entered into a consent judgment to pay $4.5 million to the Commission and the case was closed.
In addition, we have advanced a portion of the legal fees and related expenses to Mr. Farha in connection with lawsuits he filed in Delaware and Florida state court to have certain restrictions lifted on WellCare stock purportedly awarded to him during his employment with us. The Delaware and Florida state court matters have been dismissed.

In September 2016, we entered into a settlement agreement with Mr. Farha pursuant to which he paid us $7.5 million, as referenced in the April 2017 consent judgment with the Commission, and we agreed that we would not seek to recover additional legal fees previously advanced related to these matters, and that our obligation to continue advancing fees would be limited to no more than an additional $7.5 million.

We also have advanced a portion of the legal fees and related expenses to Mr. Behrens in connection with his lawsuit in Delaware state court to have certain restrictions lifted on WellCare stock purportedly awarded to him during his employment with WellCare, which the court dismissed. In October 2016, we also entered into a settlement agreement with Mr. Behrens pursuant to which he paid us $1.5 million, as referenced in the April 2017 consent judgment with the Commission, and we agreed that we would not seek to recover additional legal fees previously advanced in connection with these matters, and that our obligation to continue advancing fees would be limited to no more than an additional $1.5 million.

In June 2017, we entered into a settlement agreement with Mr. Bereday that became effective in July 2017, pursuant to which we agreed that we would not seek to recover legal fees previously advanced in connection with these matters, and that our obligation to continue advancing fees would be limited to no more than an additional $2.5 million.

In connection with these matters, we have advanced to the five individuals legal fees and related expenses from the inception of the investigations through March 31, 2019, the cumulative amounts of which has not changed materially from

27


December 31, 2018. We expense these costs as incurred and classify the costs as SG&A expense incurred in connection with the investigations and related matters.

We have exhausted our insurance policies related to reimbursement of our advancement of fees related to these matters. We are unable to estimate the total amount of these costs or a range of possible loss. Accordingly, we continue to expense these costs as incurred.

Other Lawsuits and Claims

Based on the nature of our business, we are subject to regulatory reviews or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance and benefits companies and their reviews focus on numerous facets of our business, including claims payment practices, provider contracting, competitive practices, commission payments, privacy issues and utilization management practices, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to our business practices. We continue to be subject to such reviews, which may result in additional fines and/or sanctions being imposed, premium refunds or additional changes in our business practices.

Separate and apart from the legal matters described above, we are also involved in other legal actions in the normal course of our business, including, without limitation, protests and appeals related to Medicaid procurement awards, wage and hour claims and other employment claims, claims for indemnification under purchase agreements, vendor disputes and provider disputes regarding payment of claims. Some of these actions seek monetary damages including claims for liquidated or punitive damages, which are not covered by insurance. We review relevant information with respect to these litigation matters and we update our estimates of reasonably possible losses and related disclosures. We accrue an estimate for contingent liabilities, including attorney's fees related to these matters, if a loss is probable and estimable. Currently, we do not expect that the resolution of any of these currently pending actions, either individually or in the aggregate, will differ materially from our current estimates or have a material adverse effect on our results of operations, financial condition and cash flows. However, the outcome of any legal actions cannot be predicted, and therefore actual results may differ from those estimates.

28


Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

Statements contained in this Form 10-Q for the quarterly period ended March 31, 2019 ("2019 Form 10-Q"), which are not historical fact may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and we intend such statements to be covered by the safe harbor provisions for forward-looking statements contained therein. Such statements, which may address, among other things, our financial outlook, the timing of the launch of new programs, pending new Medicaid contracts, the appropriation and payment to us by state governments of Medicaid premiums receivable, approval, financial and other effects of the proposed acquisition of us (the "Centene Transaction") by Centene Corporation ("Centene"), rate changes, market acceptance of our products and services, our ability to finance growth opportunities, our ability to respond to changes in laws and government regulations, including any repeal, replacement or modification of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the "ACA"), implementation of our growth strategies, projected capital expenditures, liquidity and the availability of additional funding sources may be found in this Item of this 2019 Form 10-Q and elsewhere in this report generally. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "targets," "predicts," "potential," "continues" or the negative of such terms or other comparable terminology. Forward-looking statements involve risks and uncertainties, including economic, regulatory, competitive and other factors that may affect our business. Please refer to the Risk Factors in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018 ("2018 Form 10-K") and in Part II, Item 1A of this 2019 Form 10-Q. These forward-looking statements are inherently susceptible to uncertainty and changes in circumstances, as they are based on management's expectations and beliefs about future events and circumstances. Given the risks and uncertainties inherent in forward-looking statements, any of our forward-looking statements could be incorrect and investors are cautioned not to place undue reliance on any of our forward-looking statements. Subsequent events and developments may cause actual results to differ, perhaps materially, from our forward-looking statements. We undertake no duty and expressly disclaim any obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

Our actual results may differ materially from those indicated by forward-looking statements as a result of various important factors, including the expiration, cancellation, delay, suspension or amendment of our state and federal contracts. In addition, our results of operations and estimates of future earnings depend, in large part, on accurately estimating and effectively managing health care benefits and other operating expenses. A variety of factors may affect our premium revenue, medical expenses, profitability, cash flows and liquidity, including the outcome of any protests and litigation related to Medicaid awards, our ability to meet the requirements of readiness reviews, competition, changes in health care practices, changes in the demographics of our members, changes in the eligibility for participation in government programs, and changes to eligibility certification requirements, higher than expected utilization of health care services by our members, changes in federal or state laws and regulations or their interpretations, inflation, provider contract changes, changes in or suspensions or terminations of our contracts with government agencies, new technologies, such as new, expensive medications, potential reductions in Medicaid and Medicare revenue, the appropriation and payment to us by state governments of Medicaid premiums receivable, our ability to negotiate actuarially sound rates, especially in new programs with limited experience, government-imposed surcharges, taxes or assessments, changes to how provider payments are made by governmental payors, the ability of state customers to launch new programs on their announced timelines, or at all, the timing of the approval by the Centers for Medicare & Medicaid Services ("CMS") of Medicaid contracts, or changes to the contracts or rates required to obtain CMS approval, major epidemics, disasters and numerous other factors affecting the delivery and cost of health care, such as major health care providers' inability to maintain their operations and our ability to implement health care value-added programs and our ability to control our medical costs and other operating expenses, including through our vendors. Governmental action or inaction could result in premium revenues not increasing to offset any increase in medical costs, the annual premium-based health insurance industry assessment (the "ACA industry fee") or other operating expenses. Once set, premiums are generally fixed for one-year periods and, accordingly, costs that exceed our estimates or our regulators' actuarial pricing assumptions during such periods generally may not be able to be recovered through higher premiums or rate adjustments. Furthermore, if we are unable to estimate accurately incurred but not reported medical costs in the current period, our future profitability may be adversely affected. Due to these factors and risks, we cannot provide any assurance regarding our future premium levels or our ability to control our future medical costs.

In addition, the risks and uncertainties include, but are not limited to
•
failure to complete the Centene Transaction could have material adverse effects on our business, results of operations, financial condition and cash flows;

29


•
our ability to pursue alternatives to the Centene Transaction is limited by provisions in the Merger Agreement (as defined herein), which could discourage a potential competing acquiror of us from making a favorable alternative transaction proposal and, in specified circumstances, could require us to pay substantial termination fees to Centene;
•
the Centene Transaction is subject to the expiration or termination of applicable waiting periods and the receipt of approvals, consents or clearances from regulatory authorities that may impose conditions that could have an adverse effect on us or, if not obtained, could prevent completion of the Centene Transaction;
•
we are subject to business uncertainties and contractual restrictions while the Centene Transaction is pending, which could materially adversely affect our business, results of operations, financial condition and cash flows;
•
uncertainties associated with the Centene Transaction may cause a loss of management personnel and other key employees, and we may have difficulty attracting and motivating management personnel and other key employees which could materially adversely affect our business, results of operations, financial condition and cash flows;
•
our progress on top priorities such as integrating care management, advocating for our members, building advanced relationships with providers and government partners;
•
delivering prudent, profitable growth; and
•
our ability to effectively identify, execute and integrate acquisitions and performance of our acquisitions once acquired, including the ability to achieve expected synergies of the Meridian acquisition within the expected time frames or at all, the ability to achieve accretion to WellCare’s earnings, revenues or other benefits expected, disruption to business relationships, operating results, and business generally of WellCare and/or Meridian and the ability to retain Meridian employees, and our ability to address operational challenges relating to the integration of Meridian with our existing business.

Due to these factors and risks, we may be required to write down or take impairment charges of assets associated with acquisitions. Furthermore, at both the federal and state government levels, legislative and regulatory proposals have been made related to, or potentially affecting, the health care industry, including but not limited to, repeal, replacement or modification of the ACA, reform of the Medicaid and Medicare programs, limitations on managed care organizations, changes to membership eligibility, and benefit mandates. Any such legislative or regulatory action could have the effect of reducing the premiums paid to us by governmental programs, increasing our medical and administrative costs or requiring us to materially alter the manner in which we operate. We are unable to predict the specific content of any future legislation, action or regulation that may be enacted or when any such future legislation or regulation will be adopted. Therefore, we cannot predict accurately the effect or ramifications of such future legislation, action or regulation on our business, financial condition, results of operations, and/or cash flows.

OVERVIEW

Introduction

WellCare Health Plans, Inc. (the "Company," "we," "us," or "our") focuses primarily on providing government-sponsored managed care services to families, children, seniors and individuals with complex medical needs primarily through Medicaid, Medicare Advantage ("MA") and Medicare Prescription Drug Plans ("PDP"), as well as individuals in the Health Insurance Marketplace. As of March 31, 2019, we served approximately 6.3 million members nationwide. As of March 31, 2019, we operated Medicaid health plans, including states where we receive Medicaid premium revenues associated with dually eligible special needs plans, in Arizona, Florida, Georgia, Hawaii, Illinois, Kentucky, Michigan, Missouri, Nebraska, New Jersey, New York, South Carolina and Texas.

As of March 31, 2019, we also operated MA coordinated care plans ("CCPs") in Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky, Louisiana, Maine, Michigan, Mississippi, New Jersey, New York, North Carolina, Ohio, South Carolina, Tennessee and Texas, as well as stand-alone Medicare PDP nationwide.

Summary of Consolidated Financial Results

Summarized below are the key highlights for the three months ended March 31, 2019. For additional information, refer to "Results of Operations" below, which discusses both consolidated and segment results.

▪
Membership at March 31, 2019 increased by 2.0 million, or 47.4%, compared with March 31, 2018. The increase was primarily driven by Meridian as well as organic growth in our Medicare PDP and Medicare Health Plans segments.


30


▪
Premiums increased 42.9% for the three months ended March 31, 2019, compared with the same period in 2018, reflecting our acquisition of Meridian in September 2018, additional members in our Florida and Arizona Medicaid health plans, and organic growth in our Medicare Health Plans and Medicare PDP segments. These increases were partially offset by the 2019 ACA Fee Moratorium (discussed in Key Development and Accomplishments below).

▪
Net Income increased $49.7 million for the three months ended March 31, 2019, compared with the same period in 2018, primarily driven by organic growth, continued improvement in operation execution across all segments and the acquisition of Meridian in September 2018.

Key Developments and Accomplishments

Presented below are key developments and accomplishments relating to progress on our business strategy that have affected, or are expected to affect, our results:

•
On March 26, 2019, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Centene under which Centene will acquire us for a combination of cash and stock. Under the terms of the Merger Agreement, our shareholders will receive $120.00 in cash and 3.38 shares of Centene common stock for each share of our common stock. The proposed transaction is subject to customary closing conditions, including, but not limited to, the approval of the Merger Agreement by our stockholders, the approval of the share issuance of Centene stock by Centene’s stockholders, and the receipt of U.S. federal antitrust clearance and certain other required regulatory approvals. The transaction is expected to close in the first half of 2020.

•
In February 2019, we received notice from the North Carolina Department of Health and Human Services (“DHHS”) that we were awarded a contract to administer the state’s Medicaid Prepaid Health Plans, which is subject to a protest process. DHHS has selected four health plans, including us, to serve North Carolina's Medicaid beneficiaries on a statewide basis. One additional health plan led by providers was selected to operate health plans in certain regions. The state is expected to implement the new managed care program, in two phases, for its 1.6 million Medicaid beneficiaries beginning November 1, 2019.

•
Effective January 1, 2019, Congress approved a one-year moratorium of the ACA industry fee for 2019 ("2019 ACA Fee Moratorium"), which also eliminated the Medicaid ACA industry fee reimbursement from our state government partners for 2019.

•
In November 2018, we completed the asset purchase of Aetna Inc.'s ("Aetna") entire standalone Medicare Part D prescription drug plan membership ("Aetna Part D membership") for total approximate consideration of $107.2 million in cash, which is subject to certain true-up provisions. Per the terms of the agreements, Aetna will provide administrative services to, and retain financial risk of, the acquired Aetna Part D membership through 2019. Therefore, the Aetna Part D membership will be excluded from our membership and results of operations until January 1, 2020.

•
In September 2018, we completed the acquisition of Meridian for approximately $2.5 billion in cash. As a result of this transaction, we expanded our Medicaid portfolio through the addition of Michigan; expanded our Medicaid presence in Illinois; and acquired an integrated PBM platform. Meridian also serves MA members in Illinois, Indiana, Michigan and Ohio, as well as Health Insurance Marketplace members in Michigan.

•
In July 2018, we received a Notice of Intent to Award a contract from the Florida Department of Health to provide statewide-managed care services to children with medically complex conditions through the Children's Medical Services Managed Care Plan ("CMS Plan"). The five-year contract award began on February 1, 2019; however, this contract is still subject to protest and appeal. Additionally, in April 2018, we received a Notice of Agency Decision from the Florida Agency for Health Care Administration (“AHCA”) to award our subsidiary, Staywell, a new five-year contract to provide managed care services to Medicaid-eligible beneficiaries, including Managed Medical Assistance and Long-Term Care beneficiaries in 10 of 11 regions. As part of the Medicaid Managed Care program, we provide statewide-managed care services to beneficiaries in the Serious Mental Illness Specialty Plan; however, this contract is still subject to protest and appeal. We are one of two managed care plans providing services to the SMI beneficiaries. The new statewide Medicaid Managed Care program began on December 1, 2018.




31




RESULTS OF OPERATIONS

Condensed Consolidated Financial Results

The following tables set forth condensed consolidated statements of operations data, as well as other key data used in our results of operations discussion for the three months ended March 31, 2019, compared with the same period in 2018.
 
For the Three Months Ended
March 31,
 
Percentage
 
2019
 
2018
 
Change
Revenues:
(Dollars in millions)
 
 
Premium
$
6,609.4

 
$
4,626.3

 
42.9%
Products and services
115.8

 
—

 
100.0%
Investment and other income
37.0

 
19.9

 
85.9%
Total revenues
6,762.2

 
4,646.2

 
45.5%
 
 
 
 
 
 
Expenses:
 
 
 
 
 
Medical benefits
5,831.7

 
3,962.0

 
47.2%
Costs of products and services
111.8

 
—

 
100.0%
Selling, general and administrative
503.8

 
355.9

 
41.6%
ACA industry fee
—

 
81.5

 
100.0%
Medicaid premium taxes
31.7

 
32.1

 
(1.2)%
Depreciation and amortization
69.6

 
36.4

 
91.2%
Interest
29.5

 
17.1

 
72.5%
Total expenses
6,578.1

 
4,485.0

 
46.7%
Income before income taxes and equity in losses of unconsolidated subsidiaries
184.1

 
161.2

 
14.2%
Equity in earnings (losses) of unconsolidated subsidiaries
0.8

 
(2.7
)
 
129.6%
Income before income taxes
184.9

 
158.5

 
16.7%
Income tax expense
33.5

 
56.8

 
(41.0)%
Net income
$
151.4

 
$
101.7

 
48.9%
Effective tax rate
18.1
%
 
35.8
%
 
(17.7)%
 
 
 
 
 
 



32


Membership

In the following tables, we have summarized membership for our business segments in each state that exceeded 5% of our total membership, as well as all other states in the aggregate, as of March 31, 2019 and 2018, respectively.
 
 
March 31, 2019
State
 
Medicaid Health Plans(1)
 
Medicare Health Plans(1)
 
Medicare PDPs
 
Total Membership
 
Percentage of
Total
Florida
 
1,008,000

 
104,000

 
65,000

 
1,177,000

 
18.7%
Illinois
 
801,000

 
27,000

 
57,000

 
885,000

 
14.0%
Michigan
 
502,000

 
22,000

 
57,000

 
581,000

 
9.2%
Georgia
 
492,000

 
52,000

 
24,000

 
568,000

 
9.0%
Kentucky
 
445,000

 
14,000

 
33,000

 
492,000

 
7.8%
Other states
 
873,000

 
339,000

 
1,394,000

 
2,606,000

 
41.3%
Health Insurance Marketplace(2)
 
—

 
—

 
—

 
7,000

 
0.1%
Total
 
4,121,000

 
558,000

 
1,630,000

 
6,316,000

 
100.0%
 
 
 
 
 
 
 
 
 
 
 

 
 
March 31, 2018
State
 
Medicaid Health Plans(1)
 
Medicare Health Plans(1)
 
Medicare PDPs
 
Total Membership
 
Percentage of
Total
Florida
 
744,000

 
97,000

 
30,000

 
871,000

 
20.3%
Georgia
 
515,000

 
49,000

 
16,000

 
580,000

 
13.5%
Kentucky
 
459,000

 
12,000

 
22,000

 
493,000

 
11.5%
Missouri
 
281,000

 
—

 
15,000

 
296,000

 
6.9%
New York
 
149,000

 
88,000

 
54,000

 
291,000

 
6.8%
Illinois
 
123,000

 
16,000

 
35,000

 
174,000

 
4.1%
Other states
 
434,000


244,000

 
901,000


1,579,000

 
36.9%
Total
 
2,705,000

 
506,000

 
1,073,000

 
4,284,000

 
100.0%
 
 
 
 
 
 
 
 
 
 
 

(1) Medicaid Health Plans and Medicare Health Plans membership includes members who are dually-eligible and participate in both our Medicaid and Medicare programs. The dually-eligible membership was 74,000 and 51,000 of our Medicaid and Medicare membership as of March 31, 2019 and 2018, respectively.
(2) Health Insurance Marketplace, included in our Corporate and Other category as it does not meet the quantification thresholds required by generally accepted accounting principles and therefore not individually reportable, includes members from Michigan. Total Michigan membership is 588,000 members.

As of March 31, 2019, membership increased approximately 2.0 million members, or 47.4%, compared with March 31, 2018. Membership discussion by segment follows:

•
Medicaid Health Plans. Membership increased by 1.4 million year-over-year, or 52.3%, to 4.1 million members as of March 31, 2019. The increase was primarily driven by the acquisition of Meridian in September 2018, as well as organic membership growth primarily in our Florida and Arizona Medicaid health plans. These increases were partially offset by net eligibility decreases in certain of our Medicaid markets.

•
Medicare Health Plans. Membership as of March 31, 2019 increased by 52,000 year-over-year, or 10.3%, to 558,000 members. The increase is a result of the acquisition of Meridian and organic growth.
 
•
Medicare PDPs. Membership as of March 31, 2019 increased 557,000 year-over-year, or 51.9%, to 1.6 million members. The increase was primarily the result of organic growth through a new enhanced product offering in 2019.


33


Premium Revenue

Premium revenue increased by approximately $2.0 billion, or 42.9%, for the three months ended March 31, 2019, compared with the same period in 2018, reflecting our acquisition of Meridian in September 2018, additional members in our Florida and Arizona Medicaid health plans and organic growth in both our Medicare Health Plans and Medicare PDP segments. The increase was partially offset by the effect of the 2019 ACA Fee Moratorium.

Medical Benefits Expense

Medical benefits expense increased by approximately $1.9 billion, or 47.2%, for the three months ended March 31, 2019, compared with the same period in 2018, primarily driven by the acquisition of Meridian in September 2018, additional members in our Florida and Arizona Medicaid health plans and organic growth in our Medicare Health Plans segment.

Selling, General and Administrative ("SG&A") Expense
 
For the three months ended March 31, 2019 and 2018, when applicable, SG&A expense included certain transaction and integrations-related costs associated with our proposed acquisition by Centene, our acquisition of Aetna membership in December 2018, our acquisition of Meridian in September 2018 and our acquisition of Universal American in April 2017 ("transaction and integration costs"). These costs include severance payments, technology integration costs, advisory, legal and other professional fees that are reflected in SG&A expense in our condensed consolidated statements of comprehensive income. Additionally, for the three months ended March 31, 2018, SG&A expense under GAAP includes aggregate costs related to previously disclosed government investigations and related litigation and resolution costs ("investigation costs"). Refer to Note 14 - Commitments and Contingencies within the condensed consolidated financial statements included in this 2019 Form 10-Q for additional discussion of these investigation costs. Although the above items may recur, we believe that by providing non-GAAP measurements exclusive of these items, we facilitate period-over-period comparisons and provide additional clarity about events and trends affecting our core operating performance, as well as providing comparability to competitor results. The investigation costs are related to a discrete incident, which we do not expect to reoccur. The transaction and integration costs are related to specific events, which do not reflect the underlying ongoing performance of our business. The non-GAAP financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. Below is a reconciliation of these non-GAAP measures with the most directly comparable financial measure calculated in accordance with GAAP.

The reconciliation of SG&A expense, including and excluding such costs, is as follows:

 
For the Three Months Ended
March 31,
 
2019
 
2018
 
(Dollars in millions)
SG&A expense (GAAP)
$
503.8

 
$
355.9

Adjustments:
 
 
 

    Investigation costs
—

 
(0.1
)
    Transaction and integration costs
(9.8
)
 
(2.7
)
Adjusted SG&A expense (non-GAAP)
$
494.0

 
$
353.1

SG&A ratio (GAAP) (1) (3)
7.5
%
 
7.7
%
Adjusted SG&A ratio (non-GAAP) (2) (3)
7.3
%
 
7.8
%

(1) SG&A expense, as a percentage of total revenues.
(2) Adjusted SG&A expense, as a percentage of total revenues, excluding Medicaid premium tax reimbursement and Medicaid ACA industry fee reimbursements. Because reimbursements for Medicaid premium tax and ACA industry fee are both included in the premium rates or reimbursement established in certain of our Medicaid contracts and recognized separately as a component of expense, we exclude these reimbursements from total revenue when calculating key ratios as we believe that these components are not indicative of operating performance.
(3) Effective July 1, 2018, the Company redefined our SG&A ratio (GAAP) to be a percentage of total revenues. Adjusted SG&A ratio was redefined to be a percentage of total revenues excluding Medicaid premium tax reimbursement and Medicaid ACA industry fee reimbursement. Accordingly, results for the three months ended March 31, 2018 were adjusted to conform to this presentation. Our SG&A ratio (GAAP) and our Adjusted SG&A ratio for the three months ended March 31, 2018 did not change from the results previously reported.


34


Our SG&A expense, for the three months ended March 31, 2019, increased approximately $147.9 million, compared with the same period in 2018. The increase was primarily the result of our acquisition of Meridian in September 2018, staffing and infrastructure costs to support organic growth and variable long-term management incentive compensation. Our SG&A ratio decreased 20 basis points for the three months ended March 31, 2019, compared with the same period in 2018 reflecting leverage in our SG&A on a higher revenue base as a result of our acquisition of Meridian in September 2018 and continued organic growth.

Our Adjusted SG&A expense, for the three months ended March 31, 2019, increased approximately $140.9 million, compared with the same period in 2018. This increase was primarily the result of our acquisition of Meridian in September 2018, staffing and infrastructure costs to support organic growth and variable long-term management incentive compensation. Our Adjusted SG&A ratio decreased 50 basis points for the three months ended March 31, 2019, compared with the same period in 2018 reflecting leverage in our SG&A on a higher revenue base as a result of our acquisition of Meridian in September 2018 and continued organic growth.

Income Tax Expense

Income tax expense for the three months ended March 31, 2019, decreased $23.3 million, or 41%, compared with the same period in 2018. The effective tax rate, for the three months ended March 31, 2019, decreased to 18.1%, compared with 35.8% for the same period in 2018. The decrease in income tax expense and the effective tax rate is primarily driven by the effect of the 2019 ACA Fee Moratorium, partially offset by higher earnings before tax. The ACA industry fee, which was nondeductible for tax purposes, had the effect of increasing our income tax rate in 2018.

Segment Reporting

Reportable operating segments are defined as components of an enterprise for which discrete financial information is available and evaluated on a regular basis by the enterprise's decision-makers to determine how resources should be allocated to an individual segment and to assess performance of those segments. Accordingly, we have three reportable segments: Medicaid Health Plans, Medicare Health Plans and Medicare PDPs.

Segment Financial Performance Measures

Our primary measurements of profitability for our reportable operating segments are premium revenue, gross margin and medical benefits ratio ("MBR"). Gross margin is defined as total revenues less investment and other income, medical benefits expense, costs of products and services, ACA industry fee expense and Medicaid premium tax expense. MBR measures the ratio of medical benefits expense to premium revenue. Our Adjusted MBR (non-GAAP) measures the ratio of medical benefits expense to premium revenue, excluding Medicaid premium taxes reimbursement and Medicaid ACA industry fee reimbursement.

We use gross margin, MBR and, where applicable, Adjusted MBR to monitor our management of medical benefits and medical benefits expense. These metrics are utilized to make various business decisions, including which health care plans to offer, which geographic areas to enter or exit and which health care providers to include in our networks.

For further information regarding premium revenues and medical benefits expense, please refer to "Premium Revenue Recognition and Premiums Receivable," and " Estimating Medical Benefits Expense and Medical Benefits Payable" in Part II – Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations, under "Critical Accounting Estimates" in our 2018 Form 10-K.


35


Reconciling Segment Results

The following table reconciles our reportable segment results to income from operations, as reported in accordance with GAAP.

 
For the Three Months Ended
March 31,
 
Percentage
 
2019
 
2018
 
Change
 
(Dollars in millions)
 
 
Gross Margin (1)
 
 
 
 
 
Medicaid Health Plans
$
419.1

 
$
304.1

 
37.8
%
Medicare Health Plans
294.9

 
221.8

 
33.0
%
Medicare PDPs
30.4

 
24.8

 
22.6
%
Corporate and Other (2)
5.6

 
—

 
100.0
%
Total gross margin
750.0

 
550.7

 
36.2
%
Investment and other income
37.0

 
19.9

 
85.9
%
Other expenses (3)
(602.9
)
 
(409.4
)
 
47.3
%
Income from operations
$
184.1

 
$
161.2

 
14.2
%
 
 
 
 
 
 
(1) Effective July 1, 2018, the Company redefined gross margin as total revenues less investment and other income, medical benefits expense, costs of products and services, the ACA industry fee expense, and Medicaid premium tax expense. Accordingly, results for the three months ended March 31, 2018 were adjusted to include Medicaid premium taxes, which decreased gross margin by $32.1 million.
(2) Corporate and other category includes businesses that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles.
(3) Effective July 1, 2018, other expenses include SG&A expenses, depreciation, amortization and interest. Accordingly, results for the three months ended March 31, 2018 were adjusted to exclude Medicaid premium taxes, which decreased other expenses by $32.1 million.



36



Medicaid Health Plans

Our Medicaid Health Plans segment includes plans for beneficiaries of Temporary Assistance for Needy Families ("TANF"), Supplemental Security Income ("SSI"), Aged Blind and Disabled ("ABD"), Children's Health Insurance Program ("CHIP") and the Long-Term Services and Supports ("LTSS") program.

Medicaid Health Plans Results of Operations

The following table sets forth the summarized results of operations and other relevant performance measures for our Medicaid Health Plans segment for the three months ended March 31, 2019 and 2018:
 
 
For the Three Months Ended
March 31,
 
Percentage
 
2019
 
2018
 
Change
 
(Dollars in millions)
 
 
Premium revenue (1)
$
4,441.8

 
$
2,713.1

 
63.7
 %
Medicaid premium tax reimbursement (1)
31.7

 
32.1

 
(1.2
)%
Medicaid ACA industry fee reimbursement (1)
—

 
64.7

 
100.0
 %
Total premiums
4,473.5

 
2,809.9

 
59.2
 %
Medical benefits expense
4,022.7

 
2,424.4

 
65.9
 %
ACA industry fee
—

 
49.3

 
100.0
 %
Medicaid premium tax
31.7

 
32.1

 
(1.2
)%
Gross margin(2) 
$
419.1

 
$
304.1

 
37.8
 %
 
 
 
 
 
 
Medicaid Health Plans MBR (1)
89.9
%
 
86.3
%
 
3.6
 %
Effect of:
 
 
 
 
 
Medicaid premium taxes
0.7
%
 
1.0
%
 


Medicaid ACA industry fee reimbursement
—
%
 
2.1
%
 


Medicaid Health Plans Adjusted MBR (1)
90.6
%
 
89.4
%
 
1.2
 %
 
 
 
 
 
 
Medicaid membership at end of period:
4,121,000

 
2,705,000

 
52.3
 %
(1) For GAAP reporting purposes, Medicaid premium tax reimbursement and Medicaid ACA industry fee reimbursement are included in premium revenue to measure our MBR. Our Medicaid Health Plans Adjusted MBR measures the ratio of our medical benefits expense to premium revenue, excluding Medicaid premium tax reimbursement and Medicaid ACA industry fee reimbursement revenue. Because reimbursements for Medicaid premium tax and the ACA industry fee are both included in the premium rates or reimbursement established in certain of our Medicaid contracts and recognized separately as a component of expense, we exclude these reimbursements from premium revenue when calculating key ratios as we believe that these components are not indicative of operating performance.
(2) Effective July 1, 2018, the Company redefined gross margin as total revenues less investment and other income, medical benefit expense, costs of products and services, the ACA industry fee expense, and Medicaid premium tax expense. Accordingly, results for the three months ended March 31, 2018 were adjusted to include Medicaid premium taxes, which decreased gross margin by $32.1 million.

Medicaid total premiums increased $1.7 billion, or 59.2%, for the three months ended March 31, 2019, compared with the same period in 2018, primarily driven by our acquisition of Meridian in September 2018 and net organic growth, including additional members in our Florida and Arizona Medicaid health plans. The increases were partially offset by the effect of the 2019 ACA Fee Moratorium.

Excluding Medicaid premium taxes and the Medicaid ACA industry fee reimbursements, Medicaid premium revenue increased $1.7 billion, or 63.7%, for the three months ended March 31, 2019 compared with the same period in 2018. The increase was primarily driven by our acquisition of Meridian in September 2018 and net organic growth, including additional members in our Florida and Arizona Medicaid health plans.

Medical benefits expense increased $1.6 billion, or 65.9%, for the three months ended March 31, 2019 compared with the same period in 2018, primarily resulting from our acquisition of Meridian in September 2018 and net organic growth, including the additional members in our Florida and Arizona Medicaid health plans. These increases were partially offset by the favorable result of continued performance in clinical and pharmacy execution.

37



Our Medicaid Health Plans segment MBR increased 360 basis points, for the three months ended March 31, 2019, compared with the same period in 2018. The increase is primarily driven by our acquisition of Meridian in September 2018, net organic growth, and the effect of the 2019 ACA Fee Moratorium. These increases were partially offset by the favorable result of continued performance in clinical and pharmacy execution.

Excluding the effect of Medicaid premium taxes and Medicaid ACA industry fee reimbursements, our Medicaid Health Plans Adjusted MBR, for the three months ended March 31, 2019, increased by 120 basis points, compared with the same period in 2018. The increase is primarily driven by our acquisition of Meridian in September 2018 and net organic growth, partially offset by the favorable result of continued performance in clinical and pharmacy execution.

Medicare Health Plans

We contract with CMS under the Medicare program to provide a comprehensive array of Part C and Part D benefits to Medicare eligible persons provided through our MA plans. Our MA plans are comprised of coordinated care plans ("CCPs"), which are primarily administered through HMOs and generally require members to seek health care services and select a primary care physician from a network of health care providers. Certain MA CCPs are administered through preferred provider organizations ("PPO") and private-fee-for-service ("PFFS"). In addition, we offer Medicare Part D coverage, which provides prescription drug benefits, as a component of most of our MA plans.

Medicare Health Plans Results of Operations

The following table sets forth the summarized results of operations and other relevant performance measures for our Medicare Health Plans segment for the three months ended March 31, 2019 and 2018:
 
For the Three Months Ended
March 31,
 
Percentage
 
2019
 
2018
 
Change
Medicare Health Plans:
(Dollars in millions)
 
 
Premium revenue
$
1,843.1

 
$
1,556.5

 
18.4
 %
Medical benefits expense
1,548.2

 
1,307.1

 
18.4
 %
ACA industry fee
—

 
27.6

 
(100.0
)%
Gross margin
$
294.9

 
$
221.8

 
33.0
 %
MBR
84.0
%
 
84.0
%
 
—
 %
Membership
558,000

 
506,000

 
10.3
 %


Medicare Health Plans premium revenue increased $286.6 million, or 18.4%, for the three months ended March 31, 2019 compared with the same period in 2018, driven by organic growth and our acquisition of Meridian in September 2018.

Medical benefits expense increased $241.1 million, or 18.4%, for the three months ended March 31, 2019 compared with the same period in 2018, driven by our acquisition of Meridian in September 2018 and organic growth. The Medicare Health Plans segment MBR is consistent with the same period in 2018.

38



Medicare PDPs

We have contracted with CMS to serve as a plan sponsor offering stand-alone Medicare Part D PDPs to Medicare eligible beneficiaries through our Medicare PDPs segment. The PDP benefit design generally results in our incurring a greater portion of the responsibility for total prescription drug costs in the early stages of a plan year and less in the latter stages of a plan year due to the members' share of cumulative out-of-pocket costs increasing throughout the plan year. As a result, the Medicare PDPs' MBR is generally lower in the second half of the year as compared with the first half. In addition, the level and mix of members who are auto assigned to us and those who actively choose our PDPs will affect the segment MBR pattern across periods.

Medicare PDPs Results of Operations

The following table sets forth the summarized results of operations and other relevant performance measures for our Medicare PDPs segment for the three months ended March 31, 2019 and 2018:
 
For the Three Months Ended
March 31,
 
Percentage
 
2019
 
2018
 
Change
Medicare PDPs:
(Dollars in millions)
 
 
Premium revenue
$
288.8

 
$
259.9

 
11.1
 %
Medical benefits expense
258.4

 
230.5

 
12.1
 %
ACA industry fee
—

 
4.6

 
(100.0
)%
Gross margin
$
30.4

 
$
24.8

 
22.6
 %
MBR
89.5
%
 
88.7
%
 
0.8
 %
Membership
1,630,000

 
1,073,000

 
51.9
 %

As noted in the table above, Medicare PDPs premium revenue, medical benefits expense and MBR increased for the three months ended March 31, 2019, compared with the same period in 2018. The increases in premium revenue and medical benefits expense were primarily a result of our new enhanced product offering in 2019. The increase in Medicare PDP MBR was primarily a result of our 2019 bid position, partially offset by the performance of the new enhanced product offering in 2019 and continued performance in pharmacy execution.

BUSINESS TRENDS AND INFLATION

Health care expenditures have grown consistently for many years, and we expect overall health care costs to continue to grow in the future due to inflation, evolving medical technology, pharmaceutical advancement, regulatory requirements, demographic trends in the U.S. population, and national interest in health and wellbeing. We use various strategies to mitigate the negative effects of health care cost inflation. Specifically, our health plans try to control medical and hospital costs through our state savings initiatives and contracts with independent providers of health care services. Through these contracted care providers, our health plans emphasize preventive health care and appropriate use of specialty and hospital services. Additionally, our contracts with states require actuarially sound premiums that include health care cost trend. While we currently believe our strategies to mitigate health care cost inflation will continue to be successful, competitive pressures, new health care and pharmaceutical product introductions, demands from health care providers and customers, applicable health care reform regulations, an increase in the expected rate of inflation for health care costs, or other factors may adversely affect our ability to control health care costs.

OUTLOOK

We expect our full year 2019 premium revenue and medical benefits expense to increase, across all segments, as compared with the full year 2018. The increases are expected to be a result of our acquisition of Meridian in September 2018 and net organic growth across all of our segments. These increases will be partially offset by the effect of the 2019 ACA Fee Moratorium. Additionally, while we anticipate improved SG&A operating leverage associated with premium revenue growth and continued synergies from our acquisitions, we expect the aggregate 2019 SG&A expense, as compared to 2018, to increase resulting from our acquisition of Meridian in September 2018 and net organic growth across all of our segments. Our effective income tax rate is expected to decrease in 2019, compared to 2018, due to the 2019 ACA Fee Moratorium.



39


LIQUIDITY AND CAPITAL RESOURCES

Each of our existing and anticipated sources of cash is affected by operational and financial risks that influence the overall amount of cash generated and the capital available to us. Additionally, we operate as a holding company in a highly regulated industry. The parent and other non-regulated companies ("non-regulated subsidiaries") are dependent upon dividends and management fees from our regulated subsidiaries, most of which are subject to regulatory restrictions. For a further discussion of risks that can affect our liquidity, see Part I – Item 1A – "Risk Factors" included in our 2018 Form 10-K.

Centene Merger Agreement
The Merger Agreement includes restrictions on the conduct of our business prior to completion of the Centene Transaction or termination of the Merger Agreement, generally requiring us to conduct our business in the ordinary course. However, we are subject to various specified restrictions unless we obtain Centene’s prior written consent, which may not be unreasonably withheld, delayed or conditioned, or expressly contemplated or permitted by the Merger Agreement or as required by applicable law. Among other things and in each case subject to certain exceptions, we may not:
•
incur additional indebtedness (excluding borrowings under our Revolving Credit Facility that are used to manage our ordinary course cash flow needs);
•
issue additional shares of our common stock, repurchase our common stock, or pay dividends;
•
acquire assets, securities or property, dispose of businesses or assets; or
•
authorize any payment of, accrual or commitment for capital expenditures in any calendar year that would exceed by more than 110% the aggregate amount of capital expenditures budgeted for such year.

Liquidity

The Company maintains liquidity at two levels: the regulated subsidiary level and the non-regulated subsidiary level.

Regulated subsidiaries
 
Our regulated subsidiaries' primary liquidity requirements include:

•
payment of medical claims and other health care services;
•
payment of certain Part D benefits paid for members on behalf of CMS;
•
SG&A costs directly incurred or paid through a management services agreement to one of our non-regulated administrative and management services subsidiaries; and
•
federal tax payments to the parent company under an intercompany tax sharing agreement.

Our regulated subsidiaries meet their liquidity needs by:

•
generating cash flows from operating activities, mainly from premium revenue;
•
receipts of prospective subsidy payments and related final settlements from CMS to reimburse us for certain Part D benefits paid for members on behalf of CMS;
•
cash flows from investing activities, including investment income and sales of investments; and
•
capital contributions received from our non-regulated subsidiaries.

We refer collectively to the cash, cash equivalents and investment balances maintained by our regulated subsidiaries as "regulated cash and investments." Our regulated subsidiaries generally receive premiums in advance of payments of claims for medical and other health care services; however, regulated cash and investments can fluctuate significantly in a particular period depending on the timing of receipts for premiums from our government partners. Our unrestricted regulated cash and investments were $5.0 billion as of March 31, 2019, an approximate $0.2 billion increase from $4.8 billion at December 31, 2018, due primarily to earnings from operations and contributions received from the parent and non-regulated subsidiaries, partially offset by dividends paid to the unregulated subsidiaries.

Our regulated subsidiaries are each subject to applicable state regulations that, among other things, require the maintenance of minimum levels of capital and surplus. We continue to maintain significant levels of aggregate excess statutory capital and surplus in our regulated subsidiaries. See further discussion under Regulatory Capital and Dividend Restrictions below.


40


Parent and Non-Regulated Subsidiaries

Liquidity requirements at the non-regulated parent and subsidiary level generally consist of:

•
payment of administrative costs not directly incurred by our regulated operations, including, but not limited to, staffing costs, business development, rent, branding and certain information technology services;
•
capital contributions paid to our regulated subsidiaries;
•
capital expenditures;
•
debt service; and
•
federal and state tax payments.
 
Our non-regulated parent and subsidiaries normally meet their liquidity requirements by:

•
management fees earned by our non-regulated administrator subsidiary under management services agreements;
•
dividends received from our regulated subsidiaries;
•
collecting federal and state tax payments from the regulated subsidiaries;
•
proceeds from issuance of debt and equity securities; and
•
cash flows from investing activities, including investment income and sales of investments.

Unregulated cash, cash equivalents and investments totaled approximately $296.4 million as of March 31, 2019, a decrease of approximately $219.6 million from $516.0 million as of December 31, 2018. The decrease is primarily due to capital contributions to our regulated subsidiaries, the semi-annual interest payment for our 2026 Notes, partially offset by dividends from certain of our regulated subsidiaries.

Medicare Part D Funding and Settlements

Funding may be provided to certain regulated subsidiaries from our unregulated subsidiaries to cover any shortfall resulting from the amount of Part D benefits paid for members on behalf of CMS that exceeds the prospective subsidy payments that these regulated subsidiaries receive from CMS. We receive certain Part D prospective subsidy payments from CMS for our MA and PDP members as a fixed monthly per member amount, based on the estimated costs of providing prescription drug benefits over the plan year, as reflected in our bids. A discussion of the subsidy components under Part D is included in Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in our 2018 Form 10-K. The benefits include the catastrophic reinsurance, premium and cost sharing for low-income Part D members, for which CMS will fully reimburse these subsidies, or recoup overpaid subsidies made during the plan year, as part of its annual settlement process that occurs in the fourth quarter of the subsequent year.

Cash Flow Activities

Our cash flows are summarized as follows:
 
For the Three Months Ended
March 31,
 
2019
 
2018
 
(In millions)
Net cash (used in) provided by operating activities
$
(30.0
)
 
$
445.7

Net cash used in investing activities
(487.5
)
 
(240.6
)
Net cash provided by financing activities
135.2

 
417.4

(Decrease) increase in cash, cash equivalents and restricted cash and cash equivalents
$
(382.3
)
 
$
622.5

 
 
 
 


41


Cash Flows from Operating Activities

We generally receive premiums in advance of payments of claims for health care services; however, cash flows related to our operations can fluctuate significantly in a particular period depending on the timing of premium receipts from our government partners.

Net cash used in operating activities for the three months ended March 31, 2019 was $30.0 million, compared with $445.7 million of net cash provided by operating activities for the same period in 2018. The decrease is primarily due to the advance receipt of April 2018 CMS Medicare premium payments in March 2018 and the timing of Medicaid premium receivable receipts, partially offset by the timing of medical claims payments.

Cash Flows from Investing Activities

Net cash used in investing activities for the three months ended March 31, 2019 was $487.5 million, compared with $240.6 million for the same period in 2018. The increase was primarily due to higher purchases of investments during the three months ended March 31, 2019.

Cash Flows from Financing Activities

Cash flows from financing activities are primarily affected by net funds received or paid for the benefit of members of our MA and PDP plans, as well as taxes withheld at the end of the vesting period for our equity-compensation awards. Cash provided by financing activities for the three months ended March 31, 2019 was $135.2 million, compared with approximately $417.4 million for the same period in 2018, primarily driven by the following:

•
Net funds received for the benefit of members was approximately $170.7 million for the three months ended March 31, 2019, compared with $416.2 million during the same period in 2018. These funds represent the net amounts of subsidies we received from CMS in connection with the low-income cost sharing, catastrophic reinsurance and coverage gap discount components of the Medicare Part D program related to the government's portion of financial responsibility, net of the amounts we paid for related prescription drug benefits, described above in "Medicare Part D Funding and Settlements." The decrease was primarily the result of the advance receipt of April CMS subsidy payments in March 2018 and our 2019 bid positioning, which resulted in lower payments received for 2019 net subsidies, and
•
Taxes withheld upon vesting of our equity-compensation awards of $36.8 million for the three months ended March 31, 2019, compared with $20.2 million for the same period in 2018.


Capital Resources

Debt

5.375% Senior Notes due 2026

On August 13, 2018, we completed the offering and sale of 5.375% unsecured senior notes due 2026 in the aggregate principal amount of $750.0 million (the “2026 Notes”). The aggregate net proceeds from the issuance of the 2026 Notes were $739.0 million, with the net proceeds from the offering being used to fund a portion of the cash consideration for our acquisition of Meridian in September 2018.

The 2026 Notes will mature on August 15, 2026, and bear interest at a rate of 5.375% per annum, payable semi-annually on February 15 and August 15 of each year, commencing on February 15, 2019.

The 2026 Notes were issued under an indenture, dated as of August 13, 2018 (the “2026 Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A. ("BNY Mellon"), as trustee. The 2026 Indenture under which the notes were issued contains covenants that, among other things, limit our ability and the ability of our subsidiaries under certain circumstances to:

•
incur additional indebtedness and issue preferred stock;
•
pay dividends or make other distributions;
•
make other restricted payments and investments;

42


•
sell assets, including capital stock of restricted subsidiaries;
•
create certain liens;
•
incur restrictions on the ability of restricted subsidiaries to pay dividends or make other payments, and in the case of our subsidiaries, guarantee indebtedness;
•
engage in transactions with affiliates; and
•
create unrestricted subsidiaries.

In addition, the 2026 Indenture requires that for the Company to merge, consolidate or sell all or substantially all of its assets, (i) either the Company must be the surviving entity, or the surviving entity or purchaser must be a U.S. entity; (ii) the surviving entity or purchaser must assume all the obligations of the Company under the 2026 Notes and the 2026 Indenture; (iii) no default or event of default (as defined under the Indenture) exits and (iv) the surviving entity, after giving pro forma effect to the transaction, (x) may incur at least $1.00 of additional indebtedness pursuant to the fixed charge coverage ratio or (y) have a fixed charge coverage ratio that is no worse than the fixed charge coverage ratio of the Company without giving pro forma effect to the transactions.

5.25% Senior Notes due 2025

On March 22, 2017, we completed the offering and sale of our 2025 Notes in the aggregate principal amount of $1,200.0 million, resulting in aggregate net proceeds of $1,182.2 million. A portion of the net proceeds from the offering was used to repay the $100.0 million outstanding under our Credit Agreement, and to redeem the full $900.0 million aggregate principal amount of our 2020 Notes. The remaining net proceeds from the offering of the 2025 Notes were used for general corporate purposes, including organic growth and working capital.

The 2025 Notes were issued under an indenture, dated as of March 22, 2017 (the "Base Indenture"), as supplemented by the First Supplemental Indenture, dated as of March 22, 2017 (the "First Supplemental Indenture" and, together with the Base Indenture, the "2025 Indenture"), each between the Company and BNY Mellon, as trustee. The 2025 Indenture under which the notes were issued contains covenants that, among other things, limit our ability and the ability of our subsidiaries under certain circumstances to:

•
incur additional indebtedness and issue preferred stock;
•
pay dividends or make other distributions;
•
make other restricted payments and investments;
•
sell assets, including capital stock of restricted subsidiaries;
•
create certain liens;
•
incur restrictions on the ability of restricted subsidiaries to pay dividends or make other payments, and in the case of our subsidiaries, guarantee indebtedness;
•
engage in transactions with affiliates; and
•
create unrestricted subsidiaries.

In addition, the 2025 Indenture requires that for the Company to merge, consolidate or sell all or substantially all of its assets: (i) either the Company must be the surviving entity, or the surviving entity or purchaser must be a U.S. entity; (ii) the surviving entity or purchaser must assume all the obligations of the Company under the 2025 Notes and the 2025 Indenture; (iii) no default or event of default (as defined under the indenture) exists; and (iv) the surviving entity, after giving pro forma effect to the transaction, (x) may incur at least $1.00 of additional indebtedness pursuant to the fixed charge coverage ratio or (y) have a fixed charge coverage ratio that is no worse than the fixed charge coverage ratio of the Company without giving pro forma effect to the transactions.

Credit Agreement

On July 23, 2018, we entered into an amended and restated credit agreement (the “Amended and Restated Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto. The Amended and Restated Credit Agreement, among other things, modified the terms of our senior unsecured revolving loan facility (the "Revolving Credit Facility") to (i) increase the total commitments under the Revolving Credit Facility from $1.0 billion to $1.3 billion and (ii) extend the maturity date under the Revolving Credit Facility from January 2021 to July 2023.

Unutilized commitments under the Amended and Restated Credit Agreement are subject to a fee of 0.20% to 0.30% depending upon our ratio of total debt to consolidated EBITDA, as calculated in accordance with the Amended and Restated Credit Agreement.

43



Revolving Credit Loans designated by us at the time of borrowing as “ABR Loans” that are outstanding under the Credit Agreement bear interest at a rate per annum equal to (i) the greatest of (a) the Prime Rate (as defined in the Credit Agreement) in effect on such day; (b) the Federal Reserve Bank of New York Rate (as defined in the Credit Agreement) in effect on such day plus 1/2 of 1%; and (c) the Adjusted LIBO Rate (as defined in the Credit Agreement) for a one-month interest period on such day plus 1%; plus (ii) the Applicable Rate. Revolving Credit Loans designated by us at the time of borrowing as “Eurodollar Loans” that are outstanding under the Credit Agreement bear interest at a rate per annum equal to the Adjusted LIBO Rate (as defined in the Credit Agreement) for the interest period in effect for such borrowing plus the Applicable Rate. Pursuant to the Amended and Restated Credit Agreement, the “Applicable Rate” decreased to a range of (A) 0.375% to 1.00% per annum for ABR Loans and (B) 1.375% to 2.00% per annum for Eurodollar Loans, in each case depending on our ratio of total debt to consolidated earnings before interest, taxes, depreciation and amortization ("EBITDA"), as calculated in accordance with the Amended and Restated Credit Agreement. The Amended and Restated Credit Agreement includes negative and financial covenants that limit certain of our and our subsidiaries’ activities, including (i) restrictions on our and our subsidiaries’ ability to incur additional indebtedness; and (ii) financial covenants that require (a) the ratio of total debt to consolidated EBITDA not to exceed a maximum and (b) a minimum interest expense and principal payment coverage ratio.

The Amended and Restated Credit Agreement also contains customary representations and warranties that must be accurate in order for us to borrow under the revolving credit facility. In addition, the Amended and Restated Credit Agreement contains customary events of default. If an event of default occurs and is continuing, we may be required immediately to repay all amounts outstanding under the Amended and Restated Credit Agreement. Lenders holding greater than 50% of the loans and commitments under the Amended and Restated Credit Agreement may elect to accelerate the maturity of the loans.

As of March 31, 2019 $200.0 million was outstanding under our Revolving Credit Facility. Additionally, we were in compliance with all covenants under the 2026 Notes, the 2025 Notes and the Amended and Restated Credit Agreement as of March 31, 2019. For additional information on our long-term debt, see Note 10 - Debt in the consolidated financial statements included in our 2018 Form 10-K.

In April 2019, we drew an additional $140.0 million under our Revolving Credit Facility for general corporate purposes, including organic growth and working capital.

Initiatives to Increase Our Unregulated Cash

Subject to certain restrictions under the Centene Merger Agreement, as discussed above, we may pursue alternatives to raise additional unregulated cash. Some of these initiatives may include, but are not limited to, obtaining dividends from certain of our regulated subsidiaries, provided sufficient capital in excess of regulatory requirements exists in these subsidiaries, and/or accessing the debt and equity capital markets. However, we cannot provide any assurances that we will obtain applicable state regulatory approvals for additional dividends to our non-regulated subsidiaries by our regulated subsidiaries or be successful in accessing the capital markets if we determine to do so. We believe that we have sufficient capital, or sufficient access to capital, including through the Revolving Credit Facility, to meet our capital needs for at least the next twelve months.  
Regulatory Capital and Dividend Restrictions

Each of our HMO and insurance subsidiaries must maintain a minimum amount of statutory capital determined by statute or regulation. Such statutes, regulations and capital requirements also restrict the timing, payment and amount of dividends and other distributions, loans or advances that may be paid to us as the sole stockholder. To the extent our HMO and insurance subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based upon current statutes and regulations, the minimum capital and surplus requirement, or net assets, for these subsidiaries was approximately $1.7 billion and $1.6 billion at March 31, 2019 and December 31, 2018, respectively. Our HMO and insurance subsidiaries were in compliance with these minimum capital requirements.

Under applicable regulatory requirements at March 31, 2019, the amount of dividends that may be paid through the remainder of 2019 by our HMO and insurance subsidiaries without prior approval by regulatory authorities is approximately $0.5 billion in the aggregate. We received $95.0 million in dividends from our regulated subsidiaries during the three-month period ended March 31, 2019, $50.0 million of which required prior regulatory approval.

For additional information on regulatory requirements, see Note 16 – Regulatory Capital and Dividend Restrictions to the consolidated financial statements included in our 2018 Form 10-K.


44


CRITICAL ACCOUNTING ESTIMATES

There have been no material changes in our critical accounting estimates during the three months ended March 31, 2019 from those previously disclosed in Part II – Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations, Critical Accounting Estimates in our 2018 Form 10-K.


45


Item 3. Quantitative and Qualitative Disclosures About Market Risk.
 
Investment Return Market Risk

As of March 31, 2019, we had cash and cash equivalents of $3.2 billion, investments classified as current assets of $1.0 billion, long-term investments of $1.1 billion and restricted investments on deposit for licensure of $274.3 million. The short-term investments classified as current assets consist of highly liquid securities with maturities between three and twelve months that are considered available for sale. Restricted assets consist of cash and cash equivalents and U.S. Treasury instruments deposited or pledged to state agencies in accordance with state rules and regulations. These restricted assets are classified as long term regardless of the contractual maturity date due to the nature of the states' requirements. The investments classified as long term are subject to interest rate risk and will decrease in value if market rates increase. Because of their contractual maturity dates, however, we would not expect the value of these investments to decline significantly as a result of a sudden change in market interest rates. Assuming a hypothetical and immediate 1% increase in market rates at March 31, 2019, the fair value of our fixed income investments would decrease by approximately $26.7 million. Similarly, a 1% decrease in market interest rates at March 31, 2019 would increase the fair value of our investments by approximately $26.7 million.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management carried out an evaluation required by Rule 13a-15 under the Exchange Act, under the leadership and with the participation of our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15 under the Exchange Act ("Disclosure Controls"). Based on the evaluation, our CEO and CFO concluded that our Disclosure Controls were effective as of the end of the period covered by this 2019 Form 10-Q.

Changes in Internal Control over Financial Reporting

On September 1, 2018, we acquired Meridian Health Plan of Michigan, Inc., Meridian Health Plan of Illinois, Inc. and MeridianRx, LLC, a pharmacy benefit manager (collectively "Meridian"), which is included in the 2019 consolidated financial statements and constituted 11.0% of total consolidated assets as of March 31, 2019 and 21.6% of total consolidated revenues for the three months ended March 31, 2019. Refer to Note 2 - Centene Plan of Merger and Acquisitions of this 2019 Form 10-Q for further discussion of the Meridian acquisition.

We continue to integrate, implement, modify and evaluate processes, information technology systems and other components of internal control over financial reporting resulting from the acquisition of Meridian and such evaluation will be reported in management’s annual assessment of internal control over financial reporting in our 2019 Annual Report on Form 10-K.  

Excluding Meridian, there has not been any change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) identified in connection with the evaluation required by Rule 13a-15(d) under the Exchange Act during the quarter ended March 31, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.



46


Part II – OTHER INFORMATION

Item 1. Legal Proceedings.

For information regarding legal proceedings, see Note 14 – Commitments and Contingencies to the condensed consolidated financial statements of this Form 10-Q.
 

Item 1A. Risk Factors.

In addition to the risk factors set forth in Part I - Item 1A - “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the “2018 Form 10-K”), investors should carefully consider the following risk factors, which relate to the proposed acquisition of us (the “Centene Transaction”) by Centene. These risks should be read in conjunction with the risk factors set forth in the 2018 Form 10-K and the other information contained in this report and our other filings with the Securities and Exchange Commission.

The Centene Transaction is subject to conditions, some or all of which may not be satisfied, or completed on a timely basis, if at all. Failure to complete the Centene Transaction could have material adverse effects on our business, results of operations, financial condition and cash flows.
The completion of the Centene Transaction is subject to a number of conditions, including, among others, (a) the adoption of the Merger Agreement by our stockholders, (b) the approval of the issuance of the shares of Centene common stock forming part of the merger consideration, as required by the listing standards of the New York Stock Exchange (the “Centene Stock Issuance”), by Centene’s stockholders, (c) the approval for listing on the New York Stock Exchange of the shares of Centene common stock to be issued in connection with the Centene Transaction, (d) the receipt of U.S. federal antitrust clearance and certain other required regulatory approvals, (e) the absence of any law or order prohibiting the consummation of the Centene Transaction or the Centene Stock Issuance, (f) the effectiveness of the registration statement on Form S-4 to be filed with the Securities and Exchange Commission by Centene for the registration of the Centene Stock Issuance under the Securities Act of 1933, (g) the absence of a material adverse effect on us or Centene, (h) no burdensome condition being a condition to the receipt of the U.S. federal antitrust clearance or the other required regulatory approvals and none of the U.S. federal antitrust clearance or the other required regulatory approvals containing, including or imposing any burdensome condition and (i) other conditions customary for a transaction of this type, which each and together make the timing and completion of the Centene Transaction uncertain.
Also, either we or Centene may terminate the Merger Agreement if the Centene Transaction has not been consummated by March 26, 2020 (subject to an automatic extension to August 26, 2020 in certain circumstances), except that this right to terminate the Merger Agreement will not be available to any party whose failure to perform any obligation under the Merger Agreement has been the cause of or the primary factor that resulted in the failure of the Centene Transaction to be consummated on or before that date.
If the Centene Transaction is not completed, our business, results of operations, financial condition and cash flows may be materially adversely affected and, without realizing any of the benefits of having completed the Centene Transaction, we will be subject to a number of risks, including the following:
•
the market price of our common stock could decline;
•
we could owe substantial termination fees to Centene under certain circumstances;
•
if the Merger Agreement is terminated and our board of directors seeks another business combination, our stockholders cannot be certain that we will be able to find a party willing to enter into a transaction on terms equivalent to or more attractive than the terms that Centene has agreed to in the Merger Agreement;
•
time and resources committed by our management to matters relating to the Centene Transaction could otherwise have been devoted to pursuing other beneficial opportunities for us;
•
we may experience negative reactions from the financial markets or from our customers or employees; and
•
we will be required to pay our costs relating to the Centene Transaction, such as legal, accounting, financial advisory and printing fees, whether or not the Centene Transaction is completed.
In addition, if the Centene Transaction is not completed, we could be subject to litigation related to any failure to complete the Centene Transaction or related to any enforcement proceeding commenced against us to perform our obligations under the Merger Agreement. The materialization of any of these risks could have material adverse effects on our business, results of operations, financial condition and cash flows.

47


Similarly, delays in the completion of the Centene Transaction could, among other things, result in additional transaction costs, loss of revenue or other negative effects associated with uncertainty about completion of the Centene Transaction.
The Merger Agreement contains provisions that limit our ability to pursue alternatives to the Centene Transaction, which could discourage a potential competing acquiror of us from making a favorable alternative transaction proposal and, in specified circumstances, could require us to pay substantial termination fees to Centene.
The Merger Agreement contains certain provisions that restrict our ability to solicit, initiate, knowingly facilitate or knowingly encourage or, subject to certain exceptions, engage in discussions or negotiations related to, or approve or recommend, any third-party proposal for an alternative acquisition transaction. Further, even if our board of directors withdraws or qualifies its recommendation with respect to the adoption of the Merger Agreement, unless the Merger Agreement has been terminated in accordance with its terms, we will still be required to submit the Centene Transaction-related proposals to a vote at the special meeting of our stockholders. In addition, Centene generally has an opportunity to offer to modify the terms of the transactions contemplated by the Merger Agreement in response to any third-party alternative acquisition proposal before our board of directors may withdraw or qualify its recommendation with respect to the Centene Transaction-related proposals.
Upon termination of the Merger Agreement, we will be required to pay to Centene (i) a termination fee of $507,658,910, which increases to $609,190,692 if such termination occurs after May 10, 2019, in connection with our acceptance of a superior proposal or a change of recommendation related thereto, (ii) a termination fee of $640,431,240 if our Board changes its recommendation in connection with an intervening event, (iii) a termination fee of $609,190,692 in the event we willfully breach our non-solicitation obligations in the Merger Agreement or (iv) a termination fee of $171,823,016 if the required vote of our stockholders is not obtained. In addition, if we receive an acquisition proposal, the Merger Agreement is later terminated under certain circumstances and within 12 months after termination we enter into an agreement to sell more than 50% of our capital stock or assets, we will be required to pay Centene a termination fee of $609,190,692, less any termination fee paid pursuant to clause (iv) above.
These provisions could discourage a potential third-party acquiror or merger partner that might have an interest in acquiring all or a significant portion of us or pursuing an alternative acquisition transaction from considering or proposing such a transaction, even if it were prepared to pay consideration with a higher per share cash or market value than the per share cash or market value proposed to be received or realized in the Centene Transaction. In particular, a termination fee, if applicable, may be substantial, and could result in a potential third-party acquiror or merger partner proposing to pay a lower price to our stockholders than it might otherwise have proposed to pay absent such a fee.
If the Merger Agreement is terminated and we determine to seek another business combination, we may not be able to negotiate a transaction with another party on terms comparable to, or better than, the terms of the Centene Transaction.
The Centene Transaction is subject to the expiration or termination of applicable waiting periods and the receipt of approvals, consents or clearances from regulatory authorities that may impose conditions that could have an adverse effect on us or, if not obtained, could prevent completion of the Centene Transaction.
Before the Centene Transaction may be completed, any waiting period (or extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the Centene Transaction must have expired or been terminated and any approvals, consents or clearances required in connection with the Centene Transaction must have been obtained under applicable law. The terms and conditions of the approvals, consents and clearances that are granted may impose requirements, limitations or costs or place restrictions on the conduct of the combined company’s business.
Under the Merger Agreement, we and Centene have agreed to use our respective reasonable best efforts to obtain such approvals, consents and clearances and therefore may be required to comply with conditions or limitations imposed by governmental authorities, except that Centene and its subsidiaries are not required to take actions that, individually or in the aggregate, would result in or would reasonably be expected to result in a burdensome condition.
In addition, regulators may impose conditions, terms, obligations or restrictions in connection with their approval of or consent to the Centene Transaction, including potential divestiture of assets, and such conditions, terms, obligations or restrictions may delay completion of the Centene Transaction or impose additional material costs on or materially limit the revenues of the combined company following the completion of the Centene Transaction. There can be no assurance that regulators will choose not to impose such conditions, terms, obligations or restrictions, and, if imposed, such conditions, terms, obligations or restrictions may delay or lead to the abandonment of the Centene Transaction.

48


We are subject to business uncertainties and contractual restrictions while the Centene Transaction is pending, which could materially adversely affect our business, results of operations, financial condition and cash flows.
In connection with the pendency of the Centene Transaction, it is possible that some customers, suppliers and other persons with whom we have a business relationship may delay or defer certain business decisions or might decide to seek to terminate, change or renegotiate their relationships with us as a result of the Centene Transaction, which could negatively affect our business, results of operations, financial condition and cash flows, as well as the market price of our common stock, regardless of whether the Centene Transaction is completed.
Under the terms of the Merger Agreement, we are subject to certain restrictions on the conduct of our business prior to completing the Centene Transaction, which may adversely affect our ability to execute certain of our business strategies, including the ability in certain cases to enter into or amend contracts, acquire or dispose of assets, incur indebtedness or incur capital expenditures. Such limitations could materially adversely affect our business, results of operations, financial condition and cash flows prior to the completion of the Centene Transaction.
Each of the risks described above may be exacerbated by delays or other adverse developments with respect to the completion of the Centene Transaction.
Uncertainties associated with the Centene Transaction may cause a loss of management personnel and other key employees, and we may have difficulty attracting and motivating management personnel and other key employees, which could materially adversely affect our business, results of operations, financial condition and cash flows.
We are dependent on the experience and industry knowledge of their management personnel and other key employees to execute our business plans. Our success depends in part upon our ability to attract, motivate and retain key management personnel and other key employees. Prior to completion of the Centene Transaction, current and prospective employees may experience uncertainty about their roles within the combined company following the completion of the Centene Transaction, which may have an adverse effect on our ability to attract, motivate or retain management personnel and other key employees.
We and Centene may be targets of securities class action and derivative lawsuits that could result in substantial costs and may delay or prevent the Centene Transaction from being completed.

Securities class action lawsuits and derivative lawsuits are often brought against public companies that have entered into merger agreements. Even if the lawsuits are without merit, defending against these claims can result in substantial costs and divert management time and resources. An adverse judgment could result in monetary damages, which could have a negative impact on our and Centene’s respective liquidity and financial condition. Additionally, if a plaintiff is successful in obtaining an injunction prohibiting completion of the Centene Transaction, then that injunction may delay or prevent the Centene Transaction from being completed, or from being completed within the expected timeframe, which may adversely affect our business, financial position and results of operation. Currently, we are not aware of any securities class action lawsuits or derivative lawsuits having been filed in connection with the Centene Transaction.


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Securities
 
None.

Issuer Purchases of Equity Securities

None.

Dividends

We have never paid cash dividends on our common stock. We currently intend to retain any future earnings to fund our business, and we do not anticipate paying cash dividends in the foreseeable future. In addition, our Amended and Restated Credit Agreement, the Indentures governing the 2026 Notes and the 2025 Notes and the Centene Merger Agreement include certain restrictions on our ability to pay cash dividends.

Our ability to pay dividends is partially dependent on, among other things, our receipt of cash dividends from our regulated subsidiaries. The ability of our regulated subsidiaries to pay dividends to us is limited by the state departments of insurance in

49


the states in which we operate or may operate, as well as requirements of the government-sponsored health programs in which we participate. Any future determination to pay dividends will be at the discretion of our board and will depend upon, among other factors, our results of operations, financial condition, capital requirements and contractual restrictions. For more information regarding restrictions on the ability of our regulated subsidiaries to pay dividends to us, please see Part I – Financial Information, Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources.

Item 3. Defaults Upon Senior Securities.

Not Applicable.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.
 
Not Applicable.

Item 6. Exhibits.

Exhibits are incorporated herein by reference or are filed with this report as set forth in the Exhibit Index.



50


EXHIBIT INDEX

 
INCORPORATED BY REFERENCE
Exhibit
Number
 
Description
 
Form
Filing Date
with SEC
Exhibit
Number
2.1
8-K
March 27, 2019
2.1
10.1
 
 
 
10.2
 
 
 
10.3
 
 
 
31.1
 
 
 
31.2
 
 
 
32.1
 
 
 
32.2
 
 
 
101.INS
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document ††
 
 
 
101.SCH
XBRL Taxonomy Extension Schema Document ††
 
 
 
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document ††
 
 
 
101.LAB
XBRL Taxonomy Extension Label Linkbase Document ††
 
 
 
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document ††
 
 
 
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document ††
 
 
 
 
* Denotes a management contract or compensatory plan, contract or arrangement
 
 
 
 
† Filed herewith.
 
 
 
 
†† Furnished herewith and not filed for purposes of Section 11 and Section 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.
 
 
 

51


SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on April 30, 2019.

 
WELLCARE HEALTH PLANS, INC.
 
By:
/s/ Andrew L. Asher
 
 
Andrew L. Asher
 
 
Executive Vice President and Chief Financial Officer (Principal Financial Officer)
 
 
 
 
By:
/s/ Michael Troy Meyer
 
 
Michael Troy Meyer
 
 
Vice President and Chief Accounting Officer (Principal Accounting Officer)


52
 EX-10.1 2 ex1014302019.htm FORM OF STOCK UNIT AWARD AGREEMENT Exhibit

Exhibit 10.1

STOCK UNIT AWARD AGREEMENT

Pursuant to a Restricted Stock Unit Award Notice and Agreement or a Performance Stock Unit Award Notice and Agreement (each, an “Award Notice”), WellCare Health Plans, Inc., a Delaware corporation (the “Company”), has granted to Participant named in the Award Notice the number of Restricted Stock Units (“RSUs”) or, RSUs, the vesting of which is conditioned upon the achievement of one or more performance goals (“PSUs”), set forth in the Award Notice, subject to the terms and conditions of the Award Notice and this Stock Unit Award Agreement (the “Award Agreement” and together with the Award Notice, the “Award Documentation”). RSUs and PSUs are referred to herein as “Stock Units”.
  
1.The Plan. The Stock Units are granted pursuant to the WellCare Health Plans, Inc. 2013 Incentive Compensation Plan (the “Plan”), a copy of which has been made available to Participant. The terms and conditions of the Plan are incorporated into this Award Agreement. As a condition to the grant of Stock Units set forth in the Award Notice, Participant agrees to be bound by all of the terms and conditions in the Award Documentation and in the Plan. If and to the extent that the Award Documentation conflicts or is inconsistent with the terms, conditions and provisions of the Plan, the Plan shall control, and the Award Documentation shall be deemed to be modified accordingly.

2.Definition of Retirement. For purposes of the Award Documentation, the following terms shall be defined as set forth below.

(a)    “Retirement” means the termination of the Participant’s employment, other than by reason of death, Disability or Cause, provided that the Participant is age 60 or older with at least five years of Recognized Employment with the Company or any Subsidiary at the time of such termination.

(b)    “Recognized Employment” means employment with the Company or any Subsidiary, and shall not include employment with a company acquired by the Company or any Subsidiary before the date of such acquisition; provided that, with respect to a Participant whose employment with the Company or a Subsidiary terminates and who is subsequently rehired, Recognized Employment shall include all time periods of the Participant’s employment with the Company or a Subsidiary.
 
3.Accelerated Vesting. Notwithstanding any other term or provision of the Award Documentation but subject to the provisions of the Plan, the Committee shall be authorized, in its sole discretion, to accelerate the vesting of all or any portion of the Stock Units under the Award Documentation, at such times and upon such terms and conditions as the Committee shall deem advisable.

4.No Rights as a Shareholder. Until the stock certificates reflecting the Shares underlying the Stock Units are issued to Participant, which may be in book-entry form, Participant shall have none of the rights of a shareholder with respect to such Shares.

5.Adjustments. If a Stock Unit is adjusted pursuant to Section 10(c) of the Plan, any such adjustment shall disregard any fractional Share and no Share will be delivered in connection with such fraction.

6.No Effect on Company Actions. Notwithstanding any term or provision of the Award Documentation to the contrary, the existence of the Award, or of any outstanding Stock Units awarded hereunder, shall not affect in any manner the right, power or authority of the Company to make, authorize or consummate: (a) any or all adjustments, recapitalizations, reorganizations, stock splits, stock dividends, combination of shares or other changes in the Company’s capital structure or its business, (b) any merger, consolidation or similar transaction by or of the Company, (c) any offer, issue or sale by the Company of any



capital stock of the Company, including any equity or debt securities, or preferred or preference stock that would rank prior to or on parity with the Stock Units and/or that would include, have or possess other rights, benefits and/or preferences superior to those that the Stock Units include, has or possesses, or any warrants, options or rights with respect to any of the foregoing, (d) the dissolution or liquidation of the Company, (e) any sale, transfer or assignment of all or any part of the stock, assets or business of the Company or (f) any other corporate transaction, act or proceeding (whether of a similar character or otherwise).

7.Tax Withholding Obligations. As a condition of this Award, Participant will pay, or otherwise provide for, to the satisfaction of the Company, any applicable federal, state, local or foreign withholding taxes that may be due as a result of the vesting of Stock Units or the issuance of Shares under this Award. In the event that the Company determines that any payment of withholding or other taxes is required, the Company will have the right to: (a) require that Participant arrange such payments to the Company, or (b) cause an immediate forfeiture of Shares subject to the Stock Units granted pursuant to the Award Documentation with a Fair Market Value on the date of forfeiture equal to the withholding or other taxes due. In addition, in the Company’s sole discretion and consistent with the Company’s rules (including, but not limited to, compliance with the Company’s Policy on Inside Information and Insider Trading) and regulations, the Company may permit Participant to pay the withholding or other taxes due as a result of the vesting of Participant’s Stock Units by delivery (on a form acceptable to the Committee or Company) of an irrevocable direction to a licensed securities broker to sell Shares and to deliver all or part of the sales proceeds to the Company in payment of the withholding or other taxes. If Participant delivers to the Company Shares already owned by Participant as payment for any withholding or other tax obligations, (c) only a whole number of Shares (and not fractional Shares) may be delivered and (d) Shares must be delivered to the Company free and clear of any liens of any kind. Delivery for this purpose may, at the election of Participant, be made either by (e) physical delivery of the certificate(s) for all such Shares tendered in payment of the withholding or other tax obligations, accompanied by duly executed instruments of transfer in a form acceptable to the Company, or (f) direction to Participant’s broker to transfer, by book entry, such Shares from a brokerage account of Participant to a brokerage account specified by the Company. If Shares are withheld from Participant to pay any withholding or other tax obligations, only a whole number of Shares (and not fractional shares) will be withheld in payment. The tax consequences to Participant (including without limitation federal, state, local and foreign income tax consequences) with respect to the Stock Units (including without limitation the grant, vesting and/or delivery thereof) are the sole responsibility of Participant. Participant shall consult with his or her own personal accountant(s) and/or tax advisor(s) regarding these matters and Participant’s filing, withholding and payment (or tax liability) obligations.

8.Non-Transferability. Unless otherwise determined by the Committee, the Stock Units may not be transferred in any manner except by will or the laws of descent and distribution, and any attempt to transfer the Stock Units in violation of this Section 8 shall be void ab initio.

9.Amendment, Modification and Assignment. The Committee may amend or modify the Award Documentation at any time as provided by Sections 10(c) and Section 10(f) of the Plan and, if applicable, consistent with Appendix A of the Award Notice. This Award (and Participant’s rights hereunder) may not be assigned, and the obligations of Participant hereunder may not be delegated, in whole or in part. The rights and obligations created hereunder shall be binding on Participant and his executors, administrators, and heirs, and on the successors and assigns of the Company.

10.Complete Agreement. The Award Documentation (together with the Plan and the Plan prospectus) constitute the entire agreement, and supersede all other prior agreements, understandings, representations and warranties, both written and oral, among the parties, with respect to the subject matter hereof.

11.No Right to Continued Employment or Service. The Award Documentation and the Award shall not confer, or be construed to confer, upon Participant any right to employment or service, or continued employment or service, with the Company or any of its Subsidiaries.


2

12.No Limit on Other Compensation Arrangements. Nothing contained in the Award Documentation shall preclude the Company or any of its Subsidiaries from adopting or continuing in effect any other or additional compensation plans, agreements or arrangements.

13.No Trust or Fund Created. Neither the Award Documentation nor the grant of Stock Units pursuant to the Award Documentation shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any of its Subsidiaries and Participant or any other person. To the extent that Participant or any other person acquires a right to receive payments from the Company or any of its Subsidiaries pursuant to the Award Documentation, such right shall be no greater than the right of any unsecured general creditor of the Company.

14.Section 409A. The Award Documentation shall be interpreted, administered and construed in a manner that is intended to avoid the imposition of interest, taxes and penalties on Participant pursuant to Section 409A of the Code. To the extent that any portion of the Stock Units constitutes “nonqualified deferred compensation” within the meaning of Section 409A of the Code, (a) to the extent required in order to avoid the imposition of any interest, penalties and additional tax under Section 409A of the Code, any Shares deliverable as a result of Participant’s termination of Continuous Service will be delayed for six months and one day following such termination of Continuous Service, or if earlier, the date of Participant’s death, if Participant is deemed to be a “specified employee” as defined in Section 409A of the Code and as determined by the Company, (b) any delivery of Shares provided for in the Award Documentation in connection with Participant’s termination of Continuous Service shall be made to Participant only upon a “separation from service” (as such term is defined and used in Section 409A of the Code), and (c) each delivery of Shares made under the Award Documentation shall be treated as a separate payment for purposes of Section 409A of the Code. Notwithstanding the foregoing, the Company does not make any representation to Participant that the Stock Units awarded pursuant to this Award Documentation are exempt from, or satisfy, the requirements of Section 409A of the Code, and the Company shall have no liability or other obligation to indemnify or hold harmless Participant or any Beneficiary for any tax, additional tax, interest or penalties that Participant or any Beneficiary may incur in the event that any provision of this Award Documentation, or any amendment or modification thereof or any other action taken with respect thereto, is deemed to violate any of the requirements of Section 409A of the Code.

15.Interpretation; Construction. Participant accepts as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Award Documentation. Section, paragraph and other headings and captions are provided solely as a convenience to facilitate reference. Such headings and captions shall not be deemed in any way material or relevant to the construction, meaning or interpretation of the Award Documentation or any term or provision hereof.

16.Notices. Any notice under the Award Documentation shall be in writing addressed (a) if to the Company, to the attention of the Company’s General Counsel at 8735 Henderson Road, Renaissance Two, Tampa, Florida 33634, or if the Company should move its principal office, to such principal office and (b) if to Participant, to Participant’s last permanent address as shown on the Company’s records, or to such other address as may be designated in a notice satisfying the requirements of this Section 16. Any notices shall be delivered personally or sent by registered or certified mail, postage prepaid, by facsimile (with proof of transmission), by courier (with proof of delivery) or by such other methods that are acceptable to the Company. Notice shall be deemed to have been duly given when delivered personally or when deposited in the United States mail or sent pursuant to such other method acceptable to the Company.

17.Non-Waiver of Breach. The waiver by any party hereto of the other party’s prompt and complete performance, or breach or violation, of any term or provision of the Award Documentation shall be effected solely in a writing signed by such party, and shall not operate nor be construed as a waiver of any subsequent breach or violation, and the waiver by any party hereto to exercise any right or remedy which he or it may possess shall not operate nor be construed as the waiver of such right or remedy by such party, or as a bar to the exercise of such right or remedy by such party, upon the occurrence of any subsequent breach or violation.

3


18.Counterparts. The Award Documentation may be executed in two or more separate counterparts, each of which shall be an original, and all of which together shall constitute one and the same agreement.

19.Forfeiture and Company Right to Recover Fair Market Value of Shares Received Pursuant to Stock Units. This section sets forth circumstances under which Participant shall forfeit all or a portion of the Stock Units, or be required to repay the Company for the value realized in respect of all or a portion of the Stock Units.

(a)    Fraud; Misconduct. In addition to the provisions set forth in Section 10(g) of the Plan, if, at any time, the Board or the Committee, as the case may be, in its sole discretion determines that any action or omission by Participant constituted (i) wrongdoing that contributed to (A) any material misstatement in or omission from any report or statement filed by the Company with the U.S. Securities and Exchange Commission or (B) a statement, certification, cost report, claim for payment, or other filing made under Medicare or Medicaid that was false, fraudulent, or for an item or service not provided as claimed, (ii) intentional or gross misconduct, (iii) a breach of a fiduciary duty to the Company or a Subsidiary, (iv) fraud or (v) non-compliance with the Company’s Code of Conduct and Business Ethics, policies or procedures to the material detriment of the Company, then in each such case, commencing with the first fiscal year of the Company during which such action or omission occurred, Participant shall forfeit (without any payment therefore) up to 100% of any Stock Units that have not been vested or settled and shall repay to the Company, upon notice to Participant by the Company, up to 100% of the Fair Market Value of the Shares at the time such Shares were delivered to Participant pursuant to the Stock Units during and after such fiscal year. The Board or the Committee, as the case may be, shall determine in its sole discretion the date of occurrence of such action or omission, the percentage of the Stock Units that shall be forfeited and the percentage of the Fair Market Value of the Shares delivered pursuant to the Stock Units that must be repaid to the Company.

(b)    Violation of Restrictive Covenants. In addition to the provisions set forth in Section 10(g) of the Plan, if Participant, during any period during which the applicable Stock Units are eligible to vest, without the consent of the Company, violates (i) a non‑competition, non-solicitation, non-interference, non-disclosure, non-disparagement or other restrictive covenant obligation and/or confidentiality agreement or other agreement to which Participant is subject as of the date of Retirement or Disability (without regard to the post-employment duration of such covenant obligation, it being understood that, solely for purposes of this provision, the post-employment duration of such covenant obligation shall be deemed to extend through the end of the period during which the applicable Stock Units are eligible to vest) or (ii) any common law fiduciary duty or duty of loyalty to the Company or a Subsidiary, then any unvested Stock Units shall be immediately forfeited without any payment to Participant and shall become null and void.
 
20.Governing Law. The Award Documentation shall be governed by the corporate laws of the State of Delaware, without giving effect to any choice of law provisions.

21.Severability. If any term or provision of the Award Documentation is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or under any applicable law, rule or regulation, then such provision shall be construed or deemed amended to conform to applicable law (or if such provision cannot be so construed or deemed amended without materially altering the purpose or intent of the Award Documentation and the grant of Stock Units hereunder, such provision shall be stricken as to such jurisdiction and the remainder of the Award Documentation and the Award hereunder shall remain in full force and effect).

4
 EX-10.2 3 ex10243019.htm FORM OF RESTRICTED STOCK AWARD NOTICE AND AGREEMENT Exhibit

Exhibit 10.2

WELLCARE HEALTH PLANS, INC. 2013 INCENTIVE COMPENSATION PLAN
RESTRICTED STOCK UNIT AWARD NOTICE AND AGREEMENT

This award is made to the Participant named below by WellCare Health Plans, Inc., a Delaware corporation (the “Company”). Subject to the terms and conditions of this Restricted Stock Unit Award Notice and Agreement and the terms and conditions of the Stock Unit Award Agreement that is an integral part of this award (together, the “Award Documentation”), the Company hereby awards under the WellCare Health Plans, Inc. 2013 Incentive Compensation Plan (the “Plan”) the Restricted Stock Units (“RSUs”) described below to Participant effective as of the Grant Date set forth below. Capitalized terms used in the Award Documentation that are not defined herein have the meanings attributed to them in the Plan.

1.    Participant: [●]

2.    Grant Date: [●]

3.    Number of RSUs Awarded: [●], subject to adjustment as provided in the Award Documentation and the Plan.

4.    Description of RSUs: Each RSU constitutes an unfunded and unsecured promise of the Company to deliver one Share to Participant on the Delivery Date (defined below).

5.    Normal Vesting Schedule: Except as set forth in Sections 7, 8 and 9 below, the following table sets forth each date upon which Participant shall become vested with respect to the number of RSUs set forth opposite such date (each such date, a “Vesting Date”), provided that the Continuous Service of Participant continues through and on the applicable Vesting Date. Except as otherwise provided in the Award Documentation, the RSUs shall vest only on the Vesting Dates specified in the table below and no partial vesting will occur prior to any Vesting Date.

Vest Date
 
Vest Quantity
 
 
 

6.    Termination of Continuous Service: Except as set forth in Sections 7, 8 and 9 below, upon the termination of Participant’s Continuous Service for any reason, any then-unvested RSUs shall be forfeited automatically without any payment to Participant and become null and void.

7.    Change in Control: In the event of a Change in Control, any then-unvested RSUs shall become immediately vested on the effective date of the termination of Participant’s Continuous Service if, within twenty-four (24) months following a Change in Control, Participant’s Continuous Service is terminated (i) by the Company or a Subsidiary without Cause, (ii) by Participant for Good Reason, (iii) for Retirement or (iv) for Disability.

8.    Retirement or Long-Term Disability: If Participant ceases to be an employee of the Company or a Subsidiary and either (i) Participant is eligible for Retirement at the time of such termination of employment and Participant’s employment is terminated for Retirement or (ii) Participant’s employment terminates due to Participant’s Disability, then (x) if such termination occurs on or prior to the one-year anniversary of the Grant Date, (1) Participant shall retain a pro-rata portion of the RSUs (with such pro-rata portion determined by multiplying the total number of RSUs granted to Participant hereunder by a fraction, the numerator of which is the number of days from the Grant Date through the date of Participant’s termination, and the denominator of which is 365), which retained RSUs shall continue to vest in equal installments on the applicable Vesting Dates as if such termination of employment had not occurred, and (2) any RSUs that are not retained by Participant

1


and otherwise eligible for continued vesting pursuant to the immediately preceding clause (x)(1) shall be forfeited automatically without any payment to Participant and become null and void, and (y) if such termination occurs following the one-year anniversary of the Grant Date, the RSUs shall continue to vest on the applicable Vesting Date as if such termination of employment had not occurred.

9.    Death: If Participant dies while employed by the Company or a Subsidiary, any then-unvested RSUs shall become immediately vested.

10.    Delivery Date: The Shares underlying the number of vested RSUs shall be delivered as soon as practicable and, in any case, within 30 days after the earlier of (i) the applicable Vesting Date on which such RSUs were originally scheduled to vest (not taking into account any acceleration of vesting pursuant to Section 7 or 8 of this Agreement) and (ii) the Participant’s death.

Participant acknowledges and agrees that by accepting this Restricted Stock Unit Award Notice and Agreement electronically through the website of the agent appointed by the Company to administer the Plan, it will act as the Participant’s electronic signature to this Restricted Stock Unit Award Notice and Agreement and Participant hereby consents and agrees to the electronic delivery of the Award Documentation. Participant acknowledges and agrees that (1) the Stock Unit Award Agreement, the Plan and the Plan prospectus are available for Participant’s review through the website of the agent appointed by the Company to administer the Plan, and, upon request, a paper version of each document will be provided to Participant and (2) Participant has reviewed and fully understands the Award Documentation, the Plan and the Plan prospectus and agrees to be bound by the terms and conditions of the Plan and the Award Documentation.


2

 EX-10.3 4 ex10343019.htm FORM OF PERFORMANCE STOCK UNIT AWARD NOTICE AND AGREEMENT Exhibit


Exhibit 10.3

WELLCARE HEALTH PLANS, INC. 2013 INCENTIVE COMPENSATION PLAN
PERFORMANCE STOCK UNIT AWARD NOTICE AND AGREEMENT

This award is made to the Participant named below by WellCare Health Plans, Inc., a Delaware corporation (the “Company”). Subject to the terms and conditions of this Performance Stock Unit Award Notice and Agreement, including Appendix A attached hereto and incorporated herein, and the terms and conditions of the Stock Unit Award Agreement that is an integral part of this award (together, the “Award Documentation”), the Company hereby awards under the WellCare Health Plans, Inc. 2013 Incentive Compensation Plan (the “Plan”) the Restricted Stock Units, the vesting of which is conditioned upon the achievement of one or more performance goals set forth on Appendix A attached hereto (“PSUs”), described below to Participant effective as of the Grant Date set forth below. Capitalized terms used in the Award Documentation that are not defined herein have the meanings attributed to them in the Plan.

1.Participant: [●]

2.Grant Date: [●]

3.Performance Period: [●]

4.Target Number of PSUs Awarded: [●], subject to adjustment as provided in the Award Documentation and the Plan. The actual number of PSUs that become eligible for vesting shall be determined by the Committee in accordance with Appendix A.

5.Vesting Date: Except as set forth in Sections 8, 9 and 10 below, [●] (the “Vesting Date”).

6.Description of PSUs: Each PSU constitutes an unfunded and unsecured promise of the Company to deliver one Share to Participant on the Delivery Date (defined below).

7.Termination of Continuous Service: Except as set forth in Sections 8, 9 and 10 below, upon the termination of Participant’s Continuous Service for any reason, any then-unvested PSUs shall be forfeited automatically without any payment to Participant and become null and void.

8.Change in Control: In the event of a Change in Control, the number of PSUs determined in accordance with Appendix A attached hereto shall become immediately vested on the earlier of (a) the Vesting Date set forth in Section 5 above or (b) the effective date of the termination of Participant’s Continuous Service if, within twenty-four (24) months following a Change in Control, Participant’s Continuous Service is terminated (i) by the Company or a Subsidiary without Cause, (ii) by Participant for Good Reason, (iii) for Retirement or (iv) for Disability.

9.Retirement or Long-Term Disability: If Participant ceases to be an employee of the Company or a Subsidiary and either (i) Participant is eligible for Retirement at the time of such termination of employment and Participant’s employment is terminated for Retirement or (ii) Participant’s employment terminates due to Participant’s Disability, then following the end of the Performance Period, if and to the extent the Committee, in accordance with Section 4 above, determines that some number of PSUs will vest, Participant will, on the Vesting Date, vest in such number of PSUs determined as follows: (x) if such termination occurs on or prior to the one-year anniversary of the Grant Date, Participant shall vest in a pro-rata portion of the PSUs (with such pro-rata portion determined by multiplying the total number of PSUs that Participant would have otherwise earned as if such termination of employment had not occurred by a fraction, the numerator of which is the number of days from the Grant Date through the date of Participant’s termination, and the denominator of which is 365), and (y) if such termination occurs following the one-year


anniversary of the Grant Date, Participant shall vest in the number of PSUs that would have been earned as if such termination of employment had not occurred.

10.Death: If Participant dies while employed by the Company or a Subsidiary, the Target Number of PSUs Awarded shall become immediately vested.

11.Cancellation: Any PSUs that do not vest pursuant to Sections 4, 8, 9 or 10 above on or before the Vesting Date shall be forfeited automatically on the Vesting Date without any payment to Participant and become null and void.

12.Delivery Date: The Shares underlying the number of vested PSUs shall be delivered as soon as practicable after the earlier of (i) the Vesting Date (not taking into account any acceleration of vesting pursuant to Sections 8 or 9 of this Agreement) and (ii) the Participant’s death, but in no event later than March 15th of the year immediately following the year in which such PSUs vest.

Participant acknowledges and agrees that by accepting this Performance Stock Unit Award Notice and Agreement electronically through the website of the agent appointed by the Company to administer the Plan, it will act as the Participant’s electronic signature to this Performance Stock Unit Award Notice and Agreement and Participant hereby consents and agrees to the electronic delivery of the Award Documentation. Participant acknowledges and agrees that (1) the Stock Unit Award Agreement, the Plan and the Plan prospectus are available for Participant’s review through the website of the agent appointed by the Company to administer the Plan, and, upon request, a paper version of each document will be provided to Participant and (2) Participant has reviewed and fully understands the Award Documentation, the Plan and the Plan prospectus and agrees to be bound by the terms and conditions of the Plan and the Award Documentation.





 EX-31.1 5 wcg-ex311_20190331.htm 302 CERTIFICATION OF CEO Exhibit
EXHIBIT 31.1

CERTIFICATION

I, Kenneth A. Burdick, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of WellCare Health Plans, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
April 30, 2019
 
/s/ Kenneth A. Burdick
 
 
 
Kenneth A. Burdick
 
 
 
Chief Executive Officer
 
 
 
(Principal Executive Officer)


 EX-31.2 6 wcg-ex312_20190331.htm 302 CERTIFICATION OF CFO Exhibit
EXHIBIT 31.2

CERTIFICATION

I, Andrew L. Asher, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of WellCare Health Plans, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
April 30, 2019
 
/s/ Andrew L. Asher
 
 
 
Andrew L. Asher
 
 
 
Executive Vice President and Chief Financial Officer
 
 
 
(Principal Financial Officer)


 EX-32.1 7 wcg-ex321_20190331.htm 906 CERTIFICATION OF CEO Exhibit
 
 
EXHIBIT 32.1



CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of WellCare Health Plans, Inc. (the "Company") for the period ended March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Form 10-Q"), I, Kenneth A. Burdick, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:
April 30, 2019
 
/s/ Kenneth A. Burdick
 
 
 
Kenneth A. Burdick
 
 
 
Chief Executive Officer
 
 
 
(Principal Executive Officer)


 EX-32.2 8 wcg-ex322_20190331.htm 906 CERTIFICATION OF CFO Exhibit
 
 
EXHIBIT 32.2



CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of WellCare Health Plans, Inc. (the "Company") for the period ended March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Form 10-Q"), I, Andrew L. Asher, Executive Vice President and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:
April 30, 2019
 
/s/ Andrew L. Asher
 
 
 
Andrew L. Asher
 
 
 
Executive Vice President and Chief Financial Officer
 
 
 
(Principal Financial Officer)


 EX-101.SCH 9 wcg-20190331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2102100 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Goodwill Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Identifiable Intangible Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Pro Forma Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - DEBT - Redemption Prices as Percentage of Principal Amount (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - DEBT - Schedule of Outstanding Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - DISCONTINUED OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - EQUITY AND EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - EQUITY AND EARNINGS PER SHARE- Calculation of Weighted-Average Common Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - EQUITY AND EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - FAIR VALUE MEASUREMENTS - Carrying Value and Fair Value of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - INVESTMENTS - Contractual Maturities of Available-for-sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - INVESTMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - INVESTMENTS - Short-term and Long-term Investments by Security Type (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - LEASES - Balance Sheet items related to operating leases (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - LEASES - Maturity of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - LEASES - Maturity of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - LEASES - Supplemental cash flow information related to leases (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - MEDICAL BENEFITS PAYABLE link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - MEDICAL BENEFITS PAYABLE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - MEDICAL BENEFITS PAYABLE - Reconciliation of Beginning and Ending Balances, by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - MEDICAL BENEFITS PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS - Schedule of Restricted Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - SEGMENT REPORTING - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - SEGMENT REPORTING - Revenue by Geographic Location (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - SEGMENT REPORTING - Segment Results (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Unit Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 wcg-20190331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 wcg-20190331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 wcg-20190331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Segment Reporting [Abstract] Revenue by Geographic Location Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Segment Results Schedule of Segment Reporting Information, by Segment [Table Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Performance Stock Units Performance Shares [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Compensation expense Share-based Compensation Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted-average period over which compensation costs are expected to be recognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Closing common stock price (in USD per share) Share Price Grants in period, weighted average grant date fair value (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Investments, Debt and Equity Securities [Abstract] INVESTMENTS Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Statement of Financial Position [Abstract] Assets Assets [Abstract] Current Assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Short-term Investments Premiums receivable, net Premiums Receivable, Net Pharmacy rebates receivable, net Other Receivables, Net, Current Funds receivable for the benefit of members Funds Receivable For The Benefit Of Members Funds held or receivable for the benefit of members represent government payments received or to be received to subsidize the member portion of medical payments for certain of our stand-alone prescription drug program members. We do not bear underwriting risk since such funds represent pass-through payments from our government partners to fund deductibles, co-payments and other participant benefits. Prepaid expenses and other current assets, net Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property, equipment and capitalized software, net Property, Plant and Equipment, Net Goodwill Goodwill Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Long-term investments Long-term Investments Restricted cash, cash equivalents and investments Restricted Cash and Investments, Noncurrent Other assets Other Assets, Noncurrent Assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Noncurrent Total Assets Assets Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Current Liabilities: Liabilities, Current [Abstract] Medical benefits payable Liability for Claims and Claims Adjustment Expense Unearned premiums Unearned Premiums Accounts payable and accrued expenses Accounts Payable and Other Accrued Liabilities, Current Funds payable for the benefit of members Funds Payable For The Benefit of Members Funds held (payable) or receivable for the benefit of members represent government payments received or to be received to subsidize the member portion of medical payments for certain of our stand-alone prescription drug program members. We do not bear underwriting risk since such funds represent pass-through payments from our government partners to fund deductibles, co-payments and other participant benefits. Other payables to government partners Other Payables To Government Partners Other payables due to government partners represent amounts due to government agencies under various contractual and plan arrangements. We estimate the amounts due to CMS for risk protection under the risk corridor provisions of our contract with CMS each period based on pharmacy claims experience. Also this line item includes reserves for the return of premium on minimum loss ratio guarantees for certain state Medicaid contracts. Total current liabilities Liabilities, Current Deferred income tax liability, net Deferred Income Tax Liabilities, Net Long-term debt, net Long-term Debt, Excluding Current Maturities Other liabilities Other Liabilities, Noncurrent Liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent Total Liabilities Liabilities Commitments and contingencies (see Note 14) Commitments and Contingencies Stockholders' Equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $0.01 par value (20,000,000 authorized, no shares issued or outstanding) Preferred Stock, Value, Issued Common stock, $0.01 par value (100,000,000 authorized, 50,302,215 and 49,993,219 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively) Common Stock, Value, Issued Paid-in capital Additional Paid in Capital Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Total Stockholders' Equity Stockholders' Equity Attributable to Parent Total Liabilities and Stockholders' Equity Liabilities and Equity Debt Disclosure [Abstract] Schedule of Outstanding Debt Obligations Schedule of Long-term Debt Instruments [Table Text Block] Business Combinations [Abstract] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Meridian Meridian [Member] Meridian [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Medicaid Health Plan Medicaid [Member] A reportable segment and business line which includes plans for beneficiaries of various Medicaid programs and state-based programs that are not a part of the Medicaid program. Medicare Health Plan Medicare Health Plans [Member] Medicare Health Plans Segment [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Changes in Goodwill Goodwill [Roll Forward] Beginning Balance Acquisition related adjustments Goodwill, Purchase Accounting Adjustments Ending Balance Total revenues Business Acquisition, Pro Forma Revenue Net income Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Information [Abstract] Business Acquisition, Pro Forma Information [Abstract] Earnings per common share: Earnings Per Share [Abstract] Basic (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Basic Diluted (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Basic [Abstract] Basic (in shares) Business Combination, Pro Forma Information, Weighted Average Common Shares Outstanding, Basic Business Combination, Pro Forma Information, Weighted Average Common Shares Outstanding, Basic Diluted (in shares) Business Combination, Pro Forma Information, Weighted Average Common Shares Outstanding, Diluted Business Combination, Pro Forma Information, Weighted Average Common Shares Outstanding, Diluted Short-term and Long-term Investments by Security Type Debt Securities, Available-for-sale [Table Text Block] Contractual Maturities of Available-for-sale Securities Investments Classified by Contractual Maturity Date [Table Text Block] Leases [Abstract] Assets [Abstract] Right of use assets Operating Lease, Right-of-Use Asset Liabilities [Abstract] Liabilities [Abstract] Current Operating Lease, Liability, Current Noncurrent Operating Lease, Liability, Noncurrent Total liabilities Operating Lease, Liability LEASES Lessee, Operating Leases [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Net Income (Loss) Attributable to Parent Adjustments to reconcile net income to cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Stock-based compensation expense Deferred taxes, net Deferred Income Tax Expense (Benefit) Other, net Other Operating Activities, Cash Flow Statement Changes in operating accounts, net of effects from acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] Premiums receivable, net Increase (Decrease) in Premiums Receivable Pharmacy rebates receivable, net Increase (Decrease) in Other Receivables Medical benefits payable Increase (Decrease) in Health Care Insurance Liabilities Unearned premiums Increase (Decrease) in Unearned Premiums Other receivables/payables to government partners Increase Decrease In Other Payables To Government Partners The net change during the reporting period in amounts due to government agencies under various contractual and plan arrangements. We estimate the amounts due from CMS for risk protection under the risk corridor provisions of our contract with CMS each period based on pharmacy claims experience. Prepaid and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accrued liabilities and other, net Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of investments Payments to Acquire Investments Proceeds from sales and maturities of investments Proceeds from Sale, Maturity and Collection of Investments Additions to property, equipment and capitalized software, net Payments to Acquire Productive Assets Net cash used in provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Repurchase and retirement of shares to satisfy employee tax withholding requirements Payments Related to Tax Withholding for Share-based Compensation Funds received for the benefit of members, net Proceeds from (Payments for) the Benefit of Members Proceeds from (Payments for) the Benefit of Members Other, net Proceeds from (Payments for) Other Financing Activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities (Decrease) increase in cash, cash equivalents and restricted cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Balance at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Balance at end of period SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Supplemental Cash Flow Information [Abstract] Cash paid for taxes, net of refunds Income Taxes Paid, Net Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities SUPPLEMENTAL DISCLOSURES OF NON-CASH TRANSACTIONS: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash additions to property, equipment, and capitalized software Capital Expenditures Incurred but Not yet Paid Discontinued Operations and Disposal Groups [Abstract] DISCONTINUED OPERATIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Fair Value Disclosures [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Carrying Value Reported Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Long-term debt, fair value Long-term Debt, Fair Value DEBT Debt Disclosure [Text Block] Income Tax Disclosure [Abstract] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent MEDICAL BENEFITS PAYABLE [Abstract] Reconciliation of the Beginning and Ending Balances of Medical Benefits Payable, by Segment Reconciliation of Medical Benefits Payable [Table Text Block] A reconciliation of the beginning and ending balances of medical benefits payable, including separate disclosure of medical benefits incurred and medical benefits paid during the reporting period. Restricted Investments Note [Abstract] RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS Restricted Assets Disclosure [Text Block] Balance sheet information related to operating leases Assets And Liabilities, Leases [Table Text Block] Assets And Liabilities, Leases [Table Text Block] Maturities of operating leases Lessee, Operating Lease, Liability, Maturity [Table Text Block] Supplemental cash flow information related to leases Lease, Cost [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, Forecast Scenario, Forecast [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Centene Centene [Member] Centene [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Aetna Part D Business Aetna Part D Business [Member] Aetna Part D Business [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Notes Senior Notes [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 5.375% Senior Notes, due August 15, 2026 Senior Notes Due 2026 Issued 2018 - 5.375 percent [Member] Senior Notes Due 2026 Issued 2018 - 5.375 percent [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Cash received per share Business Acquisition, Share Price Shares received for each common share Business Acquisition, Shares Issued Per Common Share Outstanding Business Acquisition, Shares Issued Per Common Share Outstanding Acquisition consideration transferred Business Combination, Consideration Transferred Estimated weighted average useful live of identifiable intangible assets Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Proceeds from long-term lines of credit Proceeds from Long-term Lines of Credit Aggregate principal amount Debt Instrument, Face Amount Interest rate Debt Instrument, Interest Rate, Stated Percentage Issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock Sale of stock, number of shares issued in transaction Sale of Stock, Number of Shares Issued in Transaction Investment banking, advisory, brokerage, and underwriting fees and commissions Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions Net deferred tax liabilities acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Revenue Revenues SEGMENT REPORTING Segment Reporting Disclosure [Text Block] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Reclassifications Reclassification, Policy [Policy Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Aetna Part D Membership Reinsurance Reinsurance Accounting Policy [Policy Text Block] Premium Receivable and Unearned Premiums Revenue from Contract with Customer [Policy Text Block] Medicare Part D Settlements Funds Receivable/Payable for the Benefit of Members [Policy Text Block] [Table Text Block] for Disclosure of accounting policy for Funds Receivable or Payable for the Benefit of Members [Table] ACA Industry Fee ACA Industry Fee [Policy Text Block] ACA Industry Fee [Policy Text Block] Accounting Standards Recently Adopted and Pending Adoption New Accounting Pronouncements, Policy [Policy Text Block] Proceeds from sale of available-for-sale investments Proceeds from Sale of Debt Securities, Available-for-sale Realized gains and losses on sales and redemptions of investments Debt Securities, Available-for-sale, Realized Gain (Loss) Other than temporary impairment losses Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale Restrictions on Cash and Cash Equivalents [Table] Restrictions on Cash and Cash Equivalents [Table] Restricted Cash and Cash Equivalents, Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents, Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Cash Cash [Member] Money market funds Money Market Funds [Member] U.S. government securities and other US Treasury and Government [Member] Restricted Cash and Cash Equivalents Items [Line Items] Restricted Cash and Cash Equivalents Items [Line Items] Amortized Cost Restricted Investments, Amortized Cost Basis Restricted Investments, Amortized Cost Basis Gross Unrealized Gains Restricted Investments, Gross Unrealized Gain, Before Tax Restricted Investments, Gross Unrealized Gain, Before Tax Gross Unrealized Losses Restricted Investments, Gross Unrealized Losses, Before Tax Restricted Investments, Gross Unrealized Losses, Before Tax Estimated Fair Value Restricted Cash and Cash Equivalents, Noncurrent Prior years Prior Year Claims and Claims Adjustment Expense Favorable development of medical benefits payable Net Favorable (Unfavorable) Development of Medical Benefits Payable Net Favorable (Unfavorable) Development of Medical Benefits Payable Favorable development of medical benefits payable excluding the release of the provision for moderately adverse conditions Net Favorable (Unfavorable) Development of Medical Benefits Payable, Excluding Release of the Provision for Moderately Adverse Conditions Net Favorable (Unfavorable) Development of Medical Benefits Payable, Excluding Release of the Provision for Moderately Adverse Conditions Cash paid for operating leases Operating Lease, Payments Leased assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 5.25% Senior Notes, due April 1, 2025 Senior Notes Due 2025 Issued 2017 - 5.25 percent [Member] Senior Notes Due 2025 Issued 2017 - 5.25 percent [Member] Long-term debt, net Long-term Debt, Excluding Current Maturities [Abstract] Senior notes Senior Notes, Noncurrent Revolving Credit Facility Long-term Line of Credit, Noncurrent Debt issuance costs Debt Issuance Costs, Noncurrent, Net Total long-term debt, net Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair Value, by Balance Sheet Grouping [Table Text Block] Carrying Value and Fair Value of Long-term Debt Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Changes in the Fair Value of Auction Rate Securities Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Paid in Capital Additional Paid-in Capital [Member] Retained Earnings Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Common Stock, Shares, Outstanding Beginning balance Common stock issued for vested equity-compensation awards (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Common stock issued for vested equity-compensation awards Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Repurchase and retirement of shares to satisfy tax withholding requirements (in shares) Stock Repurchased During Period, Shares Repurchase and retirement of shares to satisfy tax withholding requirements Stock Repurchased During Period, Value Stock-based compensation expense, net of forfeitures Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Ending balance (in shares) Ending balance MEDICAL BENEFITS PAYABLE Medical Benefits Payable [Text Block] Description and amounts of medical benefits payable at the end of the reporting period and other information and schedules needed to disclose the medical benefit payable account. Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] 2019 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five 2024 Lessee, Operating Lease, Liability, Payments Due Year Six Lessee, Operating Lease, Liability, Payments Due Year Six Thereafter Lessee, Operating Lease, Liability, Payments Due After Year Six Lessee, Operating Lease, Liability, Payments Due After Year Six Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Cash, cash equivalents and restricted cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Investments, including restricted investments Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments Premiums receivable, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Premiums Receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Premiums Receivable Other current assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Pharmacy Rebates Receivable And Other Current Assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Pharmacy Rebates Receivable and Other Current Assets Property, equipment and capitalized software, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Other intangible assets, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Fair value of total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Medical benefits payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable ACA Fee liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Liabilities Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Fair value of liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Fair value of net assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] 5.75% Senior Notes, due November 15, 2020 Senior Notes Due 2020 Issued 2013 - 5.75 percent [Member] Senior Notes Due 2020 Issued 2013 - 5.75 percent [Member] Borrowings outstanding Debt repurchase amount Debt Instrument, Repurchase Amount Credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Credit facility increase subject to certain conditions Line of Credit Facility, Accordian Loan Feature Line of Credit Facility, Accordion Loan Feature Commitment fee percentage on unused amount Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Name of Healthcare Plan [Axis] Name of Healthcare Plan [Axis] Name of Healthcare Plan [Axis] Name of Healthcare Plan [Domain] Name of Healthcare Plan [Domain] [Domain] for Name of Healthcare Plan [Axis] Medical Services Managed Care Plan Medical Services Managed Care Plan [Member] Medical Services Managed Care Plan [Member] Serious Mental Illness Specialty Plan Serious Mental Illness Specialty Plan [Member] Serious Mental Illness Specialty Plan [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Florida FLORIDA Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Number of reportable segments Number of Reportable Segments Term of agreement Term of Agreement Term of Agreement INCOME TAXES Income Tax Disclosure [Text Block] Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, issued (in shares) Preferred Stock, Shares Issued Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Common stock, authorized (in shares) Common Stock, Shares Authorized Common stock, issued (in shares) Common Stock, Shares, Issued Common stock, outstanding (in shares) Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Membership Membership [Member] Tradenames Trade Names [Member] Provider network Provider Network [Member] Provider networks are lists of physicians and hospitals that provide services to a health insurance plan. Technology and other Other Intangible Assets [Member] Gross Fair Value (in millions) Finite-lived Intangible Assets Acquired Weighted Average Useful Life (in years) ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Medicare PDP Prescription Drug Plans [Member] A reportable segment within the Medicare business line through which the entity offers Medicare Part D coverage to Medicare-eligible beneficiaries. Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments Operating Segments [Member] Corporate, Non-Segment Corporate, Non-Segment [Member] Premium Premiums Earned, Net Products and services Revenues from Products and Services Revenues from Products and Services Total premium and products and services revenues Revenue from Premiums, Products and Services Revenue from Premiums, Products and Services Medical benefits Policyholder Benefits and Claims Incurred, Net, Health Costs of products and services Cost of Goods and Services Sold ACA industry fee ACA Industry Fee Expense ACA Industry Fee Expense Medicaid premium taxes Medicaid Premium Taxes Medicaid Premium Taxes Total gross margin expenses Operating Costs and Expenses Gross margin Gross Profit Investment and other income Investment And Other Income Investment income represents income derived from bank deposits and investments in securities consisting of interest income from cash instruments and securities, dividend income, and income or expense derived from the amortization of investment related discounts or premiums, respectively. Other expenses Other Expenses Income from operations Operating Income (Loss) CENTENE PLAN OF MERGER AND ACQUISITIONS Business Combination Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Debt Securities Debt Securities [Member] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair value, measurements, recurring Fair Value, Measurements, Recurring [Member] Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Asset-backed securities Asset-backed Securities [Member] Corporate debt securities Corporate Debt Securities [Member] Municipal securities Municipal Bonds [Member] Residential mortgage-backed securities Residential Mortgage Backed Securities [Member] Short-term time deposits Bank Time Deposits [Member] Government and agency obligations US Government Agencies Debt Securities [Member] Other securities Other Security Investments [Member] U.S. government securities and other US Treasury Securities [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Investments Investments, Fair Value Disclosure Equity securities Equity Securities, FV-NI Restricted cash, cash equivalents and investments Restricted Investment, Fair Value Disclosure This element represents restricted investments reported on the balance sheet at period end measured at fair value by the entity. This element in intended to be used in connection with fair value disclosures required in the footnote disclosures to the financial statements. EQUITY AND EARNINGS PER SHARE Earnings Per Share [Text Block] STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Equity Award [Domain] RSUs Restricted Stock Units (RSUs) [Member] PSUs Equity Instruments Other than Options [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding as of beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Outstanding at end of period (in shares) Calculation of the Weighted-Average Common Shares Outstanding - Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Total Assets and Liabilities of Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Liability for Claims and Claims Adjustment Expense [Table] Liability for Claims and Claims Adjustment Expense [Table] Segments [Domain] Corporate and Other Corporate and Other [Member] Liability for Claims and Claims Adjustment Expense [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Reconciliation of the beginning and ending balance of medical benefits payable [Roll Forward] Reconciliation of the beginning and ending balance of medical benefits payable [Roll Forward] A roll forward is a reconciliation of the beginning and ending balance of medical benefits payable. Beginning balance Acquisitions Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions Medical benefits incurred related to Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract] Current year Current Year Claims and Claims Adjustment Expense Total Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims Medical benefits paid related to Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] Current year Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year Prior years Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years Total Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid Ending balance Premium deficiency reserve Deferred Tax Assets, Premium Deficiency Reserve Deferred Tax Assets, Premium Deficiency Reserve Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Illinois ILLINOIS Kentucky KENTUCKY Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Premium revenue as a percentage of total consolidated premium revenue Premium Revenue, Net Of Premium Tax Represents premium revenue net of premium tax of consolidated premium revenue. Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Remaining lease terms Lessee, Operating Leases, Remaining Lease Term Lessee, Operating Leases, Remaining Lease Term Operating lease expense Operating Lease, Expense Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Summary of Stock Unit Award Activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Financial Instrument [Axis] Government and agency obligations Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Debt securities: Debt Securities, Unrealized Gain (Loss) [Abstract] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Estimated Fair Value Debt Securities, Available-for-sale Equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) [Abstract] Amortized Cost Equity Securities, FV-NI, Cost Gross Unrealized Gains Equity Securities, FV-NI, Unrealized Gain Gross Unrealized Losses Equity Securities, FV-NI, Unrealized Loss Estimated Fair Value Total Debt Securities, Trading, and Equity Securities, FV-NI [Abstract] Amortized Cost Debt Securities, Trading, and Equity Securities, FV-NI, Cost Gross Unrealized Gains Debt Securities, Trading, and Equity Securities, FV-NI, Unrealized Gain Debt Securities, Trading, and Equity Securities, FV-NI, Unrealized Gain Gross Unrealized Losses Debt Securities, Trading, and Equity Securities, FV-NI, Unrealized Loss Debt, Trading, and Equity Securities, FV-NI, Unrealized Loss Estimated Fair Value Debt Securities, Trading, and Equity Securities, FV-NI Loss Contingencies [Table] Loss Contingencies [Table] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Derivative Lawsuits Derivative Lawsuits [Member] A lawsuit brought by a corporation shareholder against the directors, management and/or other shareholders of the corporation, for a failure by management. Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Mr. Farha Case Mr. Farha Case [Member] Mr. Farha Case [Member] Mr. Behrens Case Mr. Behrens Case [Member] Mr. Behrens Case [Member] Mr. Bereday Case Mr. Bereday Case [Member] Mr. Bereday Case Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Securities and Exchange Commission (SEC) United States Securities And Exchange Commission [Member] United States Securities And Exchange Commission [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Number of former officers receiving notices of cross appeal Number Of Former Employees Receiving Notices of Cross Appeal Number Of Former Employees Receiving Notices of Cross Appeal Number of former associates being pursued in action filed by entity Number Of Former Associates Being Pursued In Action Filed By Entity Number Of Former Associates Being Pursued In Action Filed By Entity Number of former employees found guilty and appealing Number Of Former Employees Found Guilty and Appealing Number Of Former Employees Found Guilty and Appealing Number of former employees being pursued in action filed by entity Number Of Former Employees Being Pursued In Action Filed By Entity Number Of Former Employees Being Pursued In Action Filed By Entity Number of actions filed in the federal and state courts between October 2007 and January 2008 Number of actions filed in the Federal Court The number of actions filed in Federal Court related to government investigations in a derivative action filed against the entity. Number of former executives being pursued in action filed by entity Number Of Former Officers Being Pursued In Action Filed By Entity The number of former officers being pursued in an action filed by the entity pursuant to a report filed by the Special Litigation Committee to the Federal Court determining, among other things, that the entity should pursue such an action. Settlement agreement, amount awarded Litigation Settlement, Amount Awarded from Other Party Maximum legal fee obligation Litigation Settlement, Legal Fee Advances, Maximum Litigation Settlement, Legal Fee Advances, Maximum Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Traditional Insurance Business Traditional Insurance Business [Member] Traditional Insurance Business [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Discontinued operations, held-for-sale Discontinued Operations, Held-for-sale [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Number Of Subsidiaries Sold Number Of Subsidiaries Sold Number Of Subsidiaries Sold Assets Disposal Group, Including Discontinued Operation, Assets [Abstract] Cash and cash equivalents Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Investments Disposal Group, Including Discontinued Operation, Investments Disposal Group, Including Discontinued Operation, Investments Reinsurance recoverables Disposal Group, Including Discontinued Operation, Reinsurance Recoverables Disposal Group, Including Discontinued Operation, Reinsurance Recoverables Other assets Disposal Group, Including Discontinued Operation, Other Assets Total Assets Disposal Group, Including Discontinued Operation, Assets Liabilities Disposal Group, Including Discontinued Operation, Liabilities [Abstract] Reserves and other policy liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities Total liabilities Funds Receivable/Payable for the Benefit of Members [Table] Funds Receivable/Payable for the Benefit of Members [Table] Disclosure of accounting policy for Funds Receivable or Payable for the Benefit of Members [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Premiums receivable, net Premiums Receivable [Member] State Partners State Partners [Member] State Partners [Member] Medicare Advantage and PDP Medicare Advantage and PDP [Member] Medicare Advantage and PDP [Member] Medicare Advantage Medicare Advantage [Member] A reportable segment within the Medicare business line which consists of Medicare Advantage coordinated care plans. Funds Receivable/Payable for the Benefit of Members [Line Items] Funds Receivable/Payable for the Benefit of Members [Line Items] [Line Items] for Disclosure of accounting policy for Funds Receivable or Payable for the Benefit of Members [Table] Membership Membership Represents the number of members enrolled in the health care plan as of the end of the reporting period. Reinsurance receivables related to premiums receivable Reinsurance Recoverables, Incurred but Not Reported Claims Reinsurance payable Reinsurance Payable Reinsurance recoverables Reinsurance Recoverables, Including Reinsurance Premium Paid Premiums revenue related to Aetna Part D Membership Medical benefits ceded related to Aetna Part D membership Medical Benefits Ceded Medical Benefits Ceded Medicaid retroactive rate change and risk score adjustments Medicaid Retroactive Rate Change and Risk Score Adjustments Medicaid Retroactive Rate Change and Risk Score Adjustments ACA industry fee Medicaid ACA industry fee reimbursement revenue Medicaid ACA Industry Fee Reimbursement Revenue Medicaid ACA Industry Fee Reimbursement Revenue Elimination of straight-line lease liabilities Deferred Rent Credit Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Shares Issued, Price Per Share Shares Issued, Price Per Share Weighted-average common shares outstanding — basic (in shares) Weighted Average Number of Shares Outstanding, Basic Dilutive effect of outstanding stock-based compensation awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Weighted-average common shares outstanding — diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Anti-dilutive stock-based compensation awards excluded from computation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Realized gains (losses) on restricted investments Restricted Investments, Realized Gains (Losses) Restricted Investments, Realized Gains (Losses) Fair Values of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Final Fair Values and Weighted Average Useful Lives for Identifiable Intangible Assets Acquired Schedule of Goodwill [Table Text Block] Unaudited Pro Forma Results Business Acquisition, Pro Forma Information [Table Text Block] Schedule of Restricted Investments Schedule of Restricted Investments [Table Text Block] [Table Text Block] for Schedule of Restricted Investments [Table] Asset-Backed And Mortgage-Backed Securities Asset-Backed And Mortgage-Backed Securities [Member] Asset-Backed And Mortgage-Backed Securities [Member] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract] Due in one year or less Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost Due after one year through five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost Due after five years through ten years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost Due after ten years Debt Securities, Available-for-sale, Allocated and Single Maturity Date, Maturity, after 10 Years, Amortized Cost Asset-backed and mortgage-backed securities Total Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost Fair Value Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract] Due in one year or less Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value Due after one year through five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value Due after five years through ten years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value Due after ten years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value Asset-backed and mortgage-backed securities Total Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value Income Statement [Abstract] Revenues: Revenues [Abstract] Investment and other income Total revenues Expenses: Cost of Revenue [Abstract] Medical benefits Selling, general and administrative Selling, General and Administrative Expense Medicaid premium taxes Premium Tax Expense An assessment levied by a state government agency on premium revenue. Depreciation and amortization Interest Interest Expense Total expenses Operating Expenses Income before income taxes and equity in losses of unconsolidated subsidiaries Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Equity in earnings (losses) of unconsolidated subsidiaries Income (Loss) from Equity Method Investments Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Net income Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Change in net unrealized gains and losses on available-for-sale securities, before tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax Income tax expense (benefit) related to other comprehensive income Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Basic (in USD per share) Earnings Per Share, Basic Diluted (in USD per share) Earnings Per Share, Diluted Weighted average common shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Basic (in shares) Diluted (in shares) EX-101.PRE 13 wcg-20190331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 14 wcg-201903311910q_htm.xml IDEA: XBRL DOCUMENT 0001279363 2019-01-01 2019-03-31 0001279363 2019-04-29 0001279363 2018-01-01 2018-03-31 0001279363 2019-03-31 0001279363 2018-12-31 0001279363 us-gaap:CommonStockMember 2018-03-31 0001279363 us-gaap:CommonStockMember 2017-12-31 0001279363 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001279363 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001279363 2018-03-31 0001279363 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001279363 us-gaap:RetainedEarningsMember 2018-12-31 0001279363 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001279363 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001279363 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001279363 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001279363 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001279363 us-gaap:CommonStockMember 2018-12-31 0001279363 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001279363 us-gaap:CommonStockMember 2019-03-31 0001279363 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001279363 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001279363 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001279363 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001279363 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001279363 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001279363 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001279363 2017-12-31 0001279363 us-gaap:RetainedEarningsMember 2018-03-31 0001279363 us-gaap:RetainedEarningsMember 2019-03-31 0001279363 us-gaap:RetainedEarningsMember 2017-12-31 0001279363 2019-01-01 0001279363 wcg:AetnaPartDBusinessMember 2019-03-31 0001279363 wcg:MedicareAdvantageandPDPMember wcg:MedicareAdvantageMember 2019-03-31 0001279363 wcg:AetnaPartDBusinessMember 2019-01-01 2019-03-31 0001279363 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001279363 wcg:StatePartnersMember wcg:MedicaidMember 2019-03-31 0001279363 us-gaap:PremiumsReceivableMember 2019-03-31 0001279363 us-gaap:PremiumsReceivableMember 2018-03-31 0001279363 wcg:AetnaPartDBusinessMember 2018-12-31 0001279363 wcg:MeridianMember us-gaap:OtherIntangibleAssetsMember 2018-09-01 2018-09-01 0001279363 wcg:MeridianMember 2018-09-01 2018-09-01 0001279363 wcg:MeridianMember us-gaap:TradeNamesMember 2018-09-01 2018-09-01 0001279363 wcg:MeridianMember wcg:ProviderNetworkMember 2018-09-01 2018-09-01 0001279363 wcg:MeridianMember us-gaap:MembershipMember 2018-09-01 2018-09-01 0001279363 wcg:MeridianMember 2019-03-31 0001279363 wcg:MedicareHealthPlansMember 2019-03-31 0001279363 wcg:MedicaidMember 2019-01-01 2019-03-31 0001279363 wcg:MeridianMember 2019-01-01 2019-03-31 0001279363 wcg:MedicaidMember 2018-12-31 0001279363 wcg:MedicareHealthPlansMember 2018-12-31 0001279363 wcg:MeridianMember 2018-12-31 0001279363 wcg:MedicaidMember 2019-03-31 0001279363 wcg:MedicareHealthPlansMember 2019-01-01 2019-03-31 0001279363 wcg:MeridianMember 2018-09-01 0001279363 wcg:CenteneMember us-gaap:ScenarioForecastMember 2020-01-01 2020-06-30 0001279363 wcg:MeridianMember wcg:SeniorNotesDue2026Issued20185.375percentMember us-gaap:SeniorNotesMember 2018-08-31 0001279363 wcg:AetnaPartDBusinessMember 2018-11-30 2018-11-30 0001279363 wcg:CenteneMember us-gaap:ScenarioForecastMember 2020-06-30 0001279363 wcg:MeridianMember 2018-08-01 2018-08-31 0001279363 us-gaap:OperatingSegmentsMember wcg:MedicaidMember 2018-01-01 2018-03-31 0001279363 stpr:KY 2019-01-01 2019-03-31 0001279363 stpr:FL 2019-01-01 2019-03-31 0001279363 stpr:IL 2019-01-01 2019-03-31 0001279363 stpr:KY 2018-01-01 2018-03-31 0001279363 stpr:FL 2018-01-01 2018-03-31 0001279363 us-gaap:OperatingSegmentsMember wcg:MedicaidMember 2019-01-01 2019-03-31 0001279363 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-03-31 0001279363 us-gaap:OperatingSegmentsMember wcg:PrescriptionDrugPlansMember 2019-01-01 2019-03-31 0001279363 us-gaap:OperatingSegmentsMember wcg:MedicareHealthPlansMember 2019-01-01 2019-03-31 0001279363 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001279363 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0001279363 us-gaap:OperatingSegmentsMember wcg:PrescriptionDrugPlansMember 2018-01-01 2018-03-31 0001279363 us-gaap:OperatingSegmentsMember wcg:MedicareHealthPlansMember 2018-01-01 2018-03-31 0001279363 us-gaap:OperatingSegmentsMember 2018-01-01 2018-03-31 0001279363 stpr:FL wcg:MedicaidMember wcg:MedicalServicesManagedCarePlanMember 2018-07-01 2018-07-31 0001279363 stpr:FL wcg:MedicaidMember wcg:SeriousMentalIllnessSpecialtyPlanMember 2018-04-01 2018-04-30 0001279363 2018-08-01 2018-08-31 0001279363 2018-08-31 0001279363 wcg:AssetBackedAndMortgageBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:BankTimeDepositsMember 2019-03-31 0001279363 us-gaap:AssetBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:MunicipalBondsMember 2018-12-31 0001279363 us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:MunicipalBondsMember 2019-03-31 0001279363 us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:ResidentialMortgageBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:BankTimeDepositsMember 2018-12-31 0001279363 us-gaap:OtherAggregatedInvestmentsMember 2018-12-31 0001279363 us-gaap:OtherAggregatedInvestmentsMember 2019-03-31 0001279363 us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0001279363 us-gaap:CashMember 2019-03-31 0001279363 us-gaap:USTreasuryAndGovernmentMember 2019-03-31 0001279363 us-gaap:MoneyMarketFundsMember 2018-12-31 0001279363 us-gaap:CashMember 2018-12-31 0001279363 us-gaap:MoneyMarketFundsMember 2019-03-31 0001279363 us-gaap:PerformanceSharesMember 2018-12-31 0001279363 us-gaap:PerformanceSharesMember 2019-01-01 2019-03-31 0001279363 us-gaap:RestrictedStockUnitsRSUMember 2019-03-31 0001279363 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001279363 us-gaap:PerformanceSharesMember 2019-03-31 0001279363 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001279363 us-gaap:RevolvingCreditFacilityMember 2018-07-23 0001279363 wcg:SeniorNotesDue2025Issued20175.25percentMember us-gaap:SeniorNotesMember 2017-03-22 0001279363 wcg:SeniorNotesDue2020Issued20135.75percentMember us-gaap:SeniorNotesMember 2017-04-07 0001279363 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2018-07-23 2018-07-23 0001279363 wcg:SeniorNotesDue2026Issued20185.375percentMember us-gaap:SeniorNotesMember 2018-08-13 0001279363 us-gaap:RevolvingCreditFacilityMember 2019-03-31 0001279363 us-gaap:RevolvingCreditFacilityMember 2017-03-22 0001279363 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2018-07-23 2018-07-23 0001279363 us-gaap:RevolvingCreditFacilityMember 2018-07-23 2018-07-23 0001279363 us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2019-04-01 2019-04-30 0001279363 wcg:SeniorNotesDue2026Issued20185.375percentMember us-gaap:SeniorNotesMember 2018-12-31 0001279363 wcg:SeniorNotesDue2025Issued20175.25percentMember us-gaap:SeniorNotesMember 2018-12-31 0001279363 us-gaap:RevolvingCreditFacilityMember 2018-12-31 0001279363 wcg:SeniorNotesDue2025Issued20175.25percentMember us-gaap:SeniorNotesMember 2019-03-31 0001279363 wcg:SeniorNotesDue2026Issued20185.375percentMember us-gaap:SeniorNotesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2019-03-31 0001279363 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2019-03-31 0001279363 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member 2019-03-31 0001279363 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member 2019-03-31 0001279363 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001279363 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0001279363 us-gaap:FairValueInputsLevel1Member 2019-03-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherAggregatedInvestmentsMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2018-12-31 0001279363 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001279363 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0001279363 us-gaap:CorporateAndOtherMember 2019-01-01 2019-03-31 0001279363 wcg:PrescriptionDrugPlansMember 2019-01-01 2019-03-31 0001279363 us-gaap:CorporateAndOtherMember 2019-03-31 0001279363 wcg:PrescriptionDrugPlansMember 2019-03-31 0001279363 us-gaap:CorporateAndOtherMember 2018-12-31 0001279363 wcg:PrescriptionDrugPlansMember 2018-12-31 0001279363 us-gaap:CorporateAndOtherMember 2018-01-01 2018-03-31 0001279363 wcg:MedicaidMember 2018-01-01 2018-03-31 0001279363 wcg:PrescriptionDrugPlansMember 2018-01-01 2018-03-31 0001279363 wcg:MedicaidMember 2017-12-31 0001279363 wcg:MedicareHealthPlansMember 2018-03-31 0001279363 wcg:PrescriptionDrugPlansMember 2018-03-31 0001279363 us-gaap:CorporateAndOtherMember 2017-12-31 0001279363 us-gaap:CorporateAndOtherMember 2018-03-31 0001279363 wcg:MedicareHealthPlansMember 2018-01-01 2018-03-31 0001279363 wcg:PrescriptionDrugPlansMember 2017-12-31 0001279363 wcg:MedicareHealthPlansMember 2017-12-31 0001279363 wcg:MedicaidMember 2018-03-31 0001279363 srt:MaximumMember 2019-01-01 2019-03-31 0001279363 us-gaap:DiscontinuedOperationsHeldforsaleMember wcg:TraditionalInsuranceBusinessMember 2019-03-31 0001279363 us-gaap:DiscontinuedOperationsHeldforsaleMember wcg:TraditionalInsuranceBusinessMember 2018-12-31 0001279363 2016-08-03 2016-08-03 0001279363 wcg:Mr.BehrensCaseMember wcg:DerivativeLawsuitsMember 2016-10-01 2016-10-31 0001279363 wcg:DerivativeLawsuitsMember 2019-03-31 0001279363 wcg:DerivativeLawsuitsMember 2012-01-31 0001279363 wcg:Mr.FarhaCaseMember wcg:DerivativeLawsuitsMember 2016-09-01 2016-09-30 0001279363 2013-06-30 0001279363 wcg:DerivativeLawsuitsMember 2013-06-30 0001279363 wcg:Mr.FarhaCaseMember wcg:DerivativeLawsuitsMember 2017-04-01 2017-04-30 0001279363 wcg:Mr.BehrensCaseMember wcg:DerivativeLawsuitsMember wcg:UnitedStatesSecuritiesAndExchangeCommissionMember 2018-05-01 2018-05-31 0001279363 wcg:Mr.BehrensCaseMember wcg:DerivativeLawsuitsMember wcg:UnitedStatesSecuritiesAndExchangeCommissionMember 2017-04-01 2017-04-30 0001279363 wcg:Mr.BeredayCaseMember wcg:DerivativeLawsuitsMember 2017-06-01 2017-06-30 0001279363 wcg:DerivativeLawsuitsMember 2008-01-31 0001279363 wcg:Mr.BehrensCaseMember wcg:DerivativeLawsuitsMember 2017-04-01 2017-04-30 0001279363 wcg:Mr.FarhaCaseMember wcg:DerivativeLawsuitsMember wcg:UnitedStatesSecuritiesAndExchangeCommissionMember 2017-04-01 2017-04-30 iso4217:USD shares pure wcg:member wcg:segment shares iso4217:USD wcg:officer wcg:action wcg:associate wcg:former_officer wcg:subsidiary wcg:employee false --12-31 Q1 2019 0001279363 false Large Accelerated Filer false 0.01 0.01 100000000 100000000 49993219 50302215 49993219 50302215 0.0525 0.05375 0 0 0 0 0.01 0.01 20000000 20000000 0 0 0 0 0 0 0 0 0 P5Y P5Y 10-Q 2019-03-31 WELLCARE HEALTH PLANS, INC. 50303407 6609400000 4626300000 115800000 0 37000000.0 19900000 6762200000 4646200000 5831700000 3962000000.0 111800000 0 503800000 355900000 0 81500000 31700000 32100000 69600000 36400000 29500000 17100000 6578100000 4485000000.0 184100000 161200000 800000 -2700000 184900000 158500000 33500000 56800000 151400000 101700000 18500000 -10300000 4700000 -2400000 13800000 -7900000 165200000 93800000 3.02 2.28 2.98 2.25 50100509 44605892 50842304 45196127 3235300000 3653900000 968600000 830100000 1567600000 1223400000 550000000.0 460600000 331600000 187300000 1127600000 477100000 7780700000 6832400000 424900000 428200000 2206400000 2227700000 986000000.0 996200000 1057600000 813200000 274300000 234700000 268800000 18700000 207200000 213600000 13205900000 11764700000 3212600000 2897400000 16900000 1400000 1304900000 964600000 1051800000 693300000 491100000 458900000 6077300000 5015600000 149000000.0 134200000 2127300000 2126400000 253900000 34900000 207200000 213600000 8814700000 7524700000 0 0 500000 500000 1967100000 1981100000 2418700000 2267300000 4900000 -8900000 4391200000 4240000000.0 13205900000 11764700000 49993219 500000 1981100000 2267300000 -8900000 4240000000.0 451484 0 142488 36800000 36800000 22800000 22800000 151400000 13800000 165200000 50302215 500000 1967100000 2418700000 4900000 4391200000 44522988 400000 591500000 1827500000 -2700000 2416700000 334521 104274 20200000 20200000 12100000 12100000 101700000 -7900000 93800000 44753235 400000 583400000 1929200000 -10600000 2502400000 151400000 101700000 69600000 36400000 22800000 12100000 6600000 -19500000 10100000 5100000 348500000 187900000 89400000 45600000 315200000 64000000.0 15500000 527000000.0 32200000 -15800000 110900000 7400000 -104600000 -24400000 -30000000.0 445700000 979000000.0 387900000 529600000 171500000 38100000 24200000 -487500000 -240600000 36800000 20200000 170700000 416200000 1300000 21400000 135200000 417400000 -382300000 622500000 3716600000 4263000000.0 3334300000 4885500000 6700000 2000000.0 54600000 32100000 5800000 3000000.0 ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WellCare Health Plans, Inc. (the "Company," "we," "us," or "our") focuses primarily on providing government-sponsored managed care services to families, children, seniors and individuals with complex medical needs primarily through Medicaid, Medicare Advantage ("MA") and Medicare Prescription Drug Plans ("PDP"), as well as individuals in the Health Insurance Marketplace. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we served approximately </span><span style="font-family:inherit;font-size:10pt;"><span>6.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> members nationwide. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we operated Medicaid health plans, including states where we receive Medicaid premium revenues associated with dually eligible special needs plans, in Arizona, Florida, Georgia, Hawaii, Illinois, Kentucky, Michigan, Missouri, Nebraska, New Jersey, New York, South Carolina and Texas. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we also operated MA coordinated care plans ("CCPs") in Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky, Louisiana, Maine, Michigan, Mississippi, New Jersey, New York, North Carolina, Ohio, South Carolina, Tennessee and Texas. We also offered stand-alone Medicare PDPs nationwide.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2018, we completed the acquisition of Meridian Health Plan of Michigan, Inc., Meridian Health Plan of Illinois, Inc., and MeridianRx, LLC, a pharmacy benefit manager ("PBM") (collectively, "Meridian"). As a result of the acquisition, we expanded our Medicaid portfolio through the addition of Michigan; expanded our Medicaid presence in Illinois; and acquired an integrated PBM platform. Meridian also serves MA members in Illinois, Indiana, Michigan, and Ohio, as well as Health Insurance Marketplace members in Michigan. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Basis of Presentation </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated balance sheets and statements of comprehensive income, changes in stockholders' equity, and cash flows include our accounts and the accounts of our subsidiaries over which we have control or are the primary beneficiary. We eliminated all intercompany accounts and transactions.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). Accordingly, certain financial information and footnote disclosures normally included in financial statements prepared in accordance with GAAP, but that are not required for interim reporting purposes, have been condensed or omitted. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto, for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, included in our Annual Report on Form 10-K ("2018 Form 10-K"), which was filed with the U.S. Securities and Exchange Commission ("SEC") in February 2019. Results for the interim periods presented are not necessarily indicative of results that may be expected for the entire year or any other interim period.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all normal recurring adjustments that we consider necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. In accordance with GAAP, we make certain estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. We base these estimates, including assumptions as to the annualized tax rate, on our knowledge of current events and anticipated future events and evaluate and update our assumptions and estimates on an ongoing basis; however, actual results may differ from our estimates. We evaluated all material events subsequent to the date of these condensed consolidated interim financial statements. Certain reclassifications were made to 2018 financial information to conform to the 2019 presentation.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pharmacy Benefit Manager</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The external revenues and costs for our PBM business are reported within "Products and Services" and "Cost of Products and Services", respectively, on the condensed consolidated statements of comprehensive income. Products and services revenues from our PBM consist of the prescription price (ingredient cost plus dispensing fee) negotiated with the retail pharmacies with which we have contracted, plus any associated administrative fees. This revenue is recognized when the claim is processed. We have the contractual obligation to pay network pharmacies for benefits provided to participating members and, therefore, act as principal in the arrangement and reflect the total prescription price as revenue, on a gross basis, in accordance with applicable accounting guidance. Costs of products and services is recognized at the time prescriptions are dispensed by pharmacies in the PBM's network to eligible members and consists primarily of ingredient costs and dispensing fees paid to retail pharmacies with which we have contracted. The overall results of our PBM business are immaterial. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Aetna Part D Membership Reinsurance</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, we completed the purchase of Aetna Inc.'s ("Aetna") entire standalone Medicare Part D prescription drug plan membership ("Aetna Part D membership"). In connection with the purchase, we also entered into an administrative services agreement and a reinsurance agreement pursuant to which Aetna provides administrative services to, and retains financial risk of, the Aetna Part D membership, effective for plan year 2019. We remain primarily liable to policyholders under this ceded insurance contract and are contingently liable for amounts recoverable from Aetna in the event that they do not meet their contractual obligations.  In the normal course, we evaluate the financial condition of our reinsurers and monitor concentrations of credit risk to minimize our exposure to significant losses from reinsurer insolvencies. As of March 31, 2019, related to the Aetna Part D membership, our condensed consolidated balance sheet included reinsured receivables of </span><span style="font-family:inherit;font-size:10pt;"><span>$30.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, primarily related to premiums receivable, and reinsured payables of </span><span style="font-family:inherit;font-size:10pt;"><span>$482.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, primarily related to pharmacy claims payables. These reinsured receivables and payables were included in prepaid expenses and other current assets, net, and accounts payable and accrued liabilities, respectively. The resulting net reinsurance recoverables of </span><span style="font-family:inherit;font-size:10pt;"><span>$452.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was included in prepaid expenses and other current assets, net on the condensed consolidated balance sheet. There were no reinsurance recoverables or reinsurance liabilities relating to the Aetna Part D membership recorded as of December 31, 2018. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In our condensed consolidated statements of comprehensive income, premium revenue and medical benefits were reported net of amounts ceded under this Aetna reinsurance arrangement. Premium revenue and medical benefits expense ceded relating to the Aetna Part D membership were </span><span style="font-family:inherit;font-size:10pt;"><span>$501.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$473.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, for the three months ended March 31, 2019. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Unconsolidated Subsidiaries</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We work with physicians and other health care professionals to operate Accountable Care Organizations ("ACOs") under the Medicare Shared Saving Program ("MSSP") and Next Generation ACO Models. ACOs were established by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the "ACA") to reward integrated, efficient care and allow providers to share in any savings they achieve as a result of improved quality and operational efficiency. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These ACOs are generally formed as limited liability companies. The ACOs are considered variable interest entities ("VIEs") under GAAP as these entities do not have sufficient equity to finance their own operations without additional financial support. We own a majority interest in our ACOs; however, we share the power to direct the activities that most significantly affect the ACOs with health care providers that are minority owners in the ACOs. This power is shared pursuant to the structure of the management committee of each of the ACOs. Accordingly, we have determined that we are not the primary beneficiary of the ACOs; therefore, we cannot consolidate their results. We perform an ongoing qualitative assessment of our variable interests in VIEs to determine whether we have a controlling financial interest and would therefore be considered the primary beneficiary of the VIE. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for our participation in the ACOs using the equity method. Gains and losses are immaterial and are reported on the face of our condensed consolidated statements of comprehensive income as equity in earnings (losses) of unconsolidated subsidiaries.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Significant Accounting Policies</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Below is a discussion of our significant accounting policies, which affected the comparability of our consolidated results of operations, financial condition or cash flows for the periods presented. Refer to Note 2 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> to the consolidated financial statements included in our 2018 Form 10-K for a complete discussion of all of our significant accounting policies.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Premium Receivables and Unearned Premiums</span></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record premiums earned but not received as premiums receivable and record premiums received in advance of the period of service as unearned premiums in our condensed consolidated balance sheets. A complete discussion of premiums receivable and unearned premiums is included in Note 2 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies </span><span style="font-family:inherit;font-size:10pt;">to the consolidated financial statements included in our 2018 Form 10-K. The premium receivable balance at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is primarily related to Medicaid contracts with our state partners of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 billion</span></span><span style="font-family:inherit;font-size:10pt;">, as well as net risk-adjusted premiums receivable under our MA and PDP contracts of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$364.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medicaid Risk-Adjusted Premiums and Retroactive Rate Changes</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed further in Note 2 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies </span><span style="font-family:inherit;font-size:10pt;">to the consolidated financial statements included in our 2018 Form 10-K, Medicaid premium rate changes are recognized in the period the change becomes effective, when the effect of the change in the rate is reasonably estimable and collection is assured. In some instances, our Medicaid premiums are subject to risk score adjustments based on the health profile of our membership. Generally, the risk score is determined by the state agency's analysis of encounter submissions of processed claims data to determine the acuity of our membership relative to the entire state's Medicaid membership. The frequency of when states adjust premiums varies, but is usually done quarterly or semi-annually on a retrospective basis. We recognize periodic changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Premiums receivable in our condensed consolidated balance sheets include net risk-adjusted premiums receivable from our Medicaid state partners related to retroactive rate changes and risk score adjustments of </span><span style="font-family:inherit;font-size:10pt;"><span>$121.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$54.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare Part D Settlements</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We receive certain Part D prospective subsidy payments from the Centers for Medicare &amp; Medicaid Services ("CMS") for our MA and PDP members as a fixed monthly per member amount, based on the estimated costs of providing prescription drug benefits over the plan year, as reflected in our bids. A discussion of the subsidy components under Part D is included in Note 2 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> to the consolidated financial statements included in our 2018 Form 10-K. CMS will fully reimburse these subsidies, or recoup overpaid subsidies made during the plan year, as part of its annual settlement process that typically occurs in the fourth quarter of the subsequent year and, accordingly, there is no insurance risk to us. Therefore, amounts received for these subsidies are not considered premium revenue, and are reported, net of the subsidy benefits paid, as funds receivable (payable) for the benefit of members in the condensed consolidated balance sheets. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, our condensed consolidated balance sheets primarily include CMS Part D payables for the 2018 and 2016 plan years. Our condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> additionally includes a payable for the 2019 plan year. We expect to settle a majority of the 2016 and 2018 net payables during the remainder of 2019. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ACA Industry Fee</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 imposed certain new taxes and fees, including an annual premium-based health insurance industry assessment (the "ACA industry fee") on health insurers, which began in 2014. In January 2018, Congress approved a one-year moratorium of the ACA industry fee for 2019, which also eliminated the Medicaid ACA industry fee reimbursement from our state government partners for 2019. Accordingly, we did not incur ACA industry fee expense nor recognize any Medicaid ACA industry fee reimbursement revenue for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. We incurred </span><span style="font-family:inherit;font-size:10pt;"><span>$81.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the ACA industry fee for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Additionally, we recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$64.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Medicaid ACA industry fee reimbursement revenue as premium revenue for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2018-07, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting</span><span style="font-family:inherit;font-size:10pt;">.” This update expands the scope of Topic 718, which currently only includes share-based payments issued to </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">employees, to include share-based payments issued to non-employees for goods and services. This guidance was effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance on January 1, 2019. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02 "</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span><span style="font-family:inherit;font-size:10pt;">", which allows entities to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 from accumulated other comprehensive income to retained earnings. The guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance prospectively on January 1, 2019. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2017, the FASB issued ASU No. 2017-08, "</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="font-family:inherit;font-size:10pt;">". This update shortens the amortization period for the premium on certain purchased callable debt securities to the earliest call date. Previously, entities generally amortize the premium as a yield adjustment over the contractual life of the security. The new guidance does not change the accounting for purchased callable debt securities held at a discount. This guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance on January 1, 2019 on a modified retrospective basis. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;">”, which for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments in its balance sheet. This standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. Subsequently, in July 2018, the FASB issued ASU 2018-11, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842), Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">” which, among other things, allows companies to elect an optional transition method to apply the new lease standard through a cumulative-effect adjustment, if any, in the period of adoption, rather than in the earliest period presented. We adopted the standard on January 1, 2019 using the optional transition method. We elected the practical expedients permitted under the transition guidance, which allows us to carryforward our historical lease classifications for existing leases. Additionally, we elected the practical expedient to not separate non-lease components from the associated lease component. As part of the adoption process, we implemented a new lease accounting system. The adoption of this guidance resulted in the initial recognition of operating lease right-of-use assets of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$259.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, operating lease liabilities of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$277.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and the elimination of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of straight-line lease liabilities, as of </span><span style="font-family:inherit;font-size:10pt;">January 1, 2019</span><span style="font-family:inherit;font-size:10pt;">. This guidance did not have a material effect on our consolidated results of operations or cash flows.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting Standards Pending Adoption</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, "</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract", </span><span style="font-family:inherit;font-size:10pt;">which</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. We are currently assessing the effect this guidance will have on our consolidated results of operations, financial condition or cash flows.</span></div><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</span>" which requires entities to use a current expected credit loss model, which is a new impairment model based on expected losses rather than incurred losses. Under this model, an entity would recognize an impairment allowance equal to its current estimate of all contractual cash flows that the entity does not expect to collect from financial assets measured at amortized cost. The entity's estimate would consider relevant information about past events, current conditions, and reasonable and supportable forecasts, which will result in recognition of lifetime expected credit losses upon loan origination. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted for annual reporting periods beginning after December 15, 2018. We are currently assessing the effect this guidance will have on our consolidated results of operations, financial condition or cash flows. 6300000 Basis of Presentation <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated balance sheets and statements of comprehensive income, changes in stockholders' equity, and cash flows include our accounts and the accounts of our subsidiaries over which we have control or are the primary beneficiary. We eliminated all intercompany accounts and transactions.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). Accordingly, certain financial information and footnote disclosures normally included in financial statements prepared in accordance with GAAP, but that are not required for interim reporting purposes, have been condensed or omitted. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto, for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, included in our Annual Report on Form 10-K ("2018 Form 10-K"), which was filed with the U.S. Securities and Exchange Commission ("SEC") in February 2019. Results for the interim periods presented are not necessarily indicative of results that may be expected for the entire year or any other interim period.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all normal recurring adjustments that we consider necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. In accordance with GAAP, we make certain estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. We base these estimates, including assumptions as to the annualized tax rate, on our knowledge of current events and anticipated future events and evaluate and update our assumptions and estimates on an ongoing basis; however, actual results may differ from our estimates. We evaluated all material events subsequent to the date of these condensed consolidated interim financial statements. Certain reclassifications were made to 2018 financial information to conform to the 2019 presentation.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pharmacy Benefit Manager</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The external revenues and costs for our PBM business are reported within "Products and Services" and "Cost of Products and Services", respectively, on the condensed consolidated statements of comprehensive income. Products and services revenues from our PBM consist of the prescription price (ingredient cost plus dispensing fee) negotiated with the retail pharmacies with which we have contracted, plus any associated administrative fees. This revenue is recognized when the claim is processed. We have the contractual obligation to pay network pharmacies for benefits provided to participating members and, therefore, act as principal in the arrangement and reflect the total prescription price as revenue, on a gross basis, in accordance with applicable accounting guidance. Costs of products and services is recognized at the time prescriptions are dispensed by pharmacies in the PBM's network to eligible members and consists primarily of ingredient costs and dispensing fees paid to retail pharmacies with which we have contracted. The overall results of our PBM business are immaterial In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all normal recurring adjustments that we consider necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. In accordance with GAAP, we make certain estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. We base these estimates, including assumptions as to the annualized tax rate, on our knowledge of current events and anticipated future events and evaluate and update our assumptions and estimates on an ongoing basis; however, actual results may differ from our estimates. We evaluated all material events subsequent to the date of these condensed consolidated interim financial statements. Certain reclassifications were made to 2018 financial information to conform to the 2019 presentation. Aetna Part D Membership Reinsurance<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>In November 2018, we completed the purchase of Aetna Inc.'s ("Aetna") entire standalone Medicare Part D prescription drug plan membership ("Aetna Part D membership"). In connection with the purchase, we also entered into an administrative services agreement and a reinsurance agreement pursuant to which Aetna provides administrative services to, and retains financial risk of, the Aetna Part D membership, effective for plan year 2019. We remain primarily liable to policyholders under this ceded insurance contract and are contingently liable for amounts recoverable from Aetna in the event that they do not meet their contractual obligations.  In the normal course, we evaluate the financial condition of our reinsurers and monitor concentrations of credit risk to minimize our exposure to significant losses from reinsurer insolvencies. 30800000 482800000 452000000.0 501000000.0 473700000 Premium Receivables and Unearned Premiums<div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record premiums earned but not received as premiums receivable and record premiums received in advance of the period of service as unearned premiums in our condensed consolidated balance sheets. A complete discussion of premiums receivable and unearned premiums is included in Note 2 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies </span><span style="font-family:inherit;font-size:10pt;">to the consolidated financial statements included in our 2018 Form 10-K. The premium receivable balance at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is primarily related to Medicaid contracts with our state partners of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 billion</span></span><span style="font-family:inherit;font-size:10pt;">, as well as net risk-adjusted premiums receivable under our MA and PDP contracts of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$364.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medicaid Risk-Adjusted Premiums and Retroactive Rate Changes</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">As discussed further in Note 2 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies </span>to the consolidated financial statements included in our 2018 Form 10-K, Medicaid premium rate changes are recognized in the period the change becomes effective, when the effect of the change in the rate is reasonably estimable and collection is assured. In some instances, our Medicaid premiums are subject to risk score adjustments based on the health profile of our membership. Generally, the risk score is determined by the state agency's analysis of encounter submissions of processed claims data to determine the acuity of our membership relative to the entire state's Medicaid membership. The frequency of when states adjust premiums varies, but is usually done quarterly or semi-annually on a retrospective basis. We recognize periodic changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured 1200000000 364000000.0 121500000 54400000 Medicare Part D Settlements<span style="font-family:inherit;font-size:10pt;">We receive certain Part D prospective subsidy payments from the Centers for Medicare &amp; Medicaid Services ("CMS") for our MA and PDP members as a fixed monthly per member amount, based on the estimated costs of providing prescription drug benefits over the plan year, as reflected in our bids. A discussion of the subsidy components under Part D is included in Note 2 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> to the consolidated financial statements included in our 2018 Form 10-K. CMS will fully reimburse these subsidies, or recoup overpaid subsidies made during the plan year, as part of its annual settlement process that typically occurs in the fourth quarter of the subsequent year and, accordingly, there is no insurance risk to us. Therefore, amounts received for these subsidies are not considered premium revenue, and are reported, net of the subsidy benefits paid, as funds receivable (payable) for the benefit of members in the condensed consolidated balance sheets. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, our condensed consolidated balance sheets primarily include CMS Part D payables for the 2018 and 2016 plan years. Our condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span> additionally includes a payable for the 2019 plan year. ACA Industry FeeThe Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 imposed certain new taxes and fees, including an annual premium-based health insurance industry assessment (the "ACA industry fee") on health insurers, which began in 2014. In January 2018, Congress approved a one-year moratorium of the ACA industry fee for 2019, which also eliminated the Medicaid ACA industry fee reimbursement from our state government partners for 2019. 81500000 64700000 Recently Adopted Accounting Standards<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2018-07, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting</span><span style="font-family:inherit;font-size:10pt;">.” This update expands the scope of Topic 718, which currently only includes share-based payments issued to </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">employees, to include share-based payments issued to non-employees for goods and services. This guidance was effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance on January 1, 2019. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU 2018-02 "</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</span><span style="font-family:inherit;font-size:10pt;">", which allows entities to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 from accumulated other comprehensive income to retained earnings. The guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance prospectively on January 1, 2019. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2017, the FASB issued ASU No. 2017-08, "</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="font-family:inherit;font-size:10pt;">". This update shortens the amortization period for the premium on certain purchased callable debt securities to the earliest call date. Previously, entities generally amortize the premium as a yield adjustment over the contractual life of the security. The new guidance does not change the accounting for purchased callable debt securities held at a discount. This guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance on January 1, 2019 on a modified retrospective basis. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:inherit;font-size:10pt;">”, which for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments in its balance sheet. This standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. Subsequently, in July 2018, the FASB issued ASU 2018-11, “</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842), Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">” which, among other things, allows companies to elect an optional transition method to apply the new lease standard through a cumulative-effect adjustment, if any, in the period of adoption, rather than in the earliest period presented. We adopted the standard on January 1, 2019 using the optional transition method. We elected the practical expedients permitted under the transition guidance, which allows us to carryforward our historical lease classifications for existing leases. Additionally, we elected the practical expedient to not separate non-lease components from the associated lease component. As part of the adoption process, we implemented a new lease accounting system. The adoption of this guidance resulted in the initial recognition of operating lease right-of-use assets of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$259.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, operating lease liabilities of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$277.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and the elimination of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of straight-line lease liabilities, as of </span><span style="font-family:inherit;font-size:10pt;">January 1, 2019</span><span style="font-family:inherit;font-size:10pt;">. This guidance did not have a material effect on our consolidated results of operations or cash flows.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting Standards Pending Adoption</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-15, "</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract", </span><span style="font-family:inherit;font-size:10pt;">which</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. We are currently assessing the effect this guidance will have on our consolidated results of operations, financial condition or cash flows.</span></div><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</span>" which requires entities to use a current expected credit loss model, which is a new impairment model based on expected losses rather than incurred losses. Under this model, an entity would recognize an impairment allowance equal to its current estimate of all contractual cash flows that the entity does not expect to collect from financial assets measured at amortized cost. The entity's estimate would consider relevant information about past events, current conditions, and reasonable and supportable forecasts, which will result in recognition of lifetime expected credit losses upon loan origination. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted for annual reporting periods beginning after December 15, 2018. We are currently assessing the effect this guidance will have on our consolidated results of operations, financial condition or cash flows. 259500000 277300000 -17800000 CENTENE PLAN OF MERGER AND ACQUISITIONS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Centene Plan of Merger</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 26, 2019, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Centene Corporation ("Centene") under which Centene will acquire us for a combination of cash and stock. Under the terms of the Merger Agreement, our shareholders will receive </span><span style="font-family:inherit;font-size:10pt;"><span>$120.00</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and </span><span style="font-family:inherit;font-size:10pt;"><span>3.38</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Centene common stock for each share of our common stock. The proposed transaction is subject to customary closing conditions, including, but not limited to, the approval of the Merger Agreement by our stockholders, the approval of the share issuance of Centene stock by Centene’s stockholders, and the receipt of U. S. federal antitrust clearance and certain other required regulatory approvals. The transaction is expected to close in the first half of 2020. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:25px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Merger Agreement includes restrictions on the conduct of our business prior to completion of the Centene Transaction or termination of the Merger Agreement, generally requiring us to conduct our business in the ordinary course. However, we are subject to various specified restrictions unless we obtain Centene’s prior written consent, which may not be unreasonably withheld, delayed or conditioned, or expressly contemplated or permitted by the Merger Agreement or as required by applicable law. Among other things and in each case subject to certain exceptions, we may not: </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">incur additional indebtedness (excluding borrowings under our Revolving Credit Facility (as defined below) that are used to manage our ordinary course cash flow needs); </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">issue additional shares of our common stock, repurchase our common stock, or pay dividends;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acquire assets, securities or property, dispose of businesses or assets; or </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">authorize any payment of, accrual or commitment for capital expenditures in any calendar year that would exceed by more than 110% the aggregate amount of capital expenditures budgeted for such year.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Aetna Medicare Part D Asset Acquisition</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in Note 1</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> - Organization, Basis of Presentation and Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> of this 2019 Form 10-Q, </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">in November 2018, we completed the purchase of Aetna's Part D membership for total cash consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$107.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is subject to certain true-up provisions. These membership assets are recorded within other intangible assets, net in the condensed consolidated balance sheets as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, and have a weighted-average useful life of </span><span style="font-family:inherit;font-size:10pt;"><span>eight years</span></span><span style="font-family:inherit;font-size:10pt;"> beginning in 2020. Per the terms of the agreement, Aetna provides administrative services to, and retains financial risk of, the Aetna Part D membership through 2019. Therefore, the Aetna Part D membership is excluded from our membership and has had, or is expected to have, an immaterial effect on our results of operations until January 1, 2020.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Meridian Business Acquisition</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 1, 2018 (the "Effective Date"), we acquired Meridian for an estimated purchase price of approximately  </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in cash, subject to certain purchase price adjustments, as described in the purchase agreement. The Meridian acquisition was funded through a combination of cash on hand, our Revolving Credit Facility, net proceeds from the August 2018 issuance of our </span><span style="font-family:inherit;font-size:10pt;"><span>5.375%</span></span><span style="font-family:inherit;font-size:10pt;"> of Senior Notes due 2026 ("2026 Notes") and net proceeds from an issuance of shares of our common stock. We included the results of Meridian's operations since the Effective Date in our condensed consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the estimated fair values of major classes of assets acquired and liabilities assumed at the Effective Date, based on our valuation assumptions, reconciled to the total consideration transferred.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>484.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments, including restricted investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Premiums receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, equipment and capitalized software, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,539.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>622.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Fair value of total assets acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,401.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>534.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ACA Fee liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Fair value of liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>881.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Fair value of net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,520.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value results from judgments about future events, which reflect certain uncertainties and rely on estimates and assumptions. The judgments used to determine the fair value assigned to each class of assets acquired and liabilities assumed, as well as intangible asset lives, can materially affect our operating results. As of the Effective Date, the expected fair value of all current assets and liabilities approximated their historical cost. As of March 31, 2019, we have preliminarily determined the fair value of assets acquired and liabilities assumed; however, the final fair values may be subject to, (i) the final valuation of intangible assets related to memberships and trade names, (ii) the final assessment and valuation of certain other assets acquired and liabilities assumed, including premiums receivable, property, equipment and capitalized software, medical benefits payable and other liabilities and (iii) the final assessment and valuation of certain income tax amounts. Therefore, the final fair values of the assets acquired and liabilities assumed may vary significantly from our preliminary estimates. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Identifiable intangible assets acquired </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Hart-Scott-Rodino Antitrust Improvements Act and other relevant laws and regulations, there were significant limitations on our ability to obtain specific information about Meridian's intangible assets prior to completion of the acquisition in September 2018. As of March 31, 2019, certain of the more significant assumptions inherent in the development of intangible asset fair values, including the following, are preliminary.</span></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:24px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">•</span><span style="font-family:inherit;font-size:10pt;">final membership attrition rates;</span></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:24px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">•</span><span style="font-family:inherit;font-size:10pt;">final discount rates selected to measure the risks inherent in the future cash flows;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">key assumptions in the valuation of the acquired technology, including, but not limited to, estimated costs associated with developers' salaries, external direct costs of materials and services; and the estimated time to replace the acquired software applications; and</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:24px;"><span style="text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">•</span><span style="font-family:inherit;font-size:10pt;">working capital adjustments and the assessment of the assets' life cycle, among other key assumptions.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the preliminary fair values and weighted average useful lives for identifiable intangible assets acquired in the Meridian acquisition as of the Effective Date of the acquisition. These preliminary estimates of fair value and weighted-average useful life may be different from the final acquisition accounting, and the difference could have a material effect on the consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.39024390243902%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Fair Value </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life (in years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Membership </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>406.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tradenames</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.9</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provider network</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.0</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.8</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>622.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.3</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the valuation of goodwill for the excess of the purchase price over the estimated fair value of the net assets acquired. The assignment of goodwill to our respective segments has not been completed at this time. The recorded goodwill related to the acquisition is deductible for tax purposes.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred taxes</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Meridian acquisition included taxable and nontaxable components resulting in differences in amounts recognized for GAAP and tax purposes. In both taxable and nontaxable business combinations, the amounts assigned to the individual assets acquired and liabilities assumed for financial statement purposes are often different from the amounts assigned or carried forward for tax purposes. We recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$49.9</span></span><span style="font-family:inherit;font-size:10pt;"> million deferred tax liability based on the estimated bases differences. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of changes in our goodwill by reportable segment is as follows for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.70731707317073%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medicaid Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medicare Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Not assigned</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>392.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,560.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,227.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition related adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>392.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,539.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,206.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Goodwill related to our September 1, 2018 Meridian acquisition is considered preliminary, pending the final allocation of the applicable purchase price. The assignment of goodwill to our respective segments has not been completed at this time.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unaudited Pro Forma Financial Information</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The results of operations and financial condition for the Meridian acquisition have been included in our condensed consolidated financial statements since the Effective Date. The unaudited pro forma financial information presented below reflects our 2018 acquisition of Meridian, assuming the acquisition occurred as of January 1, 2018. Pro forma results are not provided for the three months ended March 31, 2019, as Meridian's operations were included in our results of operations for this time period.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These pro forma results are based on estimates and assumptions and do not reflect any anticipated synergies, efficiencies or other cost savings that we expect to realize from the acquisition. The following unaudited pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the results of operations that would have occurred had the acquisition actually consummated at January 1, 2018, or project the future results of the combined company.</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.53658536585365%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pro Forma - Unaudited</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in millions, except per share data)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,673.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings per common share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.02</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.00</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average common shares outstanding:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">       Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,890,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">       Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,446,757</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The pro forma results presented in the schedule above include adjustments related to the following purchase accounting and other acquisition-related costs:</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Elimination of historical intangible asset amortization expense and addition of amortization expense based on the current preliminary values of identified intangible assets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Elimination of interest expense associated with retired obligations and addition of interest expense based on debt incurred to finance the Meridian transaction;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Elimination of results for Meridian operations not acquired; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Elimination of transaction and integration-related costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Include </span><span style="font-family:inherit;font-size:10pt;"><span>5,207,547</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock issued to finance the Meridian transaction;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to align the acquisition to our accounting policies; and </span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div>Tax effects of the adjustments noted above. 120.00 3.38 107200000 P8Y 2500000000 0.05375 The following table summarizes the estimated fair values of major classes of assets acquired and liabilities assumed at the Effective Date, based on our valuation assumptions, reconciled to the total consideration transferred.<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>484.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments, including restricted investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Premiums receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, equipment and capitalized software, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,539.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>622.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Fair value of total assets acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,401.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>534.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ACA Fee liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Fair value of liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>881.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Fair value of net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,520.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 484400000 180400000 379600000 146200000 49300000 1539400000 622000000.0 3401300000 534300000 66500000 280400000 881200000 2520100000 The following table summarizes the preliminary fair values and weighted average useful lives for identifiable intangible assets acquired in the Meridian acquisition as of the Effective Date of the acquisition. These preliminary estimates of fair value and weighted-average useful life may be different from the final acquisition accounting, and the difference could have a material effect on the consolidated financial statements. <div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.39024390243902%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Fair Value </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life (in years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Membership </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>406.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tradenames</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.9</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provider network</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.0</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.8</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>622.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.3</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><br/> 406600000 P8Y1M6D 110400000 P4Y10M24D 8300000 P15Y 96700000 P5Y9M18D 622000000.0 P7Y3M18D 1500000000 49900000 A summary of changes in our goodwill by reportable segment is as follows for the <span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.70731707317073%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medicaid Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medicare Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Not assigned</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>392.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,560.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,227.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition related adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>392.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,539.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,206.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div>(1) Goodwill related to our September 1, 2018 Meridian acquisition is considered preliminary, pending the final allocation of the applicable purchase price. 274700000 392300000 1560700000 2227700000 0 0 -21300000 -21300000 274700000 392300000 1539400000 2206400000 The following unaudited pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the results of operations that would have occurred had the acquisition actually consummated at January 1, 2018, or project the future results of the combined company.<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.53658536585365%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pro Forma - Unaudited</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in millions, except per share data)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,673.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Earnings per common share:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.02</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.00</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average common shares outstanding:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">       Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,890,397</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">       Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,446,757</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 5673600000 100900000 2.02 2.00 49890397 50446757 5207547 SEGMENT REPORTING<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On a regular basis, we evaluate discrete financial information and assess the performance of our </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> reportable segments Medicaid Health Plans, Medicare Health Plans and Medicare PDPs, to determine the most appropriate use and allocation of Company resources. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocate premium revenue, medical benefits expense, Medicaid premium taxes, the 2018 ACA industry fee and goodwill to our reportable segments. We do not allocate to our reportable segments any other assets and liabilities, investment and other income, selling, general and administrative expenses ("SG&amp;A"), depreciation and amortization, or interest expense. The Company's decision-makers primarily use premium revenue, medical benefits expense and gross margin to evaluate the performance of our reportable segments. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Corporate and Other category includes net investment and other income, SG&amp;A expenses, depreciation, amortization and interest. Also included in this category are results for operating segments that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicaid Health Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Medicaid Health Plans segment includes plans for beneficiaries of Temporary Assistance for Needy Families ("TANF"), Supplemental Security Income ("SSI"), Aged Blind and Disabled ("ABD"), Children's Health Insurance Program ("CHIP") and Long-Term Services and Supports ("LTSS") programs, among others. TANF generally provides assistance to low-income families with children. ABD and SSI generally provide assistance to low-income aged, blind or disabled individuals. CHIP provides assistance to qualifying families who are not eligible for Medicaid because their income exceeds the applicable income thresholds. The LTSS program is designed to help people with chronic illnesses or who have disabilities and need health and long-term care services, such as home care or adult day care, to enable them to stay in their homes and communities as long as possible.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Medicaid operations in Florida, Illinois and Kentucky individually account for </span><span style="font-family:inherit;font-size:10pt;">10%</span><span style="font-family:inherit;font-size:10pt;"> or more of our consolidated premium revenue for the three months ended March 31, 2019. These states and the respective Medicaid premium revenue as a percentage of total consolidated premium revenue are as follows: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.3170731707317%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended<br/>March 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Florida</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Illinois</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Kentucky</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:174%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">*Our Illinois Medicaid health plan accounted for less than 10% of our consolidated premium revenue for the three months ended March 31, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2018, we received a Notice of Intent to Award a </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year contract from the Florida Department of Health to provide statewide-managed care services to children with medically complex conditions through the Children's Medical Services Managed Care Plan ("CMS Plan"). The five-year contract award began on February 1, 2019; however, this contract is still subject to protest and appeal. Additionally, in April 2018, we received a Notice of Agency Decision from the Florida Agency for Health Care Administration (“AHCA”) to award our subsidiary, Staywell, a new </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year contract to provide managed care services to Medicaid-eligible beneficiaries, including Managed Medical Assistance and Long-Term Care beneficiaries in </span><span style="font-family:inherit;font-size:10pt;">10</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">11</span><span style="font-family:inherit;font-size:10pt;"> regions. As part of the Medicaid Managed Care program, we provide statewide-managed care services to beneficiaries in the Serious Mental Illness Specialty Plan; however, this contract is still subject to protest and appeal. We are one of two managed care plans providing services to the SMI beneficiaries. The new statewide Medicaid Managed Care program began on December 1, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare Health Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicare is a federal program that provides eligible persons age 65 and over and some disabled persons with a variety of hospital, medical and prescription drug benefits. MA is Medicare's managed care alternative to the original Medicare program, which provides individuals standard Medicare benefits directly through CMS. Our MA CCPs generally require members to seek health care services and select a primary care physician from a network of health care providers. In addition, we offer coverage of prescription drug benefits under the Medicare Part D program as a component of most of our MA plans.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare PDPs</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We offer stand-alone Medicare Part D coverage to Medicare-eligible beneficiaries in our Medicare PDPs segment. The Medicare Part D prescription drug benefit is supported by risk sharing with the federal government through risk corridors designed to limit the losses and gains of the participating drug plans and by reinsurance for catastrophic drug costs. The government subsidy is based on the national weighted average monthly bid for this coverage, adjusted for risk factor payments. Additional subsidies are provided for dually-eligible beneficiaries and specified low-income beneficiaries. The Part D program offers national in-network prescription drug coverage that is subject to limitations in certain circumstances.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Financial Information</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reportable operating segments are defined as components of an enterprise for which discrete financial information is available and evaluated on a regular basis by the enterprise's decision-makers to determine how resources should be allocated to an individual segment and to assess performance of those segments. Accordingly, we have </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> reportable segments: Medicaid Health Plans, Medicare Health Plans and Medicare PDPs.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of financial information for our reportable segments through the gross margin level and reconciliation to income from operations is presented in the table below.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.60975609756098%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medicaid Health Plan</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medicare Health Plan</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medicare PDP</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Consolidated</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31, 2019</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Premium</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,473.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,843.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,609.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Products and services</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total premium and products and services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,473.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,843.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,725.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,022.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,548.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,831.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs of products and services</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ACA industry fee</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid premium taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total gross margin expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,054.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,548.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,975.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>419.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>294.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment and other income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(602.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(602.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>419.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>294.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(560.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>184.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Premium</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,809.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,556.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,626.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Products and services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total premium and products and services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,809.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,556.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,626.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,424.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,307.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs of products and services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ACA industry fee</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid premium taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total gross margin expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,505.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,334.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,075.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>550.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment and other income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expenses </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(409.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(409.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(389.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Effective July 1, 2018, the Company redefined gross margin as total revenues less investment and other income, medical expenses, cost of products and services, the ACA industry fee expense, and Medicaid premium tax expense. Accordingly, results for the </span><span style="font-family:inherit;font-size:8pt;">three</span><span style="font-family:inherit;font-size:8pt;"> months ended </span><span style="font-family:inherit;font-size:8pt;">March 31, 2018</span><span style="font-family:inherit;font-size:8pt;"> were adjusted to include Medicaid premium taxes, which decreased gross margin by $</span><span style="font-family:inherit;font-size:8pt;"><span>32.1 million</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(2)</span></div><span style="font-family:inherit;font-size:8pt;">Effective July 1, 2018, other expenses include SG&amp;A expenses, depreciation, amortization and interest. Accordingly, results for the </span><span style="font-family:inherit;font-size:8pt;">three</span><span style="font-family:inherit;font-size:8pt;"> months ended </span><span style="font-family:inherit;font-size:8pt;">March 31, 2018</span><span style="font-family:inherit;font-size:8pt;"> were adjusted to exclude Medicaid premium taxes, which decreased other expenses by $</span><span style="font-family:inherit;font-size:8pt;"><span>32.1 million</span></span>. 3 These states and the respective Medicaid premium revenue as a percentage of total consolidated premium revenue are as follows: <div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.3170731707317%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended<br/>March 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Florida</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Illinois</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Kentucky</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.17 0.13 0.13 0.10 0.15 3 A summary of financial information for our reportable segments through the gross margin level and reconciliation to income from operations is presented in the table below.<div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.60975609756098%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medicaid Health Plan</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medicare Health Plan</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Medicare PDP</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Corporate &amp; Other</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Consolidated</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31, 2019</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Premium</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,473.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,843.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,609.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Products and services</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total premium and products and services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,473.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,843.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,725.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,022.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,548.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,831.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs of products and services</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ACA industry fee</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid premium taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total gross margin expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,054.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,548.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,975.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>419.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>294.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment and other income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(602.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(602.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>419.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>294.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(560.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>184.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Premium</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,809.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,556.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,626.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Products and services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total premium and products and services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,809.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,556.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,626.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,424.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,307.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs of products and services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ACA industry fee</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medicaid premium taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total gross margin expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,505.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,334.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,075.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross margin </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>550.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment and other income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expenses </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(409.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(409.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(389.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Effective July 1, 2018, the Company redefined gross margin as total revenues less investment and other income, medical expenses, cost of products and services, the ACA industry fee expense, and Medicaid premium tax expense. Accordingly, results for the </span><span style="font-family:inherit;font-size:8pt;">three</span><span style="font-family:inherit;font-size:8pt;"> months ended </span><span style="font-family:inherit;font-size:8pt;">March 31, 2018</span><span style="font-family:inherit;font-size:8pt;"> were adjusted to include Medicaid premium taxes, which decreased gross margin by $</span><span style="font-family:inherit;font-size:8pt;"><span>32.1 million</span></span><span style="font-family:inherit;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;">(2)</span></div><span style="font-family:inherit;font-size:8pt;">Effective July 1, 2018, other expenses include SG&amp;A expenses, depreciation, amortization and interest. Accordingly, results for the </span><span style="font-family:inherit;font-size:8pt;">three</span><span style="font-family:inherit;font-size:8pt;"> months ended </span><span style="font-family:inherit;font-size:8pt;">March 31, 2018</span><span style="font-family:inherit;font-size:8pt;"> were adjusted to exclude Medicaid premium taxes, which decreased other expenses by $</span><span style="font-family:inherit;font-size:8pt;"><span>32.1 million</span></span>. 4473500000 1843100000 288800000 4000000.0 6609400000 0 0 0 115800000 115800000 4473500000 1843100000 288800000 119800000 6725200000 4022700000 1548200000 258400000 2400000 5831700000 0 0 0 111800000 111800000 0 0 0 0 0 31700000 0 0 0 31700000 4054400000 1548200000 258400000 114200000 5975200000 419100000 294900000 30400000 5600000 750000000.0 0 0 0 37000000.0 37000000.0 0 0 0 602900000 602900000 419100000 294900000 30400000 -560300000 184100000 2809900000 1556500000 259900000 0 4626300000 0 0 0 0 0 2809900000 1556500000 259900000 0 4626300000 2424400000 1307100000 230500000 0 3962000000.0 0 0 0 0 0 49300000 27600000 4600000 0 81500000 32100000 0 0 0 32100000 2505800000 1334700000 235100000 0 4075600000 304100000 221800000 24800000 0 550700000 0 0 0 19900000 19900000 0 0 0 409400000 409400000 304100000 221800000 24800000 -389500000 161200000 32100000 32100000 <span style="font-family:inherit;font-size:11pt;font-weight:bold;">EQUITY AND EARNINGS PER SHARE</span><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Issuance of Common Stock</span></div><div style="line-height:120%;text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, we completed a public offering of our common stock and issued </span><span style="font-family:inherit;font-size:10pt;"><span>5,207,547</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock, at an offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>$265.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The net proceeds from the offering were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts and offering costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$37.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. We used the net proceeds to fund a portion of the acquisition of Meridian.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per Common Share</span></div><div style="line-height:120%;text-align:left;text-indent:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We compute basic earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding. We compute diluted earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding plus the dilutive effect of our stock-based compensation awards using the treasury stock method.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The calculation of the weighted-average common shares outstanding — diluted is as follows:</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:64%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended<br/>March 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average common shares outstanding — basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,100,509</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,605,892</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dilutive effect of outstanding stock-based compensation awards</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>741,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>590,235</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average common shares outstanding — diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,842,304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,196,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Anti-dilutive stock-based compensation awards excluded from computation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,130</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,390</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 5207547 265.00 1300000000 37700000 The calculation of the weighted-average common shares outstanding — diluted is as follows:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:64%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended<br/>March 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average common shares outstanding — basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,100,509</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,605,892</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dilutive effect of outstanding stock-based compensation awards</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>741,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>590,235</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average common shares outstanding — diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50,842,304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,196,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Anti-dilutive stock-based compensation awards excluded from computation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,130</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,390</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 50100509 44605892 741795 590235 50842304 45196127 67130 277390 INVESTMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers all of its investments as available-for-sale securities. Excluding restricted cash, cash equivalents and investments, the amortized cost, gross unrealized gains or losses and estimated fair value of short-term and long-term investments by security type are summarized in the following tables.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,127.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,128.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government and agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other securities </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,798.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,801.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,023.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,026.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>943.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>933.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government and agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other securities </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,654.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,643.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="16" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Investments in equity securities primarily consists of exchange traded funds in fixed income and preferred and hybrid securities. Equity securities were not material as of December 31, 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual maturities of debt securities at </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>889.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>889.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>571.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>573.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due after five years through ten years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due after ten years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed and mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,798.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,801.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual maturities may differ from contractual maturities due to the exercise of pre-payment options.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;"> We sold available-for-sale investments totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$420.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$80.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span>, respectively. Realized gains and losses resulting from sales and redemptions of our available-for-sale investments were immaterial for all periods presented. Additionally, we did not realize any other-than-temporary impairment during any of these periods. Excluding restricted cash, cash equivalents and investments, the amortized cost, gross unrealized gains or losses and estimated fair value of short-term and long-term investments by security type are summarized in the following tables.<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,127.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,128.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government and agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other securities </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,798.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,801.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,023.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,026.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>943.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>933.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government and agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other securities </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,654.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,643.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="16" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Investments in equity securities primarily consists of exchange traded funds in fixed income and preferred and hybrid securities. Equity securities were not material as of December 31, 2018.</span></div><br/> 154200000 200000 300000 154100000 1127900000 3500000 2700000 1128700000 197100000 2700000 100000 199700000 10100000 0 100000 10000000.0 237500000 0 0 237500000 9200000 0 100000 9100000 62000000.0 0 0 62000000.0 1798000000.0 6400000 3300000 1801100000 225100000 0 0 225100000 2023100000 6400000 3300000 2026200000 144700000 0 500000 144200000 943000000.0 500000 10100000 933400000 199600000 600000 900000 199300000 7200000 0 200000 7000000.0 242200000 0 0 242200000 44900000 0 100000 44800000 72500000 0 100000 72400000 1654100000 1100000 11900000 1643300000 Contractual maturities of debt securities at <span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>889.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>889.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>571.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>573.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due after five years through ten years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due after ten years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed and mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,798.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,801.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 889600000 889700000 571600000 573200000 147300000 149100000 13100000 12900000 176400000 176200000 1798000000.0 1801100000 420600000 80200000 RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a condition for licensure, we are required to maintain certain funds on deposit or pledged to various state agencies. Certain of our state contracts require the issuance of surety bonds. We classify restricted cash, cash equivalents and investments as long-term regardless of the contractual maturity date of the securities held, due to the nature of the states' requirements. The amortized cost, gross unrealized gains, gross unrealized losses and fair value of our restricted cash, cash equivalents and investment securities are as follows: </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government securities and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government securities and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Realized gains and losses on sales and redemptions of our restricted cash, cash equivalents and investments were not material for all periods presented. The amortized cost, gross unrealized gains, gross unrealized losses and fair value of our restricted cash, cash equivalents and investment securities are as follows: <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government securities and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government securities and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 12800000 0 0 12800000 86200000 0 0 86200000 175600000 0 300000 175300000 274600000 0 300000 274300000 11300000 0 0 11300000 51400000 0 0 51400000 172500000 0 500000 172000000.0 235200000 0 500000 234700000 STOCK-BASED COMPENSATION <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Compensation Committee awards certain equity-based compensation under our stock plans, including restricted stock units ("RSUs") and performance stock units ("PSUs"). Compensation expense related to our stock-based compensation awards was </span><span style="font-family:inherit;font-size:10pt;"><span>$22.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$12.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$121.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation cost related to unvested stock-based compensation arrangements that is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2 years</span></span><span style="font-family:inherit;font-size:10pt;">. The unrecognized compensation cost for certain of our PSUs, which are subject to variable accounting, was determined based on our closing common stock price of </span><span style="font-family:inherit;font-size:10pt;"><span>$269.75</span></span><span style="font-family:inherit;font-size:10pt;"> as of March 29, 2019 and amounted to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$33.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the total unrecognized compensation cost. Due to the nature of the accounting for these awards, future compensation cost will fluctuate based on changes in our common stock price. We estimate stock-based compensation expense based on awards ultimately expected to vest over the related service period (generally the vesting period) of the award, or to an employee’s eligible retirement date under the award agreement, if earlier. We make assumptions of forfeiture rates at the time of grant and continuously reassess our assumptions based on actual forfeiture experience. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of RSU and PSU award activity, at target, for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, is presented in the table below. For our PSUs, shares attained over target upon vesting are reflected as awards granted during the period, while shares canceled due to vesting below target are reflected as awards forfeited during the period.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding as of January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>253,235</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>606,708</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>859,943</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99,434</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>446,973</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(99,668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(351,648</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(451,316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,372</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,276</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding as of March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250,629</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>594,323</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>844,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted-average grant-date fair value of all equity awards granted during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$205.27</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Refer to Note 2 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Summary of Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> and Note 15 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based Compensation</span> to the consolidated financial statements included in our 2018 Form 10-K for additional information regarding our equity-compensation awards and related compensation cost measurement. 22800000 12100000 121000000.0 P2Y 269.75 33900000 A summary of RSU and PSU award activity, at target, for the <span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, is presented in the table below. For our PSUs, shares attained over target upon vesting are reflected as awards granted during the period, while shares canceled due to vesting below target are reflected as awards forfeited during the period.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">PSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding as of January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>253,235</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>606,708</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>859,943</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99,434</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>446,973</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(99,668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(351,648</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(451,316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,372</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,276</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding as of March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250,629</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>594,323</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>844,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 253235 606708 859943 99434 347539 446973 99668 351648 451316 2372 8276 10648 250629 594323 844952 205.27 DEBT<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our outstanding debt obligations and their classification in the accompanying condensed consolidated balance sheets (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Long-term debt, net:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.25% Senior Notes, due April 1, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,200.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,200.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.375% Senior Notes, due August 15, 2026</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revolving Credit Facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total long-term debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,127.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,126.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Notes</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, we completed the offering and sale of </span><span style="font-family:inherit;font-size:10pt;"><span>5.375%</span></span><span style="font-family:inherit;font-size:10pt;"> unsecured senior notes due 2026 in the aggregate principal amount of $</span><span style="font-family:inherit;font-size:10pt;"><span>750.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “2026 Notes”). The aggregate net proceeds from the issuance of the 2026 Notes were used to fund a portion of the cash consideration for our acquisition of Meridian. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2017, we completed the offering and sale of </span><span style="font-family:inherit;font-size:10pt;"><span>5.25%</span></span><span style="font-family:inherit;font-size:10pt;"> unsecured senior notes due 2025 in the aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$1,200.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “2025 Notes”). The aggregate net proceeds from the issuance of the 2025 Notes were primarily used to redeem the full </span><span style="font-family:inherit;font-size:10pt;"><span>$900.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of our </span><span style="font-family:inherit;font-size:10pt;"><span>5.75%</span></span><span style="font-family:inherit;font-size:10pt;"> unsecured senior notes (the "2020 Notes") on April 7, 2017, and for general corporate purposes, including organic growth and working capital.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The 2026 Notes and 2025 Notes are classified as long-term debt in our condensed consolidated balance sheet at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, based on their maturity date. Refer to Note 10 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt</span><span style="font-family:inherit;font-size:10pt;"> to the consolidated financial statements included in our 2018 Form 10-K for additional information regarding these 2026 Notes and 2025 Notes, including applicable covenants.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revolving Credit Facility</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, we entered into a credit agreement, which provided for a senior unsecured revolving loan facility (the "Revolving Credit Facility"). In July 2018, this credit agreement was amended and restated (“Amended and Restated Credit Agreement”) to increase the aggregate principle amount available under our Revolving Credit Facility from </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:inherit;font-size:10pt;">, extend the maturity date for borrowings under the Revolving Credit Facility from January 2021 to July 2023 and decrease the applicable margins for borrowings under the Revolving Credit Facility, as calculated in accordance with the Amended and Restated Credit Agreement. The Amended and Restated Credit Agreement also includes an accordion feature which allows the Company to increase the total commitments under the Revolving Credit Facility by up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$500 million</span></span><span style="font-family:inherit;font-size:10pt;">, subject to certain conditions.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unutilized commitments under the Amended and Restated Credit Agreement are subject to a fee of </span><span style="font-family:inherit;font-size:10pt;"><span>0.20%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>0.30%</span></span><span style="font-family:inherit;font-size:10pt;"> depending upon our ratio of total debt to consolidated EBITDA, as calculated in accordance with the Amended and Restated Credit Agreement.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was outstanding under the Revolving Credit Facility, which was drawn during the third quarter of 2018 to fund a portion of the Meridian acquisition in September 2018. These borrowings are classified as long-term debt in accordance with the contractual terms of the Amended and Restated Credit Agreement.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subsequent to the balance sheet date, in April 2019, an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$140.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was drawn on our Revolving Credit Facility for general corporate purposes, including organic growth and working capital.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span>, and the date of this filing, we were in compliance with all covenants under the 2026 Notes, the 2025 Notes and the Amended and Restated Credit Agreement. The following table summarizes our outstanding debt obligations and their classification in the accompanying condensed consolidated balance sheets (in millions):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Long-term debt, net:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.25% Senior Notes, due April 1, 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,200.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,200.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.375% Senior Notes, due August 15, 2026</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revolving Credit Facility</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total long-term debt, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,127.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,126.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 1200000000.0 1200000000.0 750000000.0 750000000.0 200000000.0 200000000.0 22700000 23600000 2127300000 2126400000 0.05375 750000000.0 0.0525 1200000000.0 900000000.0 0.0575 1000000000.0 1300000000 500000000 0.0020 0.0030 200000000.0 140000000.0 FAIR VALUE MEASUREMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, investments, receivables, accounts payable, medical benefits payable, long-term debt, including any current portion of long-term debt, and other liabilities. We consider the carrying amounts of cash and cash equivalents, receivables, other current assets and current liabilities to approximate their fair value due to the short period of time between the origination of these instruments and the expected realization or payment. Certain assets and liabilities are measured at fair value on a recurring basis and are disclosed below. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see the consolidated financial statements and notes thereto included in our 2018 Form 10-K. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recurring Fair Value Measurements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value on a recurring basis at </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">for Identical</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,128.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,128.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government and agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,801.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,742.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>225.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>220.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,026.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>279.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,746.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash, cash equivalents and investments:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government securities and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total restricted cash, cash equivalents and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:174%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Investments in equity securities primarily consists of exchange traded funds in fixed-income and preferred and hybrid securities. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value on a recurring basis at </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other Observable Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>933.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>933.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government and agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Investments</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,643.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,548.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash, cash equivalents and investments:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government securities and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total restricted cash, cash equivalents and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:8pt;">(1) Equity securities were not material as of December 31, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the carrying value and fair value of our long-term debt outstanding as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:46%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Other Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Unobservable Inputs<br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt - March 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,127.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,034.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt - December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,126.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,885.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The fair value of our 2026 Notes and 2025 Notes were determined based on quoted market prices; therefore, would be classified within Level 1 of the fair value hierarchy. The fair value of obligations outstanding under our Revolving Credit Facility, as of March 31, 2019 and December 31, 2018, approximated the carrying value and would be classified within Level 2 of the fair value hierarchy. Assets and liabilities measured at fair value on a recurring basis at <span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">for Identical</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,128.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,128.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government and agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,801.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,742.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>225.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>220.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,026.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>279.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,746.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash, cash equivalents and investments:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government securities and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total restricted cash, cash equivalents and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:174%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Investments in equity securities primarily consists of exchange traded funds in fixed-income and preferred and hybrid securities. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value on a recurring basis at </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other Observable Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Unobservable Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>933.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>933.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government and agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Investments</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,643.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,548.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash, cash equivalents and investments:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government securities and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total restricted cash, cash equivalents and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;"> </span>(1) Equity securities were not material as of December 31, 2018. Assets and liabilities measured at fair value on a recurring basis at <span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">for Identical</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,128.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,128.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Residential mortgage-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government and agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,801.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,742.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>225.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>220.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,026.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>279.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,746.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash, cash equivalents and investments:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government securities and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total restricted cash, cash equivalents and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:174%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) Investments in equity securities primarily consists of exchange traded funds in fixed-income and preferred and hybrid securities. </span></div><br/> 154100000 0 154100000 0 1128700000 0 1128700000 0 199700000 0 199700000 0 10000000.0 0 10000000.0 0 237500000 0 237500000 0 9100000 9100000 0 0 62000000.0 49700000 12300000 0 1801100000 58800000 1742300000 0 225100000 220900000 4200000 0 2026200000 279700000 1746500000 0 12800000 12800000 0 0 86200000 86200000 0 0 175300000 175100000 200000 0 274300000 274100000 200000 0 144200000 0 144200000 0 933400000 0 933400000 0 199300000 0 199300000 0 7000000.0 0 7000000.0 0 242200000 0 242200000 0 44800000 44800000 0 0 72400000 49800000 22600000 0 1643300000 94600000 1548700000 0 11300000 11300000 0 0 51400000 51400000 0 0 172000000.0 171800000 200000 0 234700000 234500000 200000 0 The following table presents the carrying value and fair value of our long-term debt outstanding as of <span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">: </span><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:46%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Other Observable Inputs<br/>(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Unobservable Inputs<br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt - March 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,127.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,034.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt - December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,126.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,885.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 2127300000 2034700000 200000000.0 0 2126400000 1885200000 200000000.0 0 MEDICAL BENEFITS PAYABLE<div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances of medical benefits payable, by segment, is as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the three months ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicaid Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare PDPs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate and other </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,012.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>823.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>59.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,897.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits incurred related to:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,182.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,612.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>284.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6,083.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(160.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(64.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(26.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(251.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,022.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,548.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>258.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,831.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits paid related to:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2,769.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(936.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(187.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3,894.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,147.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(451.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,621.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3,917.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,388.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(209.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5,516.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,118.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>983.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>108.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,212.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) The Medicaid Health Plans and Consolidated beginning and ending balances for 2019 include a premium deficiency reserve for our Illinois Medicaid programs ("Illinois PDR"), which amounted to </span><span style="font-family:inherit;font-size:8pt;"><span>$6.6 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$16.1 million</span></span><span style="font-family:inherit;font-size:8pt;"> at </span><span style="font-family:inherit;font-size:8pt;">March 31, 2019</span><span style="font-family:inherit;font-size:8pt;"> and December 31, 2018, respectively. See Note 2 - </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:inherit;font-size:8pt;"> in our 2018 Form 10-K for further discussion. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) The Corporate and Other category includes operating segments that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the three months ended March 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicaid Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare PDPs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,373.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>722.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,146.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits incurred related to:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,523.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,383.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>256.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,163.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(99.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(76.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(26.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(201.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,424.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,307.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>230.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,962.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits paid related to:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,659.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(859.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(218.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2,737.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(758.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(389.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(12.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,160.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2,418.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,249.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(230.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3,898.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,379.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>780.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,210.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) The Medicaid Health Plans and Consolidated beginning and ending balances for 2018 include a premium deficiency reserve for our Illinois Medicaid program ("Illinois PDR"), which amounted to </span><span style="font-family:inherit;font-size:8pt;"><span>$41.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$45.6 million</span></span><span style="font-family:inherit;font-size:8pt;"> at March 31, 2018 and December 31, 2017, respectively.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize the cost of medical benefits in the period in which services are provided, including an estimate of the cost of medical benefits incurred but not reported ("IBNR"). Medical benefits expense includes direct medical expenses and certain medically-related administrative costs. We evaluate our estimates of medical benefits payable as we obtain more complete claims information and medical expense trend data over time. We record differences between actual experience and estimates used to establish the liability, which we refer to as favorable and unfavorable prior year reserve developments, as increases or decreases to medical benefits expense in the period we identify the differences.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits payable developed favorably by approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$251.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$201.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. The release of the provision for moderately adverse conditions included in our prior year estimates was substantially offset by the provision for moderately adverse conditions established for claims incurred in the current year. Accordingly, the favorable development in our estimate of medical benefits payable related to claims incurred in prior years does not directly correspond to a decrease in medical benefits expense recognized during the period in which the favorable development is recognized.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Excluding the prior year development related to the release of the provision for moderately adverse conditions, our estimates of consolidated medical benefits payable developed favorably by approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$108.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$71.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. Such amounts are net of the development relating to refunds due to government customers with minimum loss ratio provisions. The net favorable development recognized in both 2019 and 2018 resulted primarily due to a number of operational and clinical initiatives planned and executed, that contributed to lower than expected pharmacy and medical trends, and actual claim submission time being faster than we originally assumed (i.e., our completion factors were higher than we originally assumed) in establishing our medical benefits payable in the prior years. This development does not directly correspond to an increase in our current year operating results as these reductions were offset by estimated current period medical benefits expense when we established our estimate of the current year medical benefits payable. Both completion factor and medical trend assumptions are influenced by utilization levels, unit costs, mix of business, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, our ability and practices to manage medical and pharmaceutical costs, claim submission patterns and operational changes resulting from business combinations, among others. Our actual costs were ultimately less than expected. </span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">Our Meridian acquisition in September 2018 resulted in an increase to medical benefits payable as of the acquisition date. See Note 2 - </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Centene Plan of Merger and Acquisitions</span>, for additional information on the Meridian acquisitions. A reconciliation of the beginning and ending balances of medical benefits payable, by segment, is as follows:<div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the three months ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicaid Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare PDPs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate and other </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,012.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>823.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>59.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,897.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits incurred related to:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,182.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,612.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>284.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6,083.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(160.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(64.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(26.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(251.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,022.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,548.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>258.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,831.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits paid related to:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2,769.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(936.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(187.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3,894.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,147.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(451.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,621.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3,917.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,388.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(209.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5,516.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,118.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>983.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>108.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,212.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(1) The Medicaid Health Plans and Consolidated beginning and ending balances for 2019 include a premium deficiency reserve for our Illinois Medicaid programs ("Illinois PDR"), which amounted to </span><span style="font-family:inherit;font-size:8pt;"><span>$6.6 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$16.1 million</span></span><span style="font-family:inherit;font-size:8pt;"> at </span><span style="font-family:inherit;font-size:8pt;">March 31, 2019</span><span style="font-family:inherit;font-size:8pt;"> and December 31, 2018, respectively. See Note 2 - </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:inherit;font-size:8pt;"> in our 2018 Form 10-K for further discussion. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(2) The Corporate and Other category includes operating segments that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the three months ended March 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicaid Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare Health Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicare PDPs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning balance </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,373.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>722.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,146.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits incurred related to:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,523.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,383.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>256.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,163.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(99.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(76.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(26.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(201.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,424.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,307.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>230.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,962.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical benefits paid related to:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,659.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(859.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(218.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2,737.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(758.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(389.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(12.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,160.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2,418.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,249.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(230.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3,898.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ending balance </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,379.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>780.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,210.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><span style="font-family:inherit;font-size:8pt;">(1) The Medicaid Health Plans and Consolidated beginning and ending balances for 2018 include a premium deficiency reserve for our Illinois Medicaid program ("Illinois PDR"), which amounted to </span><span style="font-family:inherit;font-size:8pt;"><span>$41.0 million</span></span><span style="font-family:inherit;font-size:8pt;"> and </span><span style="font-family:inherit;font-size:8pt;"><span>$45.6 million</span></span> at March 31, 2018 and December 31, 2017, respectively. 2012800000 823500000 59100000 2000000.0 2897400000 0 0 0 0 0 4182700000 1612700000 284700000 3200000 6083300000 -160000000.0 -64500000 -26300000 -800000 -251600000 4022700000 1548200000 258400000 2400000 5831700000 2769200000 936400000 187700000 1400000 3894700000 1147900000 451700000 21600000 600000 1621800000 3917100000 1388100000 209300000 2000000.0 5516500000 2118400000 983600000 108200000 2400000 3212600000 6600000 16100000 1373200000 722500000 50600000 0 2146300000 0 0 0 0 0 2523800000 1383100000 256900000 0 4163800000 -99400000 -76000000.0 -26400000 0 -201800000 2424400000 1307100000 230500000 0 3962000000.0 1659400000 859900000 218000000.0 0 2737300000 758600000 389300000 12800000 0 1160700000 2418000000.0 1249200000 230800000 0 3898000000.0 1379600000 780400000 50300000 0 2210300000 41000000.0 45600000 251600000 201800000 108200000 71500000 LEASES<div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In determining whether a contract contains a lease, we assess whether the arrangement meets all three of the following criteria: 1) there is an identified asset; 2) we have the right to obtain substantially all the economic benefits from use of the identified asset; and 3) we have the right to direct the use of the identified asset. This involves evaluating whether we have the right to operate the asset or to direct others to operate the asset in a manner that it determines without the supplier having the right to change those operating instructions, as well as evaluating our involvement in the design of the asset.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have right-of-use assets and liabilities for non-cancelable operating leases primarily for office space, data centers and other equipment. Our leases have remaining lease terms up to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>14</span></span><span style="font-family:inherit;font-size:10pt;"> years. The depreciable life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended March 31, 2019 operating lease expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, was recorded as SG&amp;A expense in our condensed consolidated statement of comprehensive income. </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance sheet information related to our operating leases was as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:74.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:26%;"/><td style="width:2%;"/><td style="width:44%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right of use assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of our operating lease liabilities are as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.5234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity of Operating Lease Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (remaining)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 31, 2019 the weighted-average remaining lease term was </span><span style="font-family:inherit;font-size:10pt;"><span>8.5</span></span><span style="font-family:inherit;font-size:10pt;"> years. Our lease agreements do not provide a readily determinable implicit rate nor is it available to us from our lessors. Instead, we estimate our incremental borrowing rate based on information available at lease commencement in order to discount lease payments to present value. The weighted-average discount rate of our operating leases was </span><span style="font-family:inherit;font-size:10pt;"><span>5.9%</span></span><span style="font-family:inherit;font-size:10pt;">, as of March 31, 2019. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to our operating leases is as follows:</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leased assets obtained in exchange for new operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> P14Y 17400000 Balance sheet information related to our operating leases was as follows:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:74.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:26%;"/><td style="width:2%;"/><td style="width:44%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right of use assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 249900000 32900000 235600000 268500000 Maturities of our operating lease liabilities are as follows:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.5234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity of Operating Lease Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (remaining)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350.0</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><br/> 33500000 44900000 44400000 40400000 37200000 34900000 114700000 350000000.0 81500000 268500000 P8Y6M 0.059 Supplemental cash flow information related to our operating leases is as follows:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.2578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leased assets obtained in exchange for new operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 11600000 10400000 INCOME TAXES<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our effective income tax rate on pre-tax income was </span><span style="font-family:inherit;font-size:10pt;"><span>18.1%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;"><span>35.8%</span></span><span style="font-family:inherit;font-size:10pt;"> fo</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">r the</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">months ended</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">March 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. The year-over-year decrease was primarily driven by the one-year moratorium on the non-deductible ACA industry fee for 2019 and higher excess tax benefits resulting from the settlement of stock-compensation awards in 2019.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">There were no significant changes to unrecognized tax benefits for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span>. Our unrecognized tax benefits are not expected to change significantly during the next 12 months. 0.181 0.358 DISCONTINUED OPERATIONS<div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 3, 2016, our subsidiary, Universal American, completed the sale of its Traditional Insurance business prior to our acquisition of Universal American. This was accomplished by selling </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> life insurance subsidiaries, while retaining ownership of a third life insurance subsidiary, American Progressive Life &amp; Health Insurance of New York ("Progressive"). The sale of the Traditional Insurance business underwritten by Progressive was accomplished through a 100% quota-share reinsurance treaty with a wholly-owned subsidiary of Nassau Re, that, when considered in combination with other reinsurance transactions previously entered into, resulted in the reinsurance of all of the Traditional Insurance policies that were underwritten by Progressive. Accordingly, the discontinued Traditional Insurance business did not materially affect our condensed consolidated statements of comprehensive income for any of the periods presented.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with ASC 360-10, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Property, Plant and Equipment</span><span style="font-family:inherit;font-size:10pt;"> and ASC 205-20,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Presentation of Financial Statements—Discontinued Operations</span><span style="font-family:inherit;font-size:10pt;">, the Traditional Insurance business has been reported in discontinued operations in this 2019 Form 10-Q.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the total assets and liabilities of our discontinued operations: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reinsurance recoverables</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserves and other policy liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Progressive's traditional insurance products are reinsured under quota share coinsurance treaties with unaffiliated insurers, while the life insurance risks are reinsured under either quota share coinsurance or yearly-renewable term treaties with unaffiliated insurers. Under quota share coinsurance treaties, we pay the reinsurer an agreed upon percentage of all premiums and the reinsurer reimburses us that same percentage of any losses. In addition, the reinsurer pays us certain allowances to cover commissions, the cost of administering the policies and premium taxes. Under yearly-renewable term treaties, the reinsurer receives premiums at an agreed upon rate for its share of the risk on a yearly-renewable term basis. We also use excess of loss reinsurance agreements for certain policies whereby we limit our loss in excess of specified thresholds. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We evaluate the financial condition of our Traditional Insurance reinsurers and monitor concentrations of credit risk to minimize our exposure to significant losses from reinsurer insolvencies. We are obligated to pay claims in the event that a reinsurer to whom we have ceded an insured claim fails to meet its obligations under the reinsurance agreement. We are not aware of any instances where any of our reinsurers have been unable to pay any policy claims on any reinsured business. 2 The following table summarizes the total assets and liabilities of our discontinued operations: <div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reinsurance recoverables</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserves and other policy liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 500000 100000 40600000 42800000 165700000 170200000 400000 500000 207200000 213600000 166100000 166900000 41100000 46700000 207200000 213600000 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indemnification Obligations</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under Delaware law, our charter and bylaws and certain indemnification agreements to which we are a party, we are obligated to indemnify, or we have otherwise agreed to indemnify, certain of our current and former directors, officers and associates with respect to current and future investigations and litigation, including the matters discussed in this note. The indemnification agreements for our directors and executive officers with respect to events occurring prior to May 2009 require us to indemnify an indemnitee to the fullest extent permitted by law if the indemnitee was or is or becomes a party to or a witness or other participant in any proceeding by reason of any event or occurrence related to the indemnitee's status as a director, officer, associate, agent or fiduciary of the Company or any of our subsidiaries. The indemnification agreements require us to indemnify an indemnitee against all expenses, including attorney's fees, judgments, fines, settlement amounts and interest and other charges, and any taxes as a result of the receipt of payments under the indemnification agreement. We will not indemnify the indemnitee if not permitted under applicable law. We are required to advance all expenses incurred by the indemnitee. We are entitled to reimbursement by an indemnitee of expenses advanced if the indemnitee is not permitted to be reimbursed under applicable law after a final judicial determination is made and all rights of appeal have been exhausted or lapsed.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We amended and restated our indemnification agreements in May 2009. The revised agreements apply to our officers and directors with respect to events occurring after that time. Pursuant to the 2009 indemnification agreements, we will indemnify the indemnitee against all expenses, including attorney's fees, judgments, penalties, fines, settlement amounts and any taxes imposed as a result of payments made under the indemnification agreement incurred in connection with any proceedings that relate to the indemnitee's status as a director, officer or associate of the Company or any of our subsidiaries or any other enterprise that the indemnitee was serving at our request. We will also indemnify for expenses incurred by an indemnitee if the indemnitee, by reason of his or her corporate status, is a witness in any proceeding. Further, we are required to indemnify for expenses incurred by an indemnitee in defense of a proceeding to the extent the indemnitee has been successful on the merits or otherwise. Finally, if the indemnitee is involved in certain proceedings as a result of the indemnitee's corporate status, we are </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">required to advance the indemnitee's reasonable expenses incurred in connection with such proceeding, subject to the requirement that the indemnitee repay the expenses if it is ultimately determined that the indemnitee is not entitled to be indemnified. We are not obligated to indemnify an indemnitee for losses incurred in connection with any proceeding if a determination has not been made by the Board of Directors, a committee of disinterested directors or independent legal counsel in the specific case that the indemnitee has satisfied any standards of conduct required as a condition to indemnification under Section 145 of the Delaware General Corporation Law.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to our obligations, we have advanced legal fees and related expenses to </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> former officers and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> additional associates who were criminally indicted in connection with the government investigations of the Company that commenced in 2007 related to federal criminal health care fraud charges including conspiracy to defraud the United States, false statements relating to health care matters, and health care fraud in connection with their defense of criminal charges. In June 2013, the jury in the federal criminal trial reached guilty verdicts on multiple charges for the </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> individuals that were tried in 2013. In May 2014, the individuals were sentenced and our request for restitution was denied. All </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> individuals filed notices of appeal and the government filed notices of cross appeal on </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> individuals, which the government has subsequently voluntarily dismissed. The appellate court affirmed the convictions in August 2016. Mr. Farha filed a petition for a writ of certiorari to the United States Supreme Court in January 2017. In April 2017, the United States Supreme Court declined to hear the appeal by Mr. Farha. The fifth individual, Mr. Bereday, entered a guilty plea in June 2017 in connection with the federal criminal charges, which was accepted by the court in July 2017. Mr. Bereday was sentenced in November 2017.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have also previously advanced legal fees and related expenses to these </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> individuals regarding: a dispute in Delaware Chancery Court related to whether we were legally obligated to advance fees or indemnify certain of these individuals; the class actions titled </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Eastwood Enterprises, L.L.C. v. Farha, et al</span><span style="font-family:inherit;font-size:10pt;">. and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Hutton v. WellCare Health Plans, Inc. et al</span><span style="font-family:inherit;font-size:10pt;">. filed in federal court; </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;"><span>six</span></span><span style="font-family:inherit;font-size:10pt;"> stockholder derivative actions filed in federal and state courts between October 2007 and January 2008; an investigation by the United States Securities &amp; Exchange Commission (the "Commission"); an action by the Commission filed in January 2012 against </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> individuals, Messrs. Farha, Behrens and Bereday, and a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> action against Messrs. Farha, Behrens and Bereday in federal court. We settled the class actions in May 2011. In 2010, we settled the stockholder derivative actions and we were realigned as the plaintiff to pursue our claims against Messrs. Farha, Behrens and Bereday. Pursuant to the settlement agreements described below, Messrs. Farha, Behrens and Bereday were dismissed from the federal court and state derivative actions. Pursuant to the settlement agreement with Mr. Bereday described below, Mr. Bereday was dismissed from the fee advancement case in Delaware Chancery Court. The Commission action was closed in May 2018. The </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> action is currently stayed and the stay is subject to being lifted at any time.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2017, the Commission and Mr. Farha entered into a consent judgment to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$12.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Commission and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to us. In April 2017, the Commission and Mr. Behrens also entered into a consent judgment to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Commission and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to us. In May 2018, the Commission and Mr. Bereday entered into a consent judgment to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Commission and the case was closed.</span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we have advanced a portion of the legal fees and related expenses to Mr. Farha in connection with lawsuits he filed in Delaware and Florida state court to have certain restrictions lifted on WellCare stock purportedly awarded to him during his employment with us. The Delaware and Florida state court matters have been dismissed. </span></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2016, we entered into a settlement agreement with Mr. Farha pursuant to which he paid us </span><span style="font-family:inherit;font-size:10pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, as referenced in the April 2017 consent judgment with the Commission, and we agreed that we would not seek to recover additional legal fees previously advanced related to these matters, and that our obligation to continue advancing fees would be limited to no more than an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also have advanced a portion of the legal fees and related expenses to Mr. Behrens in connection with his lawsuit in Delaware state court to have certain restrictions lifted on WellCare stock purportedly awarded to him during his employment with WellCare, which the court dismissed. In October 2016, we also entered into a settlement agreement with Mr. Behrens pursuant to which he paid us </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, as referenced in the April 2017 consent judgment with the Commission, and we agreed that we would not seek to recover additional legal fees previously advanced in connection with these matters, and that our obligation to continue advancing fees would be limited to no more than an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2017, we entered into a settlement agreement with Mr. Bereday that became effective in July 2017, pursuant to which we agreed that we would not seek to recover legal fees previously advanced in connection with these matters, and that our obligation to continue advancing fees would be limited to no more than an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with these matters, we have advanced to the </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> individuals legal fees and related expenses from the inception of the investigations through </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the cumulative amounts of which has not changed materially from </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2018. We expense these costs as incurred and classify the costs as SG&amp;A expense incurred in connection with the investigations and related matters. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have exhausted our insurance policies related to reimbursement of our advancement of fees related to these matters. We are unable to estimate the total amount of these costs or a range of possible loss. Accordingly, we continue to expense these costs as incurred. </span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Lawsuits and Claims</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Based on the nature of our business, we are subject to regulatory reviews or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance and benefits companies and their reviews focus on numerous facets of our business, including claims payment practices, provider contracting, competitive practices, commission payments, privacy issues and utilization management practices, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to our business practices. We continue to be subject to such reviews, which may result in additional fines and/or sanctions being imposed, premium refunds or additional changes in our business practices.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Separate and apart from the legal matters described above, we are also involved in other legal actions in the normal course of our business, including, without limitation, protests and appeals related to Medicaid procurement awards, wage and hour claims and other employment claims, claims for indemnification under purchase agreements, vendor disputes and provider disputes regarding payment of claims. Some of these actions seek monetary damages including claims for liquidated or punitive damages, which are not covered by insurance. We review relevant information with respect to these litigation matters and we update our estimates of reasonably possible losses and related disclosures. We accrue an estimate for contingent liabilities, including attorney's fees related to these matters, if a loss is probable and estimable. Currently, we do not expect that the resolution of any of these currently pending actions, either individually or in the aggregate, will differ materially from our current estimates or have a material adverse effect on our results of operations, financial condition and cash flows. However, the outcome of any legal actions cannot be predicted, and therefore actual results may differ from those estimates. 3 2 4 4 3 4 5 6 3 5 12500000 7500000 4500000 1500000 4500000 7500000 7500000 1500000 1500000 2500000 5 XML 15 R1.htm IDEA: XBRL DOCUMENT v3.19.1
Document and Entity Information - shares
 3 Months Ended
Mar. 31, 2019
Apr. 29, 2019
Document and Entity Information [Abstract]    
Entity Registrant Name WELLCARE HEALTH PLANS, INC.  
Entity Central Index Key 0001279363  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   50,303,407
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q1  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2019  
Entity Emerging Growth Company false  
Entity Small Business false  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Revenues:    
Premium $ 6,609.4 $ 4,626.3
Products and services 115.8 0.0
Investment and other income 37.0 19.9
Total revenues 6,762.2 4,646.2
Expenses:    
Medical benefits 5,831.7 3,962.0
Costs of products and services 111.8 0.0
Selling, general and administrative 503.8 355.9
ACA industry fee 0.0 81.5
Medicaid premium taxes 31.7 32.1
Depreciation and amortization 69.6 36.4
Interest 29.5 17.1
Total expenses 6,578.1 4,485.0
Income before income taxes and equity in losses of unconsolidated subsidiaries 184.1 161.2
Equity in earnings (losses) of unconsolidated subsidiaries 0.8 (2.7)
Income before income taxes 184.9 158.5
Income tax expense 33.5 56.8
Net income 151.4 101.7
Other comprehensive income (loss):    
Change in net unrealized gains and losses on available-for-sale securities, before tax 18.5 (10.3)
Income tax expense (benefit) related to other comprehensive income 4.7 (2.4)
Other comprehensive income (loss), net of tax 13.8 (7.9)
Comprehensive income $ 165.2 $ 93.8
Earnings per common share:    
Basic (in USD per share) $ 3.02 $ 2.28
Diluted (in USD per share) $ 2.98 $ 2.25
Weighted average common shares outstanding:    
Basic (in shares) 50,100,509 44,605,892
Diluted (in shares) 50,842,304 45,196,127
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.19.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2019
Dec. 31, 2018
Current Assets:    
Cash and cash equivalents $ 3,235.3 $ 3,653.9
Short-term investments 968.6 830.1
Premiums receivable, net 1,567.6 1,223.4
Pharmacy rebates receivable, net 550.0 460.6
Funds receivable for the benefit of members 331.6 187.3
Prepaid expenses and other current assets, net 1,127.6 477.1
Total current assets 7,780.7 6,832.4
Property, equipment and capitalized software, net 424.9 428.2
Goodwill 2,206.4 2,227.7
Other intangible assets, net 986.0 996.2
Long-term investments 1,057.6 813.2
Restricted cash, cash equivalents and investments 274.3 234.7
Other assets 268.8 18.7
Assets of discontinued operations 207.2 213.6
Total Assets 13,205.9 11,764.7
Current Liabilities:    
Medical benefits payable 3,212.6 2,897.4
Unearned premiums 16.9 1.4
Accounts payable and accrued expenses 1,304.9 964.6
Funds payable for the benefit of members 1,051.8 693.3
Other payables to government partners 491.1 458.9
Total current liabilities 6,077.3 5,015.6
Deferred income tax liability, net 149.0 134.2
Long-term debt, net 2,127.3 2,126.4
Other liabilities 253.9 34.9
Liabilities of discontinued operations 207.2 213.6
Total Liabilities 8,814.7 7,524.7
Commitments and contingencies (see Note 14)
Stockholders' Equity:    
Preferred stock, $0.01 par value (20,000,000 authorized, no shares issued or outstanding) 0.0 0.0
Common stock, $0.01 par value (100,000,000 authorized, 50,302,215 and 49,993,219 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively) 0.5 0.5
Paid-in capital 1,967.1 1,981.1
Retained earnings 2,418.7 2,267.3
Accumulated other comprehensive income (loss) 4.9 (8.9)
Total Stockholders' Equity 4,391.2 4,240.0
Total Liabilities and Stockholders' Equity $ 13,205.9 $ 11,764.7
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.19.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2019
Dec. 31, 2018
Stockholders' Equity:    
Preferred stock, par value (in USD per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 20,000,000 20,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in USD per share) $ 0.01 $ 0.01
Common stock, authorized (in shares) 100,000,000 100,000,000
Common stock, issued (in shares) 50,302,215 49,993,219
Common stock, outstanding (in shares) 50,302,215 49,993,219
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.19.1
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Millions
Total
Common Stock
Paid in Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2017   44,522,988      
Beginning balance at Dec. 31, 2017 $ 2,416.7 $ 0.4 $ 591.5 $ 1,827.5 $ (2.7)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued for vested equity-compensation awards (in shares)   334,521      
Repurchase and retirement of shares to satisfy tax withholding requirements (in shares)   (104,274)      
Repurchase and retirement of shares to satisfy tax withholding requirements (20.2)   (20.2)    
Stock-based compensation expense, net of forfeitures 12.1   12.1    
Comprehensive income 93.8     101.7 (7.9)
Ending balance (in shares) at Mar. 31, 2018   44,753,235      
Ending balance at Mar. 31, 2018 $ 2,502.4 $ 0.4 583.4 1,929.2 (10.6)
Beginning balance (in shares) at Dec. 31, 2018 49,993,219 49,993,219      
Beginning balance at Dec. 31, 2018 $ 4,240.0 $ 0.5 1,981.1 2,267.3 (8.9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued for vested equity-compensation awards (in shares)   451,484      
Common stock issued for vested equity-compensation awards 0.0        
Repurchase and retirement of shares to satisfy tax withholding requirements (in shares)   (142,488)      
Repurchase and retirement of shares to satisfy tax withholding requirements (36.8)   (36.8)    
Stock-based compensation expense, net of forfeitures 22.8   22.8    
Comprehensive income $ 165.2     151.4 13.8
Ending balance (in shares) at Mar. 31, 2019 50,302,215 50,302,215      
Ending balance at Mar. 31, 2019 $ 4,391.2 $ 0.5 $ 1,967.1 $ 2,418.7 $ 4.9
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Cash flows from operating activities:    
Net income $ 151.4 $ 101.7
Adjustments to reconcile net income to cash flows from operating activities:    
Depreciation and amortization 69.6 36.4
Stock-based compensation expense 22.8 12.1
Deferred taxes, net 6.6 (19.5)
Other, net 10.1 5.1
Changes in operating accounts, net of effects from acquisitions and divestitures:    
Premiums receivable, net (348.5) (187.9)
Pharmacy rebates receivable, net (89.4) (45.6)
Medical benefits payable 315.2 64.0
Unearned premiums 15.5 527.0
Other receivables/payables to government partners 32.2 (15.8)
Prepaid and other current assets (110.9) (7.4)
Accrued liabilities and other, net (104.6) (24.4)
Net cash (used in) provided by operating activities (30.0) 445.7
Cash flows from investing activities:    
Purchases of investments (979.0) (387.9)
Proceeds from sales and maturities of investments 529.6 171.5
Additions to property, equipment and capitalized software, net (38.1) (24.2)
Net cash used in provided by investing activities (487.5) (240.6)
Cash flows from financing activities:    
Repurchase and retirement of shares to satisfy employee tax withholding requirements (36.8) (20.2)
Funds received for the benefit of members, net 170.7 416.2
Other, net 1.3 21.4
Net cash provided by financing activities 135.2 417.4
(Decrease) increase in cash, cash equivalents and restricted cash and cash equivalents (382.3) 622.5
Balance at beginning of period 3,716.6 4,263.0
Balance at end of period 3,334.3 4,885.5
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:    
Cash paid for taxes, net of refunds 6.7 2.0
Cash paid for interest 54.6 32.1
SUPPLEMENTAL DISCLOSURES OF NON-CASH TRANSACTIONS:    
Non-cash additions to property, equipment, and capitalized software $ 5.8 $ 3.0
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.19.1
ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
 
WellCare Health Plans, Inc. (the "Company," "we," "us," or "our") focuses primarily on providing government-sponsored managed care services to families, children, seniors and individuals with complex medical needs primarily through Medicaid, Medicare Advantage ("MA") and Medicare Prescription Drug Plans ("PDP"), as well as individuals in the Health Insurance Marketplace. As of March 31, 2019, we served approximately 6.3 million members nationwide. 

As of March 31, 2019, we operated Medicaid health plans, including states where we receive Medicaid premium revenues associated with dually eligible special needs plans, in Arizona, Florida, Georgia, Hawaii, Illinois, Kentucky, Michigan, Missouri, Nebraska, New Jersey, New York, South Carolina and Texas.

In addition, as of March 31, 2019, we also operated MA coordinated care plans ("CCPs") in Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky, Louisiana, Maine, Michigan, Mississippi, New Jersey, New York, North Carolina, Ohio, South Carolina, Tennessee and Texas. We also offered stand-alone Medicare PDPs nationwide.

In September 2018, we completed the acquisition of Meridian Health Plan of Michigan, Inc., Meridian Health Plan of Illinois, Inc., and MeridianRx, LLC, a pharmacy benefit manager ("PBM") (collectively, "Meridian"). As a result of the acquisition, we expanded our Medicaid portfolio through the addition of Michigan; expanded our Medicaid presence in Illinois; and acquired an integrated PBM platform. Meridian also serves MA members in Illinois, Indiana, Michigan, and Ohio, as well as Health Insurance Marketplace members in Michigan.

Basis of Presentation

The accompanying unaudited condensed consolidated balance sheets and statements of comprehensive income, changes in stockholders' equity, and cash flows include our accounts and the accounts of our subsidiaries over which we have control or are the primary beneficiary. We eliminated all intercompany accounts and transactions.

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). Accordingly, certain financial information and footnote disclosures normally included in financial statements prepared in accordance with GAAP, but that are not required for interim reporting purposes, have been condensed or omitted. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto, for the fiscal year ended December 31, 2018, included in our Annual Report on Form 10-K ("2018 Form 10-K"), which was filed with the U.S. Securities and Exchange Commission ("SEC") in February 2019. Results for the interim periods presented are not necessarily indicative of results that may be expected for the entire year or any other interim period.

In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all normal recurring adjustments that we consider necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. In accordance with GAAP, we make certain estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. We base these estimates, including assumptions as to the annualized tax rate, on our knowledge of current events and anticipated future events and evaluate and update our assumptions and estimates on an ongoing basis; however, actual results may differ from our estimates. We evaluated all material events subsequent to the date of these condensed consolidated interim financial statements. Certain reclassifications were made to 2018 financial information to conform to the 2019 presentation.

Pharmacy Benefit Manager

The external revenues and costs for our PBM business are reported within "Products and Services" and "Cost of Products and Services", respectively, on the condensed consolidated statements of comprehensive income. Products and services revenues from our PBM consist of the prescription price (ingredient cost plus dispensing fee) negotiated with the retail pharmacies with which we have contracted, plus any associated administrative fees. This revenue is recognized when the claim is processed. We have the contractual obligation to pay network pharmacies for benefits provided to participating members and, therefore, act as principal in the arrangement and reflect the total prescription price as revenue, on a gross basis, in accordance with applicable accounting guidance. Costs of products and services is recognized at the time prescriptions are dispensed by pharmacies in the PBM's network to eligible members and consists primarily of ingredient costs and dispensing fees paid to retail pharmacies with which we have contracted. The overall results of our PBM business are immaterial.

Aetna Part D Membership Reinsurance

In November 2018, we completed the purchase of Aetna Inc.'s ("Aetna") entire standalone Medicare Part D prescription drug plan membership ("Aetna Part D membership"). In connection with the purchase, we also entered into an administrative services agreement and a reinsurance agreement pursuant to which Aetna provides administrative services to, and retains financial risk of, the Aetna Part D membership, effective for plan year 2019. We remain primarily liable to policyholders under this ceded insurance contract and are contingently liable for amounts recoverable from Aetna in the event that they do not meet their contractual obligations.  In the normal course, we evaluate the financial condition of our reinsurers and monitor concentrations of credit risk to minimize our exposure to significant losses from reinsurer insolvencies. As of March 31, 2019, related to the Aetna Part D membership, our condensed consolidated balance sheet included reinsured receivables of $30.8 million, primarily related to premiums receivable, and reinsured payables of $482.8 million, primarily related to pharmacy claims payables. These reinsured receivables and payables were included in prepaid expenses and other current assets, net, and accounts payable and accrued liabilities, respectively. The resulting net reinsurance recoverables of $452.0 million was included in prepaid expenses and other current assets, net on the condensed consolidated balance sheet. There were no reinsurance recoverables or reinsurance liabilities relating to the Aetna Part D membership recorded as of December 31, 2018.
 
In our condensed consolidated statements of comprehensive income, premium revenue and medical benefits were reported net of amounts ceded under this Aetna reinsurance arrangement. Premium revenue and medical benefits expense ceded relating to the Aetna Part D membership were $501.0 million and $473.7 million, respectively, for the three months ended March 31, 2019.

Unconsolidated Subsidiaries

We work with physicians and other health care professionals to operate Accountable Care Organizations ("ACOs") under the Medicare Shared Saving Program ("MSSP") and Next Generation ACO Models. ACOs were established by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the "ACA") to reward integrated, efficient care and allow providers to share in any savings they achieve as a result of improved quality and operational efficiency.
These ACOs are generally formed as limited liability companies. The ACOs are considered variable interest entities ("VIEs") under GAAP as these entities do not have sufficient equity to finance their own operations without additional financial support. We own a majority interest in our ACOs; however, we share the power to direct the activities that most significantly affect the ACOs with health care providers that are minority owners in the ACOs. This power is shared pursuant to the structure of the management committee of each of the ACOs. Accordingly, we have determined that we are not the primary beneficiary of the ACOs; therefore, we cannot consolidate their results. We perform an ongoing qualitative assessment of our variable interests in VIEs to determine whether we have a controlling financial interest and would therefore be considered the primary beneficiary of the VIE.
We account for our participation in the ACOs using the equity method. Gains and losses are immaterial and are reported on the face of our condensed consolidated statements of comprehensive income as equity in earnings (losses) of unconsolidated subsidiaries.
Significant Accounting Policies
Below is a discussion of our significant accounting policies, which affected the comparability of our consolidated results of operations, financial condition or cash flows for the periods presented. Refer to Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in our 2018 Form 10-K for a complete discussion of all of our significant accounting policies.
Premium Receivables and Unearned Premiums
We record premiums earned but not received as premiums receivable and record premiums received in advance of the period of service as unearned premiums in our condensed consolidated balance sheets. A complete discussion of premiums receivable and unearned premiums is included in Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in our 2018 Form 10-K. The premium receivable balance at March 31, 2019 is primarily related to Medicaid contracts with our state partners of approximately $1.2 billion, as well as net risk-adjusted premiums receivable under our MA and PDP contracts of approximately $364.0 million.
Medicaid Risk-Adjusted Premiums and Retroactive Rate Changes

As discussed further in Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in our 2018 Form 10-K, Medicaid premium rate changes are recognized in the period the change becomes effective, when the effect of the change in the rate is reasonably estimable and collection is assured. In some instances, our Medicaid premiums are subject to risk score adjustments based on the health profile of our membership. Generally, the risk score is determined by the state agency's analysis of encounter submissions of processed claims data to determine the acuity of our membership relative to the entire state's Medicaid membership. The frequency of when states adjust premiums varies, but is usually done quarterly or semi-annually on a retrospective basis. We recognize periodic changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Premiums receivable in our condensed consolidated balance sheets include net risk-adjusted premiums receivable from our Medicaid state partners related to retroactive rate changes and risk score adjustments of $121.5 million and $54.4 million as of March 31, 2019 and December 31, 2018, respectively.
Medicare Part D Settlements
We receive certain Part D prospective subsidy payments from the Centers for Medicare & Medicaid Services ("CMS") for our MA and PDP members as a fixed monthly per member amount, based on the estimated costs of providing prescription drug benefits over the plan year, as reflected in our bids. A discussion of the subsidy components under Part D is included in Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in our 2018 Form 10-K. CMS will fully reimburse these subsidies, or recoup overpaid subsidies made during the plan year, as part of its annual settlement process that typically occurs in the fourth quarter of the subsequent year and, accordingly, there is no insurance risk to us. Therefore, amounts received for these subsidies are not considered premium revenue, and are reported, net of the subsidy benefits paid, as funds receivable (payable) for the benefit of members in the condensed consolidated balance sheets. As of March 31, 2019 and December 31, 2018, our condensed consolidated balance sheets primarily include CMS Part D payables for the 2018 and 2016 plan years. Our condensed consolidated balance sheet as of March 31, 2019 additionally includes a payable for the 2019 plan year. We expect to settle a majority of the 2016 and 2018 net payables during the remainder of 2019.
ACA Industry Fee
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 imposed certain new taxes and fees, including an annual premium-based health insurance industry assessment (the "ACA industry fee") on health insurers, which began in 2014. In January 2018, Congress approved a one-year moratorium of the ACA industry fee for 2019, which also eliminated the Medicaid ACA industry fee reimbursement from our state government partners for 2019. Accordingly, we did not incur ACA industry fee expense nor recognize any Medicaid ACA industry fee reimbursement revenue for the three months ended March 31, 2019. We incurred $81.5 million for the ACA industry fee for the three months ended March 31, 2018. Additionally, we recognized $64.7 million of Medicaid ACA industry fee reimbursement revenue as premium revenue for the three months ended March 31, 2018.

Recently Adopted Accounting Standards

In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2018-07, “Compensation-Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting.” This update expands the scope of Topic 718, which currently only includes share-based payments issued to
employees, to include share-based payments issued to non-employees for goods and services. This guidance was effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance on January 1, 2019. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.

In February 2018, the FASB issued ASU 2018-02 "Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income", which allows entities to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 from accumulated other comprehensive income to retained earnings. The guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance prospectively on January 1, 2019. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.

In March 2017, the FASB issued ASU No. 2017-08, "Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities". This update shortens the amortization period for the premium on certain purchased callable debt securities to the earliest call date. Previously, entities generally amortize the premium as a yield adjustment over the contractual life of the security. The new guidance does not change the accounting for purchased callable debt securities held at a discount. This guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance on January 1, 2019 on a modified retrospective basis. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments in its balance sheet. This standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. Subsequently, in July 2018, the FASB issued ASU 2018-11, “Leases (Topic 842), Targeted Improvements” which, among other things, allows companies to elect an optional transition method to apply the new lease standard through a cumulative-effect adjustment, if any, in the period of adoption, rather than in the earliest period presented. We adopted the standard on January 1, 2019 using the optional transition method. We elected the practical expedients permitted under the transition guidance, which allows us to carryforward our historical lease classifications for existing leases. Additionally, we elected the practical expedient to not separate non-lease components from the associated lease component. As part of the adoption process, we implemented a new lease accounting system. The adoption of this guidance resulted in the initial recognition of operating lease right-of-use assets of approximately $259.5 million, operating lease liabilities of approximately $277.3 million and the elimination of $17.8 million of straight-line lease liabilities, as of January 1, 2019. This guidance did not have a material effect on our consolidated results of operations or cash flows.

Accounting Standards Pending Adoption

In August 2018, the FASB issued ASU 2018-15, "Intangibles-Goodwill and Other-Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract", which requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. We are currently assessing the effect this guidance will have on our consolidated results of operations, financial condition or cash flows.
In June 2016, the FASB issued ASU 2016-13, "Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments," which requires entities to use a current expected credit loss model, which is a new impairment model based on expected losses rather than incurred losses. Under this model, an entity would recognize an impairment allowance equal to its current estimate of all contractual cash flows that the entity does not expect to collect from financial assets measured at amortized cost. The entity's estimate would consider relevant information about past events, current conditions, and reasonable and supportable forecasts, which will result in recognition of lifetime expected credit losses upon loan origination. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted for annual reporting periods beginning after December 15, 2018. We are currently assessing the effect this guidance will have on our consolidated results of operations, financial condition or cash flows.
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.19.1
CENTENE PLAN OF MERGER AND ACQUISITIONS
 3 Months Ended
Mar. 31, 2019
Business Combinations [Abstract]  
CENTENE PLAN OF MERGER AND ACQUISITIONS CENTENE PLAN OF MERGER AND ACQUISITIONS

Centene Plan of Merger

On March 26, 2019, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Centene Corporation ("Centene") under which Centene will acquire us for a combination of cash and stock. Under the terms of the Merger Agreement, our shareholders will receive $120.00 in cash and 3.38 shares of Centene common stock for each share of our common stock. The proposed transaction is subject to customary closing conditions, including, but not limited to, the approval of the Merger Agreement by our stockholders, the approval of the share issuance of Centene stock by Centene’s stockholders, and the receipt of U. S. federal antitrust clearance and certain other required regulatory approvals. The transaction is expected to close in the first half of 2020.

The Merger Agreement includes restrictions on the conduct of our business prior to completion of the Centene Transaction or termination of the Merger Agreement, generally requiring us to conduct our business in the ordinary course. However, we are subject to various specified restrictions unless we obtain Centene’s prior written consent, which may not be unreasonably withheld, delayed or conditioned, or expressly contemplated or permitted by the Merger Agreement or as required by applicable law. Among other things and in each case subject to certain exceptions, we may not:
•
incur additional indebtedness (excluding borrowings under our Revolving Credit Facility (as defined below) that are used to manage our ordinary course cash flow needs);
•
issue additional shares of our common stock, repurchase our common stock, or pay dividends;
•
acquire assets, securities or property, dispose of businesses or assets; or
•
authorize any payment of, accrual or commitment for capital expenditures in any calendar year that would exceed by more than 110% the aggregate amount of capital expenditures budgeted for such year.

Aetna Medicare Part D Asset Acquisition

As discussed in Note 1 - Organization, Basis of Presentation and Significant Accounting Policies of this 2019 Form 10-Q,
in November 2018, we completed the purchase of Aetna's Part D membership for total cash consideration of $107.2 million, which is subject to certain true-up provisions. These membership assets are recorded within other intangible assets, net in the condensed consolidated balance sheets as of March 31, 2019 and December 31, 2018, and have a weighted-average useful life of eight years beginning in 2020. Per the terms of the agreement, Aetna provides administrative services to, and retains financial risk of, the Aetna Part D membership through 2019. Therefore, the Aetna Part D membership is excluded from our membership and has had, or is expected to have, an immaterial effect on our results of operations until January 1, 2020.

Meridian Business Acquisition

On September 1, 2018 (the "Effective Date"), we acquired Meridian for an estimated purchase price of approximately  $2.5 billion in cash, subject to certain purchase price adjustments, as described in the purchase agreement. The Meridian acquisition was funded through a combination of cash on hand, our Revolving Credit Facility, net proceeds from the August 2018 issuance of our 5.375% of Senior Notes due 2026 ("2026 Notes") and net proceeds from an issuance of shares of our common stock. We included the results of Meridian's operations since the Effective Date in our condensed consolidated financial statements.

The following table summarizes the estimated fair values of major classes of assets acquired and liabilities assumed at the Effective Date, based on our valuation assumptions, reconciled to the total consideration transferred.
Assets
(in millions)
Cash, cash equivalents and restricted cash
$
484.4

Investments, including restricted investments
180.4

Premiums receivable, net
379.6

Other current assets
146.2

Property, equipment and capitalized software, net
49.3

Goodwill
1,539.4

Other intangible assets, net
622.0

     Fair value of total assets acquired
$
3,401.3

 
 
Liabilities
 
Medical benefits payable
$
534.3

ACA Fee liability
66.5

Other liabilities
280.4

     Fair value of liabilities assumed
881.2

     Fair value of net assets acquired
$
2,520.1

 
 

The fair value results from judgments about future events, which reflect certain uncertainties and rely on estimates and assumptions. The judgments used to determine the fair value assigned to each class of assets acquired and liabilities assumed, as well as intangible asset lives, can materially affect our operating results. As of the Effective Date, the expected fair value of all current assets and liabilities approximated their historical cost. As of March 31, 2019, we have preliminarily determined the fair value of assets acquired and liabilities assumed; however, the final fair values may be subject to, (i) the final valuation of intangible assets related to memberships and trade names, (ii) the final assessment and valuation of certain other assets acquired and liabilities assumed, including premiums receivable, property, equipment and capitalized software, medical benefits payable and other liabilities and (iii) the final assessment and valuation of certain income tax amounts. Therefore, the final fair values of the assets acquired and liabilities assumed may vary significantly from our preliminary estimates.

Identifiable intangible assets acquired

Under the Hart-Scott-Rodino Antitrust Improvements Act and other relevant laws and regulations, there were significant limitations on our ability to obtain specific information about Meridian's intangible assets prior to completion of the acquisition in September 2018. As of March 31, 2019, certain of the more significant assumptions inherent in the development of intangible asset fair values, including the following, are preliminary.
•final membership attrition rates;
•final discount rates selected to measure the risks inherent in the future cash flows;
•
key assumptions in the valuation of the acquired technology, including, but not limited to, estimated costs associated with developers' salaries, external direct costs of materials and services; and the estimated time to replace the acquired software applications; and
•working capital adjustments and the assessment of the assets' life cycle, among other key assumptions.

The following table summarizes the preliminary fair values and weighted average useful lives for identifiable intangible assets acquired in the Meridian acquisition as of the Effective Date of the acquisition. These preliminary estimates of fair value and weighted-average useful life may be different from the final acquisition accounting, and the difference could have a material effect on the consolidated financial statements.

 
 
Gross Fair Value
(in millions)
 
Weighted Average
Useful Life (in years)
Membership
 
$
406.6

 
8.1
Tradenames
 
110.4

 
4.9
Provider network
 
8.3

 
15.0
Technology and other
 
96.7

 
5.8
Total
 
$
622.0

 
7.3
 
 
 
 
 

Goodwill

We recorded $1.5 billion for the valuation of goodwill for the excess of the purchase price over the estimated fair value of the net assets acquired. The assignment of goodwill to our respective segments has not been completed at this time. The recorded goodwill related to the acquisition is deductible for tax purposes.

Deferred taxes

The Meridian acquisition included taxable and nontaxable components resulting in differences in amounts recognized for GAAP and tax purposes. In both taxable and nontaxable business combinations, the amounts assigned to the individual assets acquired and liabilities assumed for financial statement purposes are often different from the amounts assigned or carried forward for tax purposes. We recorded a $49.9 million deferred tax liability based on the estimated bases differences.

Goodwill

A summary of changes in our goodwill by reportable segment is as follows for the three months ended March 31, 2019:

 
Medicaid Health Plans
 
Medicare Health Plans
 
Not assigned(1)
 
Total
Balance as of December 31, 2018
$
274.7

 
$
392.3

 
$
1,560.7

 
$
2,227.7

Acquisition related adjustments
—

 
—

 
(21.3
)
 
(21.3
)
Balance as of March 31, 2019
$
274.7

 
$
392.3

 
$
1,539.4

 
$
2,206.4

 
 
 
 
 
 
 
 
(1) Goodwill related to our September 1, 2018 Meridian acquisition is considered preliminary, pending the final allocation of the applicable purchase price. The assignment of goodwill to our respective segments has not been completed at this time.

Unaudited Pro Forma Financial Information

The results of operations and financial condition for the Meridian acquisition have been included in our condensed consolidated financial statements since the Effective Date. The unaudited pro forma financial information presented below reflects our 2018 acquisition of Meridian, assuming the acquisition occurred as of January 1, 2018. Pro forma results are not provided for the three months ended March 31, 2019, as Meridian's operations were included in our results of operations for this time period.

These pro forma results are based on estimates and assumptions and do not reflect any anticipated synergies, efficiencies or other cost savings that we expect to realize from the acquisition. The following unaudited pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the results of operations that would have occurred had the acquisition actually consummated at January 1, 2018, or project the future results of the combined company.
 
 
Pro Forma - Unaudited
(in millions, except per share data)
 
Three Months ended
March 31, 2018
Total revenues
 
$
5,673.6

Net income
 
$
100.9

 
 
 
Earnings per common share:
 
 
   Basic
 
$
2.02

   Diluted
 
$
2.00

 
 
 
Weighted average common shares outstanding:
 
 
       Basic
 
49,890,397

       Diluted
 
50,446,757

 
 
 


The pro forma results presented in the schedule above include adjustments related to the following purchase accounting and other acquisition-related costs:

•
Elimination of historical intangible asset amortization expense and addition of amortization expense based on the current preliminary values of identified intangible assets;
•
Elimination of interest expense associated with retired obligations and addition of interest expense based on debt incurred to finance the Meridian transaction;
•
Elimination of results for Meridian operations not acquired;
•
Elimination of transaction and integration-related costs;
•
Include 5,207,547 shares of our common stock issued to finance the Meridian transaction;
•
Adjustments to align the acquisition to our accounting policies; and
•
Tax effects of the adjustments noted above.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.19.1
SEGMENT REPORTING
 3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING

On a regular basis, we evaluate discrete financial information and assess the performance of our three reportable segments Medicaid Health Plans, Medicare Health Plans and Medicare PDPs, to determine the most appropriate use and allocation of Company resources.

We allocate premium revenue, medical benefits expense, Medicaid premium taxes, the 2018 ACA industry fee and goodwill to our reportable segments. We do not allocate to our reportable segments any other assets and liabilities, investment and other income, selling, general and administrative expenses ("SG&A"), depreciation and amortization, or interest expense. The Company's decision-makers primarily use premium revenue, medical benefits expense and gross margin to evaluate the performance of our reportable segments.

Our Corporate and Other category includes net investment and other income, SG&A expenses, depreciation, amortization and interest. Also included in this category are results for operating segments that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles.

Medicaid Health Plans

Our Medicaid Health Plans segment includes plans for beneficiaries of Temporary Assistance for Needy Families ("TANF"), Supplemental Security Income ("SSI"), Aged Blind and Disabled ("ABD"), Children's Health Insurance Program ("CHIP") and Long-Term Services and Supports ("LTSS") programs, among others. TANF generally provides assistance to low-income families with children. ABD and SSI generally provide assistance to low-income aged, blind or disabled individuals. CHIP provides assistance to qualifying families who are not eligible for Medicaid because their income exceeds the applicable income thresholds. The LTSS program is designed to help people with chronic illnesses or who have disabilities and need health and long-term care services, such as home care or adult day care, to enable them to stay in their homes and communities as long as possible.

Our Medicaid operations in Florida, Illinois and Kentucky individually account for 10% or more of our consolidated premium revenue for the three months ended March 31, 2019. These states and the respective Medicaid premium revenue as a percentage of total consolidated premium revenue are as follows: 
 
For the Three Months Ended
March 31,
 
2019
 
2018
Florida
17%
 
13%
Illinois
13%
 
*
Kentucky
10%
 
15%

*Our Illinois Medicaid health plan accounted for less than 10% of our consolidated premium revenue for the three months ended March 31, 2018.

In July 2018, we received a Notice of Intent to Award a five-year contract from the Florida Department of Health to provide statewide-managed care services to children with medically complex conditions through the Children's Medical Services Managed Care Plan ("CMS Plan"). The five-year contract award began on February 1, 2019; however, this contract is still subject to protest and appeal. Additionally, in April 2018, we received a Notice of Agency Decision from the Florida Agency for Health Care Administration (“AHCA”) to award our subsidiary, Staywell, a new five-year contract to provide managed care services to Medicaid-eligible beneficiaries, including Managed Medical Assistance and Long-Term Care beneficiaries in 10 of 11 regions. As part of the Medicaid Managed Care program, we provide statewide-managed care services to beneficiaries in the Serious Mental Illness Specialty Plan; however, this contract is still subject to protest and appeal. We are one of two managed care plans providing services to the SMI beneficiaries. The new statewide Medicaid Managed Care program began on December 1, 2018.

Medicare Health Plans

Medicare is a federal program that provides eligible persons age 65 and over and some disabled persons with a variety of hospital, medical and prescription drug benefits. MA is Medicare's managed care alternative to the original Medicare program, which provides individuals standard Medicare benefits directly through CMS. Our MA CCPs generally require members to seek health care services and select a primary care physician from a network of health care providers. In addition, we offer coverage of prescription drug benefits under the Medicare Part D program as a component of most of our MA plans.

Medicare PDPs

We offer stand-alone Medicare Part D coverage to Medicare-eligible beneficiaries in our Medicare PDPs segment. The Medicare Part D prescription drug benefit is supported by risk sharing with the federal government through risk corridors designed to limit the losses and gains of the participating drug plans and by reinsurance for catastrophic drug costs. The government subsidy is based on the national weighted average monthly bid for this coverage, adjusted for risk factor payments. Additional subsidies are provided for dually-eligible beneficiaries and specified low-income beneficiaries. The Part D program offers national in-network prescription drug coverage that is subject to limitations in certain circumstances.




Summary of Financial Information

Reportable operating segments are defined as components of an enterprise for which discrete financial information is available and evaluated on a regular basis by the enterprise's decision-makers to determine how resources should be allocated to an individual segment and to assess performance of those segments. Accordingly, we have three reportable segments: Medicaid Health Plans, Medicare Health Plans and Medicare PDPs.

A summary of financial information for our reportable segments through the gross margin level and reconciliation to income from operations is presented in the table below.

 
Medicaid Health Plan
Medicare Health Plan
Medicare PDP
Corporate & Other
Consolidated
For the Three Months Ended March 31, 2019
(in millions)
Premium
$
4,473.5

$
1,843.1

$
288.8

$
4.0

$
6,609.4

Products and services
—

—

—

115.8

115.8

Total premium and products and services revenues
4,473.5

1,843.1

288.8

119.8

6,725.2



 



Medical benefits
4,022.7

1,548.2

258.4

2.4

5,831.7

Costs of products and services
—

—

—

111.8

111.8

ACA industry fee
—

—

—

—

—

Medicaid premium taxes
31.7

—

—

—

31.7

Total gross margin expenses
4,054.4

1,548.2

258.4

114.2

5,975.2



 



Gross margin
419.1

294.9

30.4

5.6

750.0



 



Investment and other income
—

—

—

37.0

37.0

Other expenses
—

—

—

(602.9
)
(602.9
)
Income from operations
$
419.1

$
294.9

$
30.4

$
(560.3
)
$
184.1







For the Three Months Ended March 31, 2018





Premium
$
2,809.9

$
1,556.5

$
259.9

$
—

$
4,626.3

Products and services
—

—

—

—

—

Total premium and products and services revenues
2,809.9

1,556.5

259.9

—

4,626.3

 
 
 
 
 
 
Medical benefits
2,424.4

1,307.1

230.5

—

3,962.0

Costs of products and services
—

—

—

—

—

ACA industry fee
49.3

27.6

4.6

—

81.5

Medicaid premium taxes
32.1

—

—

—

32.1

Total gross margin expenses
2,505.8

1,334.7

235.1

—

4,075.6

 
 
 
 
 
 
Gross margin (1)
304.1

221.8

24.8

—

550.7

 
 
 
 
 
 
Investment and other income
—

—

—

19.9

19.9

Other expenses (2)
—

—

—

(409.4
)
(409.4
)
Income from operations
$
304.1

$
221.8

$
24.8

$
(389.5
)
$
161.2




(1)
Effective July 1, 2018, the Company redefined gross margin as total revenues less investment and other income, medical expenses, cost of products and services, the ACA industry fee expense, and Medicaid premium tax expense. Accordingly, results for the three months ended March 31, 2018 were adjusted to include Medicaid premium taxes, which decreased gross margin by $32.1 million.
(2)
Effective July 1, 2018, other expenses include SG&A expenses, depreciation, amortization and interest. Accordingly, results for the three months ended March 31, 2018 were adjusted to exclude Medicaid premium taxes, which decreased other expenses by $32.1 million.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.19.1
EQUITY AND EARNINGS PER SHARE
 3 Months Ended
Mar. 31, 2019
Earnings Per Share [Abstract]  
EQUITY AND EARNINGS PER SHARE EQUITY AND EARNINGS PER SHARE

Issuance of Common Stock

In August 2018, we completed a public offering of our common stock and issued 5,207,547 shares of our common stock, at an offering price of $265.00 per share. The net proceeds from the offering were approximately $1.3 billion, after deducting underwriting discounts and offering costs of approximately $37.7 million. We used the net proceeds to fund a portion of the acquisition of Meridian.

Earnings per Common Share

We compute basic earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding. We compute diluted earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding plus the dilutive effect of our stock-based compensation awards using the treasury stock method.

The calculation of the weighted-average common shares outstanding — diluted is as follows:
 
For the Three Months Ended
March 31,
 
2019
 
2018
 
 
 
 
Weighted-average common shares outstanding — basic
50,100,509

 
44,605,892

Dilutive effect of outstanding stock-based compensation awards
741,795

 
590,235

Weighted-average common shares outstanding — diluted
50,842,304

 
45,196,127

Anti-dilutive stock-based compensation awards excluded from computation
67,130

 
277,390

 
 
 
 
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.19.1
INVESTMENTS
 3 Months Ended
Mar. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
INVESTMENTS INVESTMENTS

The Company considers all of its investments as available-for-sale securities. Excluding restricted cash, cash equivalents and investments, the amortized cost, gross unrealized gains or losses and estimated fair value of short-term and long-term investments by security type are summarized in the following tables.
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
March 31, 2019
 
 
 
 
 
 
 
Debt securities:
 
 
 
 
 
 
 
Asset-backed securities
$
154.2

 
$
0.2

 
$
(0.3
)
 
$
154.1

Corporate debt securities
1,127.9

 
3.5

 
(2.7
)
 
1,128.7

Municipal securities
197.1

 
2.7

 
(0.1
)
 
199.7

Residential mortgage-backed securities
10.1

 
—

 
(0.1
)
 
10.0

Short-term time deposits
237.5

 
—

 
—

 
237.5

Government and agency obligations
9.2

 
—

 
(0.1
)
 
9.1

Other securities
62.0

 
—

 
—

 
62.0

Total debt securities
1,798.0

 
6.4

 
(3.3
)
 
1,801.1

Equity securities(1)
225.1


—


—


225.1

Total
$
2,023.1

 
$
6.4

 
$
(3.3
)
 
$
2,026.2

December 31, 2018
 

 
 

 
 

 
 

Asset-backed securities
$
144.7

 
$
—

 
$
(0.5
)
 
$
144.2

Corporate debt securities
943.0

 
0.5

 
(10.1
)
 
933.4

Municipal securities
199.6

 
0.6

 
(0.9
)
 
199.3

Residential mortgage-backed securities
7.2

 
—

 
(0.2
)
 
7.0

Short-term time deposits
242.2

 
—

 
—

 
242.2

Government and agency obligations
44.9

 
—

 
(0.1
)
 
44.8

Other securities
72.5

 
—

 
(0.1
)
 
72.4

Total(1)
$
1,654.1

 
$
1.1

 
$
(11.9
)
 
$
1,643.3

 

(1) Investments in equity securities primarily consists of exchange traded funds in fixed income and preferred and hybrid securities. Equity securities were not material as of December 31, 2018.

Contractual maturities of debt securities at March 31, 2019 are as follows:
 
 
Amortized Cost
 
Fair Value
Due in one year or less
$
889.6

 
$
889.7

Due after one year through five years
571.6

 
573.2

Due after five years through ten years
147.3

 
149.1

Due after ten years
13.1

 
12.9

Asset-backed and mortgage-backed securities
176.4

 
176.2

 Total
$
1,798.0

 
$
1,801.1

 
 
 
 


Actual maturities may differ from contractual maturities due to the exercise of pre-payment options.

We sold available-for-sale investments totaling $420.6 million and $80.2 million during the three months ended March 31, 2019 and 2018, respectively. Realized gains and losses resulting from sales and redemptions of our available-for-sale investments were immaterial for all periods presented. Additionally, we did not realize any other-than-temporary impairment during any of these periods.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.19.1
RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS
 3 Months Ended
Mar. 31, 2019
Restricted Investments Note [Abstract]  
RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS

As a condition for licensure, we are required to maintain certain funds on deposit or pledged to various state agencies. Certain of our state contracts require the issuance of surety bonds. We classify restricted cash, cash equivalents and investments as long-term regardless of the contractual maturity date of the securities held, due to the nature of the states' requirements. The amortized cost, gross unrealized gains, gross unrealized losses and fair value of our restricted cash, cash equivalents and investment securities are as follows: 

 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
March 31, 2019
 
 
 
 
 
 
 
Cash
$
12.8

 
$
—

 
$
—

 
$
12.8

Money market funds
86.2

 
—

 
—

 
86.2

U.S. government securities and other
175.6

 
—

 
(0.3
)
 
175.3

Total
$
274.6

 
$
—

 
$
(0.3
)
 
$
274.3

December 31, 2018
 

 
 

 
 

 
 

Cash
$
11.3

 
$
—

 
$
—

 
$
11.3

Money market funds
51.4

 
—

 
—

 
51.4

U.S. government securities and other
172.5

 
—

 
(0.5
)
 
172.0

Total
$
235.2

 
$
—

 
$
(0.5
)
 
$
234.7

 
 
 
 
 
 
 
 

 
Realized gains and losses on sales and redemptions of our restricted cash, cash equivalents and investments were not material for all periods presented.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.19.1
STOCK-BASED COMPENSATION
 3 Months Ended
Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION

Our Compensation Committee awards certain equity-based compensation under our stock plans, including restricted stock units ("RSUs") and performance stock units ("PSUs"). Compensation expense related to our stock-based compensation awards was $22.8 million and $12.1 million for the three months ended March 31, 2019 and 2018, respectively. As of March 31, 2019, there was $121.0 million of unrecognized compensation cost related to unvested stock-based compensation arrangements that is expected to be recognized over a weighted-average period of 2 years. The unrecognized compensation cost for certain of our PSUs, which are subject to variable accounting, was determined based on our closing common stock price of $269.75 as of March 29, 2019 and amounted to approximately $33.9 million of the total unrecognized compensation cost. Due to the nature of the accounting for these awards, future compensation cost will fluctuate based on changes in our common stock price. We estimate stock-based compensation expense based on awards ultimately expected to vest over the related service period (generally the vesting period) of the award, or to an employee’s eligible retirement date under the award agreement, if earlier. We make assumptions of forfeiture rates at the time of grant and continuously reassess our assumptions based on actual forfeiture experience.

A summary of RSU and PSU award activity, at target, for the three months ended March 31, 2019, is presented in the table below. For our PSUs, shares attained over target upon vesting are reflected as awards granted during the period, while shares canceled due to vesting below target are reflected as awards forfeited during the period.
 

 RSUs
 
PSUs
 
Total
Outstanding as of January 1, 2019
253,235

 
606,708

 
859,943

Granted
99,434

 
347,539

 
446,973

Vested
(99,668
)
 
(351,648
)
 
(451,316
)
Forfeited
(2,372
)
 
(8,276
)
 
(10,648
)
Outstanding as of March 31, 2019
250,629

 
594,323

 
844,952

 
 
 
 
 
 


The weighted-average grant-date fair value of all equity awards granted during the three months ended March 31, 2019 was $205.27.

Refer to Note 2 - Summary of Significant Accounting Policies and Note 15 - Stock-based Compensation to the consolidated financial statements included in our 2018 Form 10-K for additional information regarding our equity-compensation awards and related compensation cost measurement.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.19.1
DEBT
 3 Months Ended
Mar. 31, 2019
Debt Disclosure [Abstract]  
DEBT DEBT

The following table summarizes our outstanding debt obligations and their classification in the accompanying condensed consolidated balance sheets (in millions):
 
March 31, 2019
 
December 31, 2018
Long-term debt, net:
 
 
 
5.25% Senior Notes, due April 1, 2025
$
1,200.0

 
$
1,200.0

5.375% Senior Notes, due August 15, 2026
750.0

 
750.0

Revolving Credit Facility
200.0

 
200.0

Debt issuance costs
(22.7
)
 
(23.6
)
     Total long-term debt, net
$
2,127.3

 
$
2,126.4

 
 
 
 


Senior Notes

In August 2018, we completed the offering and sale of 5.375% unsecured senior notes due 2026 in the aggregate principal amount of $750.0 million (the “2026 Notes”). The aggregate net proceeds from the issuance of the 2026 Notes were used to fund a portion of the cash consideration for our acquisition of Meridian.

In March 2017, we completed the offering and sale of 5.25% unsecured senior notes due 2025 in the aggregate principal amount of $1,200.0 million (the “2025 Notes”). The aggregate net proceeds from the issuance of the 2025 Notes were primarily used to redeem the full $900.0 million aggregate principal amount of our 5.75% unsecured senior notes (the "2020 Notes") on April 7, 2017, and for general corporate purposes, including organic growth and working capital.

The 2026 Notes and 2025 Notes are classified as long-term debt in our condensed consolidated balance sheet at March 31, 2019, based on their maturity date. Refer to Note 10 - Debt to the consolidated financial statements included in our 2018 Form 10-K for additional information regarding these 2026 Notes and 2025 Notes, including applicable covenants.

Revolving Credit Facility

In January 2016, we entered into a credit agreement, which provided for a senior unsecured revolving loan facility (the "Revolving Credit Facility"). In July 2018, this credit agreement was amended and restated (“Amended and Restated Credit Agreement”) to increase the aggregate principle amount available under our Revolving Credit Facility from $1.0 billion to $1.3 billion, extend the maturity date for borrowings under the Revolving Credit Facility from January 2021 to July 2023 and decrease the applicable margins for borrowings under the Revolving Credit Facility, as calculated in accordance with the Amended and Restated Credit Agreement. The Amended and Restated Credit Agreement also includes an accordion feature which allows the Company to increase the total commitments under the Revolving Credit Facility by up to an additional $500 million, subject to certain conditions.

Unutilized commitments under the Amended and Restated Credit Agreement are subject to a fee of 0.20% to 0.30% depending upon our ratio of total debt to consolidated EBITDA, as calculated in accordance with the Amended and Restated Credit Agreement.

As of March 31, 2019, $200.0 million was outstanding under the Revolving Credit Facility, which was drawn during the third quarter of 2018 to fund a portion of the Meridian acquisition in September 2018. These borrowings are classified as long-term debt in accordance with the contractual terms of the Amended and Restated Credit Agreement.

Subsequent to the balance sheet date, in April 2019, an additional $140.0 million was drawn on our Revolving Credit Facility for general corporate purposes, including organic growth and working capital.

As of March 31, 2019, and the date of this filing, we were in compliance with all covenants under the 2026 Notes, the 2025 Notes and the Amended and Restated Credit Agreement.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.19.1
FAIR VALUE MEASUREMENTS
 3 Months Ended
Mar. 31, 2019
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS

Our condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, investments, receivables, accounts payable, medical benefits payable, long-term debt, including any current portion of long-term debt, and other liabilities. We consider the carrying amounts of cash and cash equivalents, receivables, other current assets and current liabilities to approximate their fair value due to the short period of time between the origination of these instruments and the expected realization or payment. Certain assets and liabilities are measured at fair value on a recurring basis and are disclosed below. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see the consolidated financial statements and notes thereto included in our 2018 Form 10-K.

Recurring Fair Value Measurements

Assets and liabilities measured at fair value on a recurring basis at March 31, 2019 are as follows:

 
 
 
Fair Value Measurements Using
 
Carrying Value
 
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
 
Significant Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Investments:
 
 
 
 
 
 
 
Debt securities:
 
 
 
 
 
 
 
Asset-backed securities
$
154.1

 
$
—

 
$
154.1

 
$
—

Corporate debt securities
1,128.7

 
—

 
1,128.7

 
—

Municipal securities
199.7

 
—

 
199.7

 
—

Residential mortgage-backed securities
10.0

 
—

 
10.0

 
—

Short-term time deposits
237.5

 
—

 
237.5

 
—

Government and agency obligations
9.1

 
9.1

 
—

 
—

Other securities
62.0

 
49.7

 
12.3

 
—

Total debt securities
1,801.1

 
58.8

 
1,742.3

 
—

Equity securities(1)
225.1

 
220.9

 
4.2

 
—

Total investments
$
2,026.2

 
$
279.7

 
$
1,746.5

 
$
—

Restricted cash, cash equivalents and investments:
 

 
 

 
 

 
 

Cash
$
12.8

 
$
12.8

 
$
—

 
$
—

Money market funds
86.2

 
86.2

 
—

 
—

U.S. government securities and other
175.3

 
175.1

 
0.2

 
—

Total restricted cash, cash equivalents and investments
$
274.3

 
$
274.1

 
$
0.2

 
$
—

 
 
 
 
 
 
 
 

(1) Investments in equity securities primarily consists of exchange traded funds in fixed-income and preferred and hybrid securities.

Assets and liabilities measured at fair value on a recurring basis at December 31, 2018 are as follows:

 
 
 
Fair Value Measurements Using
 
Carrying Value
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
Investments:
 
 
 
 
 
 
 
Asset-backed securities
$
144.2

 
$
—

 
$
144.2

 
$
—

Corporate debt securities
933.4

 
—

 
933.4

 
—

Municipal securities
199.3

 
—

 
199.3

 
—

Residential mortgage-backed securities
7.0

 
—

 
7.0

 
—

Short-term time deposits
242.2

 
—

 
242.2

 
—

Government and agency obligations
44.8

 
44.8

 
—

 
—

Other securities
72.4

 
49.8

 
22.6

 
—

Total Investments(1)
$
1,643.3

 
$
94.6

 
$
1,548.7

 
$
—

Restricted cash, cash equivalents and investments:
 

 
 

 
 

 
 

Cash
$
11.3

 
$
11.3

 
$
—

 
$
—

Money market funds
51.4

 
51.4

 
—

 
—

U.S. government securities and other
172.0

 
171.8

 
0.2

 
—

Total restricted cash, cash equivalents and investments
$
234.7

 
$
234.5

 
$
0.2

 
$
—

 
 
 
 
 
 
 
 

 (1) Equity securities were not material as of December 31, 2018.

The following table presents the carrying value and fair value of our long-term debt outstanding as of March 31, 2019 and December 31, 2018:

 
 
 
Fair Value Measurements Using
 
Carrying Value
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
Long-term debt - March 31, 2019
2,127.3

 
2,034.7

 
200.0

 
—

Long-term debt - December 31, 2018
2,126.4

 
1,885.2

 
200.0

 
—



The fair value of our 2026 Notes and 2025 Notes were determined based on quoted market prices; therefore, would be classified within Level 1 of the fair value hierarchy. The fair value of obligations outstanding under our Revolving Credit Facility, as of March 31, 2019 and December 31, 2018, approximated the carrying value and would be classified within Level 2 of the fair value hierarchy.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.19.1
MEDICAL BENEFITS PAYABLE
 3 Months Ended
Mar. 31, 2019
MEDICAL BENEFITS PAYABLE [Abstract]  
MEDICAL BENEFITS PAYABLE MEDICAL BENEFITS PAYABLE

A reconciliation of the beginning and ending balances of medical benefits payable, by segment, is as follows:
 
 
For the three months ended March 31, 2019
 
 
Medicaid Health Plans
 
Medicare Health Plans
 
Medicare PDPs
 
Corporate and other (2)
 
Consolidated
Beginning balance (1)
 
$
2,012.8

 
$
823.5

 
$
59.1

 
$
2.0

 
$
2,897.4

Acquisitions
 
—

 
—

 
—

 
—

 
—

 
 
 
 
 
 
 
 
 
 
 
Medical benefits incurred related to:
 
 
 
 
 
 
 
 
 
 
Current year
 
4,182.7

 
1,612.7

 
284.7

 
3.2

 
6,083.3

Prior years
 
(160.0
)
 
(64.5
)
 
(26.3
)
 
(0.8
)
 
(251.6
)
Total
 
4,022.7

 
1,548.2

 
258.4

 
2.4

 
5,831.7

 
 
 
 
 
 
 
 
 
 
 
Medical benefits paid related to:
 
 
 
 
 
 
 
 
 
 
Current year
 
(2,769.2
)
 
(936.4
)
 
(187.7
)
 
(1.4
)
 
(3,894.7
)
Prior years
 
(1,147.9
)
 
(451.7
)
 
(21.6
)
 
(0.6
)
 
(1,621.8
)
Total
 
(3,917.1
)
 
(1,388.1
)
 
(209.3
)
 
(2.0
)
 
(5,516.5
)
Ending balance (1)
 
$
2,118.4

 
$
983.6

 
$
108.2

 
$
2.4

 
$
3,212.6

 
 
 
 
 
 
 
 
 
 
 


(1) The Medicaid Health Plans and Consolidated beginning and ending balances for 2019 include a premium deficiency reserve for our Illinois Medicaid programs ("Illinois PDR"), which amounted to $6.6 million and $16.1 million at March 31, 2019 and December 31, 2018, respectively. See Note 2 - Summary of Significant Accounting Policies in our 2018 Form 10-K for further discussion.
(2) The Corporate and Other category includes operating segments that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles.

 
 
For the three months ended March 31, 2018
 
 
Medicaid Health Plans
 
Medicare Health Plans
 
Medicare PDPs
 
Corporate and other
 
Consolidated
Beginning balance (1)
 
$
1,373.2

 
$
722.5

 
$
50.6

 
$
—

 
$
2,146.3

Acquisitions
 
—

 
—

 
—

 
—

 
—

 
 
 
 
 
 
 
 
 
 
 
Medical benefits incurred related to:
 
 
 
 
 
 
 
 
 
 
Current year
 
2,523.8

 
1,383.1

 
256.9

 
—

 
4,163.8

Prior years
 
(99.4
)
 
(76.0
)
 
(26.4
)
 
—

 
(201.8
)
Total
 
2,424.4

 
1,307.1

 
230.5

 
—

 
3,962.0

 
 
 
 
 
 
 
 
 
 
—

Medical benefits paid related to:
 
 
 
 
 
 
 
 
 
 
Current year
 
(1,659.4
)
 
(859.9
)
 
(218.0
)
 
—

 
(2,737.3
)
Prior years
 
(758.6
)
 
(389.3
)
 
(12.8
)
 
—

 
(1,160.7
)
Total
 
(2,418.0
)
 
(1,249.2
)
 
(230.8
)
 
—

 
(3,898.0
)
Ending balance (1)
 
$
1,379.6

 
$
780.4

 
$
50.3

 
$
—

 
$
2,210.3

 
 
 
 
 
 
 
 
 
 
 
(1) The Medicaid Health Plans and Consolidated beginning and ending balances for 2018 include a premium deficiency reserve for our Illinois Medicaid program ("Illinois PDR"), which amounted to $41.0 million and $45.6 million at March 31, 2018 and December 31, 2017, respectively.

We recognize the cost of medical benefits in the period in which services are provided, including an estimate of the cost of medical benefits incurred but not reported ("IBNR"). Medical benefits expense includes direct medical expenses and certain medically-related administrative costs. We evaluate our estimates of medical benefits payable as we obtain more complete claims information and medical expense trend data over time. We record differences between actual experience and estimates used to establish the liability, which we refer to as favorable and unfavorable prior year reserve developments, as increases or decreases to medical benefits expense in the period we identify the differences.

Medical benefits payable developed favorably by approximately $251.6 million and $201.8 million for the three months ended March 31, 2019 and 2018, respectively. The release of the provision for moderately adverse conditions included in our prior year estimates was substantially offset by the provision for moderately adverse conditions established for claims incurred in the current year. Accordingly, the favorable development in our estimate of medical benefits payable related to claims incurred in prior years does not directly correspond to a decrease in medical benefits expense recognized during the period in which the favorable development is recognized.

Excluding the prior year development related to the release of the provision for moderately adverse conditions, our estimates of consolidated medical benefits payable developed favorably by approximately $108.2 million and $71.5 million for the three months ended March 31, 2019 and 2018, respectively. Such amounts are net of the development relating to refunds due to government customers with minimum loss ratio provisions. The net favorable development recognized in both 2019 and 2018 resulted primarily due to a number of operational and clinical initiatives planned and executed, that contributed to lower than expected pharmacy and medical trends, and actual claim submission time being faster than we originally assumed (i.e., our completion factors were higher than we originally assumed) in establishing our medical benefits payable in the prior years. This development does not directly correspond to an increase in our current year operating results as these reductions were offset by estimated current period medical benefits expense when we established our estimate of the current year medical benefits payable. Both completion factor and medical trend assumptions are influenced by utilization levels, unit costs, mix of business, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, our ability and practices to manage medical and pharmaceutical costs, claim submission patterns and operational changes resulting from business combinations, among others. Our actual costs were ultimately less than expected.

Our Meridian acquisition in September 2018 resulted in an increase to medical benefits payable as of the acquisition date. See Note 2 - Centene Plan of Merger and Acquisitions, for additional information on the Meridian acquisitions.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.19.1
LEASES
 3 Months Ended
Mar. 31, 2019
Leases [Abstract]  
LEASES LEASES

In determining whether a contract contains a lease, we assess whether the arrangement meets all three of the following criteria: 1) there is an identified asset; 2) we have the right to obtain substantially all the economic benefits from use of the identified asset; and 3) we have the right to direct the use of the identified asset. This involves evaluating whether we have the right to operate the asset or to direct others to operate the asset in a manner that it determines without the supplier having the right to change those operating instructions, as well as evaluating our involvement in the design of the asset.
We have right-of-use assets and liabilities for non-cancelable operating leases primarily for office space, data centers and other equipment. Our leases have remaining lease terms up to approximately 14 years. The depreciable life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.
For the three months ended March 31, 2019 operating lease expense of $17.4 million, was recorded as SG&A expense in our condensed consolidated statement of comprehensive income.
Balance sheet information related to our operating leases was as follows:
 
 
Classification
 
March 31, 2019
Assets:
 
 
 
 
Right of use assets
 
Other assets
 
$
249.9

 
 
 
 
 
Liabilities:
 
 
 
 
Current
 
Accounts payable and accrued expenses
 
$
32.9

Noncurrent
 
Other liabilities
 
235.6

Total liabilities
 
 
 
$
268.5

 
 
 
 
 

Maturities of our operating lease liabilities are as follows:
Maturity of Operating Lease Liabilities
March 31, 2019
2019 (remaining)
$
33.5

2020
44.9

2021
44.4

2022
40.4

2023
37.2

2024
34.9

Thereafter
114.7

Total lease payments
$
350.0

Less: imputed interest
$
81.5

Present value of lease liabilities
$
268.5

 
 

As of March 31, 2019 the weighted-average remaining lease term was 8.5 years. Our lease agreements do not provide a readily determinable implicit rate nor is it available to us from our lessors. Instead, we estimate our incremental borrowing rate based on information available at lease commencement in order to discount lease payments to present value. The weighted-average discount rate of our operating leases was 5.9%, as of March 31, 2019.

Supplemental cash flow information related to our operating leases is as follows:
 
Three Months Ended
March 31, 2019
Cash paid for operating leases
$
11.6

Leased assets obtained in exchange for new operating lease liabilities
10.4
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.19.1
INCOME TAXES
 3 Months Ended
Mar. 31, 2019
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES

Our effective income tax rate on pre-tax income was 18.1% for the three months ended March 31, 2019 compared with 35.8% for the three months ended March 31, 2018. The year-over-year decrease was primarily driven by the one-year moratorium on the non-deductible ACA industry fee for 2019 and higher excess tax benefits resulting from the settlement of stock-compensation awards in 2019.

There were no significant changes to unrecognized tax benefits for the three months ended March 31, 2019. Our unrecognized tax benefits are not expected to change significantly during the next 12 months.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.19.1
DISCONTINUED OPERATIONS
 3 Months Ended
Mar. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS DISCONTINUED OPERATIONS

On August 3, 2016, our subsidiary, Universal American, completed the sale of its Traditional Insurance business prior to our acquisition of Universal American. This was accomplished by selling two life insurance subsidiaries, while retaining ownership of a third life insurance subsidiary, American Progressive Life & Health Insurance of New York ("Progressive"). The sale of the Traditional Insurance business underwritten by Progressive was accomplished through a 100% quota-share reinsurance treaty with a wholly-owned subsidiary of Nassau Re, that, when considered in combination with other reinsurance transactions previously entered into, resulted in the reinsurance of all of the Traditional Insurance policies that were underwritten by Progressive. Accordingly, the discontinued Traditional Insurance business did not materially affect our condensed consolidated statements of comprehensive income for any of the periods presented.

In accordance with ASC 360-10, Property, Plant and Equipment and ASC 205-20, Presentation of Financial Statements—Discontinued Operations, the Traditional Insurance business has been reported in discontinued operations in this 2019 Form 10-Q.

The following table summarizes the total assets and liabilities of our discontinued operations:
 
 
 
 
 
 
 
March 31, 2019
 
December 31, 2018
 
 
(in millions)
Assets
 
 
 
 
Cash and cash equivalents
 
$
0.5

 
$
0.1

Investments
 
40.6

 
42.8

Reinsurance recoverables
 
165.7

 
170.2

Other assets
 
0.4

 
0.5

Total Assets
 
$
207.2

 
$
213.6

 
 
 
 
 
Liabilities
 
 
 
 
Reserves and other policy liabilities
 
$
166.1

 
$
166.9

Other liabilities
 
41.1

 
46.7

Total liabilities
 
$
207.2

 
$
213.6

 
 
 
 
 


Progressive's traditional insurance products are reinsured under quota share coinsurance treaties with unaffiliated insurers, while the life insurance risks are reinsured under either quota share coinsurance or yearly-renewable term treaties with unaffiliated insurers. Under quota share coinsurance treaties, we pay the reinsurer an agreed upon percentage of all premiums and the reinsurer reimburses us that same percentage of any losses. In addition, the reinsurer pays us certain allowances to cover commissions, the cost of administering the policies and premium taxes. Under yearly-renewable term treaties, the reinsurer receives premiums at an agreed upon rate for its share of the risk on a yearly-renewable term basis. We also use excess of loss reinsurance agreements for certain policies whereby we limit our loss in excess of specified thresholds.

We evaluate the financial condition of our Traditional Insurance reinsurers and monitor concentrations of credit risk to minimize our exposure to significant losses from reinsurer insolvencies. We are obligated to pay claims in the event that a reinsurer to whom we have ceded an insured claim fails to meet its obligations under the reinsurance agreement. We are not aware of any instances where any of our reinsurers have been unable to pay any policy claims on any reinsured business.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.19.1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
 
Indemnification Obligations

Under Delaware law, our charter and bylaws and certain indemnification agreements to which we are a party, we are obligated to indemnify, or we have otherwise agreed to indemnify, certain of our current and former directors, officers and associates with respect to current and future investigations and litigation, including the matters discussed in this note. The indemnification agreements for our directors and executive officers with respect to events occurring prior to May 2009 require us to indemnify an indemnitee to the fullest extent permitted by law if the indemnitee was or is or becomes a party to or a witness or other participant in any proceeding by reason of any event or occurrence related to the indemnitee's status as a director, officer, associate, agent or fiduciary of the Company or any of our subsidiaries. The indemnification agreements require us to indemnify an indemnitee against all expenses, including attorney's fees, judgments, fines, settlement amounts and interest and other charges, and any taxes as a result of the receipt of payments under the indemnification agreement. We will not indemnify the indemnitee if not permitted under applicable law. We are required to advance all expenses incurred by the indemnitee. We are entitled to reimbursement by an indemnitee of expenses advanced if the indemnitee is not permitted to be reimbursed under applicable law after a final judicial determination is made and all rights of appeal have been exhausted or lapsed.

We amended and restated our indemnification agreements in May 2009. The revised agreements apply to our officers and directors with respect to events occurring after that time. Pursuant to the 2009 indemnification agreements, we will indemnify the indemnitee against all expenses, including attorney's fees, judgments, penalties, fines, settlement amounts and any taxes imposed as a result of payments made under the indemnification agreement incurred in connection with any proceedings that relate to the indemnitee's status as a director, officer or associate of the Company or any of our subsidiaries or any other enterprise that the indemnitee was serving at our request. We will also indemnify for expenses incurred by an indemnitee if the indemnitee, by reason of his or her corporate status, is a witness in any proceeding. Further, we are required to indemnify for expenses incurred by an indemnitee in defense of a proceeding to the extent the indemnitee has been successful on the merits or otherwise. Finally, if the indemnitee is involved in certain proceedings as a result of the indemnitee's corporate status, we are
required to advance the indemnitee's reasonable expenses incurred in connection with such proceeding, subject to the requirement that the indemnitee repay the expenses if it is ultimately determined that the indemnitee is not entitled to be indemnified. We are not obligated to indemnify an indemnitee for losses incurred in connection with any proceeding if a determination has not been made by the Board of Directors, a committee of disinterested directors or independent legal counsel in the specific case that the indemnitee has satisfied any standards of conduct required as a condition to indemnification under Section 145 of the Delaware General Corporation Law.

Pursuant to our obligations, we have advanced legal fees and related expenses to three former officers and two additional associates who were criminally indicted in connection with the government investigations of the Company that commenced in 2007 related to federal criminal health care fraud charges including conspiracy to defraud the United States, false statements relating to health care matters, and health care fraud in connection with their defense of criminal charges. In June 2013, the jury in the federal criminal trial reached guilty verdicts on multiple charges for the four individuals that were tried in 2013. In May 2014, the individuals were sentenced and our request for restitution was denied. All four individuals filed notices of appeal and the government filed notices of cross appeal on three of the four individuals, which the government has subsequently voluntarily dismissed. The appellate court affirmed the convictions in August 2016. Mr. Farha filed a petition for a writ of certiorari to the United States Supreme Court in January 2017. In April 2017, the United States Supreme Court declined to hear the appeal by Mr. Farha. The fifth individual, Mr. Bereday, entered a guilty plea in June 2017 in connection with the federal criminal charges, which was accepted by the court in July 2017. Mr. Bereday was sentenced in November 2017.

We have also previously advanced legal fees and related expenses to these five individuals regarding: a dispute in Delaware Chancery Court related to whether we were legally obligated to advance fees or indemnify certain of these individuals; the class actions titled Eastwood Enterprises, L.L.C. v. Farha, et al. and Hutton v. WellCare Health Plans, Inc. et al. filed in federal court; six stockholder derivative actions filed in federal and state courts between October 2007 and January 2008; an investigation by the United States Securities & Exchange Commission (the "Commission"); an action by the Commission filed in January 2012 against three of the five individuals, Messrs. Farha, Behrens and Bereday, and a qui tam action against Messrs. Farha, Behrens and Bereday in federal court. We settled the class actions in May 2011. In 2010, we settled the stockholder derivative actions and we were realigned as the plaintiff to pursue our claims against Messrs. Farha, Behrens and Bereday. Pursuant to the settlement agreements described below, Messrs. Farha, Behrens and Bereday were dismissed from the federal court and state derivative actions. Pursuant to the settlement agreement with Mr. Bereday described below, Mr. Bereday was dismissed from the fee advancement case in Delaware Chancery Court. The Commission action was closed in May 2018. The qui tam action is currently stayed and the stay is subject to being lifted at any time.

In April 2017, the Commission and Mr. Farha entered into a consent judgment to pay $12.5 million to the Commission and $7.5 million to us. In April 2017, the Commission and Mr. Behrens also entered into a consent judgment to pay $4.5 million to the Commission and $1.5 million to us. In May 2018, the Commission and Mr. Bereday entered into a consent judgment to pay $4.5 million to the Commission and the case was closed.
In addition, we have advanced a portion of the legal fees and related expenses to Mr. Farha in connection with lawsuits he filed in Delaware and Florida state court to have certain restrictions lifted on WellCare stock purportedly awarded to him during his employment with us. The Delaware and Florida state court matters have been dismissed.

In September 2016, we entered into a settlement agreement with Mr. Farha pursuant to which he paid us $7.5 million, as referenced in the April 2017 consent judgment with the Commission, and we agreed that we would not seek to recover additional legal fees previously advanced related to these matters, and that our obligation to continue advancing fees would be limited to no more than an additional $7.5 million.

We also have advanced a portion of the legal fees and related expenses to Mr. Behrens in connection with his lawsuit in Delaware state court to have certain restrictions lifted on WellCare stock purportedly awarded to him during his employment with WellCare, which the court dismissed. In October 2016, we also entered into a settlement agreement with Mr. Behrens pursuant to which he paid us $1.5 million, as referenced in the April 2017 consent judgment with the Commission, and we agreed that we would not seek to recover additional legal fees previously advanced in connection with these matters, and that our obligation to continue advancing fees would be limited to no more than an additional $1.5 million.

In June 2017, we entered into a settlement agreement with Mr. Bereday that became effective in July 2017, pursuant to which we agreed that we would not seek to recover legal fees previously advanced in connection with these matters, and that our obligation to continue advancing fees would be limited to no more than an additional $2.5 million.

In connection with these matters, we have advanced to the five individuals legal fees and related expenses from the inception of the investigations through March 31, 2019, the cumulative amounts of which has not changed materially from
December 31, 2018. We expense these costs as incurred and classify the costs as SG&A expense incurred in connection with the investigations and related matters.

We have exhausted our insurance policies related to reimbursement of our advancement of fees related to these matters. We are unable to estimate the total amount of these costs or a range of possible loss. Accordingly, we continue to expense these costs as incurred.

Other Lawsuits and Claims

Based on the nature of our business, we are subject to regulatory reviews or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance and benefits companies and their reviews focus on numerous facets of our business, including claims payment practices, provider contracting, competitive practices, commission payments, privacy issues and utilization management practices, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to our business practices. We continue to be subject to such reviews, which may result in additional fines and/or sanctions being imposed, premium refunds or additional changes in our business practices.

Separate and apart from the legal matters described above, we are also involved in other legal actions in the normal course of our business, including, without limitation, protests and appeals related to Medicaid procurement awards, wage and hour claims and other employment claims, claims for indemnification under purchase agreements, vendor disputes and provider disputes regarding payment of claims. Some of these actions seek monetary damages including claims for liquidated or punitive damages, which are not covered by insurance. We review relevant information with respect to these litigation matters and we update our estimates of reasonably possible losses and related disclosures. We accrue an estimate for contingent liabilities, including attorney's fees related to these matters, if a loss is probable and estimable. Currently, we do not expect that the resolution of any of these currently pending actions, either individually or in the aggregate, will differ materially from our current estimates or have a material adverse effect on our results of operations, financial condition and cash flows. However, the outcome of any legal actions cannot be predicted, and therefore actual results may differ from those estimates.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.19.1
ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Use of Estimates In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all normal recurring adjustments that we consider necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. In accordance with GAAP, we make certain estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. We base these estimates, including assumptions as to the annualized tax rate, on our knowledge of current events and anticipated future events and evaluate and update our assumptions and estimates on an ongoing basis; however, actual results may differ from our estimates. We evaluated all material events subsequent to the date of these condensed consolidated interim financial statements.
Reclassifications Certain reclassifications were made to 2018 financial information to conform to the 2019 presentation.
Basis of Presentation Basis of Presentation

The accompanying unaudited condensed consolidated balance sheets and statements of comprehensive income, changes in stockholders' equity, and cash flows include our accounts and the accounts of our subsidiaries over which we have control or are the primary beneficiary. We eliminated all intercompany accounts and transactions.

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). Accordingly, certain financial information and footnote disclosures normally included in financial statements prepared in accordance with GAAP, but that are not required for interim reporting purposes, have been condensed or omitted. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto, for the fiscal year ended December 31, 2018, included in our Annual Report on Form 10-K ("2018 Form 10-K"), which was filed with the U.S. Securities and Exchange Commission ("SEC") in February 2019. Results for the interim periods presented are not necessarily indicative of results that may be expected for the entire year or any other interim period.

In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all normal recurring adjustments that we consider necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. In accordance with GAAP, we make certain estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. We base these estimates, including assumptions as to the annualized tax rate, on our knowledge of current events and anticipated future events and evaluate and update our assumptions and estimates on an ongoing basis; however, actual results may differ from our estimates. We evaluated all material events subsequent to the date of these condensed consolidated interim financial statements. Certain reclassifications were made to 2018 financial information to conform to the 2019 presentation.

Pharmacy Benefit Manager

The external revenues and costs for our PBM business are reported within "Products and Services" and "Cost of Products and Services", respectively, on the condensed consolidated statements of comprehensive income. Products and services revenues from our PBM consist of the prescription price (ingredient cost plus dispensing fee) negotiated with the retail pharmacies with which we have contracted, plus any associated administrative fees. This revenue is recognized when the claim is processed. We have the contractual obligation to pay network pharmacies for benefits provided to participating members and, therefore, act as principal in the arrangement and reflect the total prescription price as revenue, on a gross basis, in accordance with applicable accounting guidance. Costs of products and services is recognized at the time prescriptions are dispensed by pharmacies in the PBM's network to eligible members and consists primarily of ingredient costs and dispensing fees paid to retail pharmacies with which we have contracted. The overall results of our PBM business are immaterial
Aetna Part D Membership Reinsurance Aetna Part D Membership Reinsurance

In November 2018, we completed the purchase of Aetna Inc.'s ("Aetna") entire standalone Medicare Part D prescription drug plan membership ("Aetna Part D membership"). In connection with the purchase, we also entered into an administrative services agreement and a reinsurance agreement pursuant to which Aetna provides administrative services to, and retains financial risk of, the Aetna Part D membership, effective for plan year 2019. We remain primarily liable to policyholders under this ceded insurance contract and are contingently liable for amounts recoverable from Aetna in the event that they do not meet their contractual obligations.  In the normal course, we evaluate the financial condition of our reinsurers and monitor concentrations of credit risk to minimize our exposure to significant losses from reinsurer insolvencies.
Premium Receivable and Unearned Premiums Premium Receivables and Unearned Premiums
We record premiums earned but not received as premiums receivable and record premiums received in advance of the period of service as unearned premiums in our condensed consolidated balance sheets. A complete discussion of premiums receivable and unearned premiums is included in Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in our 2018 Form 10-K. The premium receivable balance at March 31, 2019 is primarily related to Medicaid contracts with our state partners of approximately $1.2 billion, as well as net risk-adjusted premiums receivable under our MA and PDP contracts of approximately $364.0 million.
Medicaid Risk-Adjusted Premiums and Retroactive Rate Changes

As discussed further in Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in our 2018 Form 10-K, Medicaid premium rate changes are recognized in the period the change becomes effective, when the effect of the change in the rate is reasonably estimable and collection is assured. In some instances, our Medicaid premiums are subject to risk score adjustments based on the health profile of our membership. Generally, the risk score is determined by the state agency's analysis of encounter submissions of processed claims data to determine the acuity of our membership relative to the entire state's Medicaid membership. The frequency of when states adjust premiums varies, but is usually done quarterly or semi-annually on a retrospective basis. We recognize periodic changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured
Medicare Part D Settlements Medicare Part D SettlementsWe receive certain Part D prospective subsidy payments from the Centers for Medicare & Medicaid Services ("CMS") for our MA and PDP members as a fixed monthly per member amount, based on the estimated costs of providing prescription drug benefits over the plan year, as reflected in our bids. A discussion of the subsidy components under Part D is included in Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in our 2018 Form 10-K. CMS will fully reimburse these subsidies, or recoup overpaid subsidies made during the plan year, as part of its annual settlement process that typically occurs in the fourth quarter of the subsequent year and, accordingly, there is no insurance risk to us. Therefore, amounts received for these subsidies are not considered premium revenue, and are reported, net of the subsidy benefits paid, as funds receivable (payable) for the benefit of members in the condensed consolidated balance sheets. As of March 31, 2019 and December 31, 2018, our condensed consolidated balance sheets primarily include CMS Part D payables for the 2018 and 2016 plan years. Our condensed consolidated balance sheet as of March 31, 2019 additionally includes a payable for the 2019 plan year.
ACA Industry Fee ACA Industry FeeThe Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 imposed certain new taxes and fees, including an annual premium-based health insurance industry assessment (the "ACA industry fee") on health insurers, which began in 2014. In January 2018, Congress approved a one-year moratorium of the ACA industry fee for 2019, which also eliminated the Medicaid ACA industry fee reimbursement from our state government partners for 2019.
Accounting Standards Recently Adopted and Pending Adoption Recently Adopted Accounting Standards

In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2018-07, “Compensation-Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting.” This update expands the scope of Topic 718, which currently only includes share-based payments issued to
employees, to include share-based payments issued to non-employees for goods and services. This guidance was effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance on January 1, 2019. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.

In February 2018, the FASB issued ASU 2018-02 "Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income", which allows entities to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 from accumulated other comprehensive income to retained earnings. The guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance prospectively on January 1, 2019. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.

In March 2017, the FASB issued ASU No. 2017-08, "Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities". This update shortens the amortization period for the premium on certain purchased callable debt securities to the earliest call date. Previously, entities generally amortize the premium as a yield adjustment over the contractual life of the security. The new guidance does not change the accounting for purchased callable debt securities held at a discount. This guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance on January 1, 2019 on a modified retrospective basis. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments in its balance sheet. This standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. Subsequently, in July 2018, the FASB issued ASU 2018-11, “Leases (Topic 842), Targeted Improvements” which, among other things, allows companies to elect an optional transition method to apply the new lease standard through a cumulative-effect adjustment, if any, in the period of adoption, rather than in the earliest period presented. We adopted the standard on January 1, 2019 using the optional transition method. We elected the practical expedients permitted under the transition guidance, which allows us to carryforward our historical lease classifications for existing leases. Additionally, we elected the practical expedient to not separate non-lease components from the associated lease component. As part of the adoption process, we implemented a new lease accounting system. The adoption of this guidance resulted in the initial recognition of operating lease right-of-use assets of approximately $259.5 million, operating lease liabilities of approximately $277.3 million and the elimination of $17.8 million of straight-line lease liabilities, as of January 1, 2019. This guidance did not have a material effect on our consolidated results of operations or cash flows.

Accounting Standards Pending Adoption

In August 2018, the FASB issued ASU 2018-15, "Intangibles-Goodwill and Other-Internal-Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract", which requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. We are currently assessing the effect this guidance will have on our consolidated results of operations, financial condition or cash flows.
In June 2016, the FASB issued ASU 2016-13, "Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments," which requires entities to use a current expected credit loss model, which is a new impairment model based on expected losses rather than incurred losses. Under this model, an entity would recognize an impairment allowance equal to its current estimate of all contractual cash flows that the entity does not expect to collect from financial assets measured at amortized cost. The entity's estimate would consider relevant information about past events, current conditions, and reasonable and supportable forecasts, which will result in recognition of lifetime expected credit losses upon loan origination. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted for annual reporting periods beginning after December 15, 2018. We are currently assessing the effect this guidance will have on our consolidated results of operations, financial condition or cash flows.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.19.1
CENTENE PLAN OF MERGER AND ACQUISITIONS (Tables)
 3 Months Ended
Mar. 31, 2019
Business Combinations [Abstract]  
Fair Values of Assets Acquired and Liabilities Assumed The following table summarizes the estimated fair values of major classes of assets acquired and liabilities assumed at the Effective Date, based on our valuation assumptions, reconciled to the total consideration transferred.
Assets
(in millions)
Cash, cash equivalents and restricted cash
$
484.4

Investments, including restricted investments
180.4

Premiums receivable, net
379.6

Other current assets
146.2

Property, equipment and capitalized software, net
49.3

Goodwill
1,539.4

Other intangible assets, net
622.0

     Fair value of total assets acquired
$
3,401.3

 
 
Liabilities
 
Medical benefits payable
$
534.3

ACA Fee liability
66.5

Other liabilities
280.4

     Fair value of liabilities assumed
881.2

     Fair value of net assets acquired
$
2,520.1

 
 
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination The following table summarizes the preliminary fair values and weighted average useful lives for identifiable intangible assets acquired in the Meridian acquisition as of the Effective Date of the acquisition. These preliminary estimates of fair value and weighted-average useful life may be different from the final acquisition accounting, and the difference could have a material effect on the consolidated financial statements.

 
 
Gross Fair Value
(in millions)
 
Weighted Average
Useful Life (in years)
Membership
 
$
406.6

 
8.1
Tradenames
 
110.4

 
4.9
Provider network
 
8.3

 
15.0
Technology and other
 
96.7

 
5.8
Total
 
$
622.0

 
7.3
 
 
 
 
 
Final Fair Values and Weighted Average Useful Lives for Identifiable Intangible Assets Acquired A summary of changes in our goodwill by reportable segment is as follows for the three months ended March 31, 2019:

 
Medicaid Health Plans
 
Medicare Health Plans
 
Not assigned(1)
 
Total
Balance as of December 31, 2018
$
274.7

 
$
392.3

 
$
1,560.7

 
$
2,227.7

Acquisition related adjustments
—

 
—

 
(21.3
)
 
(21.3
)
Balance as of March 31, 2019
$
274.7

 
$
392.3

 
$
1,539.4

 
$
2,206.4

 
 
 
 
 
 
 
 
(1) Goodwill related to our September 1, 2018 Meridian acquisition is considered preliminary, pending the final allocation of the applicable purchase price.
Unaudited Pro Forma Results The following unaudited pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the results of operations that would have occurred had the acquisition actually consummated at January 1, 2018, or project the future results of the combined company.
 
 
Pro Forma - Unaudited
(in millions, except per share data)
 
Three Months ended
March 31, 2018
Total revenues
 
$
5,673.6

Net income
 
$
100.9

 
 
 
Earnings per common share:
 
 
   Basic
 
$
2.02

   Diluted
 
$
2.00

 
 
 
Weighted average common shares outstanding:
 
 
       Basic
 
49,890,397

       Diluted
 
50,446,757

 
 
 
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.19.1
SEGMENT REPORTING (Tables)
 3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Revenue by Geographic Location These states and the respective Medicaid premium revenue as a percentage of total consolidated premium revenue are as follows: 
 
For the Three Months Ended
March 31,
 
2019
 
2018
Florida
17%
 
13%
Illinois
13%
 
*
Kentucky
10%
 
15%
Segment Results A summary of financial information for our reportable segments through the gross margin level and reconciliation to income from operations is presented in the table below.

 
Medicaid Health Plan
Medicare Health Plan
Medicare PDP
Corporate & Other
Consolidated
For the Three Months Ended March 31, 2019
(in millions)
Premium
$
4,473.5

$
1,843.1

$
288.8

$
4.0

$
6,609.4

Products and services
—

—

—

115.8

115.8

Total premium and products and services revenues
4,473.5

1,843.1

288.8

119.8

6,725.2



 



Medical benefits
4,022.7

1,548.2

258.4

2.4

5,831.7

Costs of products and services
—

—

—

111.8

111.8

ACA industry fee
—

—

—

—

—

Medicaid premium taxes
31.7

—

—

—

31.7

Total gross margin expenses
4,054.4

1,548.2

258.4

114.2

5,975.2



 



Gross margin
419.1

294.9

30.4

5.6

750.0



 



Investment and other income
—

—

—

37.0

37.0

Other expenses
—

—

—

(602.9
)
(602.9
)
Income from operations
$
419.1

$
294.9

$
30.4

$
(560.3
)
$
184.1







For the Three Months Ended March 31, 2018





Premium
$
2,809.9

$
1,556.5

$
259.9

$
—

$
4,626.3

Products and services
—

—

—

—

—

Total premium and products and services revenues
2,809.9

1,556.5

259.9

—

4,626.3

 
 
 
 
 
 
Medical benefits
2,424.4

1,307.1

230.5

—

3,962.0

Costs of products and services
—

—

—

—

—

ACA industry fee
49.3

27.6

4.6

—

81.5

Medicaid premium taxes
32.1

—

—

—

32.1

Total gross margin expenses
2,505.8

1,334.7

235.1

—

4,075.6

 
 
 
 
 
 
Gross margin (1)
304.1

221.8

24.8

—

550.7

 
 
 
 
 
 
Investment and other income
—

—

—

19.9

19.9

Other expenses (2)
—

—

—

(409.4
)
(409.4
)
Income from operations
$
304.1

$
221.8

$
24.8

$
(389.5
)
$
161.2




(1)
Effective July 1, 2018, the Company redefined gross margin as total revenues less investment and other income, medical expenses, cost of products and services, the ACA industry fee expense, and Medicaid premium tax expense. Accordingly, results for the three months ended March 31, 2018 were adjusted to include Medicaid premium taxes, which decreased gross margin by $32.1 million.
(2)
Effective July 1, 2018, other expenses include SG&A expenses, depreciation, amortization and interest. Accordingly, results for the three months ended March 31, 2018 were adjusted to exclude Medicaid premium taxes, which decreased other expenses by $32.1 million.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.19.1
EQUITY AND EARNINGS PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2019
Earnings Per Share [Abstract]  
Calculation of the Weighted-Average Common Shares Outstanding - Diluted The calculation of the weighted-average common shares outstanding — diluted is as follows:
 
For the Three Months Ended
March 31,
 
2019
 
2018
 
 
 
 
Weighted-average common shares outstanding — basic
50,100,509

 
44,605,892

Dilutive effect of outstanding stock-based compensation awards
741,795

 
590,235

Weighted-average common shares outstanding — diluted
50,842,304

 
45,196,127

Anti-dilutive stock-based compensation awards excluded from computation
67,130

 
277,390

 
 
 
 
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.19.1
INVESTMENTS (Tables)
 3 Months Ended
Mar. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
Short-term and Long-term Investments by Security Type Excluding restricted cash, cash equivalents and investments, the amortized cost, gross unrealized gains or losses and estimated fair value of short-term and long-term investments by security type are summarized in the following tables.
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
March 31, 2019
 
 
 
 
 
 
 
Debt securities:
 
 
 
 
 
 
 
Asset-backed securities
$
154.2

 
$
0.2

 
$
(0.3
)
 
$
154.1

Corporate debt securities
1,127.9

 
3.5

 
(2.7
)
 
1,128.7

Municipal securities
197.1

 
2.7

 
(0.1
)
 
199.7

Residential mortgage-backed securities
10.1

 
—

 
(0.1
)
 
10.0

Short-term time deposits
237.5

 
—

 
—

 
237.5

Government and agency obligations
9.2

 
—

 
(0.1
)
 
9.1

Other securities
62.0

 
—

 
—

 
62.0

Total debt securities
1,798.0

 
6.4

 
(3.3
)
 
1,801.1

Equity securities(1)
225.1


—


—


225.1

Total
$
2,023.1

 
$
6.4

 
$
(3.3
)
 
$
2,026.2

December 31, 2018
 

 
 

 
 

 
 

Asset-backed securities
$
144.7

 
$
—

 
$
(0.5
)
 
$
144.2

Corporate debt securities
943.0

 
0.5

 
(10.1
)
 
933.4

Municipal securities
199.6

 
0.6

 
(0.9
)
 
199.3

Residential mortgage-backed securities
7.2

 
—

 
(0.2
)
 
7.0

Short-term time deposits
242.2

 
—

 
—

 
242.2

Government and agency obligations
44.9

 
—

 
(0.1
)
 
44.8

Other securities
72.5

 
—

 
(0.1
)
 
72.4

Total(1)
$
1,654.1

 
$
1.1

 
$
(11.9
)
 
$
1,643.3

 

(1) Investments in equity securities primarily consists of exchange traded funds in fixed income and preferred and hybrid securities. Equity securities were not material as of December 31, 2018.
Contractual Maturities of Available-for-sale Securities Contractual maturities of debt securities at March 31, 2019 are as follows:
 
 
Amortized Cost
 
Fair Value
Due in one year or less
$
889.6

 
$
889.7

Due after one year through five years
571.6

 
573.2

Due after five years through ten years
147.3

 
149.1

Due after ten years
13.1

 
12.9

Asset-backed and mortgage-backed securities
176.4

 
176.2

 Total
$
1,798.0

 
$
1,801.1

 
 
 
 
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.19.1
RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables)
 3 Months Ended
Mar. 31, 2019
Restricted Investments Note [Abstract]  
Schedule of Restricted Investments The amortized cost, gross unrealized gains, gross unrealized losses and fair value of our restricted cash, cash equivalents and investment securities are as follows: 

 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Fair Value
March 31, 2019
 
 
 
 
 
 
 
Cash
$
12.8

 
$
—

 
$
—

 
$
12.8

Money market funds
86.2

 
—

 
—

 
86.2

U.S. government securities and other
175.6

 
—

 
(0.3
)
 
175.3

Total
$
274.6

 
$
—

 
$
(0.3
)
 
$
274.3

December 31, 2018
 

 
 

 
 

 
 

Cash
$
11.3

 
$
—

 
$
—

 
$
11.3

Money market funds
51.4

 
—

 
—

 
51.4

U.S. government securities and other
172.5

 
—

 
(0.5
)
 
172.0

Total
$
235.2

 
$
—

 
$
(0.5
)
 
$
234.7

 
 
 
 
 
 
 
 
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.19.1
STOCK-BASED COMPENSATION (Tables)
 3 Months Ended
Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Stock Unit Award Activity A summary of RSU and PSU award activity, at target, for the three months ended March 31, 2019, is presented in the table below. For our PSUs, shares attained over target upon vesting are reflected as awards granted during the period, while shares canceled due to vesting below target are reflected as awards forfeited during the period.
 

 RSUs
 
PSUs
 
Total
Outstanding as of January 1, 2019
253,235

 
606,708

 
859,943

Granted
99,434

 
347,539

 
446,973

Vested
(99,668
)
 
(351,648
)
 
(451,316
)
Forfeited
(2,372
)
 
(8,276
)
 
(10,648
)
Outstanding as of March 31, 2019
250,629

 
594,323

 
844,952

 
 
 
 
 
 
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.19.1
DEBT (Tables)
 3 Months Ended
Mar. 31, 2019
Debt Disclosure [Abstract]  
Schedule of Outstanding Debt Obligations The following table summarizes our outstanding debt obligations and their classification in the accompanying condensed consolidated balance sheets (in millions):
 
March 31, 2019
 
December 31, 2018
Long-term debt, net:
 
 
 
5.25% Senior Notes, due April 1, 2025
$
1,200.0

 
$
1,200.0

5.375% Senior Notes, due August 15, 2026
750.0

 
750.0

Revolving Credit Facility
200.0

 
200.0

Debt issuance costs
(22.7
)
 
(23.6
)
     Total long-term debt, net
$
2,127.3

 
$
2,126.4

 
 
 
 
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.19.1
FAIR VALUE MEASUREMENTS (Tables)
 3 Months Ended
Mar. 31, 2019
Fair Value Disclosures [Abstract]  
Assets and Liabilities Measured at Fair Value on a Recurring Basis Assets and liabilities measured at fair value on a recurring basis at March 31, 2019 are as follows:

 
 
 
Fair Value Measurements Using
 
Carrying Value
 
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
 
Significant Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Investments:
 
 
 
 
 
 
 
Debt securities:
 
 
 
 
 
 
 
Asset-backed securities
$
154.1

 
$
—

 
$
154.1

 
$
—

Corporate debt securities
1,128.7

 
—

 
1,128.7

 
—

Municipal securities
199.7

 
—

 
199.7

 
—

Residential mortgage-backed securities
10.0

 
—

 
10.0

 
—

Short-term time deposits
237.5

 
—

 
237.5

 
—

Government and agency obligations
9.1

 
9.1

 
—

 
—

Other securities
62.0

 
49.7

 
12.3

 
—

Total debt securities
1,801.1

 
58.8

 
1,742.3

 
—

Equity securities(1)
225.1

 
220.9

 
4.2

 
—

Total investments
$
2,026.2

 
$
279.7

 
$
1,746.5

 
$
—

Restricted cash, cash equivalents and investments:
 

 
 

 
 

 
 

Cash
$
12.8

 
$
12.8

 
$
—

 
$
—

Money market funds
86.2

 
86.2

 
—

 
—

U.S. government securities and other
175.3

 
175.1

 
0.2

 
—

Total restricted cash, cash equivalents and investments
$
274.3

 
$
274.1

 
$
0.2

 
$
—

 
 
 
 
 
 
 
 

(1) Investments in equity securities primarily consists of exchange traded funds in fixed-income and preferred and hybrid securities.

Assets and liabilities measured at fair value on a recurring basis at December 31, 2018 are as follows:

 
 
 
Fair Value Measurements Using
 
Carrying Value
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
Investments:
 
 
 
 
 
 
 
Asset-backed securities
$
144.2

 
$
—

 
$
144.2

 
$
—

Corporate debt securities
933.4

 
—

 
933.4

 
—

Municipal securities
199.3

 
—

 
199.3

 
—

Residential mortgage-backed securities
7.0

 
—

 
7.0

 
—

Short-term time deposits
242.2

 
—

 
242.2

 
—

Government and agency obligations
44.8

 
44.8

 
—

 
—

Other securities
72.4

 
49.8

 
22.6

 
—

Total Investments(1)
$
1,643.3

 
$
94.6

 
$
1,548.7

 
$
—

Restricted cash, cash equivalents and investments:
 

 
 

 
 

 
 

Cash
$
11.3

 
$
11.3

 
$
—

 
$
—

Money market funds
51.4

 
51.4

 
—

 
—

U.S. government securities and other
172.0

 
171.8

 
0.2

 
—

Total restricted cash, cash equivalents and investments
$
234.7

 
$
234.5

 
$
0.2

 
$
—

 
 
 
 
 
 
 
 

 (1) Equity securities were not material as of December 31, 2018.
Carrying Value and Fair Value of Long-term Debt The following table presents the carrying value and fair value of our long-term debt outstanding as of March 31, 2019 and December 31, 2018:

 
 
 
Fair Value Measurements Using
 
Carrying Value
 
Quoted Prices in Active Markets for Identical Assets
(Level 1)
 
Significant Other Observable Inputs
(Level 2)
 
Significant Unobservable Inputs
(Level 3)
Long-term debt - March 31, 2019
2,127.3

 
2,034.7

 
200.0

 
—

Long-term debt - December 31, 2018
2,126.4

 
1,885.2

 
200.0

 
—
Changes in the Fair Value of Auction Rate Securities Assets and liabilities measured at fair value on a recurring basis at March 31, 2019 are as follows:

 
 
 
Fair Value Measurements Using
 
Carrying Value
 
Quoted Prices in
Active Markets
for Identical
Assets
(Level 1)
 
Significant Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Investments:
 
 
 
 
 
 
 
Debt securities:
 
 
 
 
 
 
 
Asset-backed securities
$
154.1

 
$
—

 
$
154.1

 
$
—

Corporate debt securities
1,128.7

 
—

 
1,128.7

 
—

Municipal securities
199.7

 
—

 
199.7

 
—

Residential mortgage-backed securities
10.0

 
—

 
10.0

 
—

Short-term time deposits
237.5

 
—

 
237.5

 
—

Government and agency obligations
9.1

 
9.1

 
—

 
—

Other securities
62.0

 
49.7

 
12.3

 
—

Total debt securities
1,801.1

 
58.8

 
1,742.3

 
—

Equity securities(1)
225.1

 
220.9

 
4.2

 
—

Total investments
$
2,026.2

 
$
279.7

 
$
1,746.5

 
$
—

Restricted cash, cash equivalents and investments:
 

 
 

 
 

 
 

Cash
$
12.8

 
$
12.8

 
$
—

 
$
—

Money market funds
86.2

 
86.2

 
—

 
—

U.S. government securities and other
175.3

 
175.1

 
0.2

 
—

Total restricted cash, cash equivalents and investments
$
274.3

 
$
274.1

 
$
0.2

 
$
—

 
 
 
 
 
 
 
 

(1) Investments in equity securities primarily consists of exchange traded funds in fixed-income and preferred and hybrid securities.

XML 44 R30.htm IDEA: XBRL DOCUMENT v3.19.1
MEDICAL BENEFITS PAYABLE (Tables)
 3 Months Ended
Mar. 31, 2019
MEDICAL BENEFITS PAYABLE [Abstract]  
Reconciliation of the Beginning and Ending Balances of Medical Benefits Payable, by Segment A reconciliation of the beginning and ending balances of medical benefits payable, by segment, is as follows:
 
 
For the three months ended March 31, 2019
 
 
Medicaid Health Plans
 
Medicare Health Plans
 
Medicare PDPs
 
Corporate and other (2)
 
Consolidated
Beginning balance (1)
 
$
2,012.8

 
$
823.5

 
$
59.1

 
$
2.0

 
$
2,897.4

Acquisitions
 
—

 
—

 
—

 
—

 
—

 
 
 
 
 
 
 
 
 
 
 
Medical benefits incurred related to:
 
 
 
 
 
 
 
 
 
 
Current year
 
4,182.7

 
1,612.7

 
284.7

 
3.2

 
6,083.3

Prior years
 
(160.0
)
 
(64.5
)
 
(26.3
)
 
(0.8
)
 
(251.6
)
Total
 
4,022.7

 
1,548.2

 
258.4

 
2.4

 
5,831.7

 
 
 
 
 
 
 
 
 
 
 
Medical benefits paid related to:
 
 
 
 
 
 
 
 
 
 
Current year
 
(2,769.2
)
 
(936.4
)
 
(187.7
)
 
(1.4
)
 
(3,894.7
)
Prior years
 
(1,147.9
)
 
(451.7
)
 
(21.6
)
 
(0.6
)
 
(1,621.8
)
Total
 
(3,917.1
)
 
(1,388.1
)
 
(209.3
)
 
(2.0
)
 
(5,516.5
)
Ending balance (1)
 
$
2,118.4

 
$
983.6

 
$
108.2

 
$
2.4

 
$
3,212.6

 
 
 
 
 
 
 
 
 
 
 


(1) The Medicaid Health Plans and Consolidated beginning and ending balances for 2019 include a premium deficiency reserve for our Illinois Medicaid programs ("Illinois PDR"), which amounted to $6.6 million and $16.1 million at March 31, 2019 and December 31, 2018, respectively. See Note 2 - Summary of Significant Accounting Policies in our 2018 Form 10-K for further discussion.
(2) The Corporate and Other category includes operating segments that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles.

 
 
For the three months ended March 31, 2018
 
 
Medicaid Health Plans
 
Medicare Health Plans
 
Medicare PDPs
 
Corporate and other
 
Consolidated
Beginning balance (1)
 
$
1,373.2

 
$
722.5

 
$
50.6

 
$
—

 
$
2,146.3

Acquisitions
 
—

 
—

 
—

 
—

 
—

 
 
 
 
 
 
 
 
 
 
 
Medical benefits incurred related to:
 
 
 
 
 
 
 
 
 
 
Current year
 
2,523.8

 
1,383.1

 
256.9

 
—

 
4,163.8

Prior years
 
(99.4
)
 
(76.0
)
 
(26.4
)
 
—

 
(201.8
)
Total
 
2,424.4

 
1,307.1

 
230.5

 
—

 
3,962.0

 
 
 
 
 
 
 
 
 
 
—

Medical benefits paid related to:
 
 
 
 
 
 
 
 
 
 
Current year
 
(1,659.4
)
 
(859.9
)
 
(218.0
)
 
—

 
(2,737.3
)
Prior years
 
(758.6
)
 
(389.3
)
 
(12.8
)
 
—

 
(1,160.7
)
Total
 
(2,418.0
)
 
(1,249.2
)
 
(230.8
)
 
—

 
(3,898.0
)
Ending balance (1)
 
$
1,379.6

 
$
780.4

 
$
50.3

 
$
—

 
$
2,210.3

 
 
 
 
 
 
 
 
 
 
 
(1) The Medicaid Health Plans and Consolidated beginning and ending balances for 2018 include a premium deficiency reserve for our Illinois Medicaid program ("Illinois PDR"), which amounted to $41.0 million and $45.6 million at March 31, 2018 and December 31, 2017, respectively.
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.19.1
LEASES (Tables)
 3 Months Ended
Mar. 31, 2019
Leases [Abstract]  
Balance sheet information related to operating leases Balance sheet information related to our operating leases was as follows:
 
 
Classification
 
March 31, 2019
Assets:
 
 
 
 
Right of use assets
 
Other assets
 
$
249.9

 
 
 
 
 
Liabilities:
 
 
 
 
Current
 
Accounts payable and accrued expenses
 
$
32.9

Noncurrent
 
Other liabilities
 
235.6

Total liabilities
 
 
 
$
268.5

 
 
 
 
 
Maturities of operating leases Maturities of our operating lease liabilities are as follows:
Maturity of Operating Lease Liabilities
March 31, 2019
2019 (remaining)
$
33.5

2020
44.9

2021
44.4

2022
40.4

2023
37.2

2024
34.9

Thereafter
114.7

Total lease payments
$
350.0

Less: imputed interest
$
81.5

Present value of lease liabilities
$
268.5

 
 
Supplemental cash flow information related to leases Supplemental cash flow information related to our operating leases is as follows:
 
Three Months Ended
March 31, 2019
Cash paid for operating leases
$
11.6

Leased assets obtained in exchange for new operating lease liabilities
10.4
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.19.1
DISCONTINUED OPERATIONS (Tables)
 3 Months Ended
Mar. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]  
Total Assets and Liabilities of Discontinued Operations The following table summarizes the total assets and liabilities of our discontinued operations:
 
 
 
 
 
 
 
March 31, 2019
 
December 31, 2018
 
 
(in millions)
Assets
 
 
 
 
Cash and cash equivalents
 
$
0.5

 
$
0.1

Investments
 
40.6

 
42.8

Reinsurance recoverables
 
165.7

 
170.2

Other assets
 
0.4

 
0.5

Total Assets
 
$
207.2

 
$
213.6

 
 
 
 
 
Liabilities
 
 
 
 
Reserves and other policy liabilities
 
$
166.1

 
$
166.9

Other liabilities
 
41.1

 
46.7

Total liabilities
 
$
207.2

 
$
213.6

 
 
 
 
 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.19.1
ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)
member in Millions
 3 Months Ended
Mar. 31, 2019
USD ($)
member
Mar. 31, 2018
USD ($)
Jan. 01, 2019
USD ($)
Dec. 31, 2018
USD ($)
Funds Receivable/Payable for the Benefit of Members [Line Items]        
Membership | member 6.3      
Premiums revenue related to Aetna Part D Membership $ 6,609,400,000 $ 4,626,300,000    
Premiums receivable, net 1,567,600,000     $ 1,223,400,000
ACA industry fee 0 81,500,000    
Medicaid ACA industry fee reimbursement revenue 0 64,700,000    
Right of use assets 249,900,000   $ 259,500,000  
Present value of lease liabilities 268,500,000   277,300,000  
State Partners | Medicaid Health Plan        
Funds Receivable/Payable for the Benefit of Members [Line Items]        
Premiums receivable, net 1,200,000,000      
Medicare Advantage and PDP | Medicare Advantage        
Funds Receivable/Payable for the Benefit of Members [Line Items]        
Premiums receivable, net 364,000,000.0      
Premiums receivable, net        
Funds Receivable/Payable for the Benefit of Members [Line Items]        
Medicaid retroactive rate change and risk score adjustments 121,500,000 $ 54,400,000    
Aetna Part D Business        
Funds Receivable/Payable for the Benefit of Members [Line Items]        
Reinsurance receivables related to premiums receivable 30,800,000      
Reinsurance payable 482,800,000     0
Reinsurance recoverables 452,000,000.0     $ 0
Premiums revenue related to Aetna Part D Membership 501,000,000.0      
Medical benefits ceded related to Aetna Part D membership $ 473,700,000      
Accounting Standards Update 2016-02        
Funds Receivable/Payable for the Benefit of Members [Line Items]        
Elimination of straight-line lease liabilities     $ 17,800,000  
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.19.1
CENTENE PLAN OF MERGER AND ACQUISITIONS - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Nov. 30, 2018
Sep. 01, 2018
Aug. 31, 2018
Mar. 31, 2019
Mar. 31, 2018
Jun. 30, 2020
Dec. 31, 2018
Aug. 13, 2018
Business Acquisition [Line Items]                
Issuance of common stock, net of issuance costs     $ 1,300,000,000          
Investment banking, advisory, brokerage, and underwriting fees and commissions     $ 37,700,000          
Goodwill       $ 2,206,400,000     $ 2,227,700,000  
Revenue       $ 6,762,200,000 $ 4,646,200,000      
Senior Notes | 5.375% Senior Notes, due August 15, 2026                
Business Acquisition [Line Items]                
Aggregate principal amount               $ 750,000,000.0
Interest rate       5.375%       5.375%
Aetna Part D Business                
Business Acquisition [Line Items]                
Acquisition consideration transferred $ 107,200,000              
Estimated weighted average useful live of identifiable intangible assets 8 years              
Meridian                
Business Acquisition [Line Items]                
Acquisition consideration transferred   $ 2,500,000,000            
Estimated weighted average useful live of identifiable intangible assets   7 years 3 months 18 days            
Sale of stock, number of shares issued in transaction     5,207,547          
Goodwill   $ 1,539,400,000   $ 1,539,400,000     $ 1,560,700,000  
Net deferred tax liabilities acquired   $ 49,900,000            
Meridian | Senior Notes | 5.375% Senior Notes, due August 15, 2026                
Business Acquisition [Line Items]                
Interest rate     5.375%          
Scenario, Forecast | Centene                
Business Acquisition [Line Items]                
Cash received per share           $ 120.00    
Shares received for each common share           3.38    
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.19.1
CENTENE PLAN OF MERGER AND ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Mar. 31, 2019
Dec. 31, 2018
Sep. 01, 2018
Assets      
Goodwill $ 2,206.4 $ 2,227.7  
Meridian      
Assets      
Cash, cash equivalents and restricted cash     $ 484.4
Investments, including restricted investments     180.4
Premiums receivable, net     379.6
Other current assets     146.2
Property, equipment and capitalized software, net     49.3
Goodwill $ 1,539.4 $ 1,560.7 1,539.4
Other intangible assets, net     622.0
Fair value of total assets acquired     3,401.3
Liabilities      
Medical benefits payable     534.3
ACA Fee liability     66.5
Other liabilities     280.4
Fair value of liabilities assumed     881.2
Fair value of net assets acquired     $ 2,520.1
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.19.1
CENTENE PLAN OF MERGER AND ACQUISITIONS - Identifiable Intangible Assets Acquired (Details) - Meridian
$ in Millions
Sep. 01, 2018
USD ($)
Business Acquisition [Line Items]  
Gross Fair Value (in millions) $ 622.0
Weighted Average Useful Life (in years) 7 years 3 months 18 days
Membership  
Business Acquisition [Line Items]  
Gross Fair Value (in millions) $ 406.6
Weighted Average Useful Life (in years) 8 years 1 month 6 days
Tradenames  
Business Acquisition [Line Items]  
Gross Fair Value (in millions) $ 110.4
Weighted Average Useful Life (in years) 4 years 10 months 24 days
Provider network  
Business Acquisition [Line Items]  
Gross Fair Value (in millions) $ 8.3
Weighted Average Useful Life (in years) 15 years
Technology and other  
Business Acquisition [Line Items]  
Gross Fair Value (in millions) $ 96.7
Weighted Average Useful Life (in years) 5 years 9 months 18 days
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.19.1
CENTENE PLAN OF MERGER AND ACQUISITIONS - Goodwill Acquired (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2019
USD ($)
Changes in Goodwill  
Beginning Balance $ 2,227.7
Acquisition related adjustments (21.3)
Ending Balance 2,206.4
Medicaid Health Plan  
Changes in Goodwill  
Beginning Balance 274.7
Acquisition related adjustments 0.0
Ending Balance 274.7
Medicare Health Plan  
Changes in Goodwill  
Beginning Balance 392.3
Acquisition related adjustments 0.0
Ending Balance 392.3
Meridian  
Changes in Goodwill  
Beginning Balance 1,560.7
Acquisition related adjustments (21.3)
Ending Balance $ 1,539.4
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.19.1
CENTENE PLAN OF MERGER AND ACQUISITIONS - Pro Forma Financial Information (Details)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2018
USD ($)
$ / shares
shares
Business Combinations [Abstract]  
Total revenues | $ $ 5,673.6
Net income | $ $ 100.9
Earnings per common share:  
Basic (in dollars per share) | $ / shares $ 2.02
Diluted (in dollars per share) | $ / shares $ 2.00
Weighted average common shares outstanding:  
Basic (in shares) | shares 49,890,397
Diluted (in shares) | shares 50,446,757
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.19.1
SEGMENT REPORTING - Narrative (Details) - segment
 1 Months Ended 3 Months Ended
Jul. 31, 2018
Apr. 30, 2018
Mar. 31, 2019
Segment Reporting Information [Line Items]      
Number of reportable segments     3
Medical Services Managed Care Plan | Florida | Medicaid Health Plan      
Segment Reporting Information [Line Items]      
Term of agreement 5 years    
Serious Mental Illness Specialty Plan | Florida | Medicaid Health Plan      
Segment Reporting Information [Line Items]      
Term of agreement   5 years  
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.19.1
SEGMENT REPORTING - Revenue by Geographic Location (Details)
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Florida    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Premium revenue as a percentage of total consolidated premium revenue 17.00% 13.00%
Illinois    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Premium revenue as a percentage of total consolidated premium revenue 13.00%  
Kentucky    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Premium revenue as a percentage of total consolidated premium revenue 10.00% 15.00%
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.19.1
SEGMENT REPORTING - Segment Results (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Segment Reporting Information [Line Items]    
Premium $ 6,609.4 $ 4,626.3
Products and services 115.8 0.0
Medical benefits 5,831.7 3,962.0
Costs of products and services 111.8 0.0
ACA industry fee 0.0 81.5
Investment and other income 37.0 19.9
Operating Segments    
Segment Reporting Information [Line Items]    
Premium 6,609.4 4,626.3
Products and services 115.8 0.0
Total premium and products and services revenues 6,725.2 4,626.3
Medical benefits 5,831.7 3,962.0
Costs of products and services 111.8 0.0
ACA industry fee 0.0 81.5
Medicaid premium taxes 31.7 32.1
Total gross margin expenses 5,975.2 4,075.6
Gross margin 750.0 550.7
Investment and other income 37.0 19.9
Other expenses (602.9) (409.4)
Income from operations 184.1 161.2
Corporate, Non-Segment    
Segment Reporting Information [Line Items]    
Premium 4.0 0.0
Products and services 115.8 0.0
Total premium and products and services revenues 119.8 0.0
Medical benefits 2.4 0.0
Costs of products and services 111.8 0.0
ACA industry fee 0.0 0.0
Medicaid premium taxes 0.0 0.0
Total gross margin expenses 114.2 0.0
Gross margin 5.6 0.0
Investment and other income 37.0 19.9
Other expenses (602.9) (409.4)
Income from operations (560.3) (389.5)
Medicaid Health Plan | Operating Segments    
Segment Reporting Information [Line Items]    
Premium 4,473.5 2,809.9
Products and services 0.0 0.0
Total premium and products and services revenues 4,473.5 2,809.9
Medical benefits 4,022.7 2,424.4
Costs of products and services 0.0 0.0
ACA industry fee 0.0 49.3
Medicaid premium taxes 31.7 32.1
Total gross margin expenses 4,054.4 2,505.8
Gross margin 419.1 304.1
Investment and other income 0.0 0.0
Other expenses 0.0 0.0
Income from operations 419.1 304.1
Medicare Health Plan | Operating Segments    
Segment Reporting Information [Line Items]    
Premium 1,843.1 1,556.5
Products and services 0.0 0.0
Total premium and products and services revenues 1,843.1 1,556.5
Medical benefits 1,548.2 1,307.1
Costs of products and services 0.0 0.0
ACA industry fee 0.0 27.6
Medicaid premium taxes 0.0 0.0
Total gross margin expenses 1,548.2 1,334.7
Gross margin 294.9 221.8
Investment and other income 0.0 0.0
Other expenses 0.0 0.0
Income from operations 294.9 221.8
Medicare PDP | Operating Segments    
Segment Reporting Information [Line Items]    
Premium 288.8 259.9
Products and services 0.0 0.0
Total premium and products and services revenues 288.8 259.9
Medical benefits 258.4 230.5
Costs of products and services 0.0 0.0
ACA industry fee 0.0 4.6
Medicaid premium taxes 0.0 0.0
Total gross margin expenses 258.4 235.1
Gross margin 30.4 24.8
Investment and other income 0.0 0.0
Other expenses 0.0 0.0
Income from operations $ 30.4 $ 24.8
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.19.1
EQUITY AND EARNINGS PER SHARE- Calculation of Weighted-Average Common Shares Outstanding (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 3 Months Ended
Aug. 31, 2018
Mar. 31, 2019
Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Investment banking, advisory, brokerage, and underwriting fees and commissions $ 37.7    
Shares Issued, Price Per Share $ 265.00    
Issuance of common stock, net of issuance costs $ 1,300.0    
Weighted-average common shares outstanding — basic (in shares)   50,100,509 44,605,892
Dilutive effect of outstanding stock-based compensation awards (in shares)   741,795 590,235
Weighted-average common shares outstanding — diluted (in shares)   50,842,304 45,196,127
Anti-dilutive stock-based compensation awards excluded from computation (in shares)   67,130 277,390
Meridian      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Sale of stock, number of shares issued in transaction 5,207,547    
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.19.1
INVESTMENTS - Short-term and Long-term Investments by Security Type (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2019
Dec. 31, 2018
Debt securities:    
Amortized Cost $ 1,798.0 $ 1,654.1
Gross Unrealized Gains 6.4 1.1
Gross Unrealized Losses (3.3) (11.9)
Estimated Fair Value 1,801.1 1,643.3
Equity securities    
Amortized Cost 225.1  
Gross Unrealized Gains 0.0  
Gross Unrealized Losses 0.0  
Estimated Fair Value 225.1  
Total    
Amortized Cost 2,023.1  
Gross Unrealized Gains 6.4  
Gross Unrealized Losses 3.3  
Estimated Fair Value 2,026.2  
Asset-backed securities    
Debt securities:    
Amortized Cost 154.2 144.7
Gross Unrealized Gains 0.2 0.0
Gross Unrealized Losses (0.3) (0.5)
Estimated Fair Value 154.1 144.2
Corporate debt securities    
Debt securities:    
Amortized Cost 1,127.9 943.0
Gross Unrealized Gains 3.5 0.5
Gross Unrealized Losses (2.7) (10.1)
Estimated Fair Value 1,128.7 933.4
Municipal securities    
Debt securities:    
Amortized Cost 197.1 199.6
Gross Unrealized Gains 2.7 0.6
Gross Unrealized Losses (0.1) (0.9)
Estimated Fair Value 199.7 199.3
Residential mortgage-backed securities    
Debt securities:    
Amortized Cost 10.1 7.2
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses (0.1) (0.2)
Estimated Fair Value 10.0 7.0
Short-term time deposits    
Debt securities:    
Amortized Cost 237.5 242.2
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses 0.0 0.0
Estimated Fair Value 237.5 242.2
Government and agency obligations    
Debt securities:    
Amortized Cost 9.2 44.9
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses (0.1) (0.1)
Estimated Fair Value 9.1 44.8
Other securities    
Debt securities:    
Amortized Cost 62.0 72.5
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses 0.0 (0.1)
Estimated Fair Value $ 62.0 $ 72.4
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.19.1
INVESTMENTS - Contractual Maturities of Available-for-sale Securities (Details) - USD ($)
$ in Millions
Mar. 31, 2019
Dec. 31, 2018
Amortized Cost    
Due in one year or less $ 889.6  
Due after one year through five years 571.6  
Due after five years through ten years 147.3  
Due after ten years 13.1  
Asset-backed and mortgage-backed securities 1,798.0 $ 1,654.1
Total 1,798.0  
Fair Value    
Due in one year or less 889.7  
Due after one year through five years 573.2  
Due after five years through ten years 149.1  
Due after ten years 12.9  
Asset-backed and mortgage-backed securities 1,801.1 $ 1,643.3
Total 1,801.1  
Asset-Backed And Mortgage-Backed Securities    
Amortized Cost    
Asset-backed and mortgage-backed securities 176.4  
Fair Value    
Asset-backed and mortgage-backed securities $ 176.2  
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.19.1
INVESTMENTS - Narrative (Details) - USD ($)
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Investments, Debt and Equity Securities [Abstract]    
Proceeds from sale of available-for-sale investments $ 420,600,000 $ 80,200,000
Realized gains and losses on sales and redemptions of investments 0 0
Other than temporary impairment losses $ 0 $ 0
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.19.1
RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS - Schedule of Restricted Investments (Details) - USD ($)
$ in Millions
Mar. 31, 2019
Dec. 31, 2018
Restricted Cash and Cash Equivalents Items [Line Items]    
Amortized Cost $ 274.6 $ 235.2
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses (0.3) (0.5)
Estimated Fair Value 274.3 234.7
Cash    
Restricted Cash and Cash Equivalents Items [Line Items]    
Amortized Cost 12.8 11.3
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses 0.0 0.0
Estimated Fair Value 12.8 11.3
Money market funds    
Restricted Cash and Cash Equivalents Items [Line Items]    
Amortized Cost 86.2 51.4
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses 0.0 0.0
Estimated Fair Value 86.2 51.4
U.S. government securities and other    
Restricted Cash and Cash Equivalents Items [Line Items]    
Amortized Cost 175.6 172.5
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses (0.3) (0.5)
Estimated Fair Value $ 175.3 $ 172.0
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.19.1
RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Restricted Investments Note [Abstract]    
Realized gains (losses) on restricted investments $ 0 $ 0
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.19.1
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Compensation expense $ 22.8 $ 12.1
Unrecognized compensation cost $ 121.0  
Weighted-average period over which compensation costs are expected to be recognized 2 years  
Closing common stock price (in USD per share) $ 269.75  
Grants in period, weighted average grant date fair value (in USD per share) $ 205.27  
Performance Stock Units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Unrecognized compensation cost $ 33.9  
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.19.1
STOCK-BASED COMPENSATION - Summary of Stock Unit Award Activity (Details)
 3 Months Ended
Mar. 31, 2019
shares
Equity Instruments Other than Options [Roll Forward]  
Outstanding as of beginning of period (in shares) 859,943
Granted (in shares) 446,973
Vested (in shares) (451,316)
Forfeited (in shares) (10,648)
Outstanding at end of period (in shares) 844,952
RSUs  
Equity Instruments Other than Options [Roll Forward]  
Outstanding as of beginning of period (in shares) 253,235
Granted (in shares) 99,434
Vested (in shares) (99,668)
Forfeited (in shares) (2,372)
Outstanding at end of period (in shares) 250,629
PSUs  
Equity Instruments Other than Options [Roll Forward]  
Outstanding as of beginning of period (in shares) 606,708
Granted (in shares) 347,539
Vested (in shares) (351,648)
Forfeited (in shares) (8,276)
Outstanding at end of period (in shares) 594,323
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.19.1
DEBT - Schedule of Outstanding Debt Obligations (Details) - USD ($)
$ in Millions
Mar. 31, 2019
Dec. 31, 2018
Aug. 13, 2018
Mar. 22, 2017
Long-term debt, net        
Debt issuance costs $ (22.7) $ (23.6)    
Total long-term debt, net 2,127.3 2,126.4    
Revolving Credit Facility        
Long-term debt, net        
Revolving Credit Facility 200.0 200.0    
Senior Notes | 5.25% Senior Notes, due April 1, 2025        
Long-term debt, net        
Senior notes $ 1,200.0 1,200.0    
Interest rate 5.25%     5.25%
Senior Notes | 5.375% Senior Notes, due August 15, 2026        
Long-term debt, net        
Senior notes $ 750.0 $ 750.0    
Interest rate 5.375%   5.375%  
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.19.1
DEBT - Narrative (Details) - USD ($)
 1 Months Ended
Jul. 23, 2018
Apr. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Aug. 31, 2018
Aug. 13, 2018
Apr. 07, 2017
Mar. 22, 2017
Revolving Credit Facility                
Debt Instrument [Line Items]                
Borrowings outstanding     $ 200,000,000.0 $ 200,000,000.0        
Credit facility, maximum borrowing capacity $ 1,300,000,000             $ 1,000,000,000.0
Credit facility increase subject to certain conditions $ 500,000,000              
Senior Notes | 5.375% Senior Notes, due August 15, 2026                
Debt Instrument [Line Items]                
Interest rate     5.375%     5.375%    
Aggregate principal amount           $ 750,000,000.0    
Senior Notes | 5.25% Senior Notes, due April 1, 2025                
Debt Instrument [Line Items]                
Interest rate     5.25%         5.25%
Aggregate principal amount               $ 1,200,000,000.0
Senior Notes | 5.75% Senior Notes, due November 15, 2020                
Debt Instrument [Line Items]                
Interest rate             5.75%  
Debt repurchase amount             $ 900,000,000.0  
Minimum | Revolving Credit Facility                
Debt Instrument [Line Items]                
Commitment fee percentage on unused amount 0.20%              
Maximum | Revolving Credit Facility                
Debt Instrument [Line Items]                
Commitment fee percentage on unused amount 0.30%              
Meridian | Senior Notes | 5.375% Senior Notes, due August 15, 2026                
Debt Instrument [Line Items]                
Interest rate         5.375%      
Subsequent Event | Revolving Credit Facility                
Debt Instrument [Line Items]                
Proceeds from long-term lines of credit   $ 140,000,000.0            
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.19.1
FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Millions
Mar. 31, 2019
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity securities $ 225.1  
Fair value, measurements, recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 274.3 $ 234.7
Fair value, measurements, recurring | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 154.1 144.2
Fair value, measurements, recurring | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 1,128.7 933.4
Fair value, measurements, recurring | Municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 199.7 199.3
Fair value, measurements, recurring | Residential mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 10.0 7.0
Fair value, measurements, recurring | Short-term time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 237.5 242.2
Fair value, measurements, recurring | Government and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 9.1 44.8
Fair value, measurements, recurring | Other securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 62.0 72.4
Fair value, measurements, recurring | Cash    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 12.8 11.3
Fair value, measurements, recurring | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 86.2 51.4
Fair value, measurements, recurring | U.S. government securities and other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 175.3 172.0
Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 279.7 94.6
Equity securities 220.9  
Restricted cash, cash equivalents and investments 274.1 234.5
Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Residential mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Government and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 9.1 44.8
Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 49.7 49.8
Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 12.8 11.3
Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 86.2 51.4
Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. government securities and other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 175.1 171.8
Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 1,746.5 1,548.7
Equity securities 4.2  
Restricted cash, cash equivalents and investments 0.2 0.2
Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 154.1 144.2
Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2) | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 1,128.7 933.4
Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2) | Municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 199.7 199.3
Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2) | Residential mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 10.0 7.0
Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2) | Short-term time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 237.5 242.2
Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2) | Government and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2) | Other securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 12.3 22.6
Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2) | Cash    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 0.0 0.0
Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2) | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 0.0 0.0
Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2) | U.S. government securities and other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 0.2 0.2
Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Equity securities 0.0  
Restricted cash, cash equivalents and investments 0.0 0.0
Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3) | Asset-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3) | Corporate debt securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3) | Municipal securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3) | Residential mortgage-backed securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3) | Short-term time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3) | Government and agency obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3) | Other securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 0.0 0.0
Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3) | Cash    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 0.0 0.0
Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3) | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 0.0 0.0
Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3) | U.S. government securities and other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Restricted cash, cash equivalents and investments 0.0 0.0
Carrying Value | Fair value, measurements, recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 2,026.2 $ 1,643.3
Debt Securities | Fair value, measurements, recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 1,801.1  
Debt Securities | Fair value, measurements, recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 58.8  
Debt Securities | Fair value, measurements, recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments 1,742.3  
Debt Securities | Fair value, measurements, recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments $ 0.0  
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.19.1
FAIR VALUE MEASUREMENTS - Carrying Value and Fair Value of Long-term Debt (Details) - USD ($)
$ in Millions
Mar. 31, 2019
Dec. 31, 2018
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Debt Instrument [Line Items]    
Long-term debt, fair value $ 2,034.7 $ 1,885.2
Significant Other Observable Inputs (Level 2)    
Debt Instrument [Line Items]    
Long-term debt, fair value 200.0 200.0
Significant Unobservable Inputs (Level 3)    
Debt Instrument [Line Items]    
Long-term debt, fair value 0.0 0.0
Carrying Value    
Debt Instrument [Line Items]    
Long-term debt, fair value $ 2,127.3 $ 2,126.4
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.19.1
MEDICAL BENEFITS PAYABLE - Reconciliation of Beginning and Ending Balances, by Segment (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Reconciliation of the beginning and ending balance of medical benefits payable [Roll Forward]        
Beginning balance $ 2,897.4 $ 2,146.3    
Acquisitions 0.0 0.0    
Medical benefits incurred related to        
Current year 6,083.3 4,163.8    
Prior years (251.6) (201.8)    
Total 5,831.7 3,962.0    
Medical benefits paid related to        
Current year (3,894.7) (2,737.3)    
Prior years (1,621.8) (1,160.7)    
Total (5,516.5) (3,898.0)    
Ending balance 3,212.6 2,210.3    
Premium deficiency reserve 6.6 41.0 $ 16.1 $ 45.6
Medicaid Health Plan        
Reconciliation of the beginning and ending balance of medical benefits payable [Roll Forward]        
Beginning balance 2,012.8 1,373.2    
Acquisitions 0.0 0.0    
Medical benefits incurred related to        
Current year 4,182.7 2,523.8    
Prior years (160.0) (99.4)    
Total 4,022.7 2,424.4    
Medical benefits paid related to        
Current year (2,769.2) (1,659.4)    
Prior years (1,147.9) (758.6)    
Total (3,917.1) (2,418.0)    
Ending balance 2,118.4 1,379.6    
Medicare Health Plan        
Reconciliation of the beginning and ending balance of medical benefits payable [Roll Forward]        
Beginning balance 823.5 722.5    
Acquisitions 0.0 0.0    
Medical benefits incurred related to        
Current year 1,612.7 1,383.1    
Prior years (64.5) (76.0)    
Total 1,548.2 1,307.1    
Medical benefits paid related to        
Current year (936.4) (859.9)    
Prior years (451.7) (389.3)    
Total (1,388.1) (1,249.2)    
Ending balance 983.6 780.4    
Medicare PDP        
Reconciliation of the beginning and ending balance of medical benefits payable [Roll Forward]        
Beginning balance 59.1 50.6    
Acquisitions 0.0 0.0    
Medical benefits incurred related to        
Current year 284.7 256.9    
Prior years (26.3) (26.4)    
Total 258.4 230.5    
Medical benefits paid related to        
Current year (187.7) (218.0)    
Prior years (21.6) (12.8)    
Total (209.3) (230.8)    
Ending balance 108.2 50.3    
Corporate and Other        
Reconciliation of the beginning and ending balance of medical benefits payable [Roll Forward]        
Beginning balance 2.0 0.0    
Acquisitions 0.0 0.0    
Medical benefits incurred related to        
Current year 3.2 0.0    
Prior years (0.8) 0.0    
Total 2.4 0.0    
Medical benefits paid related to        
Current year (1.4) 0.0    
Prior years (0.6) 0.0    
Total (2.0) 0.0    
Ending balance $ 2.4 $ 0.0    
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.19.1
MEDICAL BENEFITS PAYABLE - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
MEDICAL BENEFITS PAYABLE [Abstract]    
Prior years $ (251.6) $ (201.8)
Favorable development of medical benefits payable 251.6 201.8
Favorable development of medical benefits payable excluding the release of the provision for moderately adverse conditions $ 108.2 $ 71.5
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.19.1
LEASES (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2019
USD ($)
Lessee, Lease, Description [Line Items]  
Operating lease expense $ 17.4
Weighted-average remaining lease term 8 years 6 months
Weighted-average discount rate 5.90%
Maximum  
Lessee, Lease, Description [Line Items]  
Remaining lease terms 14 years
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.19.1
LEASES - Balance Sheet items related to operating leases (Details) - USD ($)
$ in Millions
Mar. 31, 2019
Jan. 01, 2019
Assets [Abstract]    
Right of use assets $ 249.9 $ 259.5
Liabilities [Abstract]    
Current 32.9  
Noncurrent 235.6  
Total liabilities $ 268.5 $ 277.3
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.19.1
LEASES - Maturity of Operating Lease Liabilities (Details) - USD ($)
$ in Millions
Mar. 31, 2019
Jan. 01, 2019
Leases [Abstract]    
2019 $ 33.5  
2020 44.9  
2021 44.4  
2022 40.4  
2023 37.2  
2024 34.9  
Thereafter 114.7  
Total lease payments 350.0  
Less: imputed interest 81.5  
Present value of lease liabilities $ 268.5 $ 277.3
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.19.1
LEASES - Supplemental cash flow information related to leases (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2019
USD ($)
Leases [Abstract]  
Cash paid for operating leases $ 11.6
Leased assets obtained in exchange for new operating lease liabilities $ 10.4
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.19.1
INCOME TAXES (Details)
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Income Tax Disclosure [Abstract]    
Effective income tax rate 18.10% 35.80%
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.19.1
DISCONTINUED OPERATIONS (Details)
$ in Millions
Aug. 03, 2016
subsidiary
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Number Of Subsidiaries Sold | subsidiary 2    
Liabilities      
Total liabilities   $ 207.2 $ 213.6
Traditional Insurance Business | Discontinued operations, held-for-sale      
Assets      
Cash and cash equivalents   0.5 0.1
Investments   40.6 42.8
Reinsurance recoverables   165.7 170.2
Other assets   0.4 0.5
Total Assets   207.2 213.6
Liabilities      
Reserves and other policy liabilities   166.1 166.9
Other liabilities   41.1 46.7
Total liabilities   $ 207.2 $ 213.6
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.19.1
COMMITMENTS AND CONTINGENCIES (Details)
$ in Millions
 1 Months Ended
May 31, 2018
USD ($)
Jun. 30, 2017
USD ($)
Apr. 30, 2017
USD ($)
Oct. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Mar. 31, 2019
associate
former_officer
employee
Jun. 30, 2013
officer
employee
Jan. 31, 2012
former_officer
employee
Jan. 31, 2008
action
Loss Contingencies [Line Items]                  
Number of former officers receiving notices of cross appeal | officer             3    
Number of former employees found guilty and appealing | employee             4    
Derivative Lawsuits                  
Loss Contingencies [Line Items]                  
Number of former officers receiving notices of cross appeal | former_officer           3      
Number of former associates being pursued in action filed by entity | associate           2      
Number of former employees found guilty and appealing | employee             4    
Number of former employees being pursued in action filed by entity           5   5  
Number of actions filed in the federal and state courts between October 2007 and January 2008 | action                 6
Number of former executives being pursued in action filed by entity | employee               3  
Derivative Lawsuits | Mr. Farha Case                  
Loss Contingencies [Line Items]                  
Settlement agreement, amount awarded     $ 7.5   $ 7.5        
Maximum legal fee obligation         $ 7.5        
Derivative Lawsuits | Mr. Farha Case | Securities and Exchange Commission (SEC)                  
Loss Contingencies [Line Items]                  
Settlement agreement, amount awarded     12.5            
Derivative Lawsuits | Mr. Behrens Case                  
Loss Contingencies [Line Items]                  
Settlement agreement, amount awarded     1.5 $ 1.5          
Maximum legal fee obligation       $ 1.5          
Derivative Lawsuits | Mr. Behrens Case | Securities and Exchange Commission (SEC)                  
Loss Contingencies [Line Items]                  
Settlement agreement, amount awarded $ 4.5   $ 4.5            
Derivative Lawsuits | Mr. Bereday Case                  
Loss Contingencies [Line Items]                  
Maximum legal fee obligation   $ 2.5              
EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( -=YGDX?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ UWF>3B?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " #7>9Y.BUPTV^X K @ $0 &1O8U!R;W!S+V-O M&ULS9+!2L0P$(9?17)O)]FH8.CFHGA2$%Q0O(5D=C=LTX9DI-VWMXV[ M740?P&-F_GSS#4QCH[)]PI?41TSD,5^-H>VRLG'-]D11 62[QV!R/26ZJ;GM M4S T/=,.HK$'LT-8<7X+ ']^>BWK5K[+9#J+TZ_L%1TCKMEY\IN\?]@\,KWBXJ[BUY7D&W&CA%22?\RN M/_PNPJ%W?NO_L?%94#?PZR[T%U!+ P04 " #7>9Y.F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( -=YGD[*6[2O9 ( '0( 8 >&PO=V]R:W-H965T&UL?5;;CILP$/T5Q =?KD MPD5+E5Z*:R1[P>C9DMHFPG&\BEI:=V&1V[VC*')^4TW=L:,(Y*UMJ?B]9PU_ M;$,4OF^\U-=*F8VHR'MZ9=^8^MX?A5Y%DY5SW;).UKP+!+MLPQUZ/J#4$"SB M1\T>S FY_U657;, N#,[O06Z->^.,3&P-*PV",_@N[LT;#C2=:H^2- MM,^@O$G%V]&*=J6E;\-8=W9\#"<)&6DP 8\$/!%P]E\"&0ED(J#$!C]X9D/] M0!4M5D_-1X&>B;[,TFS:N[-G.EJI=^]%G$=W8V9$[ <$GB'0A(BT M[4D 0P)[[-'QOP(''T%@ 0)&0"R=S.@)3$] >F+IR8R>.A?@(U:P0 H*I!Y] M[0CXB P66($"*X^^<01\!(IAA36HL/;YR)$ (!B6R$")S.<3YSL9(*F%=,.; MBDE,DG@-"VU H8TOE#BQ ) 4ED QG%2Q;V'EIA6 60@$+:0N\BUDK@J V2RH M@/F[0]BS@+T2 6 6B@2"DQ@1WP)V50#,0J5 <*XC/Y6Q^_(AS%(L<,(C/Y^Q M6U,@C*L2S6IXR\35MCL9E/S6V5X[VYU:Z@[;'O 7/O3CKU1BZ$/#@O%^[''1]./1O$'4$L#!!0 ( M -=YGDX@X[JG*@0 - 2 8 >&PO=V]R:W-H965T&UL MC9C;;N,V$(9?1=!]),[P("FP#<0NBA9H@6"+MM>*31^P.KB2$F_?OCK%*W.& MB^8BENA_R'^HX2>:JUO=?&W/UG;!M[*HVG5X[KKK7YO^+K[WRM75P'0RIO=?UUN/GUL [%X,@6=M\-7>3]QX?=V:(8>NI]_#-W M&M['' *7UY^]_SPFWR?SEK=V5Q=_7P[=>1VF87"PQ_R]Z+[4MU_LG) .@SG[ MW^R'+7KYX*0?8U\7[?@_V+^W75W.O?16ROS;]'FIQL_;W/]G&!^ _JQ M?Q0@YP#Y/4"-R4_.QE1_RKM\LVKJ6]!,3^N:#T4!S[*?S/W0.,[=^%V?;=NW M?FS0K.*/H9]9LITDN)# 71'WG=]'0&Z$+9)P?!Q@QR@2?@3)YB#'>+F,3_EX MQ<:K,5XMXS-G#B:)&275*#%&9)%R,J$R9=!$DG>C63>:N)'"<3-)DL4P #I* M'3.32B]4@O=A6!^&^@#'AR$CR,0Q8:C5+,IX'PGK(Z$^G +:)F00DQB,W#JC M,F646<@>W*2LFY34FO0\W8R-SV@V3A%M,V)3IQ(B=V8S.OF9\>0"@E_\@KK1 M[NH73+$!*;99]C^J#3P@ NJ%D CHU A)O5"9U-I7=B5JG4 M5T8\2(&25+DD!>31C!3-RD4S4C1+24J946D3>39(R,,9*9R5"V>D MU 4-9(O$R03XGA;R<$8DKV'EZX%G*E*F*I>I2&D)*9U?JGH"X=OS(0]5I%!5 M+E21$E(1PC.B?BUX,(H\1I%B5+L810:0]$W,J)X2WXL8>8PBQ:AV,3IKS ./ M--D ,K),>I<"3U%,2.EI#_>0YQY2[FF7>[,F72[M2)!\J*K?]?KRX<&'%'S: M!=^L>1PG(P^;4Z$'>Y+'GA1T=GT]\*B2%%7:1=6L6;Y-M0 AM'!9SBB5,D*G MF>>92QY8DNXFM;N;E'0WJ46J4 J7H8Q2:<@,D-_-\>(O]6.9E/)5QVK?PO)L.5[YW,YWU_)XWITO5!F]UU]7E>)9PK.O.]D9% MU%L\V_QPORGLL1LND_ZZF9Y. M_/Q'YJ,$ #9%@ & 'AL+W=O*S8=&RM9KJ3$V[@NLI ")W5Y>F^NIT]L_MHGNKZ[+];^.KYKI* M9/+QXMOI]=@/+[+U\E*^^K]\__WRW(:G[%[*_E3['W_2H1@R-?^5T_%%&&R[O?^JH:2@H^_IT*3>YU M#H'S^X_2?QT;'QKS4G9^VU3_G/;]<9789+'WA_*MZK\UU]_\U* B64RM_\._ M^RK(!R>ACEU3=>/_Q>ZMZYMZ*B58JS+];)MKHOVUEN7S>*UX.,5&Z_&^'P>+U$C;A(] M2LZC1($J4H5:PLATH=)(:W+634[=H ^VN4G,K!JG;:J1&:JR2J22]U*P7@KJ M!35Y4Y!:9*$-,& M.BF0$T-J44J2ST)5TIK9L'KP8EDOEGI!M6PLK44"[2,JRXV)#1C'FG'4C$%F M'*G%&"M2)-M2F;8*8@-&"AY/@OHA?!*TV9#/YNP$*4YF4XCXB>!24C\.^Y&D M(@"ATQP;XG2A5TW$$<]."<21$=@1D%GE+!X\D^@!2DY'OP]/8DE1;#"*)\W# M:!8%';2[>"!+2F2#B2PI:R$L#Q;[ M89!LHW9X(DN*9(.1+"EO09B4) &,+'17!,N2Y[*D8#88S))AK@)1T!G/"*71 M\2[C^2PM24],K%4\5"6EJL%4E927"B3064%U8)V)<15XK@+EJL%T;G0XY'^@D@^2IEJ,5.!XC)03))9RNBT4[$, M 7BL L6JQ5@%BLO:V58 M3<3]CTPV)EG?"D5I(LA2ZV4^?1JBA:'=FK MTW05;P$_E3SZB!P94*(Z3#!%42G2 COY7/3HA:>IHC1UF%V*4E(Z;0C>69V5 ML4V@XFFJ*$T=YI=BLM3\(0&='#$ZT-$]LN*)JBA1'>:78@X&"+T8T2_1Y4_Q M,%44I@[32U%*YBJLQQA?DVX^DL/N-3:8>9HJ2E.'Z35IYD=;?-;,"=FL.9N= M,0Z'OG^6[>OIW"U>FKYOZO%0\= TO0^%AAF1+(Z^W-\?*G_HAUL3[MO;8>OM MH6\NTT%R=C_-7O\/4$L#!!0 ( -=YGDZIO%EC0@( +<' 8 >&PO M=V]R:W-H965T&ULC95MKYHP%,>_"N$#V/(H&"29+LN6;(FY MR[;7%:N06RAKJ]Q]^[6%2Z#TJKZP#_S_Y_P.UIZLH^R5EQ@+YZTF#=^ZI1#M M!@!>E+A&?$5;W,@G9\IJ).2270!O&48G;:H)\"&,08VJQLTSO7=@>4:O@E0- M/C"'7^L:L7\[3&BW=3WW?>.ENI1";8 \:]$%_\3B5WM@<@7&**>JQ@VO:.,P M?-ZZG[S-WH/*H!6_*]SQR=Q1I1PI?56+;Z>M"Q41)K@0*@22PPWO,2$JDN3X M.P1UQYS*.)V_1_^BBY?%'!''>TK^5"=1;MW$=4[XC*Y$O-#N*QX*BEQGJ/X[ MOF$BY8I$YB@HX?K;*:Y;W> /!G\T>.%=0S 8 M L, >C)=ZFW^P.H/M#^<^E.CB%Z2:$FC)7 % M/:..!Z(926@E"13B=U.GC" P 2Q !@ !X M;"]W;W)KJ_M&3?O!SR4IV;O#H[M3HNW%_@88?8&?3$7[FZ-G?W3E?*4U7]Z!Y^.RS< MH,M(%6K?=BXR?7E5:U44G2>=QS^C4_<6LS.\OW_SONN+U\4\98U:5\7?^:$] M+=S$=0[JF+T4[;?J^JL:"Y*N,U;_NWI5A<:[3'2,?54T_5]G_]*T53EZT:F4 MV<_AFI_[ZW7T_V;&&^!H@#<#@ \-Q&@@W@W$AP;A:!"^&T0?&LC10+X;)!\: M1*-!=#,(^PC^T*R^^YNLS9;SNKHZ]3"!+EDW3^$ATN.[[U[VP]G_I@>@T6]? MEQ#$<_^U^;<,V$H$=,DX2,)-I)@(H6DO0,3W47"$"*/C,+:Q@*/N-K8C$S! MDZ3'-@4)QA3;V=@,[[(RJ@_9ZL/>@S"JE[P#R3J03/LBTA=I#900>J2 CQ.Q M<2(F#NU_9,6901!B'/*!8C90S 0B2VDU,+'1]\!#,M2?448R"9M,PB1#UNPJ ML<( >F1!;CZ!C%12-I742D62(*O4"I(*C_1N:T,0 %U*.YN:Q5[*YPL!KYN! MW3P,J"@&C(C$4J"86 4P(=+ !*/]&2%#1V2 5"/6#&<+R0C=MT@F@F);!H,4 M4SI9=PRG%X\7372!5VU@9!N1=H'1[31-!=*9O?X*::;%2SPP&H^"IC5 Z7TP M#*WYPFF\I$,CF)XG0!?EEN$0H]@3=&QL;I9,K@9>Z.%_*#WP4@]?T7JPQ3Z4 M$"83&@R\V@,C]TAW9;#U/IB(PDL]<%I/-Y41,G<5/3.FOC* 5W+@I)SN*V#+ M]$Q$5$(WGV)F0KR>@RWH]MX"M@XCVOE\0IG?>[Q:HZW6UOXR,L9G422IE&U' MS%A^$J@R[CA,3&;-RSYRLB]IVF#-(!F( !$(N?X*::8U\?7,Z7!$TT*KFZ'0 MWZ)(D[(Y6_(8"%(M953R&$Y_2B?6_L\E9RF>?W>$ZH[9?V3UJU:>Q M_LQTK*I6:8VNHQ'=__V_X/E?U!+ P04 M " #7>9Y.K[SX)W($ ":% & 'AL+W=OMU$JK4[7]G 5ST4D(3<)R^N_K M7)83/./R84FRK\?O3.S'QLM[57]O3L:TLQ]E<6E6\U/;7E_"L-F=3)DW074U M%_N?0U67>6MOZV/87&N3[_M&91%B%,5AF9\O\_6R?_96KY?5K2W.%_-6SYI; M6>;UOQM35/?5'.:?#[Z=CZ>V>Q"NE]?\:/XP[9_7M]K>A8\H^W-I+LVYNLQJ M'/);T7ZK[K^8 M,2$]GXW9_V8^3&'EG1/;QZXJFO[O;'=KVJH3WI*(I4#*#& Z@.H20 5.T48)'$ON0Q]: B4DXF@BB#P)*-%+UI()I,#Q&* MF"5#F9/,($DF-N,LT-GTXR3&6U \R?[)5B+:2I@MH,CQE;!>$(/4L<)%@(%G M1*:BE52P HZ5E)FXPG' 6.WRT7:5]1())1 M$/&11^0)X:$)L'1B38G5XZRD#$2,C(74I'T5-&6>*^\E'U##T_S%#&*W*\@G+74.3%<+E&&(PC93N6Q&OH6T\Q1YA;@NMMMT#SE(9BL);%7N=H,X-2D!O@\G MSF"%L6>.D*A=0!/G M7,RF*?$-IF>*DLQ!XOM+T.X4);[!U'R_(JC(^Q.09*:2\#M;^X:,3$$2**A= M+(^BZ9& 9E >1=DT(<=*.#G1*4U][ ^_FMFNNEW:[NQD\O1QP/:*W8F0\WP# M+]OAF.QGF.'4[O>\/IXOS>R]:MNJ[$^%#E75&NLP"FRY3B;?/VX* MU\-IV7#35M?Q)#!\'$>N_P-02P,$% @ UWF>3O\KL*ZQ 0 T@, !@ M !X;"]W;W)K_$M0""O6AF? MTS:$[LB8+UO0PM_9#@S^J:W3(J#K&N8[!Z)*(*T8WVSNF1;2T")+L;,K,ML' M)0V<'?&]UL+].H&R0TZW]!9XEDT;8H 562<:^ KA6W=VZ+&9I9(:C)?6$ =U M3A^WQ],^YJ>$[Q(&O[!)[.1B[4MT/E4YW41!H* ,D4'@<84G4"H2H8R?$R>= M2T;@TKZQ?TB]8R\7X>')JA^R"FU.WU%202UZ%9[M\!&F?@Z43,U_ABLH3(]* ML$9IE4]?4O8^6#VQH!0M7L=3FG0.$_\-M@[@$X"_ ;"Q4%+^7@119,X.Q(VS M[T2\XNV1XVS*&$RC2/]0O,?HM=@>#AF[1J(IYS3F\&7.G,&0?2[!UTJ<^#]P MO@[?K2K<)?CN+X7WZP3[58)](MC_M\6UG(&PO=V]R M:W-H965T&UL?5-MCY0P$/XK37_ E66Y<]T R>T9HXDFFS/J MYRX,T%Q?L"W+^>^=%A91B5_:SG2>9YZ93O/1V!?7 7CRJJ1V!>V\[X^,N:H# MQ=V=Z4'C36.LXAY-VS+76^!U!"G)TB1Y8(H+3NXIF8O_!%>0&!Z48([*2!=74@W. M&S6SH!3%7Z==Z+B/TTUV@VT#TAF0+H!#!+ I453^CGM>YM:,Q$Z][WEXXMTQ MQ=Y4P1E;$>]0O$/OM=S='W)V#41SS&F*2=9Y.DHW3F+0! #2 P & 'AL+W=O=;*^()V(?1'QGS5@1;^QO9@ M\*:Q3HN IFN9[QV(.H&T8GRWNV5:2$/+//G.KLSM$)0T<';$#UH+]^,$RHX% MS>B+XU&V78@.5N:]:.$SA"_]V:'%%I9::C!>6D,<- 6]SXZG0XQ/ 5\EC'YU M)K&2B[5/T?A0%W07!8&"*D0&@=L5'D"I2(0ROL^<=$D9@>OS"_N[5#O6 M'JSZ)NO0%?2.DAH:,:CP:,?W,-?SBI*Y^(]P!87A40GFJ*SR:275X(/5,PM* MT>)YVJ5)^SC=\#5O11!E[NQ(W-3[7L0GSHX<>U-% M9VI%ND/Q'KW7,KO-\_0FO\*G:?\D M7"N-)Q<;\&53_QMK Z"4W0V.4(7^/936,V&<'V\P]BRS3HA1MF6T 0 T@, !D !X;"]W;W)K&UL?5-M;]L@$/XKB!]0$N)F561;:CI-J[1*4:>MGXE]?E&!>ZYXT@'-*^V 7#D74EM,]HXUQT8LT4#2M@;[$#[FPJ- M$LZ;IF:V,R#*"%*2\R5;#R1#;*R7,QQ$D#AG=TJOC MN:T;%QPL3SM1PW=P/[J3\1:;6N.]-$9RQ%?'. MB[?>>\FW^R1EET TQ1S'&+Z,F2.89Y]3\+441_X/G*_#=ZL*=Q&^^T/A[3I! MLDJ01(+DOR6NQ>S_2L(6/55@ZCA-EA38ZSC)"^\\L/<\OLGO\'':GX2I6VW) M&9U_V=C_"M&!E[*Y\2/4^ \V&Q(J%XZ?_-F,8S8:#KOI!['Y&^>_ %!+ P04 M " #7>9Y.7PA&<;4! #2 P &0 'AL+W=O2X_?M1 MLNMYF[$72:1X#@\I*AN,?7$M@"=O2FJ7T];[[L"8*UM0W%V9#C3>U,8J[M&T M#7.=!5Y%D)(LW6QNF.)"TR*+OI,M,M-[*32<+'&]4MR^'T&:(:<)_7 \B:;U MP<&*K.,-? ?_HSM9M-C,4@D%V@FCB84ZIW?)X;@+\3'@6<#@%F<2*CD;\Q*, MKU5.-T$02"A]8."X7> >I Q$*.-UXJ1SR@!THJJ'DO_9,9'F"JYYJ2J?AO< &)X4$)YBB-='$E9>^\41,+2E'\;=R%COLP MWEPG$VP=D$Z = ;L8QXV)HK*/W//B\R:@=BQ]QT/3YP<4NQ-&9RQ%?$.Q3OT M7HKDYC9CET TQ1S'F'09,T9Y.@OW13;(! #2 P &0 'AL+W=O\9LV8+B]@H[T/ZF1J.X\Z9IF.T, M\"J"E&1IDGQBB@M-BRSZCJ;(L'=2:#@:8GNEN'D[@,0AIQMZ<3R)IG7!P8JL MXPT\@_O>'8VWV,Q2"07:"M3$0)W3N\W^L OQ,>"'@,$NSB14>4 ;@\7]@_Q]I]+2=NX1[E3U&Y-J>WE%10 M\UZZ)QR^P%3/-253\=_@#-*'!R4^1XG2QI64O76H)A8O1?'7<1[# M$M=B_E;)%CU58)HX39:4V.LXR0OO/+!W:7R3W^'CM#]RTPAMR0F=?]G8_QK1 M@9>27/D1:OT'FPT)M0O'&W\VXYB-AL-N^D%L_L;%.U!+ P04 " #7>9Y. M8#?;2+0! #2 P &0 'AL+W=O/*J5>LRVGC?'1AS10-:N"O308LWE;%:>#1MS5QG0901I!7C MF\T-TT*V-$^C[V3SU/1>R19.EKA>:V'_'$&9(:-;^N9XE'7C@X/E:2=J^ G^ M5W>R:+&9I90:6B=-2RQ4&;W;'HY)B(\!OR4,;G$FH9*S,<_!^%9F=!,$@8+" M!P:!VP7N0:E A#)>)DXZIPS Y?F-_4NL'6LY"P?W1CW)TC<9O:6DA$KTRC^: MX2M,]5Q3,A7_'2Z@,#PHP1R%42ZNI.B=-WIB02E:O(Z[;.,^C#?[9(*M _@$ MX#/@-N9A8Z*H_$%XD:?6#,2.O>]$>.+M@6-OBN",K8AW*-ZA]Y)O][N470+1 M%',<8_@R9HY@R#ZGX&LICOP?.%^'[U85[B)\]T%ALDZ0K!(DD2#Y;XEK,=>? MDK!%3S78.DZ3(X7IVSC)"^\\L'<\OLE[^#CM/X2M9>O(V7A\V=C_RA@/*&5S MA2/4X >;#065#\<]GNTX9J/A33?](#9_X_PO4$L#!!0 ( -=YGDY:]^6F MM $ -(# 9 >&PO=V]R:W-H965TO&IE7$Y;[[L38ZYL00MWAQV8<%.CU<('TS;,=19$E4!:,;[9W#,M MI*%%EGP76V38>R4-7"QQO=;"_CR#PB&G6_KF>))-ZZ.#%5DG&O@*_EMWL<%B M,TLE-1@GT1 +=4X?MJ?S/L:G@.\2!K,P.7YC?U#JCW4N6?=B$^\/?'0FS(Z4RO271#O@O=6; _W&;M%HBGF/,;P M9@A2-G=AA-KP MP69#0>WC\1#.=ARST?#833^(S=^X^ 502P,$% @ UWF>3K7?*RFU 0 MT@, !D !X;"]W;W)K&UL?5/;;MP@$/T5Q <$ MK]=MMBO;4C95E4J-M$K5]IFUQS8*, [@=?+W!>RX5FOU!9CAG#,7AGQ$\VP[ M $=>E=2VH)US_9$Q6W6@N+W!'K2_:= H[KQI6F9[ [R.)"59FB0?F>)"TS*/ MOK,I3B!Q+.B.OCN>1-NYX&!EWO,6OH/[T9^-M]BB4@L% MV@K4Q$!3T+O=\90%? 3\%##:U9F$2BZ(S\'X6AZW*]R#E$'( MI_$R:](E9""NS^_J7V+MOI8+MW"/\I>H75?0 R4U-'R0[@G'!YCK^4#)7/PW MN(+T\)")CU&AM'$EU6 =JEG%IZ+XZ[0+'?=QNMEG,VV;D,Z$="$<8APV!8J9 M?^:.E[G!D9BI]ST/3[P[IKXW57#&5L0[G[SUWFNYN_V4LVL0FC&G"9.N,0N" M>?4E1+H5XI3^0T^WZ?O-#/>1OE]'/R3; MFF0!8%LO^6N($Y_%TD6_54@6GC M-%E2X:#C)*^\R\#>I?%-_L"G:7_DIA7:D@LZ_[*Q_PVB Y]*QY1N7OP%02P,$% @ UWF>3A7;Q&NT 0 T@, M !D !X;"]W;W)K&UL?5-A;]P@#/TKB!]0[DC6 MG4Y)I%ZGJI-6Z=1IVV^C\38U&"^=-TS#;&Q!5!&G%^&YWR[20'2VRZ#N; M(L/!*=G!V1 [:"W,VPD4CCG=TW?'LVQ:%QRLR'K1P%=PW_JS\19;6"JIH;,2 M.V*@SNG=_GA*0WP,^"YAM*LS"95<$%^"\;G*Z2X( @6E"PS";U>X!Z4"D9?Q M<^:D2\H 7)_?V1]B[;Z6B[!PC^J'K%R;TP,E%=1B4.X9QT>8Z_E R5S\%[B" M\N%!B<]1HK)Q)>5@'>J9Q4O1XG7:91?W<;I);F?8-H#/ +X #C$/FQ)%Y9^$ M$T5F<"1FZGTOPA/OC]SWI@S.V(IXY\5;[[T6^P//V#40S3&G*8:O8Y8(YMF7 M%'PKQ8G_ ^?;\&1381+AR1\*DVV"=),@C03I?TOH]1]L,134+AP_ M^K.9QFPR'/;S#V++-RY^ 5!+ P04 " #7>9Y.=O?1-K0! #2 P &0 M 'AL+W=O_4M0"!O6AF? MTS:$[LB8+UO0PM_8#@S>U-9I$=!T#?.= U$ED%:,;S9W3 MI:)$EW]D5F>V# MD@;.COA>:^%^GD#9(:=;^NYXD4T;HH,562<:^ +A:W=V:+&9I9(:C)?6$ =U M3A^VQ],^QJ> ;Q(&OSB36,G%VM=H?*QRNHF"0$$9(H/ [0J/H%0D0AD_)DXZ MIXS Y?F=_3G5CK5FXIF8K_!%=0&!Z5 M8([2*I]64O8^6#VQH!0MWL9=FK0/T\UA@JT#^ 3@,^"0\K Q45+^)((H,F<' MXL;>=R(^\?;(L3=E=*96I#L4[]%[+;:'VXQ=(]$4S_6^):S/U?2=BBIQISVX< ML]$(MIM^$)N_&PO M=V]R:W-H965T-L8I[-&W+7&^!UQ&D)$N3Y#U37&A:YM%WMF5N!B^%AK,E M;E"*V]\GD&8LZ(Z^.!Y$V_G@8&7>\Q:^@__1GRU:;&&IA0+MA-'$0E/0N]WQ MM _Q,>!1P.A69Q(JN1CS%(PO=4&3( @D5#XP<-RN< ]2!B*4\6OFI$O* %R? M7]@_Q=JQE@MW<&_D3U'[KJ '2FIH^"#]@QD_PUS/.TKFXK_"%22&!R68HS+2 MQ954@_-&S2PH1?'G:1HPP^V&!(:'XX?\&RG,9L, M;_KY!['E&Y=_ %!+ P04 " #7>9Y.F:2P=[4! #2 P &0 'AL+W=O MU,8J[M&T#7.=!5Y%D)(LW6P^,,6%ID46?2=;9*;W4F@X6>)Z MI;A].8(T0TX3^NIX%$WK@X,56<<;^ ;^>W>R:+&9I1(*M!-&$PMU3F^3PW$7 MXF/ #PYQ)J.1LS%,POE8YW01!(*'T@8'C=H$[D#(0H8Q?$R>=4P;@\OS* M_CG6CK6PIF8J_APM(# ]*,$=II(LK M*7OGC9I84(KBS^,N=-R'\6:_GV#K@'0"I#/@)N9A8Z*H_!/WO,BL&8@=>]_Q M\,3)(<7>E,$96Q'O4+Q#[Z5(/B89NP2B*>8XQJ3+F#F"(?N<(EU+<4S?P=-U M^'95X3;"MW\I_ ?!;I5@%PEV_RUQ+6;[)@E;]%2!;>(T.5*:7L=)7GCG@;U- MXYO\"1^G_8';1FA'SL;CR\;^U\9X0"F;*QRA%C_8;$BH?3A>X]F.8S8:WG33 M#V+S-RY^ U!+ P04 " #7>9Y.S=%A>;4! #2 P &0 'AL+W=OU,8J[M&T#7.=!5Y%D)(LV6RNF>)"TR*+OI,M,M-[*32<+'&]4MR^ M'$&:(:=;^NIX$$WK@X,56<<;^ G^5W>R:+&9I1(*M!-&$PMU3F^WAV,:XF/ M;PYQ)J.1LS%,POE=4P;@\OS*_C76 MCK6O:43,7_@ M(# ]*,$=II(LK*7OG MC9I84(KBS^,N=-R'\6:?3+!U0#(!DAEP$_.P,5%4_H5[7F36#,2.O>]X>.+M M(<'>E,$96Q'O4+Q#[Z78?DXS=@E$4\QQC$F6,7,$0_8Y1;*6XIA\@"?K\-VJ MPEV$[]XHW*\3I*L$:21(_UOB6LSUNR1LT5,%MHG3Y$AI>ATG>>&=!_8V/B+[ M%SY.^SVWC=".G(W'EXW]KXWQ@%(V5SA"+7ZPV9!0^W#\A&<[CMEH>---/XC- MW[CX"U!+ P04 " #7>9Y.$(Z F!0" "XD]*89D>ISDL03#_( M!FK[YBR58,::ZD)UHX 5/DAP&H?AF@I6U21+O>^HLE2VAE$ \!\2R ]D(^\T_,L"Q5L@M4?_@-<]\XVL7V M;'+G]$?AW]GDM?5>LVB[2>G5$0V80X^)IY@102W[*!%C$H?X0WB,AR_0#!<^ M?#%57ZUQ@B5*L/0$RWY\^"TJLD4(YO\VADEPD2C$.RA$ M*+;S%D) 47A'YTZG1@A%--?!0/-VHY/A($!=_%C402[;VL_DB7<&PO=V]R:W-H M965T0/B,&[+.D*D+*)HE9JI56JIL]> M&"Z*C:EMEO3O:QN64N*^8,_XS#DS@\?I*.2;:@!T\,Y9IS+4:-T?,59% YRJ M.]%#9TXJ(3G5QI0U5KT$6KH@SC )PP/FM.U0GCK?6>:IK.SC+0 V<4_G[ M!$R,&8K0S?'2UHVV#IRG/:WA.^@?_5D:"R\L9 =X M;6%4JWU@*[D(\6:-+V6&0IL0,"BT9:!FN<(C,&:)3!J_9DZT2-K ]?[&_NQJ M-[5";RZ@AQD[89/!848.C?X*^\RWP_$7>&_\.EQ^$9E MW78JN AM!L%=UTH(#2:5\,YTM3'OT6(PJ+3=)F8OIZF<#"WZ^<'!RZN7_P%0 M2P,$% @ UWF>3C&V3%#% 0 -P0 !D !X;"]W;W)K&UL=51ACYP@$/TKA!]PK+AN+QLUN;WFC%;R'LT9FE)+I7R<0:BIP@M\= M+[SMK'>0,A]8"U_!?AO.VEED9:FYA-YPU2,-38$?DN,I\_@ ^,YA,IL]\I5< ME'KUQJ>ZP#N?$ BHK&=@;KG"(PCAB5P:/Q=.O$KZP.W^G?TIU.YJN3 #CTK\ MX+7M"GR/40T-&X5]4=,S+/5D&"W%?X8K" ?WF3B-2@D3OJ@:C55R87&I2/8V MK[P/ZS2?I,D2%@^@2P!= ^Z##IF%0N8?F65EKM6$]'SW _,M3H[4W4WEG>$J MPIE+WCCOM:24YN3JB1;,:<;0#299$<2QKQ(T)G&B_X33>'@:S3 -X>E6_? ? M@GV48!\(]G^5F-Z4&,/LXR)95"2+$&0W(C',X4:$;!HG0;?AR1I4J;$/X[+Q MKE/Q0$/C_\#GD?K"=,M[@R[*NN<3FMPH9<&ELKMSN71NBE=#0&/]]H/;Z_DM MSX95PS*F9/U7E+\!4$L#!!0 ( -=YGDZO;O;HN $ -(# 9 >&PO M=V]R:W-H965TM M4M1IW6]B7]NH8%S [EG',_N"2]L:^N!O#D7:O&I;3VOCTP MYO(:M'!7IH4&;TICM?!HVHJYUH(H(DDKQE>K&Z:%;&B61-_)9HGIO)(-G"QQ MG=;"?AQ!F3ZE:_KI>)95[8.#94DK*O@)_E=[LFBQ2:60&AHG34,LE"F]71^. MVX"/@!<)O9N=2:CD;,QK,+X7*5V%A$!![H."P.T"=Z!4$,(TWD9-.H4,Q/GY M4_TAUHZUG(6#.Z-^R\+7*=U34D I.N6?3?\(8SW7E(S%_X +*(2'3#!&;I2+ M*\D[YXT>53 5+=Z'739Q[X>;'1]IRP0^$OA$V,#8FSPX8ROB'2;OT'O).-\E[!*$1LQQP/ 99CTA&*I/(?A2B"/_C\Z7 MZ9O%##>1OIE'O[E>%M@N"FRCP/:?$O=?2ES"?/L2A,UZJL%6<9H M>:>!O8V/R/["AVE_$K:2C2-GX_%E8_]+8SQ@*JLK'*$:/]AD*"A]..[P;(D;9W\ 4$L#!!0 ( -=YGDX1+?ZUQ0$ #<$ 9 >&PO M=V]R:W-H965T3;2F7JFJE M1CHE:ON;L]NDHN4+V[QKC].\TZZ7]+""71)H&O"P>N06<@[_\P,*S(E)Z3F MLQ^8N^+X2.W9E"[HC\+O6?/:1J\%3:*,7!W1@CG-&+K!Q"N"6/95@H8D3O2? M=!I.3X(.$Y^>;-7WAS#!+DBP\P2[OTJ,;TH,8?[C,@V*I &"Y$8DA-G=B)#- MQ0E0C7^R&I5R['V[;*)K5]Q3?_%_X'-+/3+5=+U&%VGL\_&77$MIP%J)[JR7 MUG;QNN!0&S?]9.=J?LOSPLAA:5.R_BN*=U!+ P04 " #7>9Y.J;W3+K@! M #2 P &0 'AL+W=OU[A?@CGOOW1U'TAO[ MY&H 3UZT:EQ*:^_; V,NKT$+=V5::/"F-%8+CZ:MF&LMB"*"M&)\M;IF6LB& M9DGTG6R6F,XKV<#)$M=I+>SK$93I4[JF;XY'6=4^.%B6M**"G^!_M2>+%IM8 M"JFA<=(TQ$*9TMOUX;@-\3'@MX3>S=) -P?GYC_Q9KQUK.PL&=47]DX>N4WE!20"DZY1]-?P]C/3M* MQN)_P 44AH=,4",WRL65Y)WS1H\LF(H6+\,NF[CWP\WNRPA;!O 1P"? 3=1A M@U#,_*OP(DNLZ8D=>M^*\,3K \?>Y,$96Q'O,'F'WDO&-[N$70+1&',<8O@L M9CU%,&2?)/B2Q)%_@/-E^&8QPTV$;^;J^T_TMXL$VTBP_:_$ZWSS;89Y.]F)[\K@! M #2 P &0 'AL+W=O"KK5;_P#WM^?&'-E"UJX.]-#AS>UL5IX-&W#7&]!5)&D%>-)\IYI(3M: M9-%WL45F!J]D!Q=+W*"UL+_/H,R8TQU]=3S*IO7!P8JL%PU\!_^COUBTV*)2 M20V=DZ8C%NJ*:F@%H/RCV;\#',][RB9 MB_\*-U (#YE@C-(H%U=2#LX;/:M@*EJ\3+OLXCY.-X=TIFT3^$S@"^$8X[ I M4,S\H_"BR*P9B9UZWXOPQ+L3Q]Z4P1E;$>\P>8?>6\'WQXS=@M",.4\8OL+L M%@1#]24$WPIQYO_1^39]OYGA/M+WZ^B'=%L@W11(HT#Z3XD?WI2X@4F3-T'8 MJJ<:;!.GR9'2#%V9Y.%1[2E[8! M #2 P &0 'AL+W=O=6JLSEMG>N/C-FR!2WL#?;0^9L:C1;.FZ9AMC<@JDC2BO'=[A/30G:T MR*+O;(H,!Z=D!V=#[*"U,'].H'#,:4+?'$^R:5UPL"+K10,_P/WLS\9;;%&I MI(;.2NR(@3JG]\GQE 9\!/R2,-K5F81*+H@OP?A:Y707$@(%I0L*PF]7> "E M@I!/X_>L29>0@;@^OZE_CK7[6B["P@.J9UFY-J=WE%10BT&Y)QR_P%S/+25S M\=_@"LK#0R8^1HG*QI64@W6H9Q6?BA:OTRZ[N(_339K,M&T"GPE\(=S%.&P* M%#-_%$X4F<&1F*GWO0A/G!RY[TT9G+$5\$^TO?KZ(?#MD"Z*9!&@?2?$OF'$K3H'F]"/4 0 MG 0 !D !X;"]W;W)K&UL;51MCYP@$/XKA!]P MN*RZVXV:W%[3M$F;;*[I]3.KXTL.Q *NUW]?0,_:+5^$&9YYGIF1(9ND>M4M M@$%O@O-?#12$]"L'4[S-P.>5XA]\=SUW3&N<@13:P!KZ#^3%!*.E M^*]P V[A+A.K44JN_1>5HS92+"PV%<'>YK7K_3K-)^EA"0L'T"6 K@%'KT-F M(9_Y1V98D2DY(37W?F#N%^].U/:F=$[?"G]FD]?6>RMH'&?DYH@6S'G&T UF MMR*(95\E:$CB3/\+I^'P?3##O0_?;]6/49@@#A+$GB#^I\3DKL00)@V+)$&1 M)$!PN!,)88YAD30HD@8(/MR)!##)?;O(YG8(4(V?"XU*.?9^)C?>=?0>J;]= M?^'SW'YCJNEZC:[2V#OJ;U(MI0&;2O1@"V[M4[$:'&KCM@>[5_/ S(:1P_(6 MD/5!*OX 4$L#!!0 ( -=YGDZ@IS,SL@$ -(# 9 >&PO=V]R:W-H M965T9Y[\3D;T+ZZ%L"3-ZV,RVGK?7=@S)4M:.'N ML ,3_M1HM?#!M0USG051)9)6C&\V'Y@6TM B2[&3+3+LO9(&3I:X7FMA_QQ! MX9#3+;T&GF73^AA@1=:)!GZ _]F=;/#8K%))#<9)-,1"G=/'[>&XC_@$^"5A M< N;Q$[.B*_1^5KE=!,+ @6ECPHB'!=X J6B4"CC]Z1)YY21N+2OZI]3[Z&7 MLW#PA.I%5K[-Z0,E%=2B5_X9AR\P]7-/R=3\-[B "O!82>=23 M2BA%B[?QE":=PZ1_I:T3^$3@-P0V)DJ5?Q)>%)G%@=AQ]IV(5[P]\#";,@;3 M*-*_4+P+T4O![[<9NT2A"7,<,7R!>4>PH#ZGX&LICOP_.E^G[U8KW"7Z;IG] M8;!_3\M\IL6US"W2=ABIAILD[;)D1)[DS9Y$9T7]I&G.WF'C]O^ M7=A&&D?.Z,/-IOG7B!Y"*9N[L$)M>&"SHZ#VT?P8;#NNV>AX[*87Q.9G7/P% M4$L#!!0 ( -=YGDYOD:G5U $ )P$ 9 >&PO=V]R:W-H965TMN-FMQ>T[1)FVRN:?N9U?$E!V(! MU^N_+Z!G[1[W19CAF>>9P1FR2:IGW0(8]")XKW/<&C,<"=%E"X+I.SE ;T]J MJ00SUE0-T8,"5OD@P0F-HI0(UO6XR+SOK(I,CH9W/9P5TJ,03/TY 9=3CG?X MU?'4-:UQ#E)D VO@.Y@?PUE9BZPL52>@UYWLD8(ZQP^[XREU> _XV<&D-WOD M*KE(^>R,+U6.(Y<0<"B-8V!VN<(C<.Z(;!J_%TZ\2KK [?Z5_9.OW=9R81H> M)?_55:;-\0&C"FHVP< != N@:!0&[>]MWLU#\QL&#DL;P%9'Z3B+U!+ P04 " #7>9Y.-8$& MN[XEW/._>"2 M#6B?7 O@R;-6QN6T];X[,N;*%K1P-]B!"3.;S8%I M(0TMLN0[VR+#WBMIX&R)Z[46]O<)% XYW=(7QZ-L6A\=K,@ZT< W\-^[LPT6 MFU4JJ<$XB898J'-ZOSV>]A&? #\D#&YQ)K&2"^)3-#Y7.=W$A$!!Z:.""-L5 M'D"I*!32^#5ITCED)"[/+^H?4^VAEHMP\(#JIZQ\F],[2BJH1:_\(PZ?8*KG MEI*I^"]P!17@,9,0HT3ETDK*WGG4DTI(18OG<9=R(^\?;(0V_*Z$RM2'1>\UX(?MAF[1J$)I$E>>.>!O>?I35[AX[1_%;:1QI$+^O"RJ?\UHH>0RN8F MC% ;/MAL**A]/+X+9SN.V6AX[*8?Q.9O7/P!4$L#!!0 ( -=YGD[,GPN^ M? , $8/ 9 >&PO=V]R:W-H965T[ MVBA+'7!=YF1QDMN+63WV6"QFXBS3).>/A56>LRPN_BUY*JYSF]AO T_)X2BK M 6P]6U4J MST*\5"_?=G/;K1CQE&]EY2)6MPM?\32M/"D>?UNG=A>S,NP_OWG_4B>ODGF. M2[X2Z9]D)X]S.[2M'=_'YU0^B>M7WB9$;:O-_CN_\%3!*R8JQE:D9?UK;<^E M%%GK15')XM?FGN3U_=KZ?S/##: U@,X @DD#KS7PW@W(I('?&OBW&M#6@&H& M3I-[/9GK6,:+62&N5M'LAU-<;3MR3]5R;:O!>G7J_]1\EFKTL@#FSYQ+Y:C% M+!L,]#"D0SC*>Q<"L!!+,,R!T6&(%89A0\P:PP1#S ;#A#A9#YT/KW;@#1Q$ MN ,?=>#7#OR^@\#5)K3!!#4FKS'LSL.#4#0(18(0+4B#B?I!F!OY;G5ILV]" M?0;,&T('M!A*BQFTF*>Q:B"T%XI0%C"$U889K B YT^P"E!6@<'*T[;-,C!8 MZ5-D(D)")ZB$*)4063?0N(0?,R?3!D7"V*J!1N1 M9H+7. D_D3%>F@2K35VSB%F,5\#("<& 6'(3Z>0YFQ?DAA,A2;!#H&"&\)@&IR5 _ M^UO0@! %%R7D&WMCC!!>X7#+QT@+ZA.B+IFJ3\#% $PQ@% _0L'\=/ #;^J( M!%P-P%0#"$?D ' Y@$_( >!R (@[FZ;#_!$7AR0OK6=2]Q=[(2171-T[ MM0F.JJGM7E*^E]5CH)Z+IK-K7J0XM5VKT[7.B_]02P,$% @ UWF>3N64 M- QB P 8 \ !D !X;"]W;W)K&ULE5?;>R]E$'>HL+>1SZ56'/$_*OWIC_V/"]_3 M[:YN+@2SR3[9RA^R_KE_+O59<&)9I[DLJE057BDW4_\+OEV2J EH$;]2>:S. MCKVFE!>E7IN3Y7KJHR8CF^MY:;Y)#5W]7Q29J"F.^9ZK_*-YEI>).)UEBIK&K_ M>ZM#5:O7]L0BZ1.9I-2';VR MZ^E]TE@'W\:ZY5;-Q;;#VGNZ)RI]]6U&(C8)WAHB@[GK,*2'X7W,',*(/F8! M8:(^YA[ ]!$/ ,(2>H2$XC[FR<4P"[($:&)TP@1Z74^+2\#%)2T![1%@F("" M!+0E"'L$UGHL.DS<8HH6@RDR?[!6"&J%@!:UM$)'BPHQHL1 )>8H<6OI[YDC M1 CB85^J>Y 0E(QFQ<&L.%!_:*7%'2TNN,[,3>O!A88\Y&0D+0&F)8"T&$P0 M@031Y4T8@P0QD(%E_V7L5"O8: ]B!(\C!(@)>T9 H,@V[SBHG\S ;,0NA1BB M@"< OF($8'@&8&@(Q/:(!J8 $F/=AN$I@-TQ0.W>O@-!0U7!,P"[0X B,D ! M&Q;S*]86-A>&W&6M[=R >A.&C4]8#%L11_]?W#D(H@,ZL&.Q:UF*K%FV,"!V M5A8C2+!0#+SB8,<2UV?V-)\;3*\[&8VA<7Y_!?8)Q'(T-OL);'7B6ITB9I>! MW9D>QV-B Y\%!!#C Q3P4"#T\MXGL-,)],*W/]E T, ()+#3">3TH1Z#G4ZN M<#J!G4YB>MT3(:>+6QQ KDWMG4Z4/.*^OR0NJ'VN@9G'_'-WO-; M4F[3HO)>5*WW ^U7^T:I6FI*=*-7>:>WNZ>33&[JYE#HX[+;\W4GM=J;_6QP MVE3/_@%02P,$% @ UWF>3OJ0L';* @ CPH !D !X;"]W;W)K&ULC59M;YLP$/XKB!\ ?L- E41:&TV;M$E5IW6?W<1) M4 $SXR3=OY\-%!%\;/T2;.?N>9X[^\Y>795^;4]2FN"M*NMV'9Z,:>[BN-V= M9"7:2#6RMO\%I^)X,FXAWJP:<90_I/G9/&H[BT>4?5')NBU4'6AY M6(>?\-T6Y\ZALW@NY+6=C ,7RHM2KV[R=;\.D5,D2[DS#D+8ST4^R+)T2%;' M[P$T'#F=XW3\COZY"]X&\R):^:#*7\7>G-9A%@9[>1#GTCRIZQ]#OCO;K #&1S(Z(#9/QWH MX$ _ZL &!S9SB/M0NMQLA1&;E5;70/?;VPAWBO =L]G?N<4NV=U_-CVM7;UL M*$:K^.* !IO[WH9,;,BMQ8-OD>2W)EL )$M'F]B*')424"GI .B-4@P#4!" M=@!L L!G(N][$]Z9U+U(@GC$9N%"9B2-%L)AH!KFJ:&(P )")!\/!\IMT0H,SM$23@329O[MSELQCH6D><9@E M!UER()C9Z=CF?C",1PM[BQ%8KF3+U-,F'B9&DCX*:!_:Y!<3+GH?[) M8@@O[@7<$3 #*GKA=&*X)^#$3XJ7_L03FU"VJ!7N'1AJ'AX3]Y@XCY(%(KA[ M8+]]9%[Z_?9!EML'AOL']AL(Q5[)^2TDR_!B;<,]!$--Q+LN<_^.20B*YAT^ MGEST[JGV7>AC4;?!BS+VS=#=[ >EC+28*+([?[*OPW%2RH-QP]2.=?]$ZB=& M-&PO=V]R M:W-H965T'Y0=IR[CGW'GK39JV0;ZI@3'OO%:_5QB^T;M9! MH X%JZA:B(;5YLU)R(IJ,Y7G0#62T:,+JGA $(J#BI:UGV=N;2?S3%PT+VNV MDYZZ5!65_[:,BW;C8_^V\%J>"VT7@CQKZ)G]9/I7LY-F%@PLQ[)BM2I%[4EV MVOB?\'I+D UPB-\E:]5H[-E2]D*\V5_;".+=,)H^_ M/:D_:-K \?C&_L45;XK94\5>!/]3'G6Q\1/?.[(3O7#]*MJOK"]HZ7M]]=_9 ME7$#MYD8C8/@ROU[AXO2HNI93"H5?>^>9>V>;<]_"X,#2!] A@ 2NUHZ(9?Y M9ZIIGDG1>K(SOZ'V&^,U,=X<[**SPKTSR2NS>LU#@K+@:HEZS+;#D#L,'C"! MX1]$""A"'$$X(B#I!$$($H2.(+K+@#QDV6%2AZD=)AYA[D0B4"0"1,('$0"# M0EAD"8HL 9$()HA!@GB^ERN08#7#RPX3C[R,4+R(89D$E$EFN EAEK!("HJD M ,%$EAC!^Q_-]Q-/M!">X6@/&EN*,5I,?'H,]Q$F,TP%0:L)';C=,-1OR00% MW$PX^H"O<*M@J%>>?%T^^9HL0C3^3:G"_87C.1Y#H'1"!VY##/1AB"8HX!;# MR0<\AAL(0QWTY''ZY'$:+R:V%('[C* 9MD*@\+&@8'2TV:O##RK/9:V\O=#F ME'1GV4D(S0PA6IC=49C;RC#A[*3M<&7&LCNRNXD637\="88[4?X?4$L#!!0 M ( -=YGDXO8GU$BP( .8) 9 >&PO=V]R:W-H965T@ 4]L)U[^O,0XE M8:E\+\$VLS.[=@9OTC+^*G)*I?-6E;78NKF4S<;S1);3BH@%:VBMWIP8KXA4 M4W[V1,,I.>J@JO2P[T=>18K:31.]]LS3A%UD6=3TF3OB4E6$_]G3DK5;%[FW MA9?BG,MNP4N3AISI=RI_-,]N\F7X];UNXQH23/941#UN-(G6I8=D\KCMR%U!\TN<#R^L7_2Q:MB M#D30)U;^*HXRW[HKUSG2$[F4\H6UGZDI*'0=4_U7>J6E@G>9*(V,E4+_.ME% M2%89%I5*1=[Z9U'K9VOX;V%P #8!> CH-\?KA73F'XDD:<)9Z_!^\QO2G3': M8+4W6;>HMT*_4\D+M7I-@P GWK4C,IA]C\$C#!H0GF(?)# DL<>3\" (8(( MS#'0!,$=P1(F6(($2TVPO",('XKL,9'&U!J#,8X7,:P3@CHAH!,]Z/28>*3S M :/%S'Y$H$P$R,0/,M%$!F,_6LQL6PSJQ(#."B98@00K^X-;@P1KBX-;3RN- MEW/GAGS8!;[%R1E0.%+R9U1FO(8L#LZ ;.L!+;=#&%!:SU# ID/O83X$ MNP_9V ]-_8?"R)_[PV+8@-C&@ 9D^>W$L FQC0D-*+HK*EA//I_>Z)JM*#_K M!D,X&;O4NKL9K0Y-S [K:_H?O.^ OA%^+FKA')A4E[V^DD^,2:K2\1?J/YNK MIFN8E/0DNV&LQKSO//J)9(WIJKRAM4O_ E!+ P04 " #7>9Y. [JV62T" M !B!@ &0 'AL+W=OMNFS 4?A7$ M \3F8@@106HZ59NT25&G=;\=BW=9 M 2COLV&MW/J54MT&(5E6T%"YXAVT^LZ)BX8JO15G)#L!]&A)#4,AQ@EJ:-WZ M16YK>U'D_*)8W<)>>/+2-%3\V0'C_=8/_%OAM3Y7RA10D7?T##]!_>KV0N_0 MI'*L&VAES5M/P&GK/P6;76 )%O%60R]G:\^T-W.@$IXY^UT?5;7UU[YWA!.],/7*^Z\P M-D1\;^S^.UR!:;A)HCU*SJ3]]SJ\U-5K$<4X1U,_@,@L99RM M,QQEZ0.S!Z]:X#!+EV;!G1G!<9RD9&F&9J]X ^)LAYOT2GYI[62=5:9Y.:9V.," " "(!@ &0 'AL+W=OZ&D$[G?2-EO$!)E Q2+ M!]9#IW8JQBF6:LEK)'H.^&1(E* H"!:(XK;SB\S$#KS(V%F2MH,#]\294LS_ M;(&P(?=#_S7PU-:-U %49#VNX3O('_V!JQ6:5$XMA4ZTK/,X5+G_&&[V8: ) M!O&SA4%X1X),1OA.1=0C(2DID# MLJ68L]ECB8N,L\'C]N_ML;Y%X291IU_JH#ELLZ>.1ZCHI8B3588N6FC$;"TF MNL&L;S'[>TPX(9#*8$HCXMTN#68N?"A+,T[C&1.XW8>1JQH<$KI4&PO=V]R:W-H965T<'V^,R9.8,]SCHAGU4% MH+T7SAJU]2NMVPTAJJB 4_4@6FC,SEE(3K59RI*H5@(].2?.2!0$*>&T;OP\ M<[:#S#-QT:QNX" ]=>&192TOX ?IG>Y!F14:6 M4\VA4;5H/ GGK?\8;O:AFGT3W!09! MB>\-ZK_!%9B!VTQ,C$(PY;Y><5%:\('%I,+I2S_6C1N[?F=Y<\,=HL$A&AU, M[/\YQ(-#_.JP<.+[S)S43U33/).B\V3_MUIJ#T6XB4TQ"VMTM7-[1JTRUFL> M)ZN,7"W1@-GUF&B""4<$,>QCB @+L8O>N4=O ^P1Q!*/$*,B8N>_>"-BC1,L M4(*%(XBG!&F $R0H0?(^@S2(14%I;/?CH+F5X!,[C0'6;KV MI[Q"7!IM;\_$.K;8Q\CVA)E]9UNOZQ6O-'W?_DYE63?*.PIM.H[K"V&PO=V]R:W-H965T#C5=^N7ICG?;#;UPXL_%G52GOVI_>6IK(Y% MTWZMGC?UN?+%8U_H>-C(-+6;8[$_K>]O^VN?JOO;\K4Y[$_^4[6J7X_'HOIW MZP_E^]U:K+]?^+Q_?FFZ"YO[VW/Q[/_PS9_G3U7[;7.IY7%_]*=Z7YY6E7^Z M6W\4-SN7=P5ZQ5][_UY?_;_JFO*E++]V7WY]O%NGG2-_\ ]-5T71?KSYG3\< MNII:'_^,E:XO]^P*7O__O?:?^\:WC?E2U'Y7'O[>/S8O=^MLO7KT3\7KH?E< MOO_BQP:9]6IL_6_^S1]:>>>DO<=#>:C[OZN'U[HICV,MK95C\6WXW)_ZS_?A M%_>]&"X@QP+R4J"]=ZR &@NH'P5TW_C!6=_4GXJFN+^MRO=5-8S6N>@FA;A1 M;6<^=!?[ONM_:UM;MU??[I7-;C=O746C9CMHY)5&7!2;MO;++22ZQ5:RXG)Z M@QU0.'P'!1NA^O+JNA%&X@HTK$#W%>AK SGIA$%B>\FIEUB;YHDF3>$R;:5- M%'9CH!O#W*B4N!DD[NHV0IB$#-QN4)DK58I]6.C#RQ/ M88&1)-3\0SQJYI[B4;9@R@I,-\'QIAPSHWGW.&D2RFJ@BW8/1IP C*-L$1QR M$"Z"8RY,%X%1)P#K*%\$AQT"C."P"PT71IT K*.,$3&,C3XX#\.4$9AV N". M90><9FB0@$HF@3Q"8.@)0#U'L2?24&'Z2 MPX]%3\FI1@,GD 3 )S'X) ?#5,297D\9LK%:9[$Y),HT6-F.-1$^YPP,[&, M<&H&@T\"\+%IRWDF66XC>5(8<*(P[Q3@'8V3BI,,Q4G%J1CR@F&G .QHG%0< M=A2\4'18U9ISGK^*X0 M9YW63B6$B3N@DUD:G#T:$T\#XM&8I.>)%Y5,?6#B:93:,2-@'0V[ANNB78/A MIP'\Z"36G'TZE9*M58!.:JE#SY4.["D" M)0J6-L&\TLQI_&^-, ?S1,ZMA. MX>B#TT_GH56_QO33@'XT4FH.-;"<1*K@:3HWF^[Y<)TUZ MG9A.+6'P:00^&C4USSIU&XCH @7(5*J#?80QJA=L-.I84CEZ69QW&LQB@];9 M-&Z:6$8Y[H@O3CH-1K!!22<%C>'+9S1"0!89(8-9;!"+ [L&!K/3_(_W)P;# MSBQX@V)XMMC95F_KU*5#+U@7%GT XC]3&/ M.P/6XBZTLV@Q\2P@'HV5=AYX41<"C(<""_4(T6Y!.*1W:Y;08>18A MCT9)"]+*7+,U%)))$0K;%@/4@N23=5%L13UZ6;SHMIC"%BVZ:92T\SEG5#(U M@N%K4<[)WAWSC!*.$)!%1BCP*AM1.%0%IJ9URZ.DQ9BS'',L2EJ>MLDL8[MG M2&:"BR:+<6C1Z>LX MRZ3)V,( R50:BM@.$\\!XK'C#_-;C%')U <&G4-;C-3'/.@<6(B'PJ/#J', M=30\NGG21253'YAT#I&.LM\!A*&I F3*A%(IATGG$.EH<'1@^9QR/UPE=0B\ M+G!N!^2:K'OF7V9')5,?&+T.K:QI:'3S*694,C6"F>M0BLG8,HCLS/AP%1B? MS=51P*.OGOM3D_7JH7P]-=VANZNKEY.9'V5WE)!7^J5U_*IBF/_7'"I[)L?&NR)=UZ]>*+Q\N7@W]JNG^[V5X-QRR'+TUY'H^0 M;B[G6.__ U!+ P04 " #7>9Y.$G*O7*0" "]" &0 'AL+W=O>YL[EA:-*T422 M'Y;Q [S?0FP='.*YY%^X55E(QD= M?_J@\GY9Q'D=[?F#G2C^)ZU?>)T3CJ,_^ M.[_PRL"M$L.Q$Y5RO]'NK+2H^RA&2LW>NF?9N.>UCW]S"SN@W@$-#H;[?PZX M=\"?=2"] WEW(*Y:72JN-ENFV6HAQ362W?&VS-XB>$],]7?6Z(KM_C/E4<9Z M6>&L6"07&ZC'K#L,&F.(A]E,,7! )$;!( .%9*S1Q!WEN4<1P'Q$; .(+*P" M!XN!G3\>)YJ#< 2#$!< #(64&"OFATF=9BFK_C=C$P:9*$3%IQ#CZ7#%",6 ME-(P21HD20.I>/5>IQ,2B,%,P;(@2Q9(Q6/9=!@Z8J$ D"!=P>W4R A*:#Y M2/<'27E04AZ0Y)WA)I\P901F!?4$36&T C/G$,1E%,$Y!!/3A&H4$X0!AYP M.P42"HL4SKTF$(2;!@B(HGY' !.R-#/WPY,4@*$LP\7,-8(S;0Q.%8&98X?! M%O0 T>???ACN'Q '5!"_F^+I:2&04>*?03+JX3671SR#C/X M =D9X-DW=C:[V? >IAOL/Y@\EHV*7H0V$\;-@8,0FAN=X,XH/)EOB6%3\8.V MR\RL93=0NXT6;?^QD Q?+*M_4$L#!!0 ( -=YGD[OY80Y%@4 /\< 9 M >&PO=V]R:W-H965T^>'.IZN_- M0>LV^%$6I^8N/+3M^3:*FMU!EWFSJL[Z9/YYJ>HR;\UM_1HUYUKG^[Y0640\ MCI.HS(^G<+OIGSW5VTWUUA;'DWZJ@^:M+//ZWP==5)>[D(4?#[X=7P]M]R#: M;L[YJ_Y#MW^>GVIS%UUKV1]+?6J.U2FH],]N'U76%>@1?QWUI1E=!UU7 MGJOJ>W?SZ_XNC#M&NM"[MJLB-S_O^E$715>3X?&/K32\MMD5'%]_U/ZU[[SI MS'/>Z,>J^/NX;P]WX3H,]OHE?RO:;]7E%VT[I,+ ]OXW_:X+ ^^8F#9V5='T MW\'NK6FKTM9BJ)3YC^'W>.I_+[;^CV*X +<%^+6 :7NI@+ %Q,\"LN_\P*SO MZI>\S;>;NKH$]3!;Y[P3!;L59C!WW<-^[/K_3&\;\_1]*];))GKO*K*8AP'# M1QAV142F]FL3'#7QP$EQ/FW@D2)4AEL0L!.B+R\FG4AQ!1)6(/L*Y*2"]6P4 M!DS68T[#**39#/0X@)(Q*%%RY1@O!#"9EQ2VN%U/.[SP ; $CDF/:&SAG36 M5'$9QQ5DL(+,0W$9(8A%0OR:04:R3WC M'B*P(-]1PX;"J*.P>.VH EL*\_$4"YJ0C;EPLL6&P7P<@RU;QK0=[ ?,QQ 8 M#79G;#$ W5,'41 M!F:)HE+7XB2PTPB4YA !9PM;!$ME"3+-[['!2&0P<_%*NG4"XL4HQ[A(;%82 MY4MS\4JZ=6+S@0$8UXL/['D2;:]<56"7DI]Y_>)X_^+U @8D2R(E"S:"2>Z< M(.PNTB>ELJ EX2Y"ID2PJTB?G$O2#1,AL@29$L'>)'V2,@F2,C1% +8P1=CI M)-I5.7)TB>U)?B)U4]A8E$_JIJAE9"NSPHP_\Y=WM(A)#1Q+I,(NHWRR.+64 MH%DNWCF]3:%_E MFFC'&^-/)' *^XSR2> 4-9%DGO KFN2EW)4P*>PURB=[LZ!%X2Y!ID2PQRB? MS,V"%HF M,VM6FQ6RB=KLZ!L<88&3#*=(1F//G-FT>@XJ=3U:W_RU@2[ZNW4 M=J='HZ?7T[U[WA]'_80/1X._Y_7K\=0$SU7;5F5_]/125:TVS$Q>'08'G>^O M-X5^:;O+U%S7PY'<<--69WO<&%W//+?_ 5!+ P04 " #7>9Y.45V3#K0" M !9"@ &0 'AL+W=O'5G M_+6]4"J[Y9L:LHBYKNN=->JXKPOUM:LOO:!?=]XZDX7X3:\#>KAISI M3RI^-7LN5W[OY5A4M&X+5CN_M8.ZH5%X8>U6+;\>U M&ZB(:$D/0KD@C?]W,]P@- 9A;P#QAP:1,8@L [^+3*?ZF0BR67%V=WAW6@U1HH!E)#_F M06WJ;Z??R6Q;N7O;Q$&P\F_*D<%L.TPXP(1CQ&Z*2!8]Q)XPXBU$&D'<2C-,!*H\.D&E-K3)XOO!2GB5&:&*&QOL6VPV0#FB2#.9H$ MI4D0FLBB228T$&=>A-.D*$V*T,0633JEB3S 63*4)4-8$HNEPR1#EFR16R++ M)N<':1+/!9.CP>238""P>+;YQ\&,6!8HRV(BYSB8$0 $>%D&#PC:@#)+T=D, MTTP#@ .,.$%SF$#\C:@,:Z7LP=,N#= +!V8"O;@$9,H3?3M@#O M!X U!%O<,.T(D ?@@=U$8T3@<317TX#W#I@VCZG$ >D>XY#&5'C_ *R!S*D/ M;PZ0/=[Y 2]IF-8T<@;Y-.$L]>(9)KRLX3_J.L3K.L3JV@[6@%(K6+O:_,$_ M7EVZ?A!^+NK6>6%"7A?T3_W$F*#29>#) [_(>UZ_*.E)J&DFY[R[['0+P1IS MD?/[V^3F'U!+ P04 " #7>9Y. ^*+I0D" !W!0 &0 'AL+W=O RX-B1(4>%Z,*&X[-TM,[,2SA%TD:3LX<4=<*,7\ M7PZ$#:GKNQ^!E[9NI Z@+.EQ#;] _NY/7*W0I%*V%#K1LL[A4*7NLW\XQAIO M *\M#&(V=W0E9\;>].)[F;J>-@0$"JD5L!JN< 1"M)"R\7?4=*>4FCB??ZA_ M-;6K6LY8P)&1/VTIF]3=NTX)%;X0^<*&;S#6LW.=L?@?< 6BX-J)RE$P(LS; M*2Y",CJJ*"L4O]NQ[?L$7;70B,DM)IAA_ F!E/J4 M(MA*D0-S.$&X6$1I^.#<8[[<%HDV!R A$BU-X6IV"Q3P93&\$2N/"TV_2TN_7DKS+E%K.;95I[N8=8F(@W3<0;)OR5B?BF MW+6)>PAK LWN*P5>FU];. 6[=%+?C%ETZA[/@;[OJWBNNHIM I\RMB7]Q+QN M.^&X%=2-:/;0Y-O3;[#U!+ M P04 " #7>9Y.\B/-L@$# "4#0 &0 'AL+W=O.O3FIW<\K M?OLC^U=5O"AF3QJZ8_F?[,@O:SNQK2,]D6O.7]C]&]4%A;:EJ_]!;S07<,E$ MS'%@>:-^K<.UX:S06025@KRWSZQ4S[O._Q$&!V =@+L %,P&^#K 'P6X+3-5 MZA?"R695L[M5MZM5$2D*].2+EWF0@^K=J?]$M8T8O6T"A%?N32;2F&V+P3W, M"+$S$6':05Q!H&.!0198Q?L#%CZ

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

G/,Y_0Z4AQWN,CSN M6S $%-^%FX\2E*VL0@0ML;&L-IS><"RRGHDJX(QRL=A*XF<188+AWH<]K+EH]LUT:.+U^3I;R:' 9Q/;.?C5W\8=8-/AP48BA;<' M:G^[S8:,9.M7P^D\,I_ <;YQ%'CR7)!D&R65LVUPH?V;80O(L:ADPDM<)+!UCI D M:^'G?XP+5CX?\$1ZZB='%LB-VXH7&K3#/4&,4[RL\VCV*3S@9 !]P^/D& MJ2E#Q*,41"Q.24C!([P3&OZ.U6E%Y\(

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�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end XML 78 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 258 296 1 false 66 0 false 12 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.wellcare.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 2 false false R3.htm 1002000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 1002501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.wellcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101100 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPolicies ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 2102100 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS Sheet http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitions CENTENE PLAN OF MERGER AND ACQUISITIONS Notes 8 false false R9.htm 2103100 - Disclosure - SEGMENT REPORTING Sheet http://www.wellcare.com/role/SegmentReporting SEGMENT REPORTING Notes 9 false false R10.htm 2104100 - Disclosure - EQUITY AND EARNINGS PER SHARE Sheet http://www.wellcare.com/role/EquityAndEarningsPerShare EQUITY AND EARNINGS PER SHARE Notes 10 false false R11.htm 2105100 - Disclosure - INVESTMENTS Sheet http://www.wellcare.com/role/Investments INVESTMENTS Notes 11 false false R12.htm 2106100 - Disclosure - RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS Sheet http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestments RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS Notes 12 false false R13.htm 2107100 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.wellcare.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 13 false false R14.htm 2108100 - Disclosure - DEBT Sheet http://www.wellcare.com/role/Debt DEBT Notes 14 false false R15.htm 2109100 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.wellcare.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 15 false false R16.htm 2110100 - Disclosure - MEDICAL BENEFITS PAYABLE Sheet http://www.wellcare.com/role/MedicalBenefitsPayable MEDICAL BENEFITS PAYABLE Notes 16 false false R17.htm 2111100 - Disclosure - LEASES Sheet http://www.wellcare.com/role/Leases LEASES Notes 17 false false R18.htm 2112100 - Disclosure - INCOME TAXES Sheet http://www.wellcare.com/role/IncomeTaxes INCOME TAXES Notes 18 false false R19.htm 2113100 - Disclosure - DISCONTINUED OPERATIONS Sheet http://www.wellcare.com/role/DiscontinuedOperations DISCONTINUED OPERATIONS Notes 19 false false R20.htm 2114100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.wellcare.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 2201201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesPolicies ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 21 false false R22.htm 2302301 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS (Tables) Sheet http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsTables CENTENE PLAN OF MERGER AND ACQUISITIONS (Tables) Tables http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitions 22 false false R23.htm 2303301 - Disclosure - SEGMENT REPORTING (Tables) Sheet http://www.wellcare.com/role/SegmentReportingTables SEGMENT REPORTING (Tables) Tables http://www.wellcare.com/role/SegmentReporting 23 false false R24.htm 2304301 - Disclosure - EQUITY AND EARNINGS PER SHARE (Tables) Sheet http://www.wellcare.com/role/EquityAndEarningsPerShareTables EQUITY AND EARNINGS PER SHARE (Tables) Tables http://www.wellcare.com/role/EquityAndEarningsPerShare 24 false false R25.htm 2305301 - Disclosure - INVESTMENTS (Tables) Sheet http://www.wellcare.com/role/InvestmentsTables INVESTMENTS (Tables) Tables http://www.wellcare.com/role/Investments 25 false false R26.htm 2306301 - Disclosure - RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables) Sheet http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsTables RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables) Tables http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestments 26 false false R27.htm 2307301 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.wellcare.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.wellcare.com/role/StockBasedCompensation 27 false false R28.htm 2308301 - Disclosure - DEBT (Tables) Sheet http://www.wellcare.com/role/DebtTables DEBT (Tables) Tables http://www.wellcare.com/role/Debt 28 false false R29.htm 2309301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.wellcare.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.wellcare.com/role/FairValueMeasurements 29 false false R30.htm 2310301 - Disclosure - MEDICAL BENEFITS PAYABLE (Tables) Sheet http://www.wellcare.com/role/MedicalBenefitsPayableTables MEDICAL BENEFITS PAYABLE (Tables) Tables http://www.wellcare.com/role/MedicalBenefitsPayable 30 false false R31.htm 2311301 - Disclosure - LEASES (Tables) Sheet http://www.wellcare.com/role/LeasesTables LEASES (Tables) Tables http://www.wellcare.com/role/Leases 31 false false R32.htm 2313301 - Disclosure - DISCONTINUED OPERATIONS (Tables) Sheet http://www.wellcare.com/role/DiscontinuedOperationsTables DISCONTINUED OPERATIONS (Tables) Tables http://www.wellcare.com/role/DiscontinuedOperations 32 false false R33.htm 2401402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesPolicies 33 false false R34.htm 2402402 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Narrative (Details) Sheet http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails CENTENE PLAN OF MERGER AND ACQUISITIONS - Narrative (Details) Details 34 false false R35.htm 2402403 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) Sheet http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails CENTENE PLAN OF MERGER AND ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) Details 35 false false R36.htm 2402404 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Identifiable Intangible Assets Acquired (Details) Sheet http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails CENTENE PLAN OF MERGER AND ACQUISITIONS - Identifiable Intangible Assets Acquired (Details) Details 36 false false R37.htm 2402405 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Goodwill Acquired (Details) Sheet http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails CENTENE PLAN OF MERGER AND ACQUISITIONS - Goodwill Acquired (Details) Details 37 false false R38.htm 2402406 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Pro Forma Financial Information (Details) Sheet http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsProFormaFinancialInformationDetails CENTENE PLAN OF MERGER AND ACQUISITIONS - Pro Forma Financial Information (Details) Details 38 false false R39.htm 2403402 - Disclosure - SEGMENT REPORTING - Narrative (Details) Sheet http://www.wellcare.com/role/SegmentReportingNarrativeDetails SEGMENT REPORTING - Narrative (Details) Details 39 false false R40.htm 2403403 - Disclosure - SEGMENT REPORTING - Revenue by Geographic Location (Details) Sheet http://www.wellcare.com/role/SegmentReportingRevenueByGeographicLocationDetails SEGMENT REPORTING - Revenue by Geographic Location (Details) Details 40 false false R41.htm 2403404 - Disclosure - SEGMENT REPORTING - Segment Results (Details) Sheet http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails SEGMENT REPORTING - Segment Results (Details) Details 41 false false R42.htm 2404402 - Disclosure - EQUITY AND EARNINGS PER SHARE- Calculation of Weighted-Average Common Shares Outstanding (Details) Sheet http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails EQUITY AND EARNINGS PER SHARE- Calculation of Weighted-Average Common Shares Outstanding (Details) Details 42 false false R43.htm 2405402 - Disclosure - INVESTMENTS - Short-term and Long-term Investments by Security Type (Details) Sheet http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails INVESTMENTS - Short-term and Long-term Investments by Security Type (Details) Details 43 false false R44.htm 2405403 - Disclosure - INVESTMENTS - Contractual Maturities of Available-for-sale Securities (Details) Sheet http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails INVESTMENTS - Contractual Maturities of Available-for-sale Securities (Details) Details 44 false false R45.htm 2405404 - Disclosure - INVESTMENTS - Narrative (Details) Sheet http://www.wellcare.com/role/InvestmentsNarrativeDetails INVESTMENTS - Narrative (Details) Details 45 false false R46.htm 2406402 - Disclosure - RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS - Schedule of Restricted Investments (Details) Sheet http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS - Schedule of Restricted Investments (Details) Details 46 false false R47.htm 2406403 - Disclosure - RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS - Narrative (Details) Sheet http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsNarrativeDetails RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS - Narrative (Details) Details http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsTables 47 false false R48.htm 2407402 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.wellcare.com/role/StockBasedCompensationNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 48 false false R49.htm 2407403 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Unit Award Activity (Details) Sheet http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails STOCK-BASED COMPENSATION - Summary of Stock Unit Award Activity (Details) Details 49 false false R50.htm 2408402 - Disclosure - DEBT - Schedule of Outstanding Debt Obligations (Details) Sheet http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails DEBT - Schedule of Outstanding Debt Obligations (Details) Details 50 false false R51.htm 2408404 - Disclosure - DEBT - Narrative (Details) Sheet http://www.wellcare.com/role/DebtNarrativeDetails DEBT - Narrative (Details) Details 51 false false R52.htm 2409402 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details) Details 52 false false R53.htm 2409403 - Disclosure - FAIR VALUE MEASUREMENTS - Carrying Value and Fair Value of Long-term Debt (Details) Sheet http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails FAIR VALUE MEASUREMENTS - Carrying Value and Fair Value of Long-term Debt (Details) Details 53 false false R54.htm 2410402 - Disclosure - MEDICAL BENEFITS PAYABLE - Reconciliation of Beginning and Ending Balances, by Segment (Details) Sheet http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails MEDICAL BENEFITS PAYABLE - Reconciliation of Beginning and Ending Balances, by Segment (Details) Details 54 false false R55.htm 2410403 - Disclosure - MEDICAL BENEFITS PAYABLE - Narrative (Details) Sheet http://www.wellcare.com/role/MedicalBenefitsPayableNarrativeDetails MEDICAL BENEFITS PAYABLE - Narrative (Details) Details 55 false false R56.htm 2411402 - Disclosure - LEASES (Details) Sheet http://www.wellcare.com/role/LeasesDetails LEASES (Details) Details http://www.wellcare.com/role/LeasesTables 56 false false R57.htm 2411403 - Disclosure - LEASES - Balance Sheet items related to operating leases (Details) Sheet http://www.wellcare.com/role/LeasesBalanceSheetItemsRelatedToOperatingLeasesDetails LEASES - Balance Sheet items related to operating leases (Details) Details 57 false false R58.htm 2411404 - Disclosure - LEASES - Maturity of Operating Lease Liabilities (Details) Sheet http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails LEASES - Maturity of Operating Lease Liabilities (Details) Details 58 false false R59.htm 2411405 - Disclosure - LEASES - Supplemental cash flow information related to leases (Details) Sheet http://www.wellcare.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetails LEASES - Supplemental cash flow information related to leases (Details) Details 59 false false R60.htm 2412401 - Disclosure - INCOME TAXES (Details) Sheet http://www.wellcare.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://www.wellcare.com/role/IncomeTaxes 60 false false R61.htm 2413402 - Disclosure - DISCONTINUED OPERATIONS (Details) Sheet http://www.wellcare.com/role/DiscontinuedOperationsDetails DISCONTINUED OPERATIONS (Details) Details http://www.wellcare.com/role/DiscontinuedOperationsTables 61 false false R62.htm 2414401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.wellcare.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.wellcare.com/role/CommitmentsAndContingencies 62 false false All Reports Book All Reports wcg-201903311910q.htm ex1014302019.htm ex10243019.htm ex10343019.htm wcg-20190331.xsd wcg-20190331_cal.xml wcg-20190331_def.xml wcg-20190331_lab.xml wcg-20190331_pre.xml wcg-ex311_20190331.htm wcg-ex312_20190331.htm wcg-ex321_20190331.htm wcg-ex322_20190331.htm http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "wcg-201903311910q.htm": { "axisCustom": 1, "axisStandard": 28, "contextCount": 258, "dts": { "calculationLink": { "local": [ "wcg-20190331_cal.xml" ] }, "definitionLink": { "local": [ "wcg-20190331_def.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml" ] }, "inline": { "local": [ "wcg-201903311910q.htm" ] }, "labelLink": { "local": [ "wcg-20190331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "wcg-20190331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml" ] }, "schema": { "local": [ "wcg-20190331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" ] } }, "elementCount": 504, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 24, "http://www.wellcare.com/20190331": 5, "http://xbrl.sec.gov/dei/2018-01-31": 8, "total": 37 }, "keyCustom": 54, "keyStandard": 242, "memberCustom": 22, "memberStandard": 41, "nsprefix": "wcg", "nsuri": "http://www.wellcare.com/20190331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://www.wellcare.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - EQUITY AND EARNINGS PER SHARE", "role": "http://www.wellcare.com/role/EquityAndEarningsPerShare", "shortName": "EQUITY AND EARNINGS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - INVESTMENTS", "role": "http://www.wellcare.com/role/Investments", "shortName": "INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestrictedAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS", "role": "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestments", "shortName": "RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestrictedAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.wellcare.com/role/StockBasedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - DEBT", "role": "http://www.wellcare.com/role/Debt", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.wellcare.com/role/FairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "wcg:MedicalBenefitsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - MEDICAL BENEFITS PAYABLE", "role": "http://www.wellcare.com/role/MedicalBenefitsPayable", "shortName": "MEDICAL BENEFITS PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "wcg:MedicalBenefitsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - LEASES", "role": "http://www.wellcare.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - INCOME TAXES", "role": "http://www.wellcare.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - DISCONTINUED OPERATIONS", "role": "http://www.wellcare.com/role/DiscontinuedOperations", "shortName": "DISCONTINUED OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "role": "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.wellcare.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesPolicies", "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS (Tables)", "role": "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsTables", "shortName": "CENTENE PLAN OF MERGER AND ACQUISITIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - SEGMENT REPORTING (Tables)", "role": "http://www.wellcare.com/role/SegmentReportingTables", "shortName": "SEGMENT REPORTING (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - EQUITY AND EARNINGS PER SHARE (Tables)", "role": "http://www.wellcare.com/role/EquityAndEarningsPerShareTables", "shortName": "EQUITY AND EARNINGS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - INVESTMENTS (Tables)", "role": "http://www.wellcare.com/role/InvestmentsTables", "shortName": "INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "wcg:ScheduleOfRestrictedInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables)", "role": "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsTables", "shortName": "RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "wcg:ScheduleOfRestrictedInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.wellcare.com/role/StockBasedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - DEBT (Tables)", "role": "http://www.wellcare.com/role/DebtTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.wellcare.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "wcg:ReconciliationOfMedicalBenefitsPayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - MEDICAL BENEFITS PAYABLE (Tables)", "role": "http://www.wellcare.com/role/MedicalBenefitsPayableTables", "shortName": "MEDICAL BENEFITS PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "wcg:ReconciliationOfMedicalBenefitsPayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "wcg:AssetsAndLiabilitiesLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - LEASES (Tables)", "role": "http://www.wellcare.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "wcg:AssetsAndLiabilitiesLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - DISCONTINUED OPERATIONS (Tables)", "role": "http://www.wellcare.com/role/DiscontinuedOperationsTables", "shortName": "DISCONTINUED OPERATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "wcg:Membership", "reportCount": 1, "unique": true, "unitRef": "member", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails", "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "wcg:Membership", "reportCount": 1, "unique": true, "unitRef": "member", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "D2018Q3August", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Narrative (Details)", "role": "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "shortName": "CENTENE PLAN OF MERGER AND ACQUISITIONS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "D2018Q4November30_us-gaap_BusinessAcquisitionAxis_wcg_AetnaPartDBusinessMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "shortName": "CENTENE PLAN OF MERGER AND ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "I2018Q3September1_us-gaap_BusinessAcquisitionAxis_wcg_MeridianMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "D2018Q3September1_us-gaap_BusinessAcquisitionAxis_wcg_MeridianMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Identifiable Intangible Assets Acquired (Details)", "role": "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails", "shortName": "CENTENE PLAN OF MERGER AND ACQUISITIONS - Identifiable Intangible Assets Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "D2018Q3September1_us-gaap_BusinessAcquisitionAxis_wcg_MeridianMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Goodwill Acquired (Details)", "role": "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails", "shortName": "CENTENE PLAN OF MERGER AND ACQUISITIONS - Goodwill Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2018Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402406 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS - Pro Forma Financial Information (Details)", "role": "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsProFormaFinancialInformationDetails", "shortName": "CENTENE PLAN OF MERGER AND ACQUISITIONS - Pro Forma Financial Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2018Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - SEGMENT REPORTING - Narrative (Details)", "role": "http://www.wellcare.com/role/SegmentReportingNarrativeDetails", "shortName": "SEGMENT REPORTING - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R4": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1QTD_srt_StatementGeographicalAxis_stpr_FL", "decimals": "2", "first": true, "lang": null, "name": "wcg:PremiumRevenueNetOfPremiumTax", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - SEGMENT REPORTING - Revenue by Geographic Location (Details)", "role": "http://www.wellcare.com/role/SegmentReportingRevenueByGeographicLocationDetails", "shortName": "SEGMENT REPORTING - Revenue by Geographic Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1QTD_srt_StatementGeographicalAxis_stpr_FL", "decimals": "2", "first": true, "lang": null, "name": "wcg:PremiumRevenueNetOfPremiumTax", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - SEGMENT REPORTING - Segment Results (Details)", "role": "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails", "shortName": "SEGMENT REPORTING - Segment Results (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-5", "lang": null, "name": "us-gaap:PremiumsEarnedNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "D2018Q3August", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - EQUITY AND EARNINGS PER SHARE- Calculation of Weighted-Average Common Shares Outstanding (Details)", "role": "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails", "shortName": "EQUITY AND EARNINGS PER SHARE- Calculation of Weighted-Average Common Shares Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "I2018Q3August", "decimals": "2", "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - INVESTMENTS - Short-term and Long-term Investments by Security Type (Details)", "role": "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails", "shortName": "INVESTMENTS - Short-term and Long-term Investments by Security Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - INVESTMENTS - Contractual Maturities of Available-for-sale Securities (Details)", "role": "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails", "shortName": "INVESTMENTS - Contractual Maturities of Available-for-sale Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - INVESTMENTS - Narrative (Details)", "role": "http://www.wellcare.com/role/InvestmentsNarrativeDetails", "shortName": "INVESTMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "wcg:RestrictedInvestmentsAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS - Schedule of Restricted Investments (Details)", "role": "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails", "shortName": "RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS - Schedule of Restricted Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "wcg:RestrictedInvestmentsAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS - Narrative (Details)", "role": "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsNarrativeDetails", "shortName": "RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "role": "http://www.wellcare.com/role/StockBasedCompensationNarrativeDetails", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2018Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Unit Award Activity (Details)", "role": "http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails", "shortName": "STOCK-BASED COMPENSATION - Summary of Stock Unit Award Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2018Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY", "role": "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNoncurrentNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - DEBT - Schedule of Outstanding Debt Obligations (Details)", "role": "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "shortName": "DEBT - Schedule of Outstanding Debt Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNoncurrentNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermLineOfCredit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - DEBT - Narrative (Details)", "role": "http://www.wellcare.com/role/DebtNarrativeDetails", "shortName": "DEBT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "I2018Q3Jul23_us-gaap_CreditFacilityAxis_us-gaap_RevolvingCreditFacilityMember", "decimals": "INF", "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details)", "role": "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-5", "lang": null, "name": "wcg:RestrictedInvestmentFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - FAIR VALUE MEASUREMENTS - Carrying Value and Fair Value of Long-term Debt (Details)", "role": "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails", "shortName": "FAIR VALUE MEASUREMENTS - Carrying Value and Fair Value of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - MEDICAL BENEFITS PAYABLE - Reconciliation of Beginning and Ending Balances, by Segment (Details)", "role": "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails", "shortName": "MEDICAL BENEFITS PAYABLE - Reconciliation of Beginning and Ending Balances, by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2017Q4", "decimals": "-5", "lang": null, "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - MEDICAL BENEFITS PAYABLE - Narrative (Details)", "role": "http://www.wellcare.com/role/MedicalBenefitsPayableNarrativeDetails", "shortName": "MEDICAL BENEFITS PAYABLE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "lang": null, "name": "wcg:NetFavorableUnfavorableDevelopmentofMedicalBenefitsPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - LEASES (Details)", "role": "http://www.wellcare.com/role/LeasesDetails", "shortName": "LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - LEASES - Balance Sheet items related to operating leases (Details)", "role": "http://www.wellcare.com/role/LeasesBalanceSheetItemsRelatedToOperatingLeasesDetails", "shortName": "LEASES - Balance Sheet items related to operating leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - LEASES - Maturity of Operating Lease Liabilities (Details)", "role": "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails", "shortName": "LEASES - Maturity of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - LEASES - Supplemental cash flow information related to leases (Details)", "role": "http://www.wellcare.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetails", "shortName": "LEASES - Supplemental cash flow information related to leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412401 - Disclosure - INCOME TAXES (Details)", "role": "http://www.wellcare.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "D2016Q3Aug3", "decimals": "INF", "first": true, "lang": null, "name": "wcg:NumberOfSubsidiariesSold", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - DISCONTINUED OPERATIONS (Details)", "role": "http://www.wellcare.com/role/DiscontinuedOperationsDetails", "shortName": "DISCONTINUED OPERATIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "D2016Q3Aug3", "decimals": "INF", "first": true, "lang": null, "name": "wcg:NumberOfSubsidiariesSold", "reportCount": 1, "unique": true, "unitRef": "subsidiary", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2013Q2", "decimals": "INF", "first": true, "lang": null, "name": "wcg:NumberOfFormerEmployeesReceivingNoticesofCrossAppeal", "reportCount": 1, "unique": true, "unitRef": "officer", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FI2013Q2", "decimals": "INF", "first": true, "lang": null, "name": "wcg:NumberOfFormerEmployeesReceivingNoticesofCrossAppeal", "reportCount": 1, "unique": true, "unitRef": "officer", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPolicies", "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - CENTENE PLAN OF MERGER AND ACQUISITIONS", "role": "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitions", "shortName": "CENTENE PLAN OF MERGER AND ACQUISITIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - SEGMENT REPORTING", "role": "http://www.wellcare.com/role/SegmentReporting", "shortName": "SEGMENT REPORTING", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wcg-201903311910q.htm", "contextRef": "FD2019Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 66, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r399" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r399" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r399" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r399" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r399" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r137", "r145" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r53", "r107" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingNarrativeDetails", "http://www.wellcare.com/role/SegmentReportingRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r147", "r217", "r219", "r396", "r398" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingNarrativeDetails", "http://www.wellcare.com/role/SegmentReportingRevenueByGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "stpr_FL": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "FLORIDA", "terseLabel": "Florida" } } }, "localname": "FL", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingNarrativeDetails", "http://www.wellcare.com/role/SegmentReportingRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "stpr_IL": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "ILLINOIS", "terseLabel": "Illinois" } } }, "localname": "IL", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "stpr_KY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "KENTUCKY", "terseLabel": "Kentucky" } } }, "localname": "KY", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingRevenueByGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r57", "r59", "r60" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r60", "r61", "r265" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Estimated weighted average useful live of identifiable intangible assets", "verboseLabel": "Weighted Average Useful Life (in years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r34" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Paid in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r226", "r228", "r237", "r238" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense, net of forfeitures" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to cash flows from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r122" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive stock-based compensation awards excluded from computation (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r164", "r221" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r141", "r330", "r360" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets [Abstract]", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.wellcare.com/role/LeasesBalanceSheetItemsRelatedToOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r21", "r22", "r52" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r1", "r2", "r12", "r14", "r188" ], "calculation": { "http://www.wellcare.com/role/DiscontinuedOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total Assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r155" ], "calculation": { "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r156" ], "calculation": { "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r153" ], "calculation": { "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Asset-backed and mortgage-backed securities", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r161" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth fiscal year through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost", "terseLabel": "Due after five years through ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r157", "r161", "r350" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value", "terseLabel": "Due after five years through ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r160" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost", "terseLabel": "Due after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r157", "r160", "r349" ], "calculation": { "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value", "terseLabel": "Due after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": { "auth_ref": [ "r162" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Allocated and Single Maturity Date, Maturity, after 10 Years, Amortized Cost", "terseLabel": "Due after ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "auth_ref": [ "r157", "r162", "r351" ], "calculation": { "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value", "terseLabel": "Due after ten years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": { "auth_ref": [ "r157", "r163", "r352" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value", "terseLabel": "Total" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": { "auth_ref": [ "r157", "r163", "r352" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost", "terseLabel": "Total" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r159" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost", "terseLabel": "Due in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r157", "r159", "r348" ], "calculation": { "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Due in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r150", "r154" ], "calculation": { "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Estimated Fair Value", "totalLabel": "Asset-backed and mortgage-backed securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r229", "r236" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationNarrativeDetails", "http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r268", "r269" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Short-term time deposits" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails", "http://www.wellcare.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r252", "r253" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails", "http://www.wellcare.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "auth_ref": [ "r250", "r251" ], "lang": { "en-US": { "role": { "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsProFormaFinancialInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "auth_ref": [ "r250", "r251" ], "lang": { "en-US": { "role": { "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsProFormaFinancialInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Acquisition, Pro Forma Information [Abstract]", "terseLabel": "Business Acquisition, Pro Forma Information [Abstract]" } } }, "localname": "BusinessAcquisitionProFormaInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsProFormaFinancialInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r250", "r251" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Unaudited Pro Forma Results" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Cash received per share" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r250", "r251" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net income" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsProFormaFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r250", "r251" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Total revenues" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsProFormaFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r258", "r259", "r260" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Acquisition consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "CENTENE PLAN OF MERGER AND ACQUISITIONS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r255" ], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Fair value of total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r255" ], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r255" ], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Medical benefits payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r240", "r255" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "verboseLabel": "Net deferred tax liabilities acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r255" ], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "verboseLabel": "Other intangible assets, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r255" ], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Fair value of liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r254", "r255" ], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Fair value of net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r255" ], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "terseLabel": "Other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r254", "r255" ], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, equipment and capitalized software, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r100", "r101", "r102" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Non-cash additions to property, equipment, and capitalized software" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r282", "r283" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r20", "r41", "r98" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r91", "r98", "r103" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r91", "r284" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "(Decrease) increase in cash, cash equivalents and restricted cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF NON-CASH TRANSACTIONS:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r50", "r196", "r338", "r367" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Commitments and contingencies (see Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r195", "r203" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in USD per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r33", "r210" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r33" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value (100,000,000 authorized, 50,302,215 and 49,993,219 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r64", "r66", "r67" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r64", "r66", "r262", "r266" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateAndOtherMember": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "documentation": "Component of an entity that provides financial and operational oversight and administrative support for other segments and other segments not separately reported due to size or nature of business activities. Excludes intersegment elimination and reconciling items.", "label": "Corporate and Other [Member]", "terseLabel": "Corporate and Other" } } }, "localname": "CorporateAndOtherMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r221", "r224" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r77" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Costs of products and services" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Expenses:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r28", "r30", "r31", "r331", "r332", "r358" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtRedemptionPricesAsPercentageOfPrincipalAmountDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r287", "r289" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtRedemptionPricesAsPercentageOfPrincipalAmountDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtRedemptionPricesAsPercentageOfPrincipalAmountDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Debt repurchase amount" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r48", "r108", "r211", "r212", "r213", "r214", "r286", "r287", "r289", "r354" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtRedemptionPricesAsPercentageOfPrincipalAmountDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r165" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)", "terseLabel": "Realized gains and losses on sales and redemptions of investments" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "verboseLabel": "Short-term and Long-term Investments by Security Type" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Debt Securities" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Abstract]", "terseLabel": "Total" } } }, "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cost of investment in debt investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Debt Securities, Trading, and Equity Securities, FV-NI, Cost", "totalLabel": "Amortized Cost" } } }, "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesUnrealizedGainLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Unrealized Gain (Loss) [Abstract]", "terseLabel": "Debt securities:" } } }, "localname": "DebtSecuritiesUnrealizedGainLossAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r43", "r288" ], "calculation": { "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "negatedTerseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r96", "r106", "r245", "r246" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred taxes, net" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r241", "r244" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income tax liability, net" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCredit": { "auth_ref": [ "r290" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.", "label": "Deferred Rent Credit", "negatedTerseLabel": "Elimination of straight-line lease liabilities" } } }, "localname": "DeferredRentCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r96", "r186" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r216", "r239" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "verboseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "auth_ref": [ "r3", "r4", "r14" ], "lang": { "en-US": { "role": { "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations, Held-for-sale [Member]", "terseLabel": "Discontinued operations, held-for-sale" } } }, "localname": "DiscontinuedOperationsHeldforsaleMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": { "auth_ref": [ "r1", "r2", "r12", "r188" ], "calculation": { "http://www.wellcare.com/role/DiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities", "terseLabel": "Reserves and other policy liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "auth_ref": [ "r1", "r2", "r12", "r14", "r185", "r188" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent", "verboseLabel": "Assets of discontinued operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r1", "r2", "r12", "r188" ], "calculation": { "http://www.wellcare.com/role/DiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "auth_ref": [ "r1", "r2", "r12", "r188" ], "calculation": { "http://www.wellcare.com/role/DiscontinuedOperationsDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "terseLabel": "Other assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "auth_ref": [ "r1", "r2", "r12", "r188" ], "calculation": { "http://www.wellcare.com/role/DiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r18", "r192" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "DISCONTINUED OPERATIONS" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "verboseLabel": "Earnings per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsProFormaFinancialInformationDetails", "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r74", "r114", "r117", "r119", "r120", "r121", "r124", "r344", "r375" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted average common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r74", "r114", "r117", "r119", "r120", "r121", "r124", "r344", "r375" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "EQUITY AND EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/EquityAndEarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r110", "r242", "r243" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based compensation awards.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period over which compensation costs are expected to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Estimated Fair Value", "verboseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity Securities, FV-NI, Cost", "terseLabel": "Amortized Cost" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r168" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity Securities, FV-NI, Unrealized Gain (Loss) [Abstract]", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLossAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "auth_ref": [ "r168" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Loss", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "EquitySecuritiesFvNiUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r270", "r271", "r272", "r273", "r276", "r277" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r274", "r277" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Changes in the Fair Value of Auction Rate Securities" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r271", "r282" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Assets and Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r221", "r222", "r224", "r272", "r309" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r271", "r278" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Fair Value by Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r221", "r222", "r224", "r272", "r310" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r221", "r222", "r224", "r272", "r311" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r221", "r222", "r224", "r272", "r312" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r270", "r275" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r270", "r275" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair value, measurements, recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]", "verboseLabel": "Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed.", "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]" } } }, "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r177", "r180", "r183", "r184", "r314" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r177", "r182" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r178" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Gross Fair Value (in millions)" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r171", "r172" ], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 }, "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r173", "r249" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Acquisition related adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Changes in Goodwill" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r76" ], "calculation": { "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r71", "r114", "r327", "r342", "r376" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r109" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes and equity in losses of unconsolidated subsidiaries" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r72", "r96", "r139", "r169", "r341", "r373" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.", "label": "Income (Loss) from Equity Method Investments", "terseLabel": "Equity in earnings (losses) of unconsolidated subsidiaries" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r2", "r6", "r7", "r8", "r9", "r10", "r11", "r13", "r15", "r16", "r17", "r190", "r191" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r106", "r140", "r247" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r99" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for taxes, net of refunds" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r95" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued liabilities and other, net" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities": { "auth_ref": [ "r95" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) in health care insurance liability balances during the period.", "label": "Increase (Decrease) in Health Care Insurance Liabilities", "terseLabel": "Medical benefits payable" } } }, "localname": "IncreaseDecreaseInHealthCareInsuranceLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating accounts, net of effects from acquisitions and divestitures:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r95" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "Increase (Decrease) in Other Receivables", "negatedLabel": "Pharmacy rebates receivable, net" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPremiumsReceivable": { "auth_ref": [ "r95" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The change in the premium receivable balance on the balance sheet.", "label": "Increase (Decrease) in Premiums Receivable", "negatedLabel": "Premiums receivable, net" } } }, "localname": "IncreaseDecreaseInPremiumsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r95" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInUnearnedPremiums": { "auth_ref": [ "r95" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) unearned premiums written. Excludes portion of unearned premiums amortized into income.", "label": "Increase (Decrease) in Unearned Premiums", "terseLabel": "Unearned premiums" } } }, "localname": "IncreaseDecreaseInUnearnedPremiums", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r118", "r123" ], "calculation": { "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive effect of outstanding stock-based compensation awards (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r176", "r181" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r69", "r138", "r285", "r288", "r346" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "verboseLabel": "Interest" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r90", "r92", "r99" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions": { "auth_ref": [ "r345" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of fees and commissions from banking, advisory, brokerage, and securities underwriting activities. Activities include, but are not limited to, underwriting securities, private placements of securities, investment advisory and management services, merger and acquisition services, sale and servicing of mutual funds, and other related consulting fees.", "label": "Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions", "terseLabel": "Investment banking, advisory, brokerage, and underwriting fees and commissions" } } }, "localname": "InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r390", "r391", "r393", "r394" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r390", "r391", "r393", "r394" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "verboseLabel": "Contractual Maturities of Available-for-sale Securities" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r271" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r167", "r328", "r353", "r395" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "verboseLabel": "INVESTMENTS" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Supplemental cash flow information related to leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturities of operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r302" ], "calculation": { "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r302" ], "calculation": { "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r302" ], "calculation": { "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r302" ], "calculation": { "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r302" ], "calculation": { "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r302" ], "calculation": { "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r302" ], "calculation": { "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r45" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities [Abstract]" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesBalanceSheetItemsRelatedToOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r38", "r333", "r364" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "auth_ref": [ "r1", "r2", "r12", "r14", "r185", "r188" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.wellcare.com/role/DiscontinuedOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent", "totalLabel": "Total liabilities", "verboseLabel": "Liabilities of discontinued operations" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r382", "r385" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.", "label": "Liability for Claims and Claims Adjustment Expense", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "verboseLabel": "Medical benefits payable" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions", "terseLabel": "Acquisitions" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]", "verboseLabel": "Medical benefits paid related to" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": { "auth_ref": [ "r384" ], "calculation": { "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails": { "order": 1.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "negatedTerseLabel": "Current year" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "auth_ref": [ "r384" ], "calculation": { "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails": { "order": 2.0, "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "negatedTerseLabel": "Prior years" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "auth_ref": [ "r383" ], "calculation": { "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "totalLabel": "Total" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]", "verboseLabel": "Medical benefits incurred related to" } } }, "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage on unused amount" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Settlement agreement, amount awarded" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Long-term debt, fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net", "totalLabel": "Total long-term debt, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Long-term Debt, Excluding Current Maturities [Abstract]", "terseLabel": "Long-term debt, net" } } }, "localname": "LongTermDebtNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r42" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLineOfCredit": { "auth_ref": [ "r48", "r206", "r207" ], "calculation": { "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit, Noncurrent", "terseLabel": "Revolving Credit Facility", "verboseLabel": "Borrowings outstanding" } } }, "localname": "LongTermLineOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r48", "r208" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r204", "r205" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r204", "r205" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r204", "r205" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MembershipMember": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Conveyance of right to use facility or service by organization, association, or club.", "label": "Membership [Member]", "terseLabel": "Membership" } } }, "localname": "MembershipMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "verboseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal securities" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r91", "r94", "r97" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r62", "r65", "r73", "r97", "r123", "r343", "r374" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Accounting Standards Recently Adopted and Pending Adoption" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating Costs and Expenses", "totalLabel": "Total gross margin expenses" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r294" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r293" ], "calculation": { "http://www.wellcare.com/role/LeasesBalanceSheetItemsRelatedToOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities", "totalLabel": "Total liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesBalanceSheetItemsRelatedToOperatingLeasesDetails", "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails", "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r293" ], "calculation": { "http://www.wellcare.com/role/LeasesBalanceSheetItemsRelatedToOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesBalanceSheetItemsRelatedToOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r293" ], "calculation": { "http://www.wellcare.com/role/LeasesBalanceSheetItemsRelatedToOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesBalanceSheetItemsRelatedToOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r295", "r297" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r292" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesBalanceSheetItemsRelatedToOperatingLeasesDetails", "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r300", "r303" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r299", "r303" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r137", "r145" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r19", "r112", "r133", "r267" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAggregatedInvestmentsMember": { "auth_ref": [ "r392" ], "lang": { "en-US": { "role": { "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests.", "label": "Other Security Investments [Member]", "terseLabel": "Other securities" } } }, "localname": "OtherAggregatedInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r63", "r66", "r262", "r263", "r264" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r54", "r57", "r166" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax", "terseLabel": "Change in net unrealized gains and losses on available-for-sale securities, before tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r55", "r58" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax", "terseLabel": "Income tax expense (benefit) related to other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r79", "r378" ], "calculation": { "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "negatedTerseLabel": "Other expenses" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Technology and other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other, net" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Pharmacy rebates receivable, net" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": { "auth_ref": [ "r152" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale", "terseLabel": "Other than temporary impairment losses" } } }, "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "auth_ref": [ "r93", "r384" ], "calculation": { "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "negatedTotalLabel": "Total" } } }, "localname": "PaymentsForLossesAndLossAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r88", "r225" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.", "label": "Payments Related to Tax Withholding for Share-based Compensation", "negatedTerseLabel": "Repurchase and retirement of shares to satisfy employee tax withholding requirements" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r84" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r83" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Additions to property, equipment and capitalized software, net" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares or units awarded to employees for meeting certain performance targets.", "label": "Performance Shares [Member]", "terseLabel": "PSUs", "verboseLabel": "Performance Stock Units" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationNarrativeDetails", "http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare": { "auth_ref": [ "r377" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts.", "label": "Policyholder Benefits and Claims Incurred, Net, Health", "terseLabel": "Medical benefits", "verboseLabel": "Medical benefits" } } }, "localname": "PolicyholderBenefitsAndClaimsIncurredHealthCare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in USD per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r32" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value (20,000,000 authorized, no shares issued or outstanding)" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsEarnedNet": { "auth_ref": [ "r340", "r372", "r379", "r387" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 }, "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails": { "order": 1.0, "parentTag": "wcg_RevenuefromPremiumsProductsandServices", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.", "label": "Premiums Earned, Net", "terseLabel": "Premium", "verboseLabel": "Premiums revenue related to Aetna Part D Membership" } } }, "localname": "PremiumsEarnedNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsReceivableAtCarryingValue": { "auth_ref": [ "r368" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts.", "label": "Premiums Receivable, Net", "terseLabel": "Premiums receivable, net" } } }, "localname": "PremiumsReceivableAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PremiumsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others.", "label": "Premiums Receivable [Member]", "terseLabel": "Premiums receivable, net" } } }, "localname": "PremiumsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r21", "r39", "r40" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets, net" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Proceeds from long-term lines of credit" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r87", "r89", "r111" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r82" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Proceeds from sales and maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r80", "r81", "r151" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from sale of available-for-sale investments" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r25", "r26", "r187", "r366" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, equipment and capitalized software, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReinsuranceAccountingPolicy": { "auth_ref": [ "r104", "r355", "r356", "r371", "r388", "r389" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy.", "label": "Reinsurance Accounting Policy [Policy Text Block]", "terseLabel": "Aetna Part D Membership Reinsurance" } } }, "localname": "ReinsuranceAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReinsurancePayable": { "auth_ref": [ "r370" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount as of the balance sheet date of the known and estimated amounts owed to insurers under reinsurance treaties or other arrangements.", "label": "Reinsurance Payable", "terseLabel": "Reinsurance payable" } } }, "localname": "ReinsurancePayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReinsuranceReceivablesIncurredButNotReportedClaims": { "auth_ref": [ "r365", "r380", "r381" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Estimated amount after valuation allowance of reinsurance recoverables, due from reinsurers for incurred claims not yet reported, and claims settlement expenses.", "label": "Reinsurance Recoverables, Incurred but Not Reported Claims", "terseLabel": "Reinsurance receivables related to premiums receivable" } } }, "localname": "ReinsuranceReceivablesIncurredButNotReportedClaims", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReinsuranceRecoverables": { "auth_ref": [ "r357", "r369", "r380" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves.", "label": "Reinsurance Recoverables, Including Reinsurance Premium Paid", "terseLabel": "Reinsurance recoverables" } } }, "localname": "ReinsuranceRecoverables", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r223", "r305", "r306", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResidentialMortgageBackedSecuritiesMember": { "auth_ref": [ "r158", "r221" ], "lang": { "en-US": { "role": { "documentation": "Securities collateralized by residential real estate mortgage loans.", "label": "Residential Mortgage Backed Securities [Member]", "terseLabel": "Residential mortgage-backed securities" } } }, "localname": "ResidentialMortgageBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.", "label": "Restricted Assets Disclosure [Text Block]", "verboseLabel": "RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS" } } }, "localname": "RestrictedAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.", "label": "Restricted Cash and Cash Equivalents [Axis]", "terseLabel": "Restricted Cash and Cash Equivalents, Cash and Cash Equivalents [Axis]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Restricted Cash and Cash Equivalents, Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restricted Cash and Cash Equivalents Items [Line Items]", "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]" } } }, "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r23", "r27", "r98", "r103", "r397" ], "calculation": { "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails": { "order": 3.0, "parentTag": "wcg_RestrictedInvestmentsAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Estimated Fair Value" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndInvestmentsNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.", "label": "Restricted Cash and Investments, Noncurrent", "terseLabel": "Restricted cash, cash equivalents and investments" } } }, "localname": "RestrictedCashAndInvestmentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restricted Investments Note [Abstract]" } } }, "localname": "RestrictedInvestmentsNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r35", "r215", "r363" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r105", "r220" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Premium Receivable and Unearned Premiums" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r75", "r136", "r137", "r144" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues", "verboseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingRevenueByGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails", "http://www.wellcare.com/role/FairValueMeasurementsCarryingValueAndFairValueOfLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r298", "r303" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Leased assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/LeasesSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock, number of shares issued in transaction" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reporting scenario used to indicate financial results forecast for a future period.", "label": "Scenario, Forecast [Member]", "terseLabel": "Scenario, Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r122" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r252", "r253" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Carrying Value and Fair Value of Long-term Debt" } } }, "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r48", "r108", "r211", "r212", "r213", "r214", "r286", "r287", "r289", "r354" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Outstanding Debt Obligations" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r2", "r6", "r7", "r8", "r9", "r10", "r11", "r13", "r15", "r16", "r17", "r190", "r191" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Total Assets and Liabilities of Discontinued Operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Calculation of the Weighted-Average Common Shares Outstanding - Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/EquityAndEarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.", "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r174", "r175" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Final Fair Values and Weighted Average Useful Lives for Identifiable Intangible Assets Acquired" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Fair Values of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "auth_ref": [ "r24", "r103", "r329", "r362" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table]", "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r75", "r147" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Revenue by Geographic Location" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r68", "r70", "r147" ], "lang": { "en-US": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingRevenueByGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r135", "r141", "r142", "r143", "r174" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingNarrativeDetails", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r135", "r141", "r142", "r143", "r174" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Segment Results" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r229", "r236" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationNarrativeDetails", "http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of Stock Unit Award Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]", "verboseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails", "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails", "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails", "http://www.wellcare.com/role/SegmentReportingNarrativeDetails", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "SEGMENT REPORTING" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/SegmentReportingNarrativeDetails", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r78", "r170" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorLongTermNotes": { "auth_ref": [ "r48" ], "calculation": { "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.", "label": "Senior Notes, Noncurrent", "terseLabel": "Senior notes" } } }, "localname": "SeniorLongTermNotes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r95" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Compensation expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.wellcare.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Grants in period, weighted average grant date fair value (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding as of beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Equity Instruments Other than Options [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationNarrativeDetails", "http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r227", "r230" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]", "verboseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationNarrativeDetails", "http://www.wellcare.com/role/StockBasedCompensationSummaryOfStockUnitAwardActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Closing common stock price (in USD per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r29", "r334", "r335", "r337", "r359" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "verboseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r5", "r141", "r174", "r189", "r193", "r194", "r386" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails", "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails", "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails", "http://www.wellcare.com/role/SegmentReportingNarrativeDetails", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r51", "r210" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r32", "r33", "r210", "r215" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Common stock issued for vested equity-compensation awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r210", "r215" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Common stock issued for vested equity-compensation awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r32", "r33", "r210", "r215" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchase and retirement of shares to satisfy tax withholding requirements (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r32", "r33", "r210", "r215" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchase and retirement of shares to satisfy tax withholding requirements" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r33", "r36", "r37", "r149" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total Stockholders' Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.wellcare.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets", "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r383" ], "calculation": { "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.", "label": "Current Year Claims and Claims Adjustment Expense", "terseLabel": "Current year" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r383" ], "calculation": { "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.", "label": "Prior Year Claims and Claims Adjustment Expense", "terseLabel": "Prior years" } } }, "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableNarrativeDetails", "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Tradenames" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r339" ], "calculation": { "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "terseLabel": "Estimated Fair Value" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r313" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r221", "r336" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "Government and agency obligations", "verboseLabel": "Government and agency obligations" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails", "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r221", "r336" ], "lang": { "en-US": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. government securities and other" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r221", "r224", "r336" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. government securities and other" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnearnedPremiums": { "auth_ref": [ "r361" ], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date.", "label": "Unearned Premiums", "verboseLabel": "Unearned premiums" } } }, "localname": "UnearnedPremiums", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r126", "r127", "r128", "r129", "r130", "r131", "r132" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r116", "r121" ], "calculation": { "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average common shares outstanding \u2014 diluted (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r115", "r121" ], "calculation": { "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding \u2014 basic (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Weighted average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsProFormaFinancialInformationDetails" ], "xbrltype": "stringItemType" }, "wcg_ACAIndustryFeeExpense": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "ACA Industry Fee Expense", "label": "ACA Industry Fee Expense", "terseLabel": "ACA industry fee", "verboseLabel": "ACA industry fee" } } }, "localname": "ACAIndustryFeeExpense", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "monetaryItemType" }, "wcg_ACAIndustryFeePolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ACA Industry Fee [Policy Text Block]", "label": "ACA Industry Fee [Policy Text Block]", "terseLabel": "ACA Industry Fee" } } }, "localname": "ACAIndustryFeePolicyTextBlock", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "wcg_AetnaPartDBusinessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aetna Part D Business [Member]", "label": "Aetna Part D Business [Member]", "terseLabel": "Aetna Part D Business" } } }, "localname": "AetnaPartDBusinessMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "wcg_AssetBackedAndMortgageBackedSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset-Backed And Mortgage-Backed Securities [Member]", "label": "Asset-Backed And Mortgage-Backed Securities [Member]", "terseLabel": "Asset-Backed And Mortgage-Backed Securities" } } }, "localname": "AssetBackedAndMortgageBackedSecuritiesMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/InvestmentsContractualMaturitiesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "wcg_AssetsAndLiabilitiesLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities, Leases [Table Text Block]", "label": "Assets And Liabilities, Leases [Table Text Block]", "terseLabel": "Balance sheet information related to operating leases" } } }, "localname": "AssetsAndLiabilitiesLeasesTableTextBlock", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "wcg_BusinessAcquisitionSharesIssuedPerCommonShareOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Shares Issued Per Common Share Outstanding", "label": "Business Acquisition, Shares Issued Per Common Share Outstanding", "terseLabel": "Shares received for each common share" } } }, "localname": "BusinessAcquisitionSharesIssuedPerCommonShareOutstanding", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "wcg_BusinessCombinationProFormaInformationWeightedAverageCommonSharesOutstandingBasic": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Pro Forma Information, Weighted Average Common Shares Outstanding, Basic", "label": "Business Combination, Pro Forma Information, Weighted Average Common Shares Outstanding, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "BusinessCombinationProFormaInformationWeightedAverageCommonSharesOutstandingBasic", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsProFormaFinancialInformationDetails" ], "xbrltype": "sharesItemType" }, "wcg_BusinessCombinationProFormaInformationWeightedAverageCommonSharesOutstandingDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Pro Forma Information, Weighted Average Common Shares Outstanding, Diluted", "label": "Business Combination, Pro Forma Information, Weighted Average Common Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)" } } }, "localname": "BusinessCombinationProFormaInformationWeightedAverageCommonSharesOutstandingDiluted", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsProFormaFinancialInformationDetails" ], "xbrltype": "sharesItemType" }, "wcg_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPharmacyRebatesReceivableAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Pharmacy Rebates Receivable and Other Current Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Pharmacy Rebates Receivable And Other Current Assets", "terseLabel": "Other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPharmacyRebatesReceivableAndOtherCurrentAssets", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "wcg_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedInvestments": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Investments", "terseLabel": "Investments, including restricted investments" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedInvestments", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "wcg_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Liabilities", "terseLabel": "ACA Fee liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherLiabilities", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "wcg_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPremiumsReceivable": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Premiums Receivable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Premiums Receivable", "terseLabel": "Premiums receivable, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedPremiumsReceivable", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "wcg_CenteneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Centene [Member]", "label": "Centene [Member]", "terseLabel": "Centene" } } }, "localname": "CenteneMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "wcg_DebtSecuritiesTradingandEquitySecuritiesFVNIUnrealizedGain": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Trading, and Equity Securities, FV-NI, Unrealized Gain", "label": "Debt Securities, Trading, and Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "DebtSecuritiesTradingandEquitySecuritiesFVNIUnrealizedGain", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "wcg_DebtSecuritiesTradingandEquitySecuritiesFVNIUnrealizedLoss": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt, Trading, and Equity Securities, FV-NI, Unrealized Loss", "label": "Debt Securities, Trading, and Equity Securities, FV-NI, Unrealized Loss", "terseLabel": "Gross Unrealized Losses" } } }, "localname": "DebtSecuritiesTradingandEquitySecuritiesFVNIUnrealizedLoss", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/InvestmentsShortTermAndLongTermInvestmentsBySecurityTypeDetails" ], "xbrltype": "monetaryItemType" }, "wcg_DeferredTaxAssetsPremiumDeficiencyReserve": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Premium Deficiency Reserve", "label": "Deferred Tax Assets, Premium Deficiency Reserve", "terseLabel": "Premium deficiency reserve" } } }, "localname": "DeferredTaxAssetsPremiumDeficiencyReserve", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "monetaryItemType" }, "wcg_DerivativeLawsuitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A lawsuit brought by a corporation shareholder against the directors, management and/or other shareholders of the corporation, for a failure by management.", "label": "Derivative Lawsuits [Member]", "terseLabel": "Derivative Lawsuits" } } }, "localname": "DerivativeLawsuitsMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "wcg_DisposalGroupIncludingDiscontinuedOperationInvestments": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/DiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Investments", "label": "Disposal Group, Including Discontinued Operation, Investments", "terseLabel": "Investments" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInvestments", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "wcg_DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverables": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/DiscontinuedOperationsDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Reinsurance Recoverables", "label": "Disposal Group, Including Discontinued Operation, Reinsurance Recoverables", "terseLabel": "Reinsurance recoverables" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationReinsuranceRecoverables", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "wcg_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.wellcare.com/20190331", "xbrltype": "stringItemType" }, "wcg_FundsPayableForTheBenefitofMembers": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Funds held (payable) or receivable for the benefit of members represent government payments received or to be received to subsidize the member portion of medical payments for certain of our stand-alone prescription drug program members. We do not bear underwriting risk since such funds represent pass-through payments from our government partners to fund deductibles, co-payments and other participant benefits.", "label": "Funds Payable For The Benefit of Members", "terseLabel": "Funds payable for the benefit of members" } } }, "localname": "FundsPayableForTheBenefitofMembers", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "wcg_FundsReceivableForTheBenefitOfMembers": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Funds held or receivable for the benefit of members represent government payments received or to be received to subsidize the member portion of medical payments for certain of our stand-alone prescription drug program members. We do not bear underwriting risk since such funds represent pass-through payments from our government partners to fund deductibles, co-payments and other participant benefits.", "label": "Funds Receivable For The Benefit Of Members", "verboseLabel": "Funds receivable for the benefit of members" } } }, "localname": "FundsReceivableForTheBenefitOfMembers", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "wcg_FundsReceivablePayablefortheBenefitofMembersLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Disclosure of accounting policy for Funds Receivable or Payable for the Benefit of Members [Table]", "label": "Funds Receivable/Payable for the Benefit of Members [Line Items]", "terseLabel": "Funds Receivable/Payable for the Benefit of Members [Line Items]" } } }, "localname": "FundsReceivablePayablefortheBenefitofMembersLineItems", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "wcg_FundsReceivablePayablefortheBenefitofMembersPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for Disclosure of accounting policy for Funds Receivable or Payable for the Benefit of Members [Table]", "label": "Funds Receivable/Payable for the Benefit of Members [Policy Text Block]", "terseLabel": "Medicare Part D Settlements" } } }, "localname": "FundsReceivablePayablefortheBenefitofMembersPolicyTextBlock", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "wcg_FundsReceivablePayablefortheBenefitofMembersTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for Funds Receivable or Payable for the Benefit of Members [Table]", "label": "Funds Receivable/Payable for the Benefit of Members [Table]", "terseLabel": "Funds Receivable/Payable for the Benefit of Members [Table]" } } }, "localname": "FundsReceivablePayablefortheBenefitofMembersTable", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "wcg_IncreaseDecreaseInOtherPayablesToGovernmentPartners": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net change during the reporting period in amounts due to government agencies under various contractual and plan arrangements. We estimate the amounts due from CMS for risk protection under the risk corridor provisions of our contract with CMS each period based on pharmacy claims experience.", "label": "Increase Decrease In Other Payables To Government Partners", "verboseLabel": "Other receivables/payables to government partners" } } }, "localname": "IncreaseDecreaseInOtherPayablesToGovernmentPartners", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "wcg_InvestmentAndOtherIncome": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 }, "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Investment income represents income derived from bank deposits and investments in securities consisting of interest income from cash instruments and securities, dividend income, and income or expense derived from the amortization of investment related discounts or premiums, respectively.", "label": "Investment And Other Income", "terseLabel": "Investment and other income", "verboseLabel": "Investment and other income" } } }, "localname": "InvestmentAndOtherIncome", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "monetaryItemType" }, "wcg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments Due After Year Six", "label": "Lessee, Operating Lease, Liability, Payments Due After Year Six", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "wcg_LesseeOperatingLeaseLiabilityPaymentsDueYearSix": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments Due Year Six", "label": "Lessee, Operating Lease, Liability, Payments Due Year Six", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearSix", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/LeasesMaturityOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "wcg_LesseeOperatingLeasesRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Leases, Remaining Lease Term", "label": "Lessee, Operating Leases, Remaining Lease Term", "terseLabel": "Remaining lease terms" } } }, "localname": "LesseeOperatingLeasesRemainingLeaseTerm", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "wcg_LineofCreditFacilityAccordianLoanFeature": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line of Credit Facility, Accordion Loan Feature", "label": "Line of Credit Facility, Accordian Loan Feature", "terseLabel": "Credit facility increase subject to certain conditions" } } }, "localname": "LineofCreditFacilityAccordianLoanFeature", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "wcg_LitigationSettlementLegalFeeAdvancesMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Litigation Settlement, Legal Fee Advances, Maximum", "label": "Litigation Settlement, Legal Fee Advances, Maximum", "terseLabel": "Maximum legal fee obligation" } } }, "localname": "LitigationSettlementLegalFeeAdvancesMaximum", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "wcg_MedicaidACAIndustryFeeReimbursementRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Medicaid ACA Industry Fee Reimbursement Revenue", "label": "Medicaid ACA Industry Fee Reimbursement Revenue", "terseLabel": "Medicaid ACA industry fee reimbursement revenue" } } }, "localname": "MedicaidACAIndustryFeeReimbursementRevenue", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "wcg_MedicaidMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A reportable segment and business line which includes plans for beneficiaries of various Medicaid programs and state-based programs that are not a part of the Medicaid program.", "label": "Medicaid [Member]", "terseLabel": "Medicaid Health Plan" } } }, "localname": "MedicaidMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails", "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails", "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails", "http://www.wellcare.com/role/SegmentReportingNarrativeDetails", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "domainItemType" }, "wcg_MedicaidPremiumTaxes": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Medicaid Premium Taxes", "label": "Medicaid Premium Taxes", "terseLabel": "Medicaid premium taxes" } } }, "localname": "MedicaidPremiumTaxes", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "monetaryItemType" }, "wcg_MedicaidRetroactiveRateChangeandRiskScoreAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Medicaid Retroactive Rate Change and Risk Score Adjustments", "label": "Medicaid Retroactive Rate Change and Risk Score Adjustments", "terseLabel": "Medicaid retroactive rate change and risk score adjustments" } } }, "localname": "MedicaidRetroactiveRateChangeandRiskScoreAdjustments", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "wcg_MedicalBenefitsCeded": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Medical Benefits Ceded", "label": "Medical Benefits Ceded", "terseLabel": "Medical benefits ceded related to Aetna Part D membership" } } }, "localname": "MedicalBenefitsCeded", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "wcg_MedicalBenefitsPayableAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "MEDICAL BENEFITS PAYABLE [Abstract]" } } }, "localname": "MedicalBenefitsPayableAbstract", "nsuri": "http://www.wellcare.com/20190331", "xbrltype": "stringItemType" }, "wcg_MedicalBenefitsPayableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description and amounts of medical benefits payable at the end of the reporting period and other information and schedules needed to disclose the medical benefit payable account.", "label": "Medical Benefits Payable [Text Block]", "terseLabel": "MEDICAL BENEFITS PAYABLE" } } }, "localname": "MedicalBenefitsPayableTextBlock", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayable" ], "xbrltype": "textBlockItemType" }, "wcg_MedicalServicesManagedCarePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Services Managed Care Plan [Member]", "label": "Medical Services Managed Care Plan [Member]", "terseLabel": "Medical Services Managed Care Plan" } } }, "localname": "MedicalServicesManagedCarePlanMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "wcg_MedicareAdvantageMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A reportable segment within the Medicare business line which consists of Medicare Advantage coordinated care plans.", "label": "Medicare Advantage [Member]", "terseLabel": "Medicare Advantage" } } }, "localname": "MedicareAdvantageMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "wcg_MedicareAdvantageandPDPMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare Advantage and PDP [Member]", "label": "Medicare Advantage and PDP [Member]", "terseLabel": "Medicare Advantage and PDP" } } }, "localname": "MedicareAdvantageandPDPMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "wcg_MedicareHealthPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicare Health Plans Segment [Member]", "label": "Medicare Health Plans [Member]", "verboseLabel": "Medicare Health Plan" } } }, "localname": "MedicareHealthPlansMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails", "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "domainItemType" }, "wcg_Membership": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of members enrolled in the health care plan as of the end of the reporting period.", "label": "Membership", "terseLabel": "Membership" } } }, "localname": "Membership", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "wcg_MeridianMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Meridian [Member]", "label": "Meridian [Member]", "terseLabel": "Meridian" } } }, "localname": "MeridianMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsGoodwillAcquiredDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails", "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/EquityAndEarningsPerShareCalculationOfWeightedAverageCommonSharesOutstandingDetails", "http://www.wellcare.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "wcg_Mr.BehrensCaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mr. Behrens Case [Member]", "label": "Mr. Behrens Case [Member]", "terseLabel": "Mr. Behrens Case" } } }, "localname": "Mr.BehrensCaseMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "wcg_Mr.BeredayCaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mr. Bereday Case", "label": "Mr. Bereday Case [Member]", "terseLabel": "Mr. Bereday Case" } } }, "localname": "Mr.BeredayCaseMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "wcg_Mr.FarhaCaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mr. Farha Case [Member]", "label": "Mr. Farha Case [Member]", "terseLabel": "Mr. Farha Case" } } }, "localname": "Mr.FarhaCaseMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "wcg_NameofHealthcarePlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of Healthcare Plan [Axis]", "label": "Name of Healthcare Plan [Axis]", "terseLabel": "Name of Healthcare Plan [Axis]" } } }, "localname": "NameofHealthcarePlanAxis", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "wcg_NameofHealthcarePlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Name of Healthcare Plan [Axis]", "label": "Name of Healthcare Plan [Domain]", "terseLabel": "Name of Healthcare Plan [Domain]" } } }, "localname": "NameofHealthcarePlanDomain", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "wcg_NetFavorableUnfavorableDevelopmentofMedicalBenefitsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Favorable (Unfavorable) Development of Medical Benefits Payable", "label": "Net Favorable (Unfavorable) Development of Medical Benefits Payable", "terseLabel": "Favorable development of medical benefits payable" } } }, "localname": "NetFavorableUnfavorableDevelopmentofMedicalBenefitsPayable", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "wcg_NetFavorableUnfavorableDevelopmentofMedicalBenefitsPayableExcludingReleaseoftheProvisionforModeratelyAdverseConditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Favorable (Unfavorable) Development of Medical Benefits Payable, Excluding Release of the Provision for Moderately Adverse Conditions", "label": "Net Favorable (Unfavorable) Development of Medical Benefits Payable, Excluding Release of the Provision for Moderately Adverse Conditions", "verboseLabel": "Favorable development of medical benefits payable excluding the release of the provision for moderately adverse conditions" } } }, "localname": "NetFavorableUnfavorableDevelopmentofMedicalBenefitsPayableExcludingReleaseoftheProvisionforModeratelyAdverseConditions", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "wcg_NumberOfActionsFiledInFederalCourt": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of actions filed in Federal Court related to government investigations in a derivative action filed against the entity.", "label": "Number of actions filed in the Federal Court", "terseLabel": "Number of actions filed in the federal and state courts between October 2007 and January 2008" } } }, "localname": "NumberOfActionsFiledInFederalCourt", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "wcg_NumberOfFormerAssociatesBeingPursuedInActionFiledByEntity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Former Associates Being Pursued In Action Filed By Entity", "label": "Number Of Former Associates Being Pursued In Action Filed By Entity", "terseLabel": "Number of former associates being pursued in action filed by entity" } } }, "localname": "NumberOfFormerAssociatesBeingPursuedInActionFiledByEntity", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "wcg_NumberOfFormerEmployeesBeingPursuedInActionFiledByEntity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Former Employees Being Pursued In Action Filed By Entity", "label": "Number Of Former Employees Being Pursued In Action Filed By Entity", "terseLabel": "Number of former employees being pursued in action filed by entity" } } }, "localname": "NumberOfFormerEmployeesBeingPursuedInActionFiledByEntity", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "wcg_NumberOfFormerEmployeesFoundGuiltyandAppealing": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Former Employees Found Guilty and Appealing", "label": "Number Of Former Employees Found Guilty and Appealing", "terseLabel": "Number of former employees found guilty and appealing" } } }, "localname": "NumberOfFormerEmployeesFoundGuiltyandAppealing", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "wcg_NumberOfFormerEmployeesReceivingNoticesofCrossAppeal": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Former Employees Receiving Notices of Cross Appeal", "label": "Number Of Former Employees Receiving Notices of Cross Appeal", "terseLabel": "Number of former officers receiving notices of cross appeal" } } }, "localname": "NumberOfFormerEmployeesReceivingNoticesofCrossAppeal", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "wcg_NumberOfFormerOfficersBeingPursuedInActionFiledByEntity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of former officers being pursued in an action filed by the entity pursuant to a report filed by the Special Litigation Committee to the Federal Court determining, among other things, that the entity should pursue such an action.", "label": "Number Of Former Officers Being Pursued In Action Filed By Entity", "terseLabel": "Number of former executives being pursued in action filed by entity" } } }, "localname": "NumberOfFormerOfficersBeingPursuedInActionFiledByEntity", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "wcg_NumberOfSubsidiariesSold": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Subsidiaries Sold", "label": "Number Of Subsidiaries Sold", "terseLabel": "Number Of Subsidiaries Sold" } } }, "localname": "NumberOfSubsidiariesSold", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "integerItemType" }, "wcg_OtherPayablesToGovernmentPartners": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other payables due to government partners represent amounts due to government agencies under various contractual and plan arrangements. We estimate the amounts due to CMS for risk protection under the risk corridor provisions of our contract with CMS each period based on pharmacy claims experience. Also this line item includes reserves for the return of premium on minimum loss ratio guarantees for certain state Medicaid contracts.", "label": "Other Payables To Government Partners", "verboseLabel": "Other payables to government partners" } } }, "localname": "OtherPayablesToGovernmentPartners", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "wcg_PremiumRevenueNetOfPremiumTax": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents premium revenue net of premium tax of consolidated premium revenue.", "label": "Premium Revenue, Net Of Premium Tax", "terseLabel": "Premium revenue as a percentage of total consolidated premium revenue" } } }, "localname": "PremiumRevenueNetOfPremiumTax", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/SegmentReportingRevenueByGeographicLocationDetails" ], "xbrltype": "percentItemType" }, "wcg_PremiumTaxExpense": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "An assessment levied by a state government agency on premium revenue.", "label": "Premium Tax Expense", "verboseLabel": "Medicaid premium taxes" } } }, "localname": "PremiumTaxExpense", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "wcg_PrescriptionDrugPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A reportable segment within the Medicare business line through which the entity offers Medicare Part D coverage to Medicare-eligible beneficiaries.", "label": "Prescription Drug Plans [Member]", "terseLabel": "Medicare PDP" } } }, "localname": "PrescriptionDrugPlansMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "domainItemType" }, "wcg_ProceedsfromPaymentsfortheBenefitofMembers": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from (Payments for) the Benefit of Members", "label": "Proceeds from (Payments for) the Benefit of Members", "terseLabel": "Funds received for the benefit of members, net" } } }, "localname": "ProceedsfromPaymentsfortheBenefitofMembers", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "wcg_ProviderNetworkMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Provider networks are lists of physicians and hospitals that provide services to a health insurance plan.", "label": "Provider Network [Member]", "terseLabel": "Provider network" } } }, "localname": "ProviderNetworkMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsIdentifiableIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "wcg_ReconciliationOfBeginningAndEndingBalanceOfMedicalBenefitsPayableRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of the beginning and ending balance of medical benefits payable.", "label": "Reconciliation of the beginning and ending balance of medical benefits payable [Roll Forward]", "verboseLabel": "Reconciliation of the beginning and ending balance of medical benefits payable [Roll Forward]" } } }, "localname": "ReconciliationOfBeginningAndEndingBalanceOfMedicalBenefitsPayableRollForward", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableReconciliationOfBeginningAndEndingBalancesBySegmentDetails" ], "xbrltype": "stringItemType" }, "wcg_ReconciliationOfMedicalBenefitsPayableTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A reconciliation of the beginning and ending balances of medical benefits payable, including separate disclosure of medical benefits incurred and medical benefits paid during the reporting period.", "label": "Reconciliation of Medical Benefits Payable [Table Text Block]", "verboseLabel": "Reconciliation of the Beginning and Ending Balances of Medical Benefits Payable, by Segment" } } }, "localname": "ReconciliationOfMedicalBenefitsPayableTableTextBlock", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/MedicalBenefitsPayableTables" ], "xbrltype": "textBlockItemType" }, "wcg_RestrictedInvestmentFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents restricted investments reported on the balance sheet at period end measured at fair value by the entity. This element in intended to be used in connection with fair value disclosures required in the footnote disclosures to the financial statements.", "label": "Restricted Investment, Fair Value Disclosure", "terseLabel": "Restricted cash, cash equivalents and investments" } } }, "localname": "RestrictedInvestmentFairValueDisclosure", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "wcg_RestrictedInvestmentsAmortizedCostBasis": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restricted Investments, Amortized Cost Basis", "label": "Restricted Investments, Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "RestrictedInvestmentsAmortizedCostBasis", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "wcg_RestrictedInvestmentsGrossUnrealizedGainBeforeTax": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails": { "order": 1.0, "parentTag": "wcg_RestrictedInvestmentsAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Restricted Investments, Gross Unrealized Gain, Before Tax", "label": "Restricted Investments, Gross Unrealized Gain, Before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "RestrictedInvestmentsGrossUnrealizedGainBeforeTax", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "wcg_RestrictedInvestmentsGrossUnrealizedLossesBeforeTax": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails": { "order": 2.0, "parentTag": "wcg_RestrictedInvestmentsAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restricted Investments, Gross Unrealized Losses, Before Tax", "label": "Restricted Investments, Gross Unrealized Losses, Before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "RestrictedInvestmentsGrossUnrealizedLossesBeforeTax", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsScheduleOfRestrictedInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "wcg_RestrictedInvestmentsRealizedGainsLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Restricted Investments, Realized Gains (Losses)", "label": "Restricted Investments, Realized Gains (Losses)", "terseLabel": "Realized gains (losses) on restricted investments" } } }, "localname": "RestrictedInvestmentsRealizedGainsLosses", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "wcg_RevenuefromPremiumsProductsandServices": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue from Premiums, Products and Services", "label": "Revenue from Premiums, Products and Services", "totalLabel": "Total premium and products and services revenues" } } }, "localname": "RevenuefromPremiumsProductsandServices", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "monetaryItemType" }, "wcg_RevenuesfromProductsandServices": { "auth_ref": [], "calculation": { "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 }, "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails": { "order": 2.0, "parentTag": "wcg_RevenuefromPremiumsProductsandServices", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenues from Products and Services", "label": "Revenues from Products and Services", "terseLabel": "Products and services" } } }, "localname": "RevenuesfromProductsandServices", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.wellcare.com/role/SegmentReportingSegmentResultsDetails" ], "xbrltype": "monetaryItemType" }, "wcg_ScheduleOfRestrictedInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for Schedule of Restricted Investments [Table]", "label": "Schedule of Restricted Investments [Table Text Block]", "terseLabel": "Schedule of Restricted Investments" } } }, "localname": "ScheduleOfRestrictedInvestmentsTableTextBlock", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/RestrictedCashCashEquivalentsAndInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "wcg_SeniorNotesDue2020Issued20135.75percentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes Due 2020 Issued 2013 - 5.75 percent [Member]", "label": "Senior Notes Due 2020 Issued 2013 - 5.75 percent [Member]", "verboseLabel": "5.75% Senior Notes, due November 15, 2020" } } }, "localname": "SeniorNotesDue2020Issued20135.75percentMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "wcg_SeniorNotesDue2025Issued20175.25percentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes Due 2025 Issued 2017 - 5.25 percent [Member]", "label": "Senior Notes Due 2025 Issued 2017 - 5.25 percent [Member]", "terseLabel": "5.25% Senior Notes, due April 1, 2025" } } }, "localname": "SeniorNotesDue2025Issued20175.25percentMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "domainItemType" }, "wcg_SeniorNotesDue2026Issued20185.375percentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes Due 2026 Issued 2018 - 5.375 percent [Member]", "label": "Senior Notes Due 2026 Issued 2018 - 5.375 percent [Member]", "terseLabel": "5.375% Senior Notes, due August 15, 2026" } } }, "localname": "SeniorNotesDue2026Issued20185.375percentMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CentenePlanOfMergerAndAcquisitionsNarrativeDetails", "http://www.wellcare.com/role/DebtNarrativeDetails", "http://www.wellcare.com/role/DebtRedemptionPricesAsPercentageOfPrincipalAmountDetails", "http://www.wellcare.com/role/DebtScheduleOfOutstandingDebtObligationsDetails" ], "xbrltype": "domainItemType" }, "wcg_SeriousMentalIllnessSpecialtyPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Serious Mental Illness Specialty Plan [Member]", "label": "Serious Mental Illness Specialty Plan [Member]", "terseLabel": "Serious Mental Illness Specialty Plan" } } }, "localname": "SeriousMentalIllnessSpecialtyPlanMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "wcg_StatePartnersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "State Partners [Member]", "label": "State Partners [Member]", "terseLabel": "State Partners" } } }, "localname": "StatePartnersMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/OrganizationBasisOfPresentationAndSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "wcg_TermofAgreement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term of Agreement", "label": "Term of Agreement", "terseLabel": "Term of agreement" } } }, "localname": "TermofAgreement", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "durationItemType" }, "wcg_TraditionalInsuranceBusinessMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Traditional Insurance Business [Member]", "label": "Traditional Insurance Business [Member]", "terseLabel": "Traditional Insurance Business" } } }, "localname": "TraditionalInsuranceBusinessMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/DiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "wcg_UnitedStatesSecuritiesAndExchangeCommissionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "United States Securities And Exchange Commission [Member]", "label": "United States Securities And Exchange Commission [Member]", "terseLabel": "Securities and Exchange Commission (SEC)" } } }, "localname": "UnitedStatesSecuritiesAndExchangeCommissionMember", "nsuri": "http://www.wellcare.com/20190331", "presentation": [ "http://www.wellcare.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 12 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=SL6284422-111562" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=84241550&loc=SL75117546-209714" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r18": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r19": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12053-110248" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "19A", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=107668666&loc=SL79513924-113897" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r239": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e961-128460" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL6742756-110258" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13467-108611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13476-108611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39896-112707" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(c))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(b))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(d)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6816-158387" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(13)(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(6))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),5)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),6)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.13(a)(3),(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.13(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.5)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=34713774&loc=d3e574992-122915" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99404803&loc=d3e21409-158489" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99382578&loc=d3e14764-158437" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99382578&loc=d3e14764-158437" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99382578&loc=d3e14764-158437" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(cc)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99382578&loc=d3e14764-158437" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "605", "Subparagraph": "(c)(3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "605", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99379264&loc=d3e27758-158548" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "605", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99379264&loc=d3e27830-158548" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C.4,6)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "305", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r399": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-03(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868656-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" } }, "version": "2.1" } ZIP 84 0001279363-19-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001279363-19-000017-xbrl.zip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end

U6 MTG1)!CG>1(Z'"1P%Z:]3,:N/Z*\CS#EE!:ONFC 03\RTA]N?5ZE:46TJKI^> M6WZ<%DK$$?W^=98 MI/BP#<8H%ZK>X]% 7]6H8 E*YYB?3 J5MV_#;%M\&6E5F9M01+_.\OL5[4JP MHH6 BP3X+D-IE:.H1&GUB[Q4"$POQDV2WX+E[!AJ#5MEE6X?P4ZS@T=F\#E) MZM:DZS>RL9$S'@GXW9;2&VH6 M)7'3)X9)HOM-#JQ),B"NTYJ2]7H!FXNRH+PJ>+_+Z!K8B7OSHDLT3F1TV3+D M&-X;PAKL\C7TD_D"U_U8./H"^9S7PE!.^3+P;:%;/V!%C;A85BS8%TIQJ!>Q M'VM^:"2@^+/G8YT R)8J($$W3K>K)+H&+HC>@E5'DWC(UJ#69,X,@W/R"IZ] MS_AV+GU4P.F1:#7_B!X.^A-4)]%;R. OV_O\^H!7YN@[0R^)DA9')4_3&_PW MJ.9?DGI*OA&KG>K0O&,F)3\SR?<<3Z'2-G6,D\"">=Y&2]W3Q'\'SR]V"1\M MO#X\1MEE1>/C40N6" AE7?M#8I,5OP$E64EKF'$LL3P2++"[B52D%+)>^@O* M,*RC,ER(D;0%G4IK$,JS)[%700]$K6R+@FF6LI:M\U0>8Q)L4I_PMO4/Q/=[ MS6=&?$B?H[3F\Y<:W'^*^\+:2CF-N MH[8XA.->NS5VKN'8<(@9S+HN;YKY51_K L#XS/ZX>\!#59NA$\[EJK*SH4@; MAHQO=>\B[=0P6$QR^*5%/)T&P@%P_M"DT&WU78T M>4R*OV'@SRA7 0_00,DA3S;GGD%N@N]LJ)U6#6>YGS'I>1N<$;O#*]8[[=P] MS'N(HZT41.#]6TZUILDZY58"CRJ66*X90BWAM"LP;*+WY DD"0X/BS[F\W2! M4A0>S#0$$Q#>GP''D[I&"AI<3P61&["59\ZE-[F[0XW2#78RVY+G.5DR >5N M<4#3)>0) FV2!W C>4%2U0;W(W,!M=NA@Y\> W/'N""I<9AJ9=SH=&H#Q4D+ MU-> SI8_JKZPX>R'!U+45F11%$2I@D_,9/:0 4_2Z$WL(%OB_3"5OZ*)OWWB M]53O")K"\M[9D\I:(B2^QKMXZV1A4\1.R(RD=7^;O7JP,5?@<6( MR!K))Z6/I,G)T9\O+SQ#H)^%/!/LP]"K1!T@[;;8.4I)/1\&>NEX3T57R!]7 MU@.$+)WOMBX. K,VIOMNC9*!%".\+P$+_==\PX5^,EIU+L+4C#,"PZL/SL4. MGVYP)'-09M7IXQ)"Q'.'EJ91#M"7[5U$S+^X^TH;35=?/<.@=_#X8+@2^=#[ MQ8KDP60%CV\>J*)X*>B<8 ZAMB(FLG< 4G$9>HWINQ2X2J_AYP<^GK]&DP3WT)L4Q6&&\@TC,#OVP&M4S-QL MXT)RL[KZ>;_)FI#DVJ@<\]/W ZSU*,?UQL2FSLM9L]1(]T5=P&%F]/G134LM=(9LKL_PE%970 M6Q!R"<:].-PE>7GD4JI8&6)DA(]P]^"9B!DX,R?4F/:4/=5C>Z=>JMB?R3(07F]BF'C=+*PM-H676@-(8))\.]O3;CJ+ZO M-^P;';OE!W^#[YKHNQSKXC-O4C@$$O:KW.!\-+%Z4B@G4 AD(S&W_\QUC6O2 MK'#(FI? 1X!S?OC2]RAKT<<9JH!H8+IO&+?//F5TOLB@4J-C0)_U 8HU%QQ"A@KDZP MQ//I1^219/$D62?P$2YM2LD:$BI61S2[[=7/ 4N2%8 TL9SG/<55/P_R+A[])T#I-*+B3E5J4D!XWTW!CA$NY4//+JN1O] M2)UNIS4(G06#?JOO/ZG+1*PMG8W*'JVR$WZ:;K<+D3Z_^'Q.#84[5[WG -;N MGM"5QK<117 AS\G3SEJ2>\^_),OU3YY8&DO$7,B/4TH,KLAX%UQ!G? N^Y;. MV?\!JXZ5F_RUL$TG)!E7 P[.M4,)5R0MU:\>,Z]2@,L+Y-ML M3MI"J"20W!"RH!X!VPH)PP>8D/"?23T RD>(]@#GVH+.^VQYB_YUL<]%?R]R/'=50EE*2WB? B 4O4RL 4L6&U)\E9O8ACKX=X7X2R78Z2,90?F( M)82S>XWY5W)2QA4KS(/3&/8P2!&89HXI2F5@D1-Q4K_:4\CR3*))1;U]B< X M7')ZE5%E*'*6R@SUX.LLZ/'X4OAEZ)D%AO?IT%A'O>!S_A\_$)0<96 ,SK;0 MUW(>"65;D0>.6-.ZB63A:+ RZC&MJ)N887V.OT\Y,I?#Q%- $6&?(.M=U2#:*G<[R4C3W8G+A3 M2EK 2GOD1S#UA1GQV;X"J_:&-SE& $Z.WDVF;S"!E"NT:RZ-OG#>W,G19/H% MKL0WG+9'-KUMKLB%KTQLY/[&26=#XN(RCX[)KE:S*MW!MU-TG.:F%9#!W4A+?9^C#\XF_XBC7'.%* 0; MYDUHDA\G.;*@$V>>KZY,[E#=<&=C9Z"A373G"KML@Q?E7FZYL!QE9^/53DNT M=Z@\$&^TSV$4 WSU_=R6)%9M'K.R,O"HX]#I%V'!;G2DB!NNQI"8L@,L M-,8:V_#_Y)S)HADI7L^65WF+OCUM ]\>69=4RC98,WKEBZDC&;R?7S-\EV! MQZO;"J:DAL>2!B\GJ_HI2Q=SXW?P!K!-R%ID=\[M+@.2I!A4(CW#Y%0QLU5W MX=:7-]%NPW2UYZ?Y0"/:2A@(;RY+\W_4!JIN&?:$+?,Y"#-B]QJ7V#_7IK+B M?M@H[H<@[KW&\2$E4 L1XN-^]U4DJH%*77+6.%B-!5T?:ST3\M6"*T %6D64 M6+"\[Q^VI_G=Z:X0!$E)L:0G6'3 ; 43(MY=PE>4&99HM)E";8+D)4S)]WME M847>ADIN%(;,5>TB ^#9$6,D=J'/1U<2 CHL9G(.%+G+:>0\\V XZ/J&TVG& M1X;N*_X.O9N:!NVV*9Y61*$%>HJ%G:;.R[$@NH >NGCV\.YT]JUF#.?=YIZ2 M> -U4?4_6F-RB"#"!$E/K!BXAR66X]8EA7 R-)4#84Z&I%]0/2%S)(>N\3), MYV;S%84&D\&MAM:S)I&.D$\[]#6R@NQ30P!"0[+D8'*X\X<5%U M)S+E>A.N#3:_&5#-WO=A^>:)2MVE#T*O4892^AA:=I0'3BC#7+IG\J3,HU18 ME'2<7<&01)O-TQU#B9&L *Y&VQ=?(6Q:JDO!S9I^RPJS5VM,LF<&S9HW"FJ, MJ6]34L-U6SA/IU.H3#5$Z2)R0JE/<&MEI;@":309!F&74D!G&,8<)\53 4KI M<_*6A:>/@HE@T4WN$H5#858CJ>H"C=W!F3&5X\I3%B$8:?GNT<@@-6@]L/HD M9&#'G9%)K\5@=R D*N]1>((R\Y;/T.]U#I6/G%IC^#IEI+")+A,<3)/=/8:F MGA-D@YC,$,4=+DX5H=BK=J<$)@^JAL$$PZB\T6^FY,%LJ/;)J;PA20_I:M(+ -]5*0R.>/$'2]9 M^"J.23B/R^T32#T>*YU=,WKKS+W59*@B&%\K;<710UY4OJ/<0\Q-,C@V7L 4 MR5*4/T&L$E1+2:ERG.$4*J0HLK\'DZ+2%44KCNKF,.!/M4W69)YI^2S>SK/".424C!MI5+#3V0F#F!9]*3$7YZ)/"1A F6SJ?"GE67$Z8YA8&# W<$[>7O MKD&JWVN?]MCIX3;U+K'+%>8@>JT"70;G7%[Q@3/71!WI=8=@@GUD'4_S^<(K MLF/7#.'.#7-F 3!) MQ<%D5L[8=;E^_A+-A;L C!HQ-!('#3N8W,MY;SIYGO7MDW[@CKCPH:I3$'G7 MM+>^@$71BN[2N?2&V6:PG]"9 )J$U$.L?(R(E7^'4[%)[U$WSS':(V,5@[=$ M3X=>@ 0%,KK4H;ML4Z#2L;AC[QHL-]U?(9)S(2M4'BL;/MJYF[G<7U?EN 81 MO.'Z:DKB,V%YI=QG,U"\EK-,[)55GO46&E."$#8*J>/F@=A1R%09^0GYB&K6 M6M'/)K.\E.&$>3DY/)) L,2U8*:]6Z%U2@A=M[0NY67GB3]N\ 2A4H)4\0Q.\:MR7! 8ZG HQ=.3?2[LSF[ M,4:,'**5-43!47CNN7VR);V+Y+&%/K>2B2FX;;R;9TD1D,D!,WQ#B!C>D03: M0!-\S3)Q^)/$UDP] (9D;V&HM#XG<+M$.6_SS29_I/?Z+,.;]&N^H"(5.8C> M)3/.(3Y),%/LCM/$,%WYE5=2"$P3RP8IUYX>5.( ?[ RR-FKG_R \3RU _;R MKBS(T,WBRVXK7^;4T"$BA#G0N@O_#A7I6EMF7&YXDP-%Q-KDG$MZE:7Y$K[Q M)_S5/5.!T4F/$_\+E;!245VR8);2W@DDIT4[Y4CGG%%GM>1EAM"78#-P0@<7 M&U#N/:XXL]"2N@ZA<=_IM']@N7D/+'=/Z7J4P\$'5,U;;G=S=GO@.(H=9W MO; 4^\>BI@B-/-#;"@4<5 MJ7VC&,^:DTHE@X) X?!K:IK*O"BQY66);R&>RR$9$0O8O/ M@=*ACO2+"2INV> ZJ/<6(,,O0N<$$M+ARCEEW&Z[3Q8&4->19#$[RQ,PIT_#69&$[ M$&1E$Z< ";*>F?BCI(6E@8.T1A/'O!I*?]M[?O'&6@=HU,0CWA43:)OXL$&K M-QK\0%F)!*Q*,@]3GM F[ X)=@O^H4^EBK/Z$N03\]SFPTTS49@O675U;*0D M L%F. KXA0L#HY 7GLG]K0?WH63J'-VM9&V3HE)08B:<<44ILY3 JR@,43#* MUJ]XNBT2;3VHDL\#*Y9 S1$ER01PZQV.@ CW M0*Z3FY8TN2*Z*PUE$!M6 ,?=?I#.)!>W-@LZI^U>I%S%G;B0>\,1K"OCUDT[&+9_CNW MK"31B9[EI3R.>G&_W8$WV#X^35W X/)!KP\78T839@#ZZMKA$.1,I:E5U"5R MA2.I8YWQ&&MKPNM6Z;9FO-UX (*VPQSNK]?M1=OT5U"/!(/L%@MJ \ O[]-D MK!\5@+N5_.: ]#:2;M (G\;[S+]-5>>P2L*,$N,9]RO)&2+# '?9"_98"7\Y M7'VXX2MA2"/HC!QFOG:7%'GGUWPU#B%00FY0NYN6QW,8]4Q1--OP5&)MI)]@%OKC,0;Y M\LI<[,47(2*5=I\ME? JB(,FQ9*,9(DK=)(%3S49IWAI\)+0@W$PFWA!5HN# M\K+>"Q7@"(LZDEO?ASZ"IGDYG^79[>I/#0N31Q/FH@F#U9&8; M,L/KTZ\$R),\JA0B7Q6?DUL/BQ*@]Z#K+G&N)8(N%,&,F!?L:Q&?S"S \&,! M:322ZN3V.*.LCI>5,:Z;]K?C:*GISTN3L:"+V0HGO')6U!QV[R)?JX.](@$- M9]@]L+7J4!PQ8(%;Z)9S S![6>MAN]WP]#!6;)P0?*4F]O"W8 @MG&$AZ1ZL M^X'U4YV+G$H^2N&?_EOZ5"(#W1'L&D=_*MU/9P^K?)'?/SWKVBU7%%7P[)G$ MA -=@'7*A78.J5%P(UPUDAXT8=[J3SX,[%Y'D'64EL*(V,$$5-BH9XWFS4]1 MHB#L"[FQQ2-BB\P<"'6 I^ %PX]L"<^>9HLT3 @ID?H@U=D*"2N+"&*AW 79 M6>)?)0>^WDC(;.@/:P[;B]/D.4OG/8$ODN;X9]<3T1L$KBGU1&;SA6?S 6># MEY)/Y)6%#@3#H#T$+7Z,6B:>VG1HHY<.5-E^ZPQU^*^" \Q BF-0B3L#4+D_ MNVUH1/K9L#4"\W,<<$$?!,8H,E<"!7J"0HNWHK#Y6+,KPAOER3>GPZSRE?YI MDH!\?C7PB>=<=O(:N$ I ,$Q,2[0:EX:W.4JNLT1S['^G2[B8EPB&DK36F)C M.7#ZC_9>.5CUP?'5["$WS(@CCAAXJ=G?E8&0!WRSR?C)E,55717+UTET#+;L MF?/)SLV*&4NRH?SUEI+_S"JT_.Z9B("F&C?3U YU/'6[9,4,K)$9V[ELGZ1 M]\7!]39GT6M?WF-;"'G?>_#I5;[UA#OIO!)1X'I;U2//H;4[PJ(BL-+/NB N MCM'\'[;IDV[<[8[@-^M?U.UC3T9)*7?_GG31VG_E_@W'4)IE[0#(_T # #'9 MI^F\K]G 2/RJM[-^3Q:E.E0]J,!0D8PK<\1P*JK5@GPP+A1]?U<)]L6!S\-Y M0#&.),CO\#KVY]#]5\)\KTM>43ZLI99OHE NBWZ!B[#1W<@T\\CZ8*D0K%K2 M +N^P-0(%'=*H6OTVYH;!.S8-+%#:Z:24)970K@F$"V94Q*5BUG=M#0!^]D M\JC4>V0K2)W-X0!^G?"&ZV"@BE?=:)V8:P;GIRRU7""'I%$)G5-,;Y8XCII1E MB\SECAFJK#-SHR\V6TF%"SM*;!NWCHFIAM MMMAMV9^*:4J_E(T6>VMA6WKK<_IG\?BL'??.1NY9@W;<[P_CT6"D*4HE)O&B M0DR;8O8 *AWJ0[?Y5[?5@N.KI!%Z;O3Q)Q]^]CJW6?Q3?029K#ZWXB+,3S;. MR8I7(2B!TL)FVJVF8U7M18$RHQY3:XEY+Y::A9P\%QJ%/S6-V@-5ZJA*UCRW M)YU;*.K*R"L/<:.FDB:7WAOB5_K#R>1,-0YT8]K,N!O-=D9!H!ILXT-LN4Y;M">\45!;[VX&F0AS%**.8#FAX/?Z18- MU$7IZHGL" .!F6EGP;OH<[K$!0/"3+#UY]95 M?UREZ?PI>B?-=8%[/T^NWB'G3G=KK6-9:!WTDZOY/YI.+_&J"?;J?0.[@WTJ M;[,"J89@&),W;_&"/"W[^\Z7B@G_(5_>GG[&NQ,&&438=8SOC M"#]\GB*(V)KO+@)?-3JG80*&ZCXCRT\<6!]4I%-1#+6SL+0-E@$#A[UYRZ^> M7E:?U_PX;%\<1[=$$R#P7$EB6@&W(IQPT] (_/B.VH'YH3WDCE5=0QJ/N9;- M+:-FNL,DE;(HNP TBN@XEH4.$E;)RLY$[U![2!=K$!$Y\(32:9.O,%*V6/BT M41PFPTCCK&VP$[-@%0^(08UAF:E\*.CT''.J)B:CX0CI.\SGFB,&^CQYHD_H M;$L9+Q!F1JVU@'Q/HC-C&)VP+AE+<+GXT&'+TQL,@N:*3D#&/0.29;U!G]$'5Z/WCJX1__ MP],/R=09P$>X!.ZBNG;42ETQF1<"(K=B2G]'"H^E"LI57?MVU^B&9A)@3BBHYBTIJJ2R 7($=8:+6)4>>P<$I*KB8_GT]P]BF M('PPXRB6^N4Z7C"KW+BVRONG3L0'![D-U^N:Z6*:8ST\16EVH3Z0X<9!8G4Z M:-MP3+=4J>VV8< <%!UT#V^YN9 M2 HL$?069_:8A]1GE4WB*\.55E3;\NY3ZG@ M6,NW]'&DM3K-P3$*)B.0XP)D^W# NC8&-2GC (]2IX?HE=QWCV&"&?KP(2\H M;P!^\I1.$FZ5F*4@[=S(RZY)$: MW%W.O.%<"P*;8&$'@DL.]4ET?GY=5"JZ?",_@H!,?PN:=!16Z2P$[L*U?. 1 M:T<=27AV,6XD85V_#VY#*]*,]DY.C4ZY21,?QGMP:FOZZWB(7N().MQ=5)92 M3@2A1%!VB NJ30.(B\I_4-^]P8G7C:I WB2=W_X5O$2M',]^?: 2KL M*56AK*6U!<8E"3GY(:&"/-?X3S>'@654/J ;9OD&A'Z^"7592O6A^[6U!MK& M5(ZAZ0%!RTS7IY"OI"BI!\7D.J=M F='O@8>YLO)QR:EY7YPB@B;E1#-5]K" MIY(:HR#(M]G<1U!T4>+(P5;C=S3E.Y".7!@F]OK$5)H%V+9!((C5V*:5I;P)=Y,*U9MIGME@(RW[+0 MRO61QAMOV]?X!!B/G*O^DL)F.J#[>L6UVR -BM1@#CSC!$0Q_C7)%BZMP7XXZL?8 M=&Y B0GC?J_5P8C6>-S"W GLG7$<#>-A^XQ*-NIZZY:S(_3?3@<3MOCG9VT$ MS&ASI#7L;?*L@](A\8 Z8.*.83BC[J#5K998].-VM]L:88)%?PP7= =C&'47 M_A_$XUX'OGFF37#S5#KT=OQ9\4DWW53^M][;'=&XFNZA+YEX 8\Z;S),F;H MA%/N=/KP^R ^&R&=WML[^T!"(.<9)N'U,!MOT!I&HT$;%OJRV17;/, 1W$@_ MF#?=P)IN.!FVN_#J5_Z7R_H]=2Q#/9;!'O-PCZ,33-_!M!M@V'$?KCAT"XP- MTW?C+6&':'\*Z7,7[YWQ:%7GN$BPP$&_B5BL^&F#/Y.[= ^=_*-J :J^X(N*D/_^MEA!_=Q/E= M&&0C8^&7^SB_&P_:)&#B7@_SJ[J]@7D<[(L1.!&PQ-I]T">1^LK_TK@/>,C',NAC'C;L@]X8$<=H M'PRQ] NGYQ.1R$GEDC*V/F8$?*8:3$!9;,48IDDL&,%B3X!&[4 ?GU'HPUKN MDC+D!ISSV)SR(;/XV%>@9-CXS4'>.TY'>_$$#2Q>3F MZO+J_32ZOKB)IC]/;BXJ%VLF#M;6$V!Y[ #N.+!>T#NKR(&B9.!?BD+R)F%!N5_Z9 MKA;]N#L<8'Z12WI2#U-=];:[G1>VW'JM9UNO$2*9Y(-3:AJ8RH@:0Q:M%.5( M3V!]JJM8*3=9&QG8?O*I<1EG>9R8%;(CD%?*M:@O@C+YC:TP&4O7B#CAEU2P MY!@==>:[4);SMM2(OE4H#ORC4J*QVI'O+;\C8!Q?Y]R4Q=6R(YA+_M8_> P, MF\=%(3 RC-PO=HUP0XXD\R],K'\(YXCVJC? MB4=G@VAPUHY!Z_@]HYO[?+]QOPOZ6C_J#^+.V3#N=$=4Y7CJ5O2YX830'OEU9\OII\QH:F"@Q<4]!/2.]AJ--VUWV\ S9 MEN[)&N(7B*U1+:#9PPY]KFOQ]O))6PV2/G)*,TN<]7LP-;SZI",TZ_5@1 W\ M@( @;?C_I$T> _R@=R@_C,+UZ<+]H[WA3U\3B") M7U'BX."0W@Q8H3F7IG/P &ZOJ.E*'.*3.C."@GJZW63S4"177DD**"7#N8;D M]15:+0>5C)YGN-H!T=U5V*;:H[B<@%*2ET;LO=TQ#- J94 YS1,YCL9CY"_^ M=T37L6[L+E57,87M&0!L,.K /8-1#_>,N\-)NQ'N9/S9=;M<1<>QDQB3"G67! Q(X3W1&VH7 ;&=M->( MHB9S-/+4(?QIU?H+6X1Y=Z,8K&7:C$=[? M"\W1%X\%LRZ24E$;F)XI-%=3(0)).*K/6:3S>[[> MH8WZ%L>TH\\]PH3O;N<;;6NHG.IH+9P7C L+4&'$S!&N_=*+=35-QV,AC:". MF_G"E&C7<.P3M<#1"TI]9&++S*N$JI+T2LJ7^U%G90# #E,5:SXWFF.H+TH! MW(MH$-AS5%*'WYI M35M!X-M,T'D9.^3"-6Y !Q&59H0P6U6%1J?3H6+.)W2D3^@Z7@5\)B%YX.>@3=2]4.!@5@: ][:QH#[[+RF 4@9@'G/ M.4&_;K&*@PU7A^!+RD.=A>MQ>-DKL>80<2W"'%^!J;R8 WXS_:(0A#9L'5YT M31>UPF%J/42I#/LY*QSA&8^[7=.?@\ZSCO4.'UX:KX=9I55W;=->AVF$8\ ^ MX6W;) 2%D@-8"(9.OGHSSQT)'*5E[61MSP;-P;!8H+=!/T_.,*MZBWRKGJXH M/UHRO7>HE$D3GDNXA*XU3A5'FU,J#(C*(^%P.ABT %?18[P;/Z[UPX)Z. B* M_+MG9KT8W2'5_D:!?[1G,!ODS.%8R_X9MTA1K#VR2KW4MI3WS;P8.UBD"@49 M\62QPU-S:XH42X /50IP+R,Y+)KYHU+]J'[&Q5:)8;D%V .*JS/92K=+7E-Z;[1;PVQTU5A=O1.,+_3U,8,0F> 3VSF>%I@V]R+5 M-W!S&;HP50XB\'8"3I W-KU$:%GWFA82L:#9R&'\R;AMZ]LH=0<]\O\.V\-X MU!Y'X\%9?-;O@:[%]U>-.[WX[-!E\1M12[3*IS2KJB"58I;H7G!GN MV(U.;7+><^CHR.\,N3[ &XU LJ=Y10VZ>/.Y\ADZ&8Q^U*SKX-W/89L11*A9 M%')AE"O'N0BIU DW6SG!3JYR;3?R/.)YD-GUNNK@+6O 'YQ5A:,CO-O7$2S* MX(< V)D-)BZJ8'1N3A+KMMOB7.#?!!:ZYE:.H7*SHZZF&?'/YL8*_%#^26OC M[$L./YYTV8=\TD4 !\4!6E3G1&Y-=#WWY#?TE 3(U7OCO$$\E;(8T),!K"GS MW:U(RZ<#BYZY"M&P=3U=0P*IY417F&M-<"SD4.7 MO/Q8-I:82(VJ7MB?1#8 MVN-<2JW/8:^<0NS6AV)K>@%H&F5CE+;4L/=0,G:?I>+@0"HJ*S:0>,!#-/4X'RVX'$/#X+!K5_#@RPOH>Q&.0>,?(=PGJN-4^C6$A/_@9L M@RZ5Z#/G@E?L&&L^Y=2J8H;>BT>INRPA1#*I# >Q9>(H0C8,T>)"9@:.G?(1TVG 4D,@0E?EY"*=1[KI6:0\6S?@6H[4&A3)SZ=DE MK.1Y:^->NLBQ5,7UM2$V:QP2VLN7I<:S6'%0&@4=]54F40N%5*:4-' M(Y72E]L&X67/O,^O:;>#[Q-J@GI&F$ZIG:CG&,XZ*W['6PF@R_0JSKAB=J/] M J5:YJ E88EPT*7<5]G!#R3Z5CI34C9G@ZZV-DNQO.):C:S]@PXC]RU(Y[68 MA&8C'P_:;=/8IJ:7AR^319BZW39;J(E>\_X#J1'Z)Q+*?03)WVYUL7E1#K_T MX)=YJH!]9#F1OQA%CB_)GHN("\3;Q9O+SV\GWW>E&[Q-Q^%ABUO=JKP',22O M.[EC-LEC*=:3@0G[5]@A6TZ&(J'^DCZSK(.*UW=BQSIDCMA\NK0)0ACSQAXL?D0E'P9FE00]6>HV M$P)FI0?JYXSRO&70^$VZS9_1V%&9U@6R$4W?5+C0KD?E-7G1JC^;B-+T\B\4 M8CC7/@C:WS46O7YHGV DCJJ5/]B<+CDU%7/GOQ@PQ8-@DK7.HKZ)U_,+;$*&3Q/$Z/H9)?_A.[A\SA#\98D>KTL9!HV)!DT9 M!K5I!@=G&/3H9X>R6L.YOSQE1;,.^-^.RY5U0?^_5[;>Z4NR];Z/ *SZE?^/ MEX'[*NY&1L"-#A)V05IL^-=!:;%C M_O&LN*,7>[)ON'=Z3=.RY#EO)@CZ,SS@3B2NC1]Q%(G"/4F"K4E"-4 MFRAT<(Y0&WYBI>=W$D@]SM+&?P>U NEO2MZM"X=)Y+@(S0VO5U83XDJ&=_Y< M5).P)"ORYQ\A<0Z1,\])ES#^%IU68K82M8+3EDN;VU8?J=Q=)80&NT ;&&-" M6?" LAW]\>+MY?GD0_3FXNKBW248T->3OTS>?*A48S9=M\=$;[QE4L;6$+/% M]U6FDAOF +':N556H_E,)3;WDK=17V/V?(#Z)0U)0ABC$/&6-S/6 @=@'6_< M]-03P4(,%EJ4GG&7H3@& GU @=9N/#X;P7*:/B6'%^I78 (<%KG/_ *!)_8[ MY;OWX\Z8<32&'?RW.T8NQ%3W8=P>]P@0 8,)G+IUTADB=R&B0Y]R%4\(GN 5 MIBY23D-WT#&!VN=!.FI:IV9[1GO2C4?#,RKL.#GK#;FHOC,><9"XPW_W@(1] M^B0<>HQ9^6>2>2%A91[M29O_ 2)0W;V.'QYUUAE1N09\UQN/^==N^TQZPC M M!O&@,R1R7 1<[%:\TQE3"<[9N,?G5GO,BC5]VHMA\;#B!1O=6+B]"BI.P&#[ M]P\*-&)SUR7 E7?/4^E\08G:F*WNHKY5Y$U%UHU.CMR7UV]OJ.,VN_--*MSQ ML)SC#W3Q.9$UEG2=;"_G04YA(_^>M)'F,-_=;D.;%ATYNZ*@YAVX@;EX\1 X MZ_\"$-*'2L+Q=Y:$!TE!V$U43W,,.F"7I6"[E-P-VZ:/PN4?)0FQ4W*/04;& M!$,T& 9(+)TA?AN(E#.!]1@-61!T62(YA0NH:Z3)89@MC3-X1C)B^9@,9TP8 M,B3>QC0P/Z!XU!N1[ KF,0*Y3 (0849(LM$196X$X4F-M)QDA,G(P^&[;E]D M,DXIN ]E,5]6*QJ1#;@@:S1FQ)]!NZ1_=T$ZMJ7X[7M+Q_%WDHZ'"<>^3=8F MZ=@?6'FY+>_+.NDX*DO'7TP6MCA:&96EHCY)>HUXWN$O'J-'N30X@&%(PGN. M73U.XSMDFVDK599]F MP=/GFZ@93"BJK) M-I$,6>J"YAK\!0T2-?HA@4:?_!M4HQ?6D0^CS J.4;I>@"[22BFQG"R#NG'R M%62T @[N5O[OM1,"CM=-Q^ BYJ[I')BG&GE-5RBX96_C.EI&@]%(KYXG@:\P M/0EKI!PO@+;5G;OA4X"_E&S/ZF:PIUCF?L MPP$E:%C#LD'W&W9W*V/:F%GN 5<,MF[RGUV_K]?!)7A5,0,6LD M\V$;A2V.8*.,$*[M.^Z3Z-)@,'4(XA62$5DQBY(]:1(>-AXST,NW^1*Q M0QC;'B3[$DYG++64%!E'W,*C)-4OK&&,3#K+AE-A,*UT;MSQ,J+$X/0XH#8! MPY[!B2\-T& -Z=#AOBLK<<>GW](90K_$;!M0+DEVNQ-^6>2/%*5/5CZ0O7Y( MX$R9/04G"ITD!97OQY#K;GF2MM!5K M]8_VJ&>P8'$(/F3W#WL?\HKB&2IJ*(<$'M?(I7HD^%V/BT9]1?PZ/2L'5CY- M3'--K0[LC3+7.;*0]($-8U^Y-I5>O)K^[IIVP1*C4%,,.^H8#T][) ML8,D1P#KY>T.Q!$M@MY+2=(%^5*+)^ H@@U J>4J&Z20+!9N1%?T:HM6LCZ" M/S M?(]J2LYLZ"0=-A'Z1.GPO.^H*H$SZWV9F^]!HAM96\D)_I\XM,G]Y[FM^=[IJSL>ZHQF)U MRL6%)>CW!?.WUP+(\L=&P3!1!/B(V:";45Z^C>6AAV[-26>X\^5!/*H4<3K< MXR6-5#*5 RVMT_='8^IP07&(B^R.:_/,I/!AZ!^,LB6*O:0,04#O8B^ZH]T5JNV3OG MZH85(0%B0(6%J"3"A*7.P]RYTJ0YWO@ZNJ&-@W7\GH'9 RU_(" P^O8^>([V M?L!)*0%5%,;9!H%)G0^%,%O/X(!8J7[RJ9Q'2M 40RVV,Y_#ZX=C!'D.D)MJ M"%!)@+2T^*AU%7#O)W!M"H2HJPN*C$HH\N5OBM M&_7;_%L/0#0S)A.CIBKK.(]=F&?AX*M?[ &?2:]QD#&FI M+3J/&>_ZFN/?/L1=G;]2K3;#?EM7FULG,HBE\#$B(O9M8->7$#-CYV3.B/1F M97R)=28@TTGLK[#Q:($BWE?3($"$G&X4L@<2Y-R[!C3!9!Z+^BOJ+HGJV48; M1+JT>WZ^J^H*/&:^"<96IH'E%JC-.D?#9I[*@<4 M>4%HBY/AOJM^D)G=_M& M=//MHG?T0Q;59"*VP!R;E8MQA&?I+A$(I5/U\&P=*32&_?]BV5)Y'V2I# MWCES%1&LP; VZ?+(Z-1+'_=NTPYLERJRY_FGCQ?1Y\G_6U4&!(&G@FJKT=U$'@00:6.\.SHT M*L;LA+OM%-T2I^+[$>4!$,X>"$JI?67T_-/5Y\OK[YBZ4(L]S>[\LJ0R,8 MDX26H/( N>)2 ;36/".-/F\25\?C>]TZJY/=(:[;>5!Q77V1& *D6A!P@/@> M*!N&NE)33SO2%7U+*C?X3##=&19%SI?\$73\XB%;<_D!EV,U/0&FKV/A?KUH MUG_%0_M.N]94^OK"8Z] \/P%>SR=')F[M)FDD@M)]PRY'&SYEO>:'4.%*@K* MF(!@:_\0_74'9_PIXW/;CEV(A0VJB#3 >P2%>O%TBE29FWG3+$"^)KOH)F5O M7LQN(*VV87EKO C\1#8.PO6H@*GW$RR MM>9 D/7&_HIFXM6X_^=V\SVS+/-L'B00HL4L8-L':-]%D_K-Q< MP:KA5GJEHKW)]#SJ#=NGG7:,4X2;,"Z&W@^/:[UVZ:MX=;<]..W2U?1XU-9>Y\X"ZD]XN2J#B9;68/BAN6_M=MIHSR5U/7. M<,@XO,.A:_1BK^ACU45_Z V'4-D/WF^VV8\%Y?-[@ &W6UW_%"^L/Y]:4;S;7JMN.\I[ X: M)5L+E$+^_'BPNOJ0*7%+V>3)BC[R6;*I,^=BZ;"!-8I$2>&PS;#U7N?CQB Z M2\4B6:;EAX"T83#/4IO.\&$P-'J,IB)013LGEE"E]E=I",%.:0&BUY0)S5)( M?832XAP%/5B48/LI7AZ>]$(N##VV9>)M%-( M13I6G$GSKOB-ZX#J7\KU81P M+UVL^-\5J2JH5*:*X3FSDXUM:A']W)0?40>%T^A1O%:2(5X48K[(75?/EW%3W2_80ZM.,B7N81;/W?2(0/?4>DT1\S-2C4+ZRA,;H"H,9A69)Z93H6+&M%GL4QC)D$L: @PME*WWTB#)YR5M&:.#/+&2R:D:4T9Q M1/$([*&:9G:YD9NX+6HB;AKE<6/;+%1=9EHJY53YCPG!6ITYV.1=$1"20SST M!^*C2N( 8@BA5XG@1R@$2?BII-P#&R ZX=9/!6\D) ;RW"!$2(H:4Z&K3B8% MH7%F6](Y<)I\WFDS6_:QH, 3-"3*CV.P0M9_\#N:)MT]XY6:!7D=X9!^9&3I M'??U<#1US!![1HBI<(B>?)?!V:=*]M: @GCM+[#!7&_9/,N"= M:\=E\MZV,/I5^@3S M,0L=@_&@# M/0/LYEJE6[3Q9/Z51;HAE\GW*[_)/0.C6=M%*JA9-M1\6UX1*GW47#]^W;R& M]7EWFSDH&*T\O'Y2 L*?4/'Y AN4:U0>\RF8OO'&9*,27M@P7&+8M* MTM_3;P\)-U-#I/9D7:!)@I.N@T)B)VDCQV8K)S@TX^QK1EX]?PU.Y\DY%ZV M]>+K63DEG0A0 >*,Q&N@&.:=ZWXFV=4\4CI0B,T:6>QOV5=P=;)@I6;_%O-; M*%NN<_9_!EO)[1U:S@,V4)">!E;1*IUY0SX4E*)!LB1\N2 DT::B\'"QY[[B MB*/O/LVK63T>*+.7""Y(]'_=42-!%10"V:3+B(=A[<8.-VEE/\;AN?' 1Q() M/5<>P/3@:BUW*E4.H%;TCBLS:ML=O'RDF(9PI^'#Q)YTKL\%';%< MN9O7A61@E6(UC%[L&$].AA?@9?'IY-HFU/+=)E7#S;\.?:%("9,R8W"YZYXB M$MX>';=FZZJ@E6*;>MVVQ QWOL77X1L=QYZ43@CD#GPK<0@)%SG[WN0(QXRE MLUX/3@1%3$XW4%-5-TBMV,[Y<$ P,,[!NJ=D(T3P6Z@/4&R@&3I7ZO<\C@Q] M_04GCZRPP1_(2O+Z-T'U"#LN4('EC=_?,MX=\CSC/$XD&.3=4S'0\1]&U[&95HZ_M#K;0"SK+GQ MD+/W<[;)EI+ B*59LVW]ZN/43!)JR10I26I)ZN2HY9SC*NV1U8_OTCF#;\G; M02B2>YP*J.XVR6ZN>J$Y'M%-NLXVF 6*P<^4K\,7?UE16@>Y(_& !/F=6D>J MS:RU;Q(CB77/ZA#JZ9!MK/!T,Y#Q"C#D"O6%3H\]$+_NJ$*.[9GRS+>2'I+, MT#E_O\L68*8 H7$MJ&7-$J4#0CLJ132^=">JD]3369\V/%0)W^D)-"U!5?9C MW1ON+KJ!',>T6J29^T.1WH;;,MONM@YF+5V1J)D@D'YY%'<9"B80!)F4*XM^ MJ+XGPT:52V?4H45NH),ER&<+WQ2;Q'7ST !K.&5 .Y)X9%:@]RF5 MKI[XIL6"N_K 8ON^6RSE'@5IG5F,^=N]B#)PU;T<0.G6[)Y2&0.<(:F6]^> M"([R3<;Y,RE"E6W@[7I0!,R*T7,\-&#OX/NS .IT1"OG /!&\;/WSU/,O>8] M]L!=NU(E)PAC-VKQDV=WP-*>HC%=\ ;#+0DG"P/M/[0^M,Y;T5?A 5A@ M-$6B%I'CYQT8'RO\\A?8$>?E\M88.[.WW!W,](B[HRN-$_\I*K)O'&!'1R1U M5MYD7[GJ3(=8N97@L+=N#_JBKT^@ O#ZPN&!5_FMT1[_Q%J,.8:4D4K[PP-Z M<"#V0E,_SITC6N!^_0='K^CQ/&1]KKG>S<%LUJXS[T*A56(FV&.@.*/+7Q;A M30J7BSO/;3TRY"+01L"46^HX]/G//Z"R,MR7C@S&>0W;.".[TR&1 [^T21>Q MMSRSK@2-*5Q.L(/W*]:DR)._P(YLV=T=Y2:A I1*MQFJ?SI\9E6SW)K!)M^+ MT !O4T$B/(3J/'1W0/C\D8"2AEVK1#AL="PGK6RKCK8D^&I'Y;1$K@N2XH\& MH=32!L3*P\)4^'3!;/1<() V)?Y#A&OV2B](@7X2;8&9 [FNL$81%]TLX(Q) MYQQH>1+/2LVA9@<&C_3':UH"^@8JXVS5,T+\E#Q1CRE?M"7$+SWT>!1>LBL. M'8KC%CQ;#AU1__D!=6H'I(NP9SC,&=]O)"02-'N+V:$4Z*L8)A4(X@/.5[^L M-8H#!G5VZ$,@J2D"UG$S/O+=(M]D\\2>%J3HX+CTI'1YUBB3A/G@#>Y0DW9. M"/6+*08+Z>4B*E.VU I)=-9P^R2_97?B8']V4!I\\2Y1HW=>ENI<:@'M]\L- MIN':R!K6JU#28E+DK@B9G5(WJ?+9:4^X8I[SJ[SC=#G/*;'*>(V"L;D1/>:[ M!2>Z%&GZ&WNS.=9K;$_#'77*61@[*4JF&;TIM)4%^ILR-.0QE/2'+^ !W?I\ M_RUF_W*U.E4CE7"D+:E\ /?[L+N*CAJ&1Q83I@]8_3^+O?4AUJ[B483+F7TF*$A(SX/F)DV-=E; M:G'-0KZ$R/\5*-LM4_:9(54.3 UHEZW+YP2)[\6S0HO9B*"2%TX3.^L:8X+F MML1N"*2L>LASV7/BN&7#:&[S%>GE-8B'O_@"))XW%X FQH?,E>#2^%@3?8J& M>J1FOW/-1"V9A-[>_C?!1W(753(_S5$31ETELF25:@3O3L-[@F5VWO;=2LM# M BQQ235T_8TLKC<34GFM! M,(6:J%H!W8M?4WNQ3Z5S05U\ ABELR?JW"4#MA7P7$)>?FU8USW-EZGG5ITH M[2[0&[!N8R;P;3X9FX+2+N2,$1)^=X'/DG)/B:Z8(@I+(#\>;=?@./XVX$:* MQ,FH5%=9)CH<"IYZN3\_-,7RI.+KC]]N*14N1/%['M5?L,7#C]HZ_)*G?JEM(Q8 ^?SB>%7GD\$ M$%G C5O./Z_+1*> '*B,M3T)I+4HY3*LL-!K8>"QD_FO.TUDUM/?M=\ Z0[$ M0Z^9"V0@8.VZE&6.E/9O)@!F4N 4P<+BCA0^M_J.>BCIDW4*AZ7(8SL)$G_4 MX]9UYG;0,_5])#BCGQSM:A9,AP3@GGQE&'"DY&--\Z%#&2 M->NYECX&XPC@NLCK #_O